<SEC-DOCUMENT>0001144204-14-028653.txt : 20140508
<SEC-HEADER>0001144204-14-028653.hdr.sgml : 20140508
<ACCEPTANCE-DATETIME>20140508163117
ACCESSION NUMBER:		0001144204-14-028653
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20140331
FILED AS OF DATE:		20140508
DATE AS OF CHANGE:		20140508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		14825431

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v376666_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;FORM 10-Q</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the quarterly period ended March 31, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number) </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><B><U>Florida</U></B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center"><B><U>65-0643773</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(I.R.S. Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>of incorporation or organization)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>2 Snunit Street</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Science Park</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>POB 455</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B><U>Carmiel, Israel</U></B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B><U>20100</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>+972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B><BR>
<FONT STYLE="font-size: 10pt"><B>(Former name, former address and former fiscal year, if changed since last report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;large accelerated filer&rdquo;
and &ldquo;accelerated filer&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%; text-indent: 0in">Large accelerated filer</TD>
    <TD STYLE="width: 46%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 25%; text-indent: 0in">Accelerated filer</TD>
    <TD STYLE="width: 6%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml; </FONT>(Do not check if a smaller reporting company)</TD>
    <TD STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On May 1, 2014, approximately 93,606,460
shares of the Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="toc"></A>FORM 10-Q<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 79%">&nbsp;</TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Page</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#parti"><B>PART I &ndash; FINANCIAL INFORMATION</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD><A HREF="#cautionary"><B>Cautionary Statement Regarding Forward-Looking Statements</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">ii</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><A HREF="#partiitem1">Item&nbsp;1.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#partiitem1">Financial Statements</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><A HREF="#balancesheet">Condensed Consolidated Balance Sheets &ndash;</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in"><A HREF="#balancesheet">As of March 31, 2014 (Unaudited) and December 31, 2013</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">1</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><A HREF="#operations">Condensed Consolidated Statements of Operations (Unaudited) &ndash;</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in"><A HREF="#operations">For the Three Months Ended March 31, 2014 and 2013</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><A HREF="#changesincapitaldeficiency">Condensed Consolidated Statement of Changes in Capital Deficiency (Unaudited) &ndash;</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in"><A HREF="#changesincapitaldeficiency">For the Three Months Ended March 31, 2014 and 2013</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">3</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in"><A HREF="#cashflows">Condensed Consolidated Statements of Cash Flows (Unaudited) &ndash;</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in"><A HREF="#cashflows">For the Three Months Ended March 31, 2014 and 2013</A></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">4</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.3in"><A HREF="#notes">Notes to Condensed Consolidated Financial Statements</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">6</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><A HREF="#item2">Item&nbsp;2.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#item2">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">10</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#item3">Item 3.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#item3">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">15</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><A HREF="#item4">Item&nbsp;4.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#item4">Controls and Procedures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">16</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="text-align: center"><A HREF="#partii"><B>PART II &ndash; OTHER INFORMATION</B></A></TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#partiiitem1">Item&nbsp;1.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#partiiitem1">Legal Proceedings</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><A HREF="#partiiitem1a">Item&nbsp;1A.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#partiiitem1a">Risk Factors</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#partiiitem2">Item&nbsp;2.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#partiiitem2">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><A HREF="#partiiitem3">Item&nbsp;3.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#partiiitem3">Defaults Upon Senior Securities</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#partiiitem4">Item&nbsp;4.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#partiiitem4">Mine Safety Disclosures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top"><A HREF="#partiiitem5">Item&nbsp;5.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#partiiitem5">Other Information</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><A HREF="#partiiitem6">Item&nbsp;6.</A></TD>
    <TD STYLE="vertical-align: bottom"><A HREF="#partiiitem6">Exhibits</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#signatures">Signatures</A></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">19</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix Ltd., our
wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="cautionary"></A><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions &ldquo;Business,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Risk Factors,&rdquo;
and other statements included elsewhere in this Quarterly Report on Form 10-Q, which are not historical, constitute &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies
for the future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; and words or phrases
of similar import, as they relate to our company or our subsidiaries or our management, are intended to identify forward-looking
statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with
respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy
of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement
is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements
are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed
or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the commercialization efforts for taliglucerase alfa in the United States, Israel, Brazil and other countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk of significant delays in the commercial introduction of taliglucerase alfa in the United States, Brazil, Israel and
other markets as planned;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the acceptance and use of taliglucerase alfa or any of our product candidates, if approved, by physicians,
patients and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to supply drug product pursuant to our supply arrangement with the Brazilian Ministry of Health, or the Brazilian
MOH;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that we will not be able to develop a successful sales and marketing organization for taliglucerase alfa in Israel
or for any other product candidate in a timely manner, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>failure or delay in the commencement or completion of our preclinical studies and clinical trials which may be caused by several
factors, including: unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; slower
than expected rates of patient recruitment; inability to monitor patients adequately during or after treatment; inability or unwillingness
of medical investigators and institutional review boards to follow our clinical protocols; or lack of sufficient funding to finance
our clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy, that our product
candidates will not have the desired effects or include undesirable side effects or other unexpected characteristics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial
services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in the approval or the potential rejection of any application filed with or submitted to the regulatory authorities
reviewing taliglucerase alfa outside of the United States, Israel, Brazil and other countries in which taliglucerase alfa is already
approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to establish and maintain strategic license, collaboration and distribution arrangements, and to manage our relationships
with Pfizer Inc., <FONT STYLE="font-family: Times New Roman, Times, Serif">with Funda&ccedil;&atilde;o Oswaldo Cruz, or Fiocruz,
an arm of the Brazilian MOH</FONT>, or any other collaborator, distributor or partner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to finance our research programs, the expansion of our manufacturing capabilities and the ongoing
costs in the case of delays in regulatory approvals for taliglucerase alfa outside of the United States, Israel, Brazil and other
countries in which taliglucerase alfa is already approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in our preparation and filing of applications for regulatory approval of our other product candidates in the United
States, the European Union and elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products that are competitive to our product candidates may be granted orphan drug status in certain territories
and, therefore, will be subject to potential marketing and commercialization restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of development of competing therapies and/or technologies by other companies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any lack of progress of our research and development activities and our clinical activities with respect to any product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product liability risks, and risks of securing adequate levels of product liability and clinical trial insurance
coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our 2018 convertible
notes, or any other indebtedness;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of infringing a third party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of obtaining patents covering our products and processes and in successfully enforcing our intellectual property
rights against third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to biosimilar legislation and/or healthcare reform in the United States or elsewhere; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors,
collaborative partners, licensees and clinical trial sites.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration, or the FDA, or foreign regulatory authorities may not accept or approve a marketing application
filed by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed under the heading
<FONT STYLE="text-transform: uppercase">&quot;</FONT>Risk Factors<FONT STYLE="text-transform: uppercase">&quot;</FONT> in our Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2013, and are described from time to time in the reports we file
with the U.S. Securities and Exchange Commission, or the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="parti"></A>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="partiitem1"></A>Item&nbsp;1. Financial
Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B><A NAME="balancesheet"></A>CONDENSED CONSOLIDATED BALANCE SHEETS</B></FONT><BR>
(U.S. dollars in thousands)<BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 5.75pt">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">77,690</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">86,398</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable - Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,091</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,609</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,457</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,527</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,957</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">88,561</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">97,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,622</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,578</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,098</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">DEFERRED CHARGES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">135</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">141</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">103,416</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,639</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,254</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,533</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,073</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,609</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,781</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,696</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0in">Convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,151</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,048</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0in">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,655</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,796</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0in">Liability in connection with collaboration operation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,371</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0in">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,407</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,368</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">110,213</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">113,583</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136,994</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">140,279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">COMMITMENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">CAPITAL DEFICIENCY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(33,578</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,946</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities net of capital deficiency</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">103,416</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">113,333</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B><A NAME="operations"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</B></FONT><BR>
<FONT STYLE="font-size: 10pt">(U.S. dollars in thousands, except share data)</FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,&nbsp;2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,&nbsp;2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 76%; font-weight: bold">REVENUES</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,696</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,568</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMPANY&rsquo;S SHARE IN COLLABORATION AGREEMENT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">687</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF REVENUES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,073</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(971</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,310</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,997</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">RESEARCH AND DEVELOPMENT EXPENSES (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,152</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,754</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Less &ndash; grants and reimbursements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,431</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,067</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,323</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,711</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,103</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING LOSS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,468</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,429</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">FINANCIAL EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(915</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL INCOME</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">38</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">122</TD><TD STYLE="text-align: left; padding-bottom: 1pt"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL INCOME (EXPENSES) &ndash; NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(877</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">108</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS FOR THE PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,345</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,321</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS PER SHARE OF COMMON STOCK &ndash; BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.05</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED
    IN COMPUTING LOSS PER SHARE &ndash; BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,686,638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">92,184,220</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">(1) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">428</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">870</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 9pt">(2) Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">242</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">497</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.35pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="changesincapitaldeficiency"></A>CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN CAPITAL DEFICIENCY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands, except share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">paid&ndash;in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR>
 shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-size: 1pt; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-size: 1pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 40%; font-weight: bold">Balance at December 31, 2012</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">93,489,809</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">93</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">180,145</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(183,595</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(3,357</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Changes during the three-month period ended March 31, 2013:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation related to restricted stock award</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,020</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Exercise of options granted to employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2013</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93,502,230</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">94</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">181,539</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(187,916</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,283</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at December 31, 2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93,551,098</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">94</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">184,345</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(211,385</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(26,946</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Changes during the three-month period ended March 31, 2014:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Share-based compensation related to restricted stock award</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">508</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">508</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Exercise of options granted to employees (includes net exercise)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2014</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93,606,460</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">94</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">185,058</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(218,730</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(33,578</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;Represents an amount less than $1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&#9;&nbsp;&nbsp;&nbsp;Common Stock, $0.001 par value; Authorized &ndash; as
of March 31, 2014 and 2013 - 150,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The accompanying notes are an integral part of the condensed
consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="cashflows"></A>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(7,345</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,321</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Adjustments required to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">670</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,367</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Depreciation and write down of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">828</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">926</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Financial expense (income), net (mainly exchange differences)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(78</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Changes in accrued liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Gain on amounts funded in respect of employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Amortization of debt issuance costs and debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Decrease in deferred revenues (including non-current portion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,901</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,740</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Increase in accounts receivable and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(744</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Decrease (increase) in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,430</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,734</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Decrease in accounts payable and accruals (including long term )</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(450</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,005</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,340</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(9,586</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(263</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(642</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Investment in restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(57</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Amounts funded in respect of employee rights upon retirement, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(47</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(370</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(689</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt; padding-bottom: 1pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">31</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">31</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">110</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">NET DECREASE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,708</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,165</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-size: 10pt"><B>BALANCE OF CASH AND CASH EQUIVALENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>AT BEGINNING OF PERIOD</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">86,398</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52,035</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">77,690</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">41,870</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Continued) -  2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2014</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">SUPPLEMENTARY INFORMATION ON
    INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">138</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1pt solid; text-align: right">815</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Exercise of options granted to employees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">28</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="notes"></A>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Protalix BioTherapeutics, Inc. (collectively with its
subsidiaries, the &ldquo;Company&rdquo;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused
on the development and commercialization of recombinant therapeutic proteins based on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP>
protein expression system (&ldquo;ProCellEx&rdquo;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under
the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&ldquo;EMA&rdquo;) application process
in the European Union. The Company&rsquo;s two subsidiaries are referred to collectively herein as the &ldquo;Subsidiaries.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">On May 1, 2012, the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) approved taliglucerase alfa for injection, the Company&rsquo;s first approved drug product, as an enzyme replacement
therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase
alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa
was also approved by the Israeli Ministry of Health (the &ldquo;Israeli MOH&rdquo;) in September 2012, by the Brazilian Ministry
of Health (the &ldquo;Brazilian MOH&rdquo;) in March 2013 and by the applicable regulatory authorities of certain other countries.
Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory
authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Taliglucerase alfa is being marketed in the United States
under the brand name ELELYSO&trade; by Pfizer Inc. (&ldquo;Pfizer&rdquo;), the Company&rsquo;s commercialization partner, as provided
in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &ldquo;Pfizer Agreement&rdquo;). The
Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Protalix Ltd. granted Pfizer an exclusive, worldwide
license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since
2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities
for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million
in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related
milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA&rsquo;s
approval of taliglucerase alfa in the United States. The agreement provides
that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa
on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel
and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement,
there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods
sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">On June 18, 2013, Protalix Ltd. entered into a Supply
and Technology Transfer Agreement (the &ldquo;Brazil Agreement&rdquo;) with Funda&ccedil;&atilde;o Oswaldo Cruz (&ldquo;Fiocruz&rdquo;),
an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO<SUP>TM</SUP>. The
first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed,
to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer
to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole
expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz
has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement.
In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally,
Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately
$280 million worth of taliglucerase alfa. The Brazil agreement became effective during the first quarter of 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">During the three months ended March 31, 2014, the
Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">To facilitate the arrangement with Fiocruz, Pfizer amended
its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization
and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as
defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil
on Protalix Ltd.&rsquo;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Protalix Ltd. is required to pay a fee equal to 5% of
the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement
pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to
the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In addition to the approvals from the FDA, the Israeli
MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company
is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions.
Currently, marketing authorization applications have been filed in a number of countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Currently, patients are being treated with taliglucerase
alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, patients are being treated globally through
the Company&rsquo;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company
announced that the French regulatory authority had granted an Autorisation Temporaire d&rsquo;Utilisation (ATU), or Temporary Authorization
for Use, for taliglucerase alfa for the treatment of Gaucher disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">An ATU is the regulatory mechanism used by the French
Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need
exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization
for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations
to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or
named patient provisions in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In addition to taliglucerase alfa, the Company is working
on the development of certain other products using ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">In addition to the approval of taliglucerase alfa for
marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&rsquo;s development
programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell
its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to
support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory
approval process for each of its product candidates during their respective developmental periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Obtaining marketing approval with respect to any product
candidate in any country is directly dependent on the Company&rsquo;s ability to implement the necessary regulatory steps required
to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Basis of Presentation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for
the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet
at December 31, 2013 has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s Common Stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;) outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Diluted LPS does not include 7,471,571 and 18,913,153
shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion
of the convertible notes (issued in September 2013) for the three months ended March 31, 2013 and 2014, respectively, because the
effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-indent: -17.85pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Inventory at March 31, 2014 and December&nbsp;31,
2013 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">March 31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">December 31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 76%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,076</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,342</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">170</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,281</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,523</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,527</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,957</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">During the three months ended March 31, 2014,
the Company recorded approximately $1.1 million for write-down of inventory under cost of revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 &ndash; FAIR VALUE MEASUREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The Company measures fair value and discloses fair
value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale
of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The accounting standard establishes a fair value
hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 1: Quoted prices (unadjusted) in active markets
that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level
1 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 2: Observable prices that are based on inputs
not quoted on active markets, but corroborated by market data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">Level 3: Unobservable inputs are used when little
or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">In determining fair value, the Company utilizes
valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible
and considers counterparty credit risk in its assessment of fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">The fair value of the financial instruments included
in the working capital of the Company is usually identical or close to their carrying value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 &ndash; STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">During the three months ended March
31, 2014, the Company issued a total of 55,362 shares of Common Stock in connection with the exercise of a total of 56,122 options
by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $43,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="item2"></A>Item&nbsp;2. Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial
statements and the related notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the year ended
December 31, 2013. Some of the information contained in this discussion and analysis, particularly with respect to our plans and
strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You
should read &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2013 for a discussion
of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking
statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP>
protein expression system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary, biobetter
and biosimilar versions of recombinant therapeutic proteins, based on our plant cell-based expression technology, that
primarily target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Our
initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders,
such as Gaucher disease and Fabry disease. We believe ProCellEx will enable us to develop proprietary recombinant proteins
that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications.
Because we are primarily targeting biologically equivalent versions of highly active, well-tolerated and commercially
successful therapeutic proteins, we believe our development process is associated with relatively less risk compared to other
biopharmaceutical development processes for completely novel therapeutic proteins. We are now also applying the unique
properties of our ProCellEx system for the oral delivery of therapeutic proteins, with the first two product candidates being
glucocerebrosidase and antiTNF fusion protein, and we are performing research focused on the oral delivery of antibodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May 1, 2012, the U.S. Food and Drug Administration, or the FDA, approved for sale our first commercial product, taliglucerase alfa
for injection, which is being marketed in the United States and Israel under the brand name ELELYSO<SUP>TM</SUP>, as an enzyme
replacement therapy, or ERT, for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.
Subsequently, taliglucerase alfa was approved by the Brazilian National Health Surveillance Agency (Agencia Nacional de Vigilancia
Sanitaria, or ANVISA) in March 2013, by the Israeli Ministry of Health, or the Israeli MOH, in September 2012, and by the applicable
regulatory authorities in Uruguay, Mexico and Chile. Taliglucerase alfa will be marketed under the name UPLYSO<FONT STYLE="font-size: 10pt"><SUP>TM</SUP>
</FONT>in Brazil and certain other Latin American countries. Taliglucerase alfa is our proprietary, recombinant form of glucocerebrosidase,
or GCD, that is produced or expressed through ProCellEx. Taliglucerase alfa is the first plant cell-based recombinant therapeutic
protein to be approved by the FDA or by the regulatory authorities with jurisdiction over any substantial market. Gaucher disease
is a rare and serious lysosomal</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">storage disorder with severe and
debilitating symptoms. Gaucher patients suffer from mutations in or deficiencies of GCD, an enzyme that is naturally found in human
cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed in the
United States by Pfizer Inc., or Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement
by and between Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer
an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but we retained those
rights in Israel and in Brazil. We have agreed to a specific allocation between Protalix Ltd. and Pfizer of the responsibilities
for the continued development efforts for taliglucerase alfa outside of Israel. Protalix Ltd. has been marketing taliglucerase
alfa in Israel since 2013 and in Brazil since January 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 18, 2013, we entered into a Supply and Technology Transfer
Agreement, or the Brazil Agreement, with Fiocruz, for taliglucerase alfa. The agreement became effective in January 2014. The technology
transfer is designed to be completed in four stages and is intended to transfer to Fiocruz the capacity and skills required for
the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality,
and cost-effective supply of taliglucerase alfa. The initial term of the technology transfer is seven years. Under the agreement,
Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of
the term. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per
year. Additionally, we are not required to complete the final stage of the technology transfer until Fiocruz purchases at least
approximately $280 million worth of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Brazil Agreement may be extended for an additional five-year
term, as needed, to complete the technology transfer. All of the terms of the arrangement, including the minimum annual purchases,
will apply during the additional term. Upon completion of the technology transfer, and subject to Fiocruz receiving approval from
ANVISA to manufacture taliglucerase alfa in its facility in Brazil, the agreement will enter into the final term and will remain
in effect until our last patent in Brazil expires. During such period, Fiocruz will be the sole provider of this important treatment
option for Gaucher patients in Brazil and shall pay us a single-digit royalty on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate the arrangement with Fiocruz, we and Pfizer agreed
to an amendment of our exclusive license and supply agreement, which amendment provides for the transfer of the commercialization
and other rights to taliglucerase alfa in Brazil back to us. As consideration for the transfer of the commercialization and supply
rights, we agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license
and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on our behalf in connection
with the supply of taliglucerase alfa to Fiocruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay a fee equal to 5% of the net proceeds generated
in Brazil to our agent for services provided in assisting us complete the Brazil Agreement pursuant to an agency agreement between
us and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing approval
for taliglucerase alfa in additional countries and jurisdictions. In addition to those countries in which taliglucerase alfa has
been approved, marketing authorization applications have been filed in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to naive and switch studies in adults which were successfully completed, we conducted a 12-month clinical trial of na&iuml;ve
and switchover pediatric patients, which was successfully completed in 2012. Based on the data from this study, </FONT>an application
for a supplement to the NDA for ELEYSO, allowing a pediatric use indication to be added to the product label, has recently been
submitted by Pfizer to the FDA.<FONT STYLE="font-family: Times New Roman, Times, Serif"> Patients in the extension trials are still
being treated with taliglucerase alfa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with taliglucerase alfa
on a commercial basis in the United States, Brazil, Israel and Chile. Globally, patients are being treated through our extension
trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs
designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. In France,
Gaucher patients are being treated with taliglucerase alfa through an Autorisation Temporaire d&rsquo;Utilisation (ATU), or Temporary
Authorization for Use, a regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available
to patients in France when a genuine public health need exists. In addition to the United States and France, taliglucerase alfa
is currently being provided to Gaucher patients under special access agreements or named patient provisions in certain countries.
Hundreds of patients, in the aggregate, have been treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) PRX-102, a therapeutic protein candidate for the
treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, currently in a phase I/II clinical trial for which
the first patient was treated in December 2012. We expect to complete patient recruitment and report interim results by the
end of 2014, and to report final results during the first half of 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) PRX-112, an orally administered
glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD enzyme
produced and encapsulated within carrot cells, the subject of a phase I clinical study. We announced positive results from
the phase I trial in February 2014. We expect to commence a   phase IIa clinical trial treating 10  Gaucher patients for 28
days within the next few months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
PRX-106, </FONT>our oral antiTNF product candidate <FONT STYLE="font-family: Times New Roman, Times, Serif">which is being developed
as </FONT>an orally-administered treatment for immune mediated disorders using plant cells as a natural capsule for the expressed
protein. We are currently conducting preclinical studies on oral antiTNF for several attractive indications, and we expect to initiate
a phase I clinical trial of oral anti TNF for the oral treatment of autoimmune diseases in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease
1 under development for the treatment of cystic fibrosis, to be administered by inhalation. We held a pre-IND meeting with the
FDA in 2012, and plan to file an IND with the FDA following the completion of toxicology studies in 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
for the rights to commercialize taliglucerase alfa worldwide (other than Brazil and Israel), which we licensed to Pfizer, we hold
the worldwide commercialization rights to all of our proprietary development</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">candidates.
We have built an internal marketing team designed to serve the Israeli and Brazilian market for taliglucerase alfa and we intend
to establish internal commercialization and marketing teams for our other product candidates in North America, the European Union
and in other significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition, we
continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical
companies and academic research institutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have not been any changes to
our significant accounting policies since the Annual Report on Form 10-K for the year ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended March 31, 2014 compared to the three
months ended March 31, 2013</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $6.7&nbsp;million during the three months
ended March 31, 2014, an increase of $3.1 million, or 88%, from revenues of $3.6&nbsp;million for the three months ended March
31, 2013. Revenues for the three months ended on March 31, 2014 included $3.5 million of products sold in Brazil, $1.1 million
in Israel and $1.0 million in connection with products we delivered at cost to Pfizer under the Pfizer Agreement. Revenues also
represent a pro rata amortization of the $65.0&nbsp;million upfront and milestone payments of $1.1&nbsp;million in each quarterly
period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $687,000 as our share of net income from
the collaboration under the Pfizer Agreement during the three months ended March 31, 2014, an increase of $287,000, or 72%, from
revenue of $400,000 for the three months ended March 31, 2013. Our share in the collaboration agreement recorded during the three
months ended March 31, 2014 represents our 40% share of the net income generated during the period, which was primarily the result
of revenues generated by Pfizer in the United States which exceeded the expenses during such period. Under the terms and conditions
of the Pfizer Agreement, we record income or loss equal to 40% of the profit or loss realized from sales of taliglucerase alfa
and related expenses incurred based on reports we receive from Pfizer summarizing the results of the collaborative activities under
the Pfizer Agreement for the applicable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $4.1 million for the three
months ended March 31, 2014, an increase of $3.1 million from cost of revenues of $971,000 for the three months ended March
31, 2013. Cost of revenues for the three months ended March 31, 2014 consists of the costs of the $1.0 million of products
we delivered at cost to Pfizer under the Pfizer Agreement, write-down of inventory of $1.1 million, and certain fixed costs
relating to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, and to a much lesser
extent, the direct cost of products we sold in Israel and Brazil for which revenues were recognized during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were
$8.2&nbsp;million for the three months ended March 31, 2014, an increase of $398,000, or 5%, from $7.8&nbsp;million for the
three months ended March 31, 2013. The increase resulted primarily from an increase of $109,000 in materials and an increase
of $127,000 in costs related to salaries expense. The increase also
resulted from a decrease in reimbursement of expenses equal to $2.1 million in accordance with the terms and conditions of
the Pfizer Agreement during the three months ended March 31, 2014 and from the Office of the Chief Scientist of the Israeli
Ministry of Industry, Trade and Labor, compared to the total reimbursement of approximately $2.4 million during the three
months ended March 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Selling, General and Administrative
Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Selling, general and administrative
expenses were $3.7&nbsp;million for the three months ended March 31, 2014, an increase of $1.6 million, or 76%, from
$2.1&nbsp;million for the three months ended March 31, 2013. The increase resulted primarily from sales and marketing
expenses of approximately $1.0 million, primarily in connection with sales in Brazil, and an increase of $564,000 in
salaries expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial expenses were $877,000 for the
three months ended March 31, 2014 compared to financial income of $108,000 for the three months ended March 31, 2013. Financial
expenses resulted primarily from interest expense of $887,000 for the 4.5% convertible note which was partially offset by financial
income which resulted primarily from interest earned on short term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures which supersedes our product sales revenue, we have not been profitable and have generated operating losses
since our inception with the exception of the quarter ended on June 30, 2012 due to the $25.0 million milestone payment we received
from Pfizer in connection with FDA approval of taliglucerase alfa in that period. To date, we have funded our operations primarily
with proceeds equal to $31.3&nbsp;million from the sale of shares of convertible preferred and ordinary shares of Protalix Ltd.,
and an additional $14.1&nbsp;million in connection with the exercise of warrants issued in connection with the sale of such shares,
through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50&nbsp;million in connection with
an underwritten public offering of our common stock and on each of March 23, 2011 and February 22, 2012, we generated gross proceeds
of $22.0 million and $27.2 million, respectively, in connection with underwritten public offerings of our common stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the foregoing, on September 18, 2013, we completed
a private placement of $69.0 million in aggregate principal amount of 4.50% convertible notes due 2018, or the Notes, including
$9.0 million aggregate principal amount of Notes related to the offering&rsquo;s initial purchaser&rsquo;s over-allotment option,
which was exercised in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement and subsequently
paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.&rsquo;s meeting a certain milestone. Protalix Ltd. also received
a milestone payment of $25.0 in connection with the FDA&rsquo;s approval of taliglucerase alfa in May 2012. Protalix Ltd. is also
entitled to payments equal to 40% of the net profits earned by Pfizer on its global sales of taliglucerase alfa (except in Israel).
In calculat</FONT>ing net profits there are certain agreed upon limits on the amounts that may be deducted from gross sales for
certain expenses and costs of goods sold. Pfizer has also paid Protalix Ltd. $8.3 million in connection with the successful achievement
of certain milestones under the Clinical Development Agreement between Pfizer and Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that the funds currently available
to us as are sufficient to satisfy our capital needs for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $8.3&nbsp;million
for the three months ended March 31, 2014. The net loss for the three months ended March 31, 2014 of $7.3 million was further increased
by a decrease of $2.9 million in deferred revenues and a decrease of $450,000 in accounts payable, but was partially offset by
a decrease of $1.4 million in inventories, share based compensation of $670,000, and $828,000 in depreciation. Net cash used in
investing activities for the three months ended March 31, 2014 was $370,000 and consisted primarily of purchases of property and
equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $9.6&nbsp;million
for the three months ended March 31, 2013. The net loss for the three months ended March 31, 2013 of $4.3 million was further increased
by a decrease of $2.7 million in deferred revenues, a decrease of $3.0 million in accounts payable and an increase in inventories,
but was partially offset by share based compensation of $1.4 million and $926,000 in depreciation. Net cash used in investing activities
for the three months ended March 31, 2013 was $689,000 and consisted primarily of purchases of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur significant expenditures in the
near future. However, we anticipate that we will generate revenues to offset such losses as Pfizer&rsquo;s commercialization efforts
for taliglucerase alfa in the United States and as our commercialization efforts for taliglucerase alfa in Brazil and Israel progress,
and as taliglucerase alfa is launched by Pfizer in other countries in which taliglucerase alfa was recently approved. We also anticipate
that we will generate additional revenues after additional anticipated marketing approvals of taliglucerase alfa are granted in
new countries. We expect to continue to incur significant research and development expenses, including expenses related primarily
to the clinical trials of PRX-102 and oral glucocerebrosidase and the advancement of our other product candidates into clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and cash
equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for the foreseeable
future. We have based this estimate on assumptions that are subject to change and may prove to be wrong, and we may be required
to use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated
with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital
outlays and operating expenditures associated with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many factors, including the progress of Pfizer&rsquo;s commercialization efforts for taliglucerase alfa in the United States
and other countries, the progress of our commercialization efforts for taliglucerase alfa in Brazil and Israel and, if anticipated
marketing approvals of taliglucerase alfa are granted in other jurisdictions, the progress of Pfizer&rsquo;s global commercialization
efforts for taliglucerase alfa, the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review
of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims
and other intellectual property rights, the number and development requirements of other product candidates that we pursue and
the costs of commercialization activities, including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We may need to finance our future cash needs
through public or private equity offerings, debt financings, or corporate collaboration and licensing arrangements. We currently
do not have any commitments for future external funding. We may need to raise additional funds more quickly if one or more of our
assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate.
We may also decide to raise additional funds even before we need them if the conditions for raising capital are favorable. Any
sale of additional equity or debt securities will likely result in dilution to our shareholders. The incurrence of indebtedness
would result in increased fixed obligations and could also result in covenants that would restrict our operations. Additional equity
or debt financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at
all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development
programs, reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or others that may
require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the three months ended March 31, 2014 or the three months ended March 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the three months ended March 31, 2014 or the three months ended March 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of March 31, 2014 and March 31, 2013.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="item3"></A>Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic
environment in which our operations are conducted is the U.S. dollar. We consider the currency of the primary economic
environment to be the currency in which we generate revenues and expend cash. Most of our revenues are denominated in U.S.
dollars, approximately 50% of our expenses and capital expenditures are incurred in U.S. dollars, and a significant source of
our financing has been provided in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in
currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and
non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate
of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in
the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximately 35% of our costs, including salaries, expenses
and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;months&nbsp;ended<BR> March&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;<BR> December&nbsp;31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%">Average rate for period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.497</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.708</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3.611</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.648</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.471</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="item4"></A>Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report
on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of management, including our
Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to
reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly
Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated
and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on the controls evaluation, our
Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly
Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required
to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by
the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management,
including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are
being prepared.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion
of two or more people or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are
subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes to our internal controls over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended March 31, 2014
that has materially affected, or that is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><A NAME="partii"></A><B>PART II &ndash;
OTHER INFORMATION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="partiiitem1"></A>Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="partiiitem1a"></A>Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">There have been no material changes to the
risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2013.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="partiiitem2"></A>Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B>Unregistered Sales of Equity
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">There were
no unregistered sales of equity securities during the three months ended March 31, 2014. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="partiiitem3"></A>Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="partiiitem4"></A>Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="partiiitem5"></A>Item&nbsp;5. Other Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><A NAME="partiiitem6"></A>Item&nbsp;6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" NOWRAP>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Incorporated&nbsp;by&nbsp;Reference</B></P></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit</B><BR>
        <B>Number</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 39%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><BR>
        <B>Exhibit&nbsp;Description</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><BR>
        <B>Form</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>File&nbsp;Number</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Exhibit</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Date</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Filed</B><BR>
        <B>Herewith</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Articles of Incorporation of the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">333-48677</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 26, 1998</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated June 9, 2006</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated December 13, 2006</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated December 26, 2006</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated February 26, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Bylaws of the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 28, 2013</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.1&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Agreement between Protalix Ltd. and Comercio e Servi&ccedil;os Ltda. dated June 17, 2013</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 6.95pt; text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">10.2&dagger;</TD>
    <TD STYLE="width: 40%">Amendment dated June 18, 2013 to the Exclusive License and Supply Agreement between Pfizer Inc. and Protalix Ltd., dated as of November 30, 2009 </TD>
    <TD STYLE="width: 7%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-left: 6.95pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 6.95pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.3&dagger;</TD>
    <TD>Technology Transfer and Supply Agreement made as of June 18, 2013 by and between Protalix Ltd. and Funda&ccedil;&atilde;o Oswaldo Cruz</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 6.95pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 6.95pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.1</TD>
    <TD>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.2</TD>
    <TD>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer </TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>XBRL SHEMA FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>XBRL CALCULATION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="signatures"></A>SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 41%">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 8, 2014</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>David Aviezer, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 8, 2014</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer, Treasurer and Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>v376666_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="color: Black">Exhibit 10.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="color: Black"><B><U>Execution
Version</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>[***] Represents
material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request
for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; color: Black"><B><U>AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: Black">This Agreement
is made and entered into on this <U> 17 </U> day of June, 2013 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">Between</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; color: Black"><B><U>PROTALIX
LTD.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">a company duly
incorporated under the laws of Israel of 2 Snunit Street, Science Park, P.O. Box 455, Carmiel 20100, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">(<B>&ldquo;Protalix&rdquo;</B>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>ATME Comercio
e Servi&ccedil;os Ltda</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">a company duly
incorporated under the laws of Brazil</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">of Alameda Tocantis,
75, room 1110, Alphaville, Barueri CEP 06455-020, Sao Paulo, Brazil</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">(<B>&ldquo;ATME&rdquo;</B>)
</FONT></P>

<P STYLE="color: purple; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="color: purple; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.15pt"><FONT STYLE="color: Black">WHEREAS:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Protalix
                                         and ATME entered into that certain May 2012 Agreement (the &ldquo;<B><U>Original Agreement</U></B>&rdquo;)
                                         and this Agreement amends and restates in its entirety the Original Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: purple; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.15pt; text-align: left"><FONT STYLE="color: Black"><B>WHEREAS</B>:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Protalix is engaged, <I>inter
alia</I>, in the development, manufacture, marketing, distribution and sale, both on its own and together with Pfizer, Inc. (&ldquo;<B>Pfizer</B>&rdquo;),
of a proprietary enzyme replacement therapy product for the treatment of Gaucher Disease based on taliglucerase alfa (the &ldquo;
<B>Product</B>&rdquo;; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.15pt"><FONT STYLE="color: Black"><B>WHEREAS</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Protalix
                                         and Pfizer entered into that certain Exclusive License and Supply Agreement, dated November
                                         30, 2009 (the &quot;<B>Original Pfizer Agreement</B>&quot;), which is expected by Pfizer
                                         and Protalix to be amended by letter in 2013 to provide Protalix exclusive rights to
                                         commercialize the Product in the Territory (the &ldquo;<B>Pfizer Amendment</B>&rdquo;,
                                         and the Original Pfizer Agreement, as amended by the Pfizer Amendment, the &quot;<B>Pfizer
                                         Agreement</B>&quot;); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: purple; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.15pt; text-align: left"><FONT STYLE="color: Black"><B>WHEREAS</B>:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Protalix is interested in
penetrating the market for the Product(s) in Brazil (the &ldquo;<B>Territory</B>&rdquo;) by way of sales of the Product(s) in
the Territory and/or entering into a definitive transfer of technology and supply agreement with a manufacturer in, and for, the
Territory; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: purple; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.15pt; text-align: left"><FONT STYLE="color: Black"><B>WHEREAS</B>:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">ATME has the requisite knowledge,
experience and expertise to assist Protalix in achieving its objectives for the Product(s) in the Brazilian market; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: purple; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.15pt; text-align: left"><FONT STYLE="color: Black"><B>WHEREAS</B>:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">At Protalix&rsquo;s request
and in furtherance of its aims, and based on the parties&rsquo; understanding regarding mutually agreeable compensation of ATME
if a successful transaction with respect to the Brazilian market were consummated, ATME applied such knowledge, experience and
expertise to assist Protalix in its efforts to enter into a definitive agreement to supply the Product(s) to Fundacao Oswaldo
Cruz, an agency of the Federal Brazilian Ministry of Health (&ldquo;<B>Fiocruz</B>&rdquo;) for distribution and sale in the Brazilian
market; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: purple; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.15pt; text-align: left"><FONT STYLE="color: Black"><B>WHEREAS</B>:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Such assistance from ATME
has contributed to the success of such efforts by Protalix which is expected to result in the execution of a definitive Technology
Transfer and Supply Agreement in 2013 by and between Protalix and Fiocruz (the &ldquo;<B>2013 Contract)</B>&rdquo; and, together
with all other agreements with FIOCRUZ that contain substantially the same economics of the 2013 Contract, (the &ldquo;<B>Other
Contract/s</B>&rdquo;) if any, entered into between Protalix and Fiocruz, within [***] years from the date of the 2013 Contract,
for the transfer of technology with respect to, and the supply of, Product(s) to Fiocruz for distribution and sale in the Brazilian
market, the &ldquo;<B>Contracts</B>&rdquo;); and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; color: purple; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.15pt; text-align: left"><FONT STYLE="color: Black"><B>WHEREAS</B>:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The parties wish to confirm
their understanding regarding the compensation by Protalix of ATME in consideration of such assistance and such contribution by
ATME to Protalix&rsquo;s efforts and success in entering into, and the substantial economic benefits which may be realized by
Protalix pursuant to, the Contracts (such assistance and contribution being sometimes referred to as the &ldquo;<B>Services</B>&rdquo;).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.15pt; text-align: justify; text-indent: -84.15pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="color: Black"><B>NOW
THEREFORE, it is agreed between the parties hereto that the Original Agreement is hereby amended and restated in its entirety
to read</B> <B>as follows<FONT STYLE="font: 10pt Times New Roman, Times, Serif">:</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Fees</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.85pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">1.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Upon
                                         the terms and subject to the conditions set forth herein, and in reliance on ATME&rsquo;s
                                         representations and warranties contained herein and in the Certification attached hereto
                                         as Exhibit A (the &ldquo;<B>Certification</B>&rdquo;), Protalix hereby agrees to pay
                                         ATME five percent (5%) of its Proceeds under the 2013 Contract and four percent (4%)
                                         of its Proceeds under the Other Contract/s (collectively, the &ldquo;<B>Fees</B>&rdquo;).
                                         For purposes of this Section, &ldquo;<B>Proceeds</B>&rdquo; shall mean the revenue for
                                         supply of Product(s) actually collected and recognized by Protalix from Fiocruz pursuant
                                         to the applicable Contract in accordance with US GAAP or any other accounting practice
                                         adopted by Protalix from time to time, after deduction of any commissions or royalties
                                         payable to third parties in respect to any activities under the applicable Contract and
                                         any amounts refunded for Product returns.<B> </B>For the avoidance of doubt, no (i) amounts
                                         paid to Protalix in reimbursement of expenses or for technical services performed pursuant
                                         to the applicable Contract; (ii) revenue collected or recognized by Protalix for Product
                                         supplied (or agreed to be supplied) at cost and not pursuant to Section 7 of the 2013
                                         Contract (or any similar provision of any other Contract); or (iii) revenue collected
                                         or recognized by Protalix for Product supplied (or agreed to be supplied) prior to the
                                         date of this Agreement, shall be included in the definition of &ldquo;<B>Proceeds</B>&rdquo;
                                         under this Agreement. Notwithstanding the foregoing, in the event of a material change
                                         in the economic terms of the applicable Contract, the Parties will negotiate in good
                                         faith to adjust the Fees to reflect such change in economic terms.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.85pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.85pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">1.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                         Fees constitute the sole and entire consideration and compensation which ATME is entitled
                                         to receive for the Services (and, except to the extent expressly agreed in writing by
                                         Protalix and ATME, any other services provided to Protalix by ATME, or any employee or
                                         principal thereof, to the extent related to the Product(s) in the Territory). Protalix
                                         shall not be required to reimburse ATME for any costs or expenses incurred by ATME in
                                         connection with this Agreement, the Services or otherwise, all of which shall be ATME&rsquo;s
                                         sole responsibility.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Terms
                                         of Payment</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">2.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Payment
                                         of Fees, if any shall have become payable, shall be made within [***] after Protalix
                                         receipt of any payment from FIOCRUZ with respect to Proceeds. Protalix shall provide
                                         ATME with a quarterly report which shall set forth the amount of Proceeds in respect
                                         of the preceding quarter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">2.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">The
                                         Fees shall be paid in the same currency as the Proceeds and shall be inclusive of all
                                         sales and other taxes and fees, which shall be borne by ATME.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">2.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">If
                                         Protalix is required by applicable law to make any tax deduction, tax withholding or
                                         similar payment or withholding from any amount paid or payable by Protalix hereunder,
                                         including but not limited to on account of income tax, tax on profit or any other taxes
                                         or fees imposed on ATME (&ldquo;<B>Withholding Tax</B>&rdquo;), then Protalix shall notify
                                         ATME of this requirement and shall deduct the Withholding Tax from the payments referred
                                         to above, as prescribed by applicable law and shall not be required to &ldquo;gross-up&rdquo;
                                         or otherwise increase any such payments to accommodate for such Withholding Tax.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">2.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Notwithstanding
                                         anything to the contrary herein, Protalix shall be obligated to pay the Fees only (i)
                                         after ATME has obtained and secured all consents, permits, licenses and approvals, if
                                         any, required in connection with the execution, delivery, performance, validity and enforceability
                                         of this Agreement, and provided copies thereof to Protalix, [***].<STRIKE> </STRIKE></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Termination</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.75pt; text-align: justify; text-indent: -18.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.05pt"></TD><TD STYLE="width: 18.7pt"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">This
                                         Agreement (i) shall automatically terminate (with respect to the applicable Contract,
                                         or as a whole if in relation to all existing Contracts) upon the termination of the applicable
                                         Contract for any reason and (ii) may be terminated by Protalix by notice to ATME if the
                                         representation or warranty of ATME in Section 7.2.3, 7.2.4 or 7.2.5 shall have been or
                                         be inaccurate in any material respect or ATME shall have failed to perform or comply
                                         in any material respect with any covenant of ATME contained herein</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.75pt; text-align: justify; text-indent: -18.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>




<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.05pt"></TD><TD STYLE="width: 18.7pt"><FONT STYLE="color: Black">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Without
                                         limiting the generality of paragraph 3(a) and for the avoidance of doubt, Protalix may
                                         terminate this Agreement, effective immediately upon notice by Protalix to ATME, if (i)
                                         Protalix determines, based on information from sources it reasonably believes are credible,
                                         that any representation, warranty or other statement contained in the Certification is
                                         inaccurate in any material respect or (ii) ATME shall have failed to perform or comply
                                         in any material respect with any covenant or agreement of ATME set forth in the Certification.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.75pt; text-align: justify; text-indent: -18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.75pt; text-align: justify; text-indent: -18.7pt"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.75pt; text-align: justify; text-indent: -18.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.05pt"></TD><TD STYLE="width: 18.7pt"><FONT STYLE="color: Black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Upon
                                         termination of this Agreement in accordance with its terms, all rights and duties of
                                         the parties hereunder shall cease, except that (i) ATME shall be entitled to payment
                                         of Fees in accordance with the provisions of Section 3 above to the extent such Fees
                                         became payable prior to the effective date of termination and provided such termination
                                         was not pursuant to clause (ii) of paragraph (a) or pursuant to paragraph (b) of this
                                         Section 3, (ii) the provisions of Section 4 below shall survive any such termination
                                         and (iii) such termination shall not relieve a party from liability for breach prior
                                         to such termination of any representation, warranty, covenant or agreement set forth
                                         herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Confidentiality</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">ATME
acknowledges that proprietary and/or confidential information of Protalix and/or Pfizer and/or relating to the Product(s), this
Agreement and/or any Contract (including, without limitation, information relating to the business, operations, research and development
activities, products, technology or other intellectual property of Protalix or Pfizer) may have been obtained by or disclosed
to ATME in the course of, for the purpose of, or otherwise in connection with, the performance (or anticipated performance) of,
the Services, whether orally, in writing, electronically or in any other form, and whether obtained or disclosed prior to or during
the Term (collectively, the &ldquo;<B>Confidential Information</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">ATME
agrees to keep the Confidential Information and the terms of this Agreement and the Contracts in strict confidence and ATME shall
not, without the prior written consent of Protalix, disclose such information to any third party. Upon the termination of this
Agreement for any reason or upon request by Protalix, ATME shall promptly return to Protalix (or, at Protalix&rsquo;s option,
destroy) any and all Confidential Information and any and all manifestations and copies of the Confidential Information in the
possession or control of ATME. The provisions of this Section 4 shall survive any expiration or termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Independent
                                         Contractor</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">ATME
has been, is and shall remain at all times an independent contractor for all purposes (including, but not limited to employee
benefits, unemployment benefits, income tax withholding, health and other insurance), and is not, and shall not represent itself
as, the agent, partner, officer or employee of Protalix. The Parties acknowledge and agree that ATME has assisted Protalix only
in relation to the Contracts and has not been appointed an agent of Protalix, as defined under the Brazilian Agency Law or any
other applicable law, and, therefore, is not entitled to any benefits, payments, protections or indemnities established by any
such laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">For
the removal of doubt, ATME has had, currently has, and shall have, no authority to bind or commit Protalix by or to any contract
or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Costs
                                         and Expenses</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">Each
party shall bear all of its own costs and expenses incurred both directly or indirectly as a result of performing its obligations
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.1pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.1pt"><FONT STYLE="color: Black">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Additional
                                         Representations, Warranties and Covenants of ATME</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">7.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">ATME
                                         acknowledges that it has been advised that Protalix is a party to the Pfizer Agreement
                                         which addresses, <I>inter alia,</I> Protalix&rsquo;s rights to register, manufacture,
                                         market, distribute and sell the Product in the Territory, and that it is subject to certain
                                         restrictions thereunder. ATME hereby represents and warrants to Protalix, and covenants
                                         with Protalix, that it shall not have any claim against Protalix, of any nature, in respect
                                         of the exercise, by Pfizer, of its rights under the Pfizer Agreement, regardless of whether
                                         ATME was previously informed of such rights or not;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">7.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">ATME
                                         hereby further represents and warrants to Protalix, and covenants with Protalix, that</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 56.7pt"><FONT STYLE="color: Black">7.2.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">it
                                         does not have any pre-existing obligations that are inconsistent with this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 56.7pt"><FONT STYLE="color: Black">7.2.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">so
                                         long as ATME remains entitled to receive Fees hereunder, it shall not render services
                                         to any other person or entity to facilitate, directly or indirectly, the promotion, marketing
                                         or sale in Brazil of any product for the treatment of Gaucher Disease or any other Product
                                         covered under any Contract.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 56.7pt"><FONT STYLE="color: Black">7.2.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">in
                                         its performance of the Services and otherwise in connection with its activities, communications
                                         and other conduct relating, directly or indirectly, to any Contract or this Agreement,
                                         it has complied, and shall comply, with all, and has not taken and shall not take any
                                         action that would cause Protalix to violate any, (i) applicable laws and regulations,
                                         <FONT STYLE="font-size: 10pt">including the U.S. Foreign Corrupt Practices Act of 1977
                                         (the &ldquo;<B>FCPA</B>&rdquo;),</FONT> including but not limited to acquiring and maintaining
                                         any consents, permits, licenses and approvals and fulfilling any reporting requirements
                                         which may be applicable to the Services or this Agreement, in the Territory, and (ii)
                                         of Pfizer&rsquo;s Anti-Bribery and Anti-Corruption Principles set forth on Appendix 10.1(t)
                                         of the Pfizer Agreement, a copy of which is attached hereto as Exhibit B (for this purpose
                                         substituting throughout such document &ldquo;Protalix&rdquo; for &ldquo;Pfizer&rdquo;
                                         in each place that the word &ldquo;Pfizer&rdquo; appears (the &ldquo;<B>Principles</B>&rdquo;));</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 56.7pt"><FONT STYLE="color: Black">7.2.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">the
                                         representations, warranties and other statements contained in the Certification are true
                                         and correct, and ATME has performed and complied, and will perform and comply, with the
                                         covenants and agreements of ATME set forth therein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 56.7pt"><FONT STYLE="color: Black">7.2.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">it
                                         has not employed or utilized as a subcontractor or otherwise, does not currently employ
                                         or utilize as a subcontractor or otherwise, and will not employ or utilize as a subcontractor
                                         or otherwise, any person that has been debarred or has otherwise been disqualified or
                                         suspended from performing scientific or clinical investigations or otherwise subjected
                                         to any restrictions or sanctions by the ANVISA or any other Governmental Authority or
                                         professional body with respect to the performance of scientific or clinical investigations,
                                         or any person finally convicted of a criminal offense, with no existing rights to appeal
                                         such conviction, in relation to: (i) the development or approval (including the process
                                         for development or approval) of an abbreviated drug application; (ii) the development
                                         or approval of any drug product or otherwise relating to the regulation of any drug product;
                                         or (iii) bribery payment of illegal gratuities, fraud, perjury, racketeering, blackmail,
                                         extortion, falsification or destruction of records or interference with, obstructions
                                         of an investigation into a prosecution of any criminal offense; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 56.7pt"><FONT STYLE="color: Black">7.2.6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">[***]</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -56.7pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 56.7pt"><FONT STYLE="color: Black">7.2.7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Protalix
                                         will allow ATME or independent accounting firm or law firm designated by Protalix, periodic,
                                         but not less than annually, access to Protalix&rsquo;s relevant books and records for
                                         the purpose of confirming the accuracy of the quarterly reports provided by Protalix
                                         to ATME hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">7.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">ATME
                                         shall provide Protalix with an updated executed copy of the Certification annually for
                                         five (5) years after the execution of the 2013 Contract.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">7.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">[***]</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Pfizer
                                         Indemnification Agreement; Indemnification of Protalix</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">8.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">ATME
                                         hereby agrees that neither ATME nor [***] and/or any of their affiliates, principals,
                                         officers, directors, employees, owners, family members, agents, contractors, or consultants,
                                         whether such persons are acting independently or as agents of [***] and/or ATME (each
                                         such person or entity, together with [***] and/or ATME, an &quot;<B><U>ATME Person</U></B>&quot;)
                                         will assert any claims against Pfizer for which Protalix has indemnified Pfizer pursuant
                                         to Protalix's agreement to indemnify Pfizer against any claims asserted by any ATME Person
                                         and certain other claims relating to Protalix's relationship and interactions with ATME
                                         (the &ldquo;<B>Pfizer Indemnification</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -42.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.4pt"></TD><TD STYLE="width: 42.5pt"><FONT STYLE="color: Black">8.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">ATME
                                         shall indemnify, defend and hold Protalix and its affiliates, and their respective directors,
                                         officers, shareholders, representatives, agents, successors, assigns, licensors and employees
                                         harmless from and against all liability, claims, losses, damages, causes of actions,
                                         and costs and expenses (including reasonable attorney&rsquo;s fees) resulting from or
                                         arising out of (a) any acts or omissions of ATME in connection with ATME&rsquo;s performance
                                         of the Services, (b) the inaccuracy or breach of any representation, warranty, covenant
                                         or agreement made by ATME in this Agreement or in the Certification or the Principles,
                                         (c) any acts or omissions of ATME or of any principal, owner, affiliate, officer, director,
                                         employee, contractor, consultant or agent of ATME that are inconsistent with ATME's agreement
                                         not to assert claims against Pfizer set forth in Section 8.1 above, (d) any inquiry,
                                         investigation, litigation or proceeding by a governmental authority or third party regarding
                                         any ATME Person in connection with the commercialization of the Product in Brazil by
                                         Protalix, any Contract, or any other actions of an ATME Person on behalf of Protalix,
                                         or (e) any amounts Protalix is required to pay to Pfizer under the Pfizer Indemnification.
                                         The provisions of this Section 8 shall survive any termination of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Notices</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">Except
as otherwise<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>provided in this Agreement, all notices permitted
or required by this Agreement shall be in writing and shall be deemed to have been duly served (i) if personally delivered, when
actually delivered; (ii) if sent by facsimile, upon transmission thereof (receipt of which has been orally confirmed by the recipient);
or (iii) 7 (seven) business days after being mailed, postage prepaid, return receipt requested, if sent by registered mail and
addressed to the address of the parties set out below or in accordance with such other address information as the party to receive
notice may provide in writing to the other party in accordance with the above notice provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify"><FONT STYLE="color: Black"><U>If to Protalix:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify"><FONT STYLE="color: Black"><B>Protalix
Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify"><FONT STYLE="color: Black">2
Snunit Street Science Park</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify"><FONT STYLE="color: Black">P.O.
Box 455</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify"><FONT STYLE="color: Black">Carmiel
20100</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify"><FONT STYLE="color: Black">Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify"><FONT STYLE="color: Black">Facsimile:
+ 972-4-988-8092</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify"><FONT STYLE="color: Black">Attention:
Dr David Aviezer CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">&#9;<U>If
to ATME</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black"><B>ATME
Comercio e Servi&ccedil;os Ltda</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">Alameda
Tocantes, 75</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">Alphaville,
Barueri, CEP 06455-020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">Sao
Paulo Brazil</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">Facsimile:
+55.11-4195-6621</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">Attention:
Abraham Meizler</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Governing
                                         Law and Jurisdiction</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">This
Agreement shall be governed by and construed in accordance with the laws of Israel, without giving effect to its principles of
conflicts of law that direct that the laws of another jurisdiction apply and the parties hereto hereby submit to the exclusive
jurisdiction of the competent courts in Tel-Aviv- Jaffa. Notwithstanding the foregoing, Protalix may apply to any court of competent
jurisdiction in Brazil or any other applicable jurisdiction for injunctive or other equitable relief or to enforce any judgment
obtained against ATME in connection with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Entire
                                         Agreement; Amendments</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">This
Agreement constitutes the entire agreement between the parties hereto in respect of their Product-related collaboration in the
Territory, and supersedes all prior agreements or understandings between the parties relating to the subject-matter hereof. This
Agreement may only be amended by a written document signed by both of the parties to this Agreement. This Agreement shall be binding
on and inure to the benefit of the parties hereto and their respective successors and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">12.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Assignment</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">ATME
is not entitled to assign or transfer this Agreement or any rights or obligations hereunder, without the prior written consent
of Protalix which may be withheld in its sole and absolute discretion. Protalix shall have the right to assign its rights and
obligations pursuant to this Agreement, in whole or in part, to Pfizer or any other party which may have an interest in the applicable
Product; <U>provided</U> that it provides written notice to ATME following such assignment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">13.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Severability
                                         </U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">The
provisions of this Agreement are severable and, in the event that any court of competent jurisdiction determines that any one
or more of the provisions or part of a provision contained in this Agreement shall, for any reason, be held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision or part
of a provision of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">14.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Waivers</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">No
waiver of any term of this Agreement shall be effective unless set forth in writing and duly executed by or on behalf of the party
hereto waiving such term or condition. Neither the waiver of any term or condition of this Agreement, nor the failure to enforce
or exercise any rights or remedies available under this Agreement, shall be deemed or construed to be a waiver of such term or
condition for any similar instance in the future or of any subsequent breach of this Agreement. All rights, remedies, undertakings,
obligations and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other
remedy, right, undertaking, obligation or agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">15.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Publicity</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">ATME
shall not make any press release or public statement (written or oral) concerning the terms of, or events related to, this Agreement
or any Contract, or concerning the Services, Protalix, Pfizer, or the Product(s), without the prior written consent of Protalix
which may be withheld in its sole and absolute discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.4pt; text-align: justify; text-indent: -28.4pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.4pt"><FONT STYLE="color: Black">16.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B><U>Counterparts</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.05pt; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">This
Agreement may be executed in counterparts (including counterparts transmitted by facsimile), each of which shall be deemed to
be an original, but which taken together shall be deemed to be an original and to constitute one and the same instrument<FONT STYLE="font-size: 10pt">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Black"><FONT STYLE="font-size: 10pt"></FONT><B><I>[Intentionally
left blank]</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: 0in"><FONT STYLE="color: Black"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: 0in"><FONT STYLE="color: Black"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: 0in"><FONT STYLE="color: Black"><B><I>IN WITNESS WHEREOF</I></B><I>, the parties hereto have caused this Agreement to be duly executed as of the date first aforementioned.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: 0in"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><B>PROTALIX LTD.</B></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><B>ATME Comercio e Servi&ccedil;os Ltda.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 5%">By: </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; width: 37%">/s/ David Aviezer</TD>
    <TD STYLE="text-align: left; width: 15%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 5%">By: </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; width: 38%">/s/ Abraham Meizler</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Name: </TD>
    <TD STYLE="text-align: left">David Aviezer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Name:</TD>
    <TD STYLE="text-align: left"> Abraham Meizler</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Title: </TD>
    <TD STYLE="text-align: left">CEO</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Title: </TD>
    <TD STYLE="text-align: left">President/Partner</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Date: </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">June 18, 2013</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Date: </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">June 17, 2013</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: left; text-indent: 0in"><FONT STYLE="color: Black"><I>&nbsp;&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>Exhibit A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><U>Certification</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>Exhibit B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><U>Pfizer's
Anti-Bribery and Anti-Corruption Principles</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: Black">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>Exhibit C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><U>Training
Completion Form</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: Black">[***]</FONT></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>v376666_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="color: Black">Exhibit 10.2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="color: Black">Execution Copy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><FONT STYLE="color: Black"><B>[***]
Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to
a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="color: Black">June 18, 2013</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Pfizer Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">235 East 42nd Street</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">New York, NY 10017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">USA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 15%; font-size: 10pt"><FONT STYLE="color: Black">Attention:</FONT></td>
    <td style="width: 85%; font-size: 10pt"><FONT STYLE="color: Black">Diem Nguyen, General Manager, Biosimilars</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 18%; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td style="width: 9%; font-size: 10pt"><FONT STYLE="color: Black">Re:</FONT></td>
    <td style="width: 73%; font-size: 10pt"><FONT STYLE="color: Black">Amendment to the Exclusive License and Supply Agreement
    between <U>Pfizer Inc. and Protalix Ltd., dated as of November 30, 2009</U>.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Dear Ms. Nguyen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">We refer to
the Exclusive License and Supply Agreement between Pfizer Inc. (&quot;<U>Pfizer</U>&quot;) and Protalix Ltd. (&quot;<U>Protalix</U>&quot;),
dated as of November 30, 2009 (the &quot;<U>Agreement</U>&quot;). Capitalized terms used but not defined herein have the respective
meanings ascribed thereto in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">In connection
with the anticipated execution by Protalix and Funda&ccedil;&atilde;o Oswaldo Cruz (&quot;<U>Fiocruz</U>&quot;) of a Technology
Transfer and Supply Agreement (the &quot;<U>Technology Transfer Agreement</U>&quot;), substantially in the form attached hereto
as Exhibit A, providing for the transfer of certain technology and supply of certain product by Protalix to Fiocruz, Protalix
and Pfizer wish to amend the Exclusive License and Supply Agreement, pursuant to and as set forth in this letter (this &quot;<U>Letter
Amendment</U>&quot;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">For good and
valuable consideration the receipt and sufficiency of which Pfizer and Protalix hereby acknowledge, Pfizer and Protalix hereby
agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
acknowledges and agrees that following execution of this Letter Amendment, notwithstanding any provision of the Agreement to the
contrary, (i) Protalix shall have the exclusive rights to research, Develop or Commercialize the Drug Substance or Licensed Product
in Brazil and to Manufacture (including Fill/Finish) the Drug Substance or Licensed Product for sale in Brazil, and (ii) Protalix
shall have the right to enter into, and perform any of its obligations under, the Technology Transfer Agreement without obtaining
any additional consents from Pfizer with respect thereto or having Pfizer participate therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
consideration for the amendments to the Agreement set forth herein, including the right for Protalix to enter into and perform
the Technology Transfer Agreement as set forth in paragraph 1 of this Letter Amendment, Protalix shall pay Pfizer [***] twelve
million five hundred fifty thousand dollars ($12,550,000) of Protalix's Net Profits per calendar year, commencing on [***], arising
from the Commercialization of the Drug Substance and Licensed Product in Brazil, for so long as the Technology Transfer Agreement,
the Agreement and this subsequent Letter Amendment remain in effect, provided that for the period of [***], Protalix shall pay
Pfizer [***] eighteen million eight hundred twenty-five thousand dollars ($18,825,000) of Protalix&rsquo;s Net Profits arising
from the Commercialization of the Drug Substance and Licensed Product in Brazil. Payments pursuant to this paragraph 2 shall be
made on a quarterly basis (i.e., January 1 through March 31, April 1 through June 30, July 1 through September 30, October 1 through
December 31) by Protalix within sixty (60) days of the close of each such quarter and will not be refundable. [***]. For the avoidance
of doubt, (i) Protalix shall not be required pursuant to this Letter Amendment to pay to Pfizer any amount above twelve million
five hundred fifty thousand dollars ($12,550,000) for any year [***], and any additional Net Profits arising from the Commercialization
of the Drug Substance and Licensed Product in Brazil in any such year shall be retained by Protalix, and (ii) if Protalix's Net
Profit arising from the Commercialization of the Drug Substance and Licensed Product in Brazil is less than twelve million five
hundred fifty thousand dollars ($12,550,000) for any year [***], then Protalix shall only be required to pay Pfizer such lesser
amount for such year (and Protalix shall not be required to pay any amounts to make up for such shortfall in such year or in any
of the following years); provided that, in the event there is a net loss in Brazil, Pfizer shall have no liability to Protalix
for such net loss (or any portion thereof). Pfizer and Protalix shall review the operating plan for Brazil on an annual basis,
beginning with the first Joint Steering Committee meeting following approval of the Licensed Product for commercialization in
Brazil. Protalix shall have the sole authority and exclusive right to determine all operating plans and strategies for the Drug
Substance and Licensed Product in Brazil; provided that Protalix shall reasonably consider any comments on such plans and strategies
that Pfizer may communicate through the Steering Committee or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything in Section 14 of the Agreement to the contrary, Pfizer shall have the right to terminate the grant of rights to Protalix
for Brazil contained herein and in the relevant Sections of the Agreement (as amended hereby) if Protalix or its designee Fiocruz
fails to achieve approval of the Licensed Product in Brazil within [***] of the date of this Letter Amendment; <U>provided</U>
that, if at the end of such [***] period, Protalix or its designee Fiocruz is continuing to take good faith commercially reasonable
efforts to achieve such approval and such approval is reasonably likely to be obtained within [***] of the date of this Letter
Agreement, Pfizer shall not be entitled to terminate the rights granted hereunder. Pfizer also shall have the right to terminate
the grant of rights to Protalix for Brazil contained herein and in the relevant Sections of the Agreement (as amended hereby)
if the Technology Transfer Agreement between Protalix and Fiocruz terminates before completion of the contemplated technology
transfer. In order to terminate pursuant to this paragraph 3, Pfizer must give written notice within ten (10) days after Pfizer&rsquo;s
termination right pursuant to this paragraph first arises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the avoidance of doubt, as used in this Letter Amendment, the term &quot;Commercialize&quot; includes the activities referred
to in Section 1.12 of the Agreement with respect to both Drug Substance and Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
1.10 of the Agreement is hereby deleted in its entirety and replaced with the following: &quot;&quot;Capacity Cap&quot; means
the Current Capacity Cap or, after the Increased Capacity Goal is achieved, the Increased Capacity Cap.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
1.131 of the Agreement is hereby amended to add &quot;and Brazil&quot; immediately following the reference therein to &quot;Israel&quot;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
1.74 of the Agreement is hereby amended to [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
4.3(c)(v) of the Agreement is hereby amended to delete the reference therein to: &quot;, including plans and strategies for[***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
5.2(c) of the Agreement is hereby amended by deleting it in its entirety and inserting the following sentences: &quot;With respect
to the Drug Substance Manufacturing capacity of the current Protalix manufacturing facility (the &quot;<U>First Floor Facility</U>&quot;),
Pfizer and Protalix shall dedicate capacity to those patients then-currently receiving Licensed Product. Allocation of Drug Substance
shall be performed monthly and agreed to by the Supply Chain Committee, wherein such allocation assumes sufficient production
of Drug Substance in an amount equal to [***] equivalents per month. Allocation within and outside the Territory shall occur at
the final step of shared production between Pfizer and Protalix, which will depend on where the supply chain segregates in the
month of allocation; that is, allocation may describe any of Drug Substance or Licensed Product, depending on a given month (such
allocation priority, including as set forth herein, the &quot;<U>Allocation Priority</U>&quot;). Priority shall be given to [***].
Overages or excess inventory in a given month will be allocated to technical programs, inventory builds, and commercial sales
as recommended and agreed upon by the Supply Chain Committee. Subject to and in accordance with the terms of this Section 5 and
the Quality Agreement, Protalix shall supply all quantities of Drug Substance ordered by Pfizer under this Agreement for clinical
and commercial use in the Field in the Territory.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Agreement is hereby amended to replace the term &quot;Allocation Percentage&quot; with the term &quot;Allocation Priority&quot;,
for each instance such term is referenced in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
5.5(e) of the Agreement is hereby amended to add the following sentence at the end of such section: &quot;Notwithstanding anything
to the contrary in this Agreement [***].&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
5.6 of the Agreement is hereby amended to add the following new Section 5.6(f): &quot;Protalix shall provide to Pfizer monthly
forecasts of the quantities of Drug Substance and Licensed Products Protalix anticipates requiring for supply outside of the Territory
on a rolling four-calendar quarter basis, each of which shall update the prior projections (the &quot;<U>Protalix Projections</U>&quot;).
On the Effective Date, or such later date that allows for delivery outside of the Territory, Protalix shall issue to Pfizer an
initial forecast (the &quot;<U>Initial Protalix Forecast</U>&quot;) for the four (4) calendar quarters commencing with the first
quarter post approval of the Licensed Product for commercialization in Brazil, together with a firm purchase order for the first
quarter for Licensed Product for delivery outside the Territory. The quantities of Licensed Product deliveries specified for the
following quarter of the Initial Protalix Forecast shall be binding and the remaining two (2) quarters for the Initial Protalix
Forecast shall be non-binding. Thereafter, ninety (90) days prior to the first business day of each subsequent calendar quarter,
Protalix shall deliver to Pfizer a rolling four (4) calendar quarter forecast updating the prior forecast. The quantities of the
Licensed Product deliveries for the following one (1) quarter shall be binding and the remaining two (2) quarters of such forecast
shall be non-binding. Purchase orders for material outside the Territory will be issued in accordance with the Manufacturing Service
and Supply Agreement between Pfizer Inc. [***] and Protalix.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
5.6 of the Agreement is hereby amended to add the following new Section 5.6(g): &quot;The parties hereby agree to create and follow
a monthly inventory accountability process, commencing in the month the Technical Transfer Agreement is executed, to provide both
Protalix and Pfizer full transparency of global inventory positions of both Parties, movement of inventory between locations,
consumption of inventory for technical trials, stability sampling, clinical programs and Commercialization both outside and inside
the Territory, each as conducted by such Party.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
5.8 of the Agreement is hereby amended to add the following new Section 5.8(d): &quot;<U>Delivery Terms of Final Product or Packaged
Product for Brazil</U>. Notwithstanding anything in this Agreement to the contrary, any Licensed Product purchased by Protalix
from Pfizer for purposes of Commercialization in Brazil, whether in fully-packaged form or in naked vials, shall be supplied to
Protalix [***]. Such Licensed Product shall be shipped [***]. Protalix shall be responsible for [***] and for compliance with
all applicable Laws and Regulatory Approvals for the Licensed Product in Brazil.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the avoidance of doubt, until full completion of the Technology Transfer, as defined in the Technology Transfer Agreement, the
Quality Agreement (including the change control procedures outlined in the Quality Agreement) shall apply to all proposed changes
to the Drug Substance, Licensed Product manufacturing process and testing with respect to all territories including Brazil, with
the intention of ensuring one common Drug Substance and Licensed Product process across territories and fungible inventory, as
practical. Upon completion of the Technology Transfer, with respect to Brazil, Protalix shall reasonably consult with Pfizer regarding
any proposed changes to the Drug Substance process with respect to Brazil, with the intention of ensuring one common Drug Substance
process across territories and fungible inventory, such consultation as practical, but no less frequently than once per calendar
year. Protalix shall use Commercially Reasonable Efforts to accommodate the suggestions of the Supply Chain Committee relating
to any such proposed change, but shall retain sole discretion regarding whether any such proposed change shall be implemented
with respect to Brazil, including implementation of any change that would create segregated specifications and inventories for
Brazil.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
5.13 of the Agreement is hereby deleted in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this Letter Amendment and solely for purposes of establishing the accounting and procedure for payment in connection
with the approval and commercialization of the Licensed Product in Brazil, (i) Section 7 of the Agreement is hereby amended to
replace all references to &quot;Pfizer&quot; with &quot;Protalix,&quot; all references to &quot;Protalix&quot; with &quot;Pfizer&quot;,
and all references to &quot;the Territory&quot; with &quot;Brazil&quot;; (ii) Section 7.1(a)(iii) will not apply; (iii) Section
7.1(b) is amended to delete the phrase (as revised) &quot;Pfizer shall pay Pfizer&rsquo;s share of the Net Loss, if any, to Protalix&quot;;
and (iv) Sections 7.1(c) (i)-(iii), 7.1(d) and 7.6(a)-(c) will not apply. For all other purposes, Section 7 shall remain unchanged,
except as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this Letter Amendment and solely for purposes of establishing the accounting and procedure for payment in connection
with the approval and commercialization of the Licensed Product in Brazil, Section 7.1(c)(iv) is further amended to replace all
references to &ldquo;each party&rsquo;s share of Net Profit&rdquo; to &ldquo;Pfizer&rsquo;s share of Net Profit&rdquo;. All references
to &ldquo;Net Loss&rdquo; shall not apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
all purposes other than establishing the accounting and procedure for payment in connection with the approval and commercialization
of the Licensed Product in Brazil, Section 7.1(c)(i) of the Agreement is hereby amended to change the amount [***] to [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
7.5 of the Agreement is hereby amended to add the following immediately after the reference to &quot;calculation of Actual Price
to be verified.&quot;: &quot;Protalix shall, and shall cause its Affiliates and sublicensees to keep accurate books and records
setting forth all payments and other transfers made by Protalix or any of its Affiliates or sublicensees in connection with the
Technology Transfer Agreement.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this Letter Amendment and the approval and commercialization of the Licensed Product in Brazil:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Section 7.6 is hereby amended
by adding the following, new Section 7.6(d): &quot;<U>VAT</U>. It is understood and agreed between the Parties that any payments
made by Protalix to Pfizer under this Agreement are exclusive of any value added or similar tax (VAT), which shall be added thereon
as applicable.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Section 7.6 is hereby amended
by adding the following, new Section 7.6(e): &quot;<U>Tax Cooperation with respect to Brazil</U>. To the extent Protalix is required
to deduct and withhold taxes on any payments to Pfizer, Protalix shall pay the amounts of such taxes to the proper Governmental
Authority in a timely manner and promptly transmit to Pfizer an official tax certificate or other evidence of such withholding
sufficient to enable Pfizer to claim credits for such payments of taxes. Pfizer shall provide to Protalix any tax forms that may
be reasonably necessary in order for Protalix not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral
income tax treaty. Pfizer shall use reasonable efforts to provide any such tax forms to Protalix at least thirty (30) days prior
to the due date for any payments for which Pfizer desires that Protalix apply a reduced withholding rate. Each Party shall provide
the other with reasonable assistance to enable the recovery, as permitted by law, of withholding taxes, or similar obligations
resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax.
Each party further agrees to provide reasonable cooperation to the other party, at the other party&rsquo;s expense, in connection
with any official or unofficial tax audit or contest relating to payments made by Protalix to Pfizer under this Agreement.&quot;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Section 7.6 is hereby amended
by adding the following, new Section 7.6(f): &quot;<U>Withholding Taxes with respect to Licensed Product Commercialized in Brazil</U>.
If Protalix is required to make a payment to Pfizer subject to a deduction of tax or withholding tax, (i) if such withholding
or deduction obligation arises as a result of any failure on the part of Protalix to comply with applicable tax laws or filing
or record retention requirements, that has the effect of modifying the tax treatment of the parties hereto (a &quot;<U>Protalix
Withholding Tax Action</U>&quot;), then the sum payable by Protalix (in respect of which such deduction or withholding is required
to be made) shall be increased to the extent necessary to ensure that Pfizer receives a sum equal to the sum which it would have
received had no such Protalix Withholding Tax Action occurred, (ii) otherwise, the sum payable by Protalix (in respect of which
such deduction or withholding is required to be made) shall be made to Pfizer after deduction of the amount required to be so
deducted or withheld, which deducted or withheld amount shall be remitted to the applicable Governmental Authority in accordance
with applicable Law.&quot;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Notwithstanding anything to
the contrary herein, (i) if Pfizer&rsquo;s invoicing to Protalix for the compensation due under this Letter Amendment (or Protalix&rsquo;s
payment to Pfizer of any such amounts) or any other amounts required to be paid by Protalix to Pfizer in connection with the Letter
Amendment or&nbsp; Technology Transfer Agreement (including the purchase of Licensed Product) would trigger the application of
any value added or similar tax (VAT), Pfizer and Protalix shall negotiate in good faith to reach an agreement with respect thereto
(including with respect to any reasonable and legally permissible arrangements to minimize or mitigate such taxes), with the intent
of preserving the economics of the current arrangement between Protalix and Pfizer to the extent reasonably possible, and (ii)
Pfizer shall not change the route of shipments of Licensed Products nor change the seller of the Licensed Products to a non-U.S.
entity in any manner that would trigger the application of any such taxes for which Protalix is responsible hereunder absent agreement
by the parties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
9.4(b) of the Agreement is hereby amended to add the following immediately after the reference to &quot;Except as set forth in
<U>Sections</U> <U>9.3</U>, <U>9.4(a)</U> or <U>9.4(c)</U>&quot; therein:&quot;, or with respect to any activities or contemplated
activities of Protalix relating to the Brazilian market&quot;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
10.1(r) of the Agreement is hereby amended to (1) add the following immediately after the reference &ldquo;Protalix&rdquo;: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
10.1 of the Agreement is hereby amended by adding a new subsection (v): [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
10.1 of the Agreement is hereby amended by adding a new subsection (w): [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
10.1 of the Agreement is hereby amended by adding a new subsection (x): [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
10.1 of the Agreement is hereby amended by adding a new subsection (y): [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
10.1 of the Agreement is hereby amended by adding a new subsection (z): [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Appendix
10.1(t) is hereby deleted in its entirety and replaced with the attached new Appendix 10.1(t) hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit
I is hereby deleted in its entirety and replaced with attached new Exhibit I hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any other termination right Pfizer has in the Agreement, Pfizer may terminate this Letter Amendment (including the grant of rights
to Protalix for Brazil contained herein and in relevant Sections of the Agreement (as amended hereby)) if Protalix breaches 10.1(v),
(w), (y) or (z) of the Agreement (as amended hereby). In order to terminate pursuant to this paragraph with respect to any such
breach, Pfizer must give written notice of termination to Protalix specifying such breach within fifteen (15) Business Days after
Pfizer&rsquo;s termination right pursuant to this paragraph first arises with respect to such breach. Such termination shall be
effective [***] after such written notice of termination is given, provided that such termination shall not be effective if (i)
such breach has been cured within such [***] period, (ii) other than with respect to breach of Section 10.1 (z), within [***]
of receiving such notice, [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
14.2(a) is hereby amended to add the following: &ldquo;For the avoidance of doubt, and notwithstanding the foregoing, a breach
of sections 10.1(r), (t), or (u) shall be considered a material breach for purposes of this section 14.2(a).&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">33.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
14.2(b) of the Agreement is hereby amended to add the following immediately after the reference to &ldquo;applicable Laws are
being or have been made&rdquo;: &ldquo;or promised&rdquo; and to add the following immediately after the reference to &quot;to
Government Officials by Protalix&rdquo;: &ldquo;or any agent or subcontractor engaged in activities on behalf of Protalix&rdquo;
and to add the following immediately after the reference to &quot;Protalix's provision of services to any Third Party&quot;: &quot;or
in connection with the Technology Transfer Agreement.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">34.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this Letter Amendment and solely for the calculation of Net Profits and Net Loss in connection with the approval and
commercialization of the Licensed Product in Brazil, Exhibit E of the Agreement shall be amended to: [***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">35.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protalix
or its designee Fiocruz shall have the right to file a marketing authorization application in Brazil and seek Regulatory Approval
for such application for the Licensed Product. In support of, and solely for use in connection with, the prosecution of such marketing
authorization application and obtaining Regulatory Approvals for the Licensed Product in Brazil, Pfizer hereby grants to Protalix
and its designee Fiocruz an exclusive right of access/reference in Brazil to any data, including clinical dossiers controlled
by Pfizer or any of its Affiliates that relate to the Drug Substance or Licensed Product in Brazil, and Pfizer shall provide a
signed statement to this effect, if requested by Protalix or its designee Fiocruz to the extent required in Brazil or otherwise
provide appropriate notification of such right of Protalix or its designee Fiocruz to the applicable Regulatory Authority in Brazil.
Pfizer shall (and shall cause its relevant Affiliates to) provide such assistance (including, without limitation, executing any
documents or taking any actions reasonably requested by Protalix or its designee Fiocruz) as Protalix or its designee Fiocruz
reasonably requires to obtain Regulatory Approvals (including, without limitation, filing marketing authorization applications)
in its own name for the Licensed Product in Brazil (including cancellation of the corresponding marketing authorization held by
Pfizer or Pfizer&rsquo;s Affiliate in Brazil if required by applicable Law or by an applicable Regulatory Authority in order for
Protalix or its designee Fiocruz to obtain such Regulatory Approval). Protalix and its designee Fiocruz shall have the sole right
to apply for and secure exclusivity rights that may be available under the Law of Brazil, including any Regulatory Exclusivity.
Pfizer shall use Commercially Reasonable Efforts to cooperate with Protalix and its designee Fiocruz and to take such reasonable
actions to assist Protalix and its designee Fiocruz, in obtaining such exclusivity rights in Brazil, as Protalix or its designee
Fiocruz may reasonably request from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">36.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
any marketing authorization application for Licensed Product submitted by Protalix or its designee Fiocruz is approved by the
National Sanitary Surveillance Agency of the Brazilian Government (or any successor or replacement agency that has the authority
to grant the necessary Regulatory Approvals) (&quot;<U>Anvisa</U>&quot;) and any other required Regulatory Approval is obtained
by Protalix or its designee Fiocruz, and with respect to any Pfizer or Pfizer Affiliate Regulatory Approvals and regulatory filings
(including, without limitation, marketing authorizations) in Brazil and related data: (i) Pfizer shall provide Protalix notice
of all meetings, conferences, and discussions (including meeting of experts convened by any Regulatory Authority in Brazil concerning
any topic relevant to the Licensed Product) scheduled with any Regulatory Authority in Brazil concerning any regulatory matters
relating to the Licensed Product promptly after the scheduling of such meeting, conference, or discussion (to the extent Pfizer
is made aware of them in advance). Protalix or its designee Fiocruz shall be entitled to have one or more representatives present
at all such meetings unless prohibited by Applicable Law or unless reasonably impracticable under the circumstances. Protalix
or its designee Fiocruz and Pfizer shall use all reasonable efforts to agree in advance on the scheduling of such meetings, conferences
and discussions and on the objectives to be accomplished at such meetings, conferences and discussions and the agenda for the
meetings, conferences and discussions with such Regulatory Authority; <U>provided</U> that Pfizer shall have final decision-making
authority over such matters, (ii) Pfizer shall provide Protalix or its designee Fiocruz with copies, which copies may be in draft
form, of all material submissions to any Regulatory Authority in Brazil relating to the Licensed Product, to be provided sufficiently
in advance of such planned submission to such Regulatory Authority in order to allow Protalix or its designee Fiocruz to provide
comments regarding such submission, which comments shall be considered by Pfizer in good faith with respect to such submission;
<U>provided</U> that Pfizer shall have final decision-making authority over such matters; (iii) Pfizer and Protalix (or Protalix's
designee Fiocruz) shall provide to the other, as soon as reasonably practicable but in no event more than three (3) Business Days
after its receipt, copies of any material documents or other material correspondence received from any Regulatory Authority in
Brazil; and (iv) Pfizer shall reasonably cooperate with Protalix or its designee Fiocruz regarding (a) filings and communications
with any Regulatory Authority, (b) patient advocacy and support, and (c) pharmacovigilance activities, in each case, in Brazil
with respect to the Drug Substance or the Licensed Product; <U>provided</U> that Pfizer shall have final decision-making authority
over such matters. For purposes of clarification, Pfizer is not obligated to pursue additional indications and/or submissions
in Brazil other than required modifications due to those related to safety under the current, Pfizer marketing authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">37.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
Protalix or its designee Fiocruz has successfully received Regulatory Approval for the Licensed Product, Protalix shall have the
sole authority and exclusive right to determine all regulatory plans and strategies for the Licensed Product in Brazil; <U>provided
</U>that Protalix or its designee Fiocruz shall reasonably consider any comments on such plans and strategies that Pfizer may
communicate through the Steering Committee or otherwise. Protalix (or one or more of its designated Affiliates) or its designee
Fiocruz will own its marketing authorization application and be responsible for preparing, seeking, submitting and maintaining
all related regulatory commitments including filings and Regulatory Approvals for the Licensed Product in Brazil, including preparing
all reports necessary as part of a regulatory filing or Regulatory Approval. Until Protalix or its designee Fiocruz have successfully
received Regulatory Approval for the Licensed Product in Brazil (and the corresponding marketing authorization held by Pfizer
or its Affiliate in Brazil has been cancelled), Protalix and its designee Fiocruz shall have express and irrevocable authorization
and approval for Protalix and its designee Fiocruz to import the Licensed Product and Drug Substance into Brazil under Pfizer's
or its Affiliates&rsquo; Regulatory Approvals with Regulatory Authorities in Brazil, as allowed under applicable law, which express
authorization and approval is set forth in writing on Exhibit E to this Letter Amendment (and which will be attached as an appendix
to the Technology Transfer Agreement). Pfizer or Pfizer&rsquo;s relevant Affiliate shall issue one or more of such authorizations
as reasonably required by Protalix or its designee Fiocruz.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">38.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
and Protalix shall negotiate in good faith to execute a Transitional Services Agreement (&quot;<U>TSA</U>&quot;) for the Licensed
Product within [***] of the effective date of this Letter Amendment, under which Pfizer will provide reasonable transitional services
as needed, including those services set forth on Exhibit F. Within [***] of the execution of the Technology Transfer Agreement,
and annually thereafter, Protalix and Pfizer shall mutually agree upon a written list of any services in addition to those set
forth on Exhibit F to be performed under the TSA, which services are required to be performed under applicable Law. Protalix is
liable to Pfizer for all actual Pfizer costs associated with providing such transitional services, as defined in the TSA and agreed
upon by the Parties as set forth herein, from the date of the execution of this Letter Amendment, which costs shall not, in any
event, exceed the costs set forth on Exhibit F, unless otherwise expressly agreed in advance by Protalix and Pfizer in writing.
Notwithstanding the foregoing, Protalix shall be responsible for expenses relating to the engagement by Protalix of fully-dedicated
medical personnel in Brazil to support the Licensed Product, as needed. Pfizer&rsquo;s obligation to provide Immediate Transitional
Services (as identified in Exhibit F and to be defined in the TSA) shall terminate upon the earlier of (a) [***] following Protalix&rsquo;s
or its designee Fiocruz&rsquo;s receipt of Regulatory Approval of the Licensed Product in Brazil or (b) with respect to a specific
Immediate Transitional Service(s) or all Immediate Transitional Services, [***] upon written notice from Protalix. Pfizer agrees
to provide Continued Transitional Services (as identified in Exhibit F and to be defined in the TSA) for at least [***] following
the execution of the TSA, until mutually agreed upon by the parties; <U>provided</U> that Pfizer&rsquo;s obligation to provide
Continued Transitional Services shall [***] following the execution of the TSA. Protalix may terminate specific or all Continued
Transitional Services at any time [***] after the execution of the TSA, by providing [***] written notice to Pfizer. The TSA shall
be appended hereto upon execution of such TSA as Exhibit G. Pfizer and Protalix shall negotiate in good faith to execute a revised
pharmacovigilance agreement upon approval of Protalix or its designee Fiocruz&rsquo;s marketing authorization of the Licensed
Product in Brazil. Such written plan shall ensure that adverse event and other safety information is exchanged according to a
schedule that will permit each Party to comply with applicable Laws, including any local regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">39.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
acknowledges and agrees that, while this Letter Amendment is in effect, Protalix is permitted to sublicense to Fiocruz the Product
Marks pursuant to the Technology Transfer Agreement for use as they exist on the labeling and packaging of finished packaged product
at the time such finished packaged product is supplied to Fiocruz, and subject to the quality control provisions set forth in
the Technology Transfer Agreement, which shall be at least as protective as those set forth in Section 4.9(d) of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">40.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
acknowledges and agrees that, while this Letter Amendment is in effect, Protalix is permitted to sublicense to Fiocruz any drug
product manufacturing-related enhancements to or new presentations of Licensed Product developed or otherwise owned by Pfizer
or its Affiliates (&quot;<U>Pfizer Improvements</U>&quot;), pursuant to the Technology Transfer Agreement, subject to the provisions
set forth herein; <U>provided</U> that the Pfizer Improvements are used solely for the Licensed Product by Protalix and Fiocruz.
In the event Protalix chooses to sublicense such Pfizer Improvements to Fiocruz, Pfizer shall provide reasonable technical support
(&quot;<U>Technical Support</U>&quot;) to transfer technical manufacturing information (all data in Pfizer&rsquo;s possession
or control relating to process conditions, in-process controls, analytical methodology and formulation) relating solely to the
Pfizer Improvement in connection with such sublicense to Protalix.&nbsp; Such Technical Support shall consist only of the transfer
of the technical manufacturing information, as well as access to and availability of Pfizer personnel knowledgeable with respect
to the Pfizer Improvement, including consultation by phone.&nbsp; Technical Support for each Pfizer Improvement will be limited
to 40 person hours. &nbsp;Pfizer is not obligated to provide equipment, material, or additional people as part of Technical Support
related to any Pfizer Improvement. Should additional Technical Support be required beyond the 40 person hours to complete the
transfer of the technical manufacturing information (&quot;<U>Additional Technical Support</U>&quot;), Protalix shall provide
to Pfizer a written request prior to initiation of such Additional Technical Support. Pfizer and Protalix must mutually agree
on the Additional Technical Support.&nbsp; Protalix is liable to Pfizer for all actual Pfizer costs associated with Technical
Support and Additional Technical Support to Protalix, including out-of pocket expenses (including, without limitation, reasonable
travel, lodging and meal expenses) and costs of Pfizer's personnel, the latter to be charged to Protalix on a per-hour basis,
at an hourly rate of [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">41.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
15.1 of the Agreement is hereby amended by (i) deleting the period at the end of subsection (a)(iii) thereof and replacing it
with a semi-colon and (ii) adding the following new subsection (a)(iv): &quot;(A) any claim made by an ATME Person against Pfizer
for any consideration allegedly owed to an ATME Person in connection with Commercialization of the Licensed Product in Brazil,
or the Technology Transfer Agreement, or (B) any inquiry, investigation, litigation or proceeding by a governmental authority
or Third Party regarding any ATME Person in connection with the Commercialization of the Licensed Product in Brazil by Protalix,
the Technology Transfer Agreement, or any other actions of an ATME Person on behalf of Protalix.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">42.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pfizer
and Protalix shall reasonably cooperate in good faith to execute any additional amendments or agreements, and take any other actions
reasonably necessary to properly effectuate the terms and conditions of this Letter Amendment and to make the Agreement (and any
related agreements) consistent with this Letter Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">43.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Letter Amendment is not effective until the Technology Transfer Agreement in substantially the same form as of the date hereof
has been signed by Protalix and Fiocruz and is in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">44.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms and existence of this Letter Amendment (including the Exhibits hereto) and any negotiations between Pfizer and Protalix
relating hereto shall be deemed the Confidential Information of both Pfizer and Protalix and shall be subject to the provisions
of the Agreement relating to Confidential Information. Notwithstanding the foregoing, Pfizer acknowledges and agrees that Protalix
BioTherapeutics, Inc. shall have the right to describe (and, as reasonably necessary, include) this Letter Amendment in its U.S.
Securities and Exchange Commission (&quot;<U>SEC</U>&quot;) filings; <U>provided</U>, that Pfizer and Protalix agree to reasonably
cooperate with each other to prepare a redacted version of this Letter Amendment to be so filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">45.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Letter Amendment shall be governed by and construed in accordance with the substantive laws of the State of New York, without
regard to conflicts of law rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">46.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms of the Agreement shall remain in full force and effect, other than as set forth in this Letter Amendment or pursuant to
the terms of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">47.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
provision of an unsigned draft of this Letter Amendment shall not be deemed an offer by, or create any obligation on behalf of,
the party providing such draft. This Letter Amendment shall become effective only upon the execution of this Letter Amendment
by both Pfizer and Protalix. This Letter Amendment may be executed in any counterparts, each of which, when executed, shall be
deemed to be an original and which together shall constitute one and the same document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Please indicate your agreement with the foregoing
by countersigning a copy of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">PROTALIX LTD.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>David Aviezer, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and agreed this 18th day of June, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PFIZER INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid">/s/ Diem Nguyen</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Diem Nguyen</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: General Manager, Biosimilars</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><U>Exhibit A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B><U>Exhibit
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B><U>Exhibit
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B><U>Exhibit
E</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">English-Language Version:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="color: Black"><B>To
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="color: Black"><B>Ag&ecirc;ncia
Nacional de Vigil&acirc;ncia Sanit&aacute;ria (ANVISA/MS)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black"><B>DECLARATION
OF IMPORT AUTHORIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black">BY
LEGAL ENTITY WHICH DOES NOT HOLD REGULARIZATION BEFORE ANVISA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black">(Legal
Basis: RDC N&ordm; 81/08 &ndash; CHAPTER VII &ndash; ITEM 7B)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>REFERENCE: Import License/IL
n&ordm;</B> _____/_________________-________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">The company Laborat&oacute;rios
PFIZER Ltda., a limited liability company organized and existing under Brazilian law, with its principal place of business at
Avenida Presidente Tancredo De Almeida Neves, 1555, in the City of Guarulhos, State of S&atilde;o Paulo, enrolled in the CNPJ
under No. 46.070.868/0001-69, duly regularized before ANVISA &ndash; Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria
under N&ordm; 1.00216-6, represented by its Legal Representative and Legal Responsible and by its Technical Responsible Jos&eacute;
Claudio Bumerad, CPF n&ordm; 057.594.678-40, CRF-SP n&ordm; 43.746, undersigned, grants authorization to import, directly from
its supplier Protalix Ltd., the product indicated below, and which holds the regularization document before Minist&eacute;rio
da Sa&uacute;de/Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Authorized
    Importer:</B></FONT></td>
    <td style="width: 71%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Fiocruz
                                         &ndash; Instituto de Tecnologia em Imunobiol&oacute;gicos, Bio-Manguinhos</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">CNPJ n&ordm; 33.781.055/0015-30</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 49%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><B>Description
    of the health product:</B></FONT></td>
    <td style="width: 31%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><B>Registration
    n&ordm; at ANVISA</B></FONT></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><B>Term</B></FONT></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><U>Product:
                                         Uplyso* (alfataliglicerase)</U></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><U>Therapeutic class: Enzyme
        for replacement</U></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">(*) Mark applied.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><U>1.0216.0229.001-3</U></FONT></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><U>24
    months</U></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">In compliance
with the determination of RDC n&ordm; 81/08, we authorize exclusively the importer mentioned above to use the abovementioned register,
and, therefore, its transfer is prohibited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">We expressly
assume the commitment to and compliance with the standards and procedures of health legislation, as well as recognize the penalties
to which we may be subject, pursuant to Law No. 6437, August 1977.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Legal Representative:
___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Legal Responsible:___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Technical Responsible:
Jos&eacute; Claudio Bumerad &ndash; CPF n&ordm; 057.594.678-40/ CRF-SP n&ordm; 43.746</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Valid for two
years from issuance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Rio de Janeiro,
__________________________.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Legal Representative </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Legal Responsible</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">_____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">Technical Responsible</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><U>Portuguese-Language Version</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="color: Black"><B>&Agrave;
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="color: Black"><B>Ag&ecirc;ncia
de Vigil&acirc;ncia Sanit&aacute;ria (ANVISA/MS)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black"><B>DECLARA&Ccedil;&Atilde;O
DE AUTORIZA&Ccedil;&Atilde;O DE IMPORTA&Ccedil;&Atilde;O</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black">POR
PESSOA JUR&Iacute;DICA N&Atilde;O DETENTORA DA REGULARIZA&Ccedil;&Atilde;O JUNTO &Agrave; ANVISA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black">(Base
legal: RDC N&ordm; 81/08 &ndash; CAP&Iacute;TULO VII &ndash; ITEM 7B)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: white"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>REFERENTE: Licen&ccedil;a de
Importa&ccedil;&atilde;o/LI n&ordm;</B> _____/_________________-________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">A empresa Laborat&oacute;rios PFIZER
Ltda., com uma sociedade limitada constitu&iacute;da e existente de acordo com as leis do Brasil, com sua sede social na Av. Presidente
Tancredo de Almeida Neves, 1555 na Cidade de Guarulhos, Estado de S&atilde;o Paulo, inscrita no CNPJ sob n&ordm;. 46.070.868/0001-69,
devidamente regularizada na ANVISA &ndash; Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria sob o N&ordm; <U>1.00216-6</U>,
representada pelo seu Representante Legal ______________________________, Respons&aacute;vel Legal ______________________________,
e por seu Respons&aacute;vel T&eacute;cnico Jos&eacute; Claudio Bumerad, CPF n&ordm; 057.594.678-40, CRF-SP n&ordm; 43.746, abaixo
assinados, concede Autoriza&ccedil;&atilde;o para Importa&ccedil;&atilde;o, diretamente de sua fornecedora Protalix Ltd, do Produto
abaixo indicado, do qual somos detentores do(s) documento(s) de regulariza&ccedil;&atilde;o perante o Minist&eacute;rio da Sa&uacute;de/Ag&ecirc;ncia
Nacional de Vigil&acirc;ncia Sanit&aacute;ria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="color: Black"><B>Importador
    Autorizado:</B></FONT></td>
    <td style="width: 71%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Fiocruz
                                         &ndash; Instituto de Tecnologia em Imunobiol&oacute;gicos, Bio-Manguinhos</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">CNPJ n&ordm; 33.781.055/0015-30</FONT></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 49%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><B>Descri&ccedil;&atilde;o
    do produto para sa&uacute;de:</B></FONT></td>
    <td style="width: 31%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><B>N&ordm;
    de Registro ANVISA</B></FONT></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><B>Validade</B></FONT></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><U>Produto:
                                         Uplyso* (alfataliglicerase)</U></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><U>Classe terap&ecirc;utica:
        Enzima para reposi&ccedil;&atilde;o</U></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">(*) Marca depositada.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><U>1.0216.0229.001-3</U></FONT></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="color: Black"><U>24
    meses</U></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Cumprindo a
determina&ccedil;&atilde;o da RDC n&ordm; 81/08, autorizamos &uacute;nica e exclusivamente o importador acima citado a utilizar
e registro supracitado, sendo, portanto, verdade o repasse do mesmo.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Assumimos expressamente
o compromisso de observ&acirc;ncia e cumprimento das normas e procedimentos pela legisla&ccedil;&atilde;o sanit&aacute;ria, bem
como de ci&ecirc;ncia das penalidades as quais ficaremos sujeitos, nos termos da lei n&ordm; 6.437, de agosto de 1977.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Representante
Legal: ___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Respons&aacute;vel
Legal: ___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Respons&aacute;vel
T&eacute;cnico: Jos&eacute; Claudio Bumerad &ndash; CPF n&ordm; 057.594.678-40/ CRF-SP n&ordm; 43.746</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">V&aacute;lido
por 2 anos da emiss&atilde;o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Rio de Janeiro,
______ de _______________ de _________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">_____________________________
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;___________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">Representante
Legal do Respons&aacute;vel Legal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representante Legal</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">___________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="color: Black">Respons&aacute;vel
T&eacute;cnico</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">Exhibit F</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B><U>SERVICES
TO BE INCLUDED IN TRANSITIONAL SERVICES AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">[***]</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><U>Exhibit G</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B><U>TRANSITIONAL
SERVICES AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT><FONT STYLE="color: Black">[***]</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B><U>Exhibit
I</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Pursuant to Section 10(u) of the
Exclusive License and Supply Agreement between <U>Pfizer Inc. (&ldquo;Pfizer&rdquo;) and Protalix Ltd. (&ldquo;Protalix&rdquo;)
, dated as of November 30, 2009</U> and the amendment thereto dated [x],</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">I hereby certify:</FONT><BR>
<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">PROTALIX LTD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 10%"><FONT STYLE="color: Black">NAME:&nbsp;&nbsp;</FONT></td>
    <td style="width: 35%; border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td style="width: 55%"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="color: Black">TITLE:&nbsp;&nbsp;</FONT></td>
    <td style="border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="color: Black">DATE:&nbsp;&nbsp;</FONT></td>
    <td style="border-bottom: Black 1pt solid"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="color: Black">Appendix
10.1(t)&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 85%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1.5pt solid; padding-top: 6pt; padding-bottom: 6pt"><FONT STYLE="font-size: 10pt; color: Black"><B>International
    Anti-Bribery and Anti-Corruption Principles</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Pfizer has
a longstanding corporate policy that prohibits colleagues or anyone acting on our behalf from providing any payment or benefit
to any person or entity in order to improperly influence a government official or to gain an unfair business advantage. Pfizer
is committed to performing with integrity, and acting ethically and legally in accordance with all applicable laws and regulations,
including, but not limited to, anti-bribery and anti-corruption laws. We expect the same commitment from the consultants, agents,
representatives or other companies and individuals acting on our behalf (&ldquo;Business Associates&rdquo;), as well as those
acting on behalf of Business Associates, in connection with work for Pfizer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B><I>Bribery of Government Officials</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Most countries have laws that forbid
making, offering or promising any payment or anything of value (directly or indirectly) to a government official when the payment
is intended to influence an official act or decision to award or retain business. Under Pfizer&rsquo;s policies, &ldquo;government
official&rdquo; is broadly interpreted and includes: (i) any elected or appointed government official (<I>e.g.</I>, a member of
a ministry of health); (ii) any employee or person acting for or on behalf of a government official, agency, or enterprise performing
a governmental function; (iii) any political party, candidate for public office, officer, employee, or person acting for or on
behalf of a political party or candidate for public office; or (iv) an employee or person acting for or on behalf of a public
international organization (<I>e.g.</I>, the United Nations). &ldquo;Government&rdquo; is meant to include all levels and subdivisions
of governments (<I>i.e.</I>, local, regional, or national and administrative, legislative, or executive). Because this definition
of &ldquo;government official&rdquo; is so broad, it is likely that Business Associates will interact with a government official
in the ordinary course of their business on behalf of Pfizer. For example, doctors employed by government-owned hospitals would
be considered &ldquo;government officials&rdquo; under Pfizer&rsquo;s policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">The U.S. Foreign Corrupt Practices
Act of 1977 (the &ldquo;FCPA&rdquo;) prohibits making, promising, or authorizing the making of a payment or providing anything
of value to a non-U.S. government official to improperly or corruptly induce that official to make any governmental act or decision
to assist a company in obtaining or retaining business, or to otherwise obtain an improper advantage. The FCPA also prohibits
a company or person from using another company or individual to engage in any of the foregoing activities. As a U.S. company,
Pfizer must comply with the FCPA and could be held liable as a result of acts committed anywhere in the world by a Business Associate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">Appendix
10.1(t)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: Black"><B>Anti-Bribery and Anti-Corruption Principles Governing Interactions with Governments and Government Officials</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Business Associates must communicate
and abide by the following principles with regard to their interactions with governments and government officials:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Business
                                         Associates, and those acting on their behalf in connection with work for Pfizer, may
                                         not directly or indirectly make, promise, or authorize the making of a corrupt payment
                                         or provide anything of value to any government official to induce that government official
                                         to make any governmental act or decision to help Pfizer obtain or retain business. Business
                                         Associates, and those acting on their behalf in connection with work for Pfizer, may
                                         never make a payment to or offer a government official any item or benefit, regardless
                                         of value, as an improper inducement for such government official to approve, reimburse,
                                         prescribe, or purchase a Pfizer product, to influence the outcome of a clinical trial,
                                         or otherwise improperly to benefit Pfizer&rsquo;s business activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Business
                                         Associates, and those acting on their behalf in connection with work for Pfizer, need
                                         to understand whether local laws, regulations, or operating procedures (including requirements
                                         imposed by government entities such as government-owned hospitals or research institutions)
                                         impose any limits, restrictions, or disclosure requirements on compensation, financial
                                         support, donations, or gifts that may be provided to government officials. Business Associates,
                                         and those acting on their behalf in connection with work for Pfizer, must take into account
                                         and comply with any applicable restrictions in conducting their Pfizer-related activities.
                                         If a Business Associate is uncertain as to the meaning or applicability of any identified
                                         limits, restrictions, or disclosure requirements with respect to interactions with government
                                         officials, that Business Associate should consult with his or her primary Pfizer contact
                                         before undertaking their activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Business
                                         Associates, and those acting on their behalf in connection with work for Pfizer, are
                                         not permitted to offer facilitation payments.&nbsp; A &ldquo;facilitation payment&rdquo;
                                         is a nominal, unofficial payment to a government official for the purpose of securing
                                         or expediting the performance of a routine, non-discretionary governmental action.&nbsp;
                                         Examples of facilitation payments include payments to expedite the processing of licenses,
                                         permits or visas for which all paperwork is in order.&nbsp; In the event that a Business
                                         Associate, or someone acting on their behalf in connection with work for Pfizer, receives
                                         or becomes aware of a request or demand for a facilitation payment or bribe in connection
                                         with work for Pfizer, the Business Associate shall report such request or demand promptly
                                         to his or her primary Pfizer contact before taking any further action.&nbsp;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">Appendix
10.1(t)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="color: Black"><B><I>Commercial Bribery</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Bribery and
corruption can also occur in non-government, business to business relationships. Most countries have laws which prohibit offering,
promising, giving, requesting, receiving, accepting, or agreeing to accept money or anything of value in exchange for an improper
business advantage. Examples of prohibited conduct could include, but are not limited to, the provision of inappropriate gifts
or hospitality, kickbacks, or investment opportunities offered to improperly induce the purchase of goods or services. Pfizer
colleagues are not permitted to offer, give, solicit or accept bribes, and we expect our Business Associates, and those acting
on their behalf in connection with work for Pfizer, to abide by the same principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Anti-Bribery and Anti-Corruption
Principles Governing Interactions with Private Parties and Pfizer Colleagues</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Business Associates must communicate
and abide by the following principles with regard to their interactions with private parties and Pfizer colleagues:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Business
                                         Associates, and those acting on their behalf in connection with work for Pfizer, may
                                         not directly or indirectly make, promise, or authorize the making of a corrupt payment
                                         or provide anything of value to any person to induce that person to provide an unlawful
                                         business advantage for Pfizer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Business
                                         Associates, and those acting on their behalf in connection with work for Pfizer, may
                                         not directly or indirectly, solicit, agree to accept, or receive a payment or anything
                                         of value as an improper inducement in connection with their business activities performed
                                         for Pfizer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="color: Black"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; color: Black">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">Pfizer
                                         colleagues are not permitted to receive gifts, services, perks, entertainment, or other
                                         items of more than token or nominal monetary value from Business Associates, and those
                                         acting on their behalf in connection with work for Pfizer. Moreover, gifts of nominal
                                         value are only permitted if they are received on an infrequent basis and only at appropriate
                                         occasions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="color: Black"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 23; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>v376666_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit
10.3</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]
Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to
a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">TECHNOLOGY
TRANSFER AND SUPPLY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT (this &ldquo;AGREEMENT&rdquo;) is made as of _________ __, 2013 by and between <B>PROTALIX
LTD.</B>, a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park,
P.O.B 455, Carmiel 20100, Israel (&ldquo;PROTALIX&rdquo;), and <B>FUNDA&Ccedil;&Atilde;O OSWALDO CRUZ</B>, an agency of the Brazilian
Ministry of Health organized under the laws of Brazil, including its manufacturing unit &ldquo;BIO-MANGUINHOS&rdquo;, with registered
offices at Avenida Brasil, 4365, Manguinhos, Rio de Janeiro, RJ, Cep 21045-900, Brazil, CGC NI 33.781.055/0001-35, represented
by its President, Dr. PAULO ERNANI GADELHA VIEIRA, hereinafter collectively referred to as &quot;FIOCRUZ&quot;. For the purposes
of this AGREEMENT, PROTALIX and FIOCRUZ each are referred to as a &ldquo;PARTY&rdquo; and collectively as the &ldquo;PARTIES&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS,
</B>PROTALIX owns or otherwise controls certain patents, patent applications, technology, know-how and scientific and technical
information relating to an enzyme replacement therapy for the treatment of Gaucher Disease; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS,
</B>FIOCRUZ is a foundation affiliated with the Ministry of Health of the Brazilian Government and is a manufacturer of vaccines
predominantly for the Brazil National Program of Immunization (&ldquo;NPI&rdquo;) which<FONT STYLE="font-size: 10pt"> </FONT>owns,
controls and operates <FONT STYLE="text-transform: uppercase">Bio-Manguinhos</FONT>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHEREAS,
</B>FIOCRUZ desires to obtain from PROTALIX, and PROTALIX desires to provide to FIOCRUZ, (i) the necessary rights and technical
assistance and information, in various stages, to enable FIOCRUZ to MANUFACTURE and supply the <FONT STYLE="text-transform: uppercase">Product
</FONT>in the <FONT STYLE="text-transform: uppercase">Territory</FONT> (as defined below), and (ii) the SUPPLIED MATERIALS (as
defined below), pursuant to and in accordance with the terms of this AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE,</B> in consideration of the premises, and the mutual covenants and agreements set forth herein, the PARTIES hereby
agree as follows:</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
1. &#9;DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         purposes of this AGREEMENT, the following terms shall have the meaning ascribed to such
                                         term herein:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;ADVISORY
COMMITTEE&rdquo; shall mean the committee organized and acting pursuant to Article&nbsp;5.5 which shall have the overall responsibility
for advising on and monitoring the implementation of the TECHNOLOGY TRANSFER up to and including the first successful production
of the FINAL PRODUCT for commercial sale, pursuant to and in accordance with the terms and conditions of this AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;AFFILIATE&rdquo;
means any entity directly or indirectly controlled by, controlling, or under common control with, a PARTY to this AGREEMENT, but
only for so long as such control shall continue. For purposes of this definition, Article 12.3(d) and Article 20.6 only, &ldquo;control&rdquo;
(including, with correlative meanings, &ldquo;controlled by&rdquo;, &ldquo;controlling&rdquo; and &ldquo;under common control
with&rdquo;) means (a) possession, direct or indirect, of the power to direct or cause direction of the management or policies
of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise), or (b) beneficial
ownership of at least 50% of the voting securities or other ownership interest (whether directly or pursuant to any option, warrant
or other similar arrangement) or other comparable equity interests of an entity, it being understood and agreed that for purposes
of clause (a), neither ownership of voting securities or other ownership interests of an entity nor membership or representation
on (if less than half of the members of) an entity&rsquo;s board of directors shall, by themselves, be presumed to constitute
the power to direct or cause direction of the management or policies of such entity. With respect to the grant of license or other
rights by PROTALIX hereunder, &ldquo;AFFILIATE&rdquo; shall exclude any <FONT STYLE="text-transform: uppercase">Third PARTY</FONT>
that becomes an <FONT STYLE="text-transform: uppercase">Affiliate</FONT> due to such <FONT STYLE="text-transform: uppercase">Third
PARTY</FONT>&rsquo;s acquisition of PROTALIX or any other <FONT STYLE="text-transform: uppercase">Person</FONT> with an ownership
interest in PROTALIX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;ANVISA&rdquo;
means the National Sanitary Surveillance Agency of the Brazilian Government (or any successor or replacement agency that has the
authority to grant the necessary GOVERNMENTAL APPROVALS).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;BULK
PRODUCT&rdquo; means the DRUG SUBSTANCE component of a PRODUCT in liquid or frozen form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;BUSINESS
DAY&rdquo; means a day other than a Saturday, Sunday, or bank or other public holiday in Brazil and/or Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&quot;CELL
BANK&quot; means a cell bank of vials with carrot cells producing <I>taliglucerase alfa</I> with information on its characterization
and release, as well as information on its origin, plasmid, nature and sequence of the gene used, that is able to provide a sufficient
number of vials for the production of the PRODUCT for a period time not less than 20 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;CERTIFICATE
OF ACCEPTANCE&rdquo; means a certificate in the form attached hereto as Appendix III, executed by PROTALIX and FIOCRUZ to confirm
the COMPLETION of each STAGE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;CHALLENGE&rdquo;
shall have the meaning ascribed to such term in Article 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;COMMERCIALIZATION&rdquo;
means the marketing, distribution, offering for sale, selling and importation of the PRODUCTS. When used as a verb, &ldquo;<U>Commercialize</U>&rdquo;
means to engage in Commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;COMPOUND&rdquo;
means (a) a plant cell expressed recombinant Glucocerebrosidase enzyme having the sequence set forth in <U>Exhibit A</U> to this
AGREEMENT, and (b) any analogs, derivatives and variants thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;COMPLETION&rdquo;
means the completion of a STAGE after achieving the COMPLETION REQUIREMENTS of such STAGE, as confirmed by the ADVISORY COMMITTEE
and the execution of the CERTIFICATE OF ACCEPTANCE by FIOCRUZ and PROTALIX, evidencing such completion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;COMPLETION
REQUIREMENTS&rdquo; mean, in relation to each STAGE and the TECHNOLOGY TRANSFER as a whole, the corresponding requirements established
in Article 5.2 and Appendix II for advancement to the next STAGE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;CONFIDENTIAL
INFORMATION&rdquo; shall have the meaning ascribed to such term in Article 11.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;CONTROL&rdquo;
or &ldquo;CONTROLLED&rdquo; means, with respect to any compound, material, <FONT STYLE="text-transform: uppercase">Technology</FONT>,
or intellectual property right, that a PARTY owns or has a license to use, commercialize, manufacture, market, distribute or sell,
and has the ability to grant to the other PARTY access and/or a license or a sublicense (as applicable under this AGREEMENT) to
such compound, material, <FONT STYLE="text-transform: uppercase">Technology</FONT>, or intellectual property right as provided
for herein without violating (a) the terms of any agreement or other arrangements with any <FONT STYLE="text-transform: uppercase">Third
PARTY</FONT> existing before or after the <FONT STYLE="text-transform: uppercase">EXECUTION Date</FONT> or (b) any LAW applicable
to such license or sublicense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;DISCLOSING
PARTY&rdquo; shall have the meaning ascribed to such term in Article 11.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;DRUG
SUBSTANCE&rdquo; means the <FONT STYLE="text-transform: uppercase">Compound</FONT> component of a pharmaceutical drug product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;EFFECTIVE
DATE&rdquo; shall have the meaning ascribed to such term in Article 3.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;EXECUTION
DATE&rdquo; means the date on which the last PARTY signs this AGREEMENT so as to make it signed by each of the PARTIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;FACILITIES&rdquo;
means the facilities of FIOCRUZ in BIO-MANGUINHOS related to the PRODUCT, including the primary production facility, the secondary
facilities and the quality control laboratories to be adequated or built and validated, maintained and operated by FIOCRUZ, solely,
for each <FONT STYLE="text-transform: uppercase">STAGE</FONT>, after receipt by FIOCRUZ of written approval of PROTALIX following
a full inspection of such facility to ensure such facility is acceptable for the purpose contemplated hereunder for such <FONT STYLE="text-transform: uppercase">STAGE</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;FIELD&rdquo;
means enzyme replacement therapy for the treatment of Gaucher Disease for the approved indications, dosage forms and strengths.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;FILL/FINISH&rdquo;
means (a) formulating the <FONT STYLE="text-transform: uppercase">Product</FONT> using <FONT STYLE="text-transform: uppercase">Drug
Substance</FONT> and required excipients, (b) filling the <FONT STYLE="text-transform: uppercase">Product</FONT> into vials, (c)
lyophilization of the <FONT STYLE="text-transform: uppercase">Drug Substance</FONT> for incorporation into the <FONT STYLE="text-transform: uppercase">Product</FONT>,
and (d) testing, including ongoing stability testing, and release of the <FONT STYLE="text-transform: uppercase"> Product</FONT>.
For the avoidance of doubt, <FONT STYLE="text-transform: uppercase">Fill/Finish</FONT> shall not include any activities included
in the definition of <FONT STYLE="text-transform: uppercase">Labeling and Packaging</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;FINAL
PRODUCT&rdquo; shall mean PRODUCT produced entirely by FIOCRUZ at the FACILITIES from the CELL BANK.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;FINISHED
PACKAGED PRODUCT&rdquo; means the PRODUCT that has undergone FILL/FINISH and LABELING AND PACKAGING to be supplied by PROTALIX
to FIOCRUZ until the registration of PRODUCT 2 by ANVISA in PROTALIX's or FIOCRUZ's name.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;FORCE
MAJEURE EVENT&rdquo; shall have the meaning ascribed to such term in Article 20.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;FORECAST&rdquo;
shall have the meaning ascribed to such term in Article 6.2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;GOOD
MANUFACTURING PRACTICES&rdquo; or &ldquo;<U>GMP</U>&rdquo; means all applicable Good Manufacturing Practices including, (a) the
applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality
standards appropriate for their intended use, as defined in ANVISA RDC 17 and RDC 66-07 laying down the principals and guidelines
of good manufacturing practice, (b) WHO GMP guidelines, and (c) the equivalent <FONT STYLE="text-transform: uppercase">Laws</FONT>
in any relevant country or other sovereign entity in which PRODUCT is marketed, manufactured, distributed, offered for sale, sold
or imported by or on behalf of FIOCRUZ, each as may be amended and applicable from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;GOVERNMENTAL
AUTHORITY&rdquo; means any court, agency, department, authority or other instrumentality of any national, state, country, city
or other political subdivision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;GOVERNMENTAL
APPROVAL&rdquo; means the authorizations and approvals (including regulatory and pricing approvals) of a <FONT STYLE="text-transform: uppercase">Governmental
Authority</FONT> that are necessary for the TECHNOLOGY TRANSFER, or the COMMERCIALIZATION, MANUFACTURE, use or exploitation of
the SUPPLIED MATERIALS, COMPOUND, DRUG SUBSTANCE or PRODUCTS in the TERRITORY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;GOVERNMENT
OFFICIAL&rdquo; shall have the meaning ascribed to such term in Article 17.2(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;IMPROVEMENT&rdquo;
means any enhancements to the <FONT STYLE="text-transform: uppercase">Protalix Technology</FONT> enabling superior productivity,
therapeutic activity, feasibility, profitability and/or improvement of the production processes included in the <FONT STYLE="text-transform: uppercase">Protalix
Technology</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;INDEMNIFIED
PARTY&rdquo; shall have the meaning ascribed to such term in Article 16.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;INDEMNIFYING
PARTY&rdquo; shall have the meaning ascribed to such term in Article 16.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&quot;INITIAL
FORECAST&quot; shall have the meaning ascribed to such term in Article 6.2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;INPI&rdquo;
means the Brazilian National Institute of Industrial Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;LABELING
AND PACKAGING&rdquo; means the final product labeling and packaging of the <FONT STYLE="text-transform: uppercase">Product</FONT>
as intended for commercial distribution and sale of such PRODUCT to THIRD PARTIES in the TERRITORY, including insertion of materials
such as patient inserts, patient medication guides, professional inserts and any other written, printed or graphic materials accompanying
the <FONT STYLE="text-transform: uppercase">Product</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;LAWS&rdquo;
means all laws, statutes, rules, regulations, codes, administrative or judicial orders, judgments, decrees, injunctions and/or
ordinances of any <FONT STYLE="text-transform: uppercase">Governmental Authority</FONT>, and other legal requirements of any kind,
whether currently in existence or hereafter promulgated, enacted, adopted or amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;LOSSES&rdquo;
means any and all damages (including all incidental, consequential, statutory and treble damages), awards, deficiencies, settlement
amounts, defaults, assessments, fines, dues, penalties, costs, fees (including reasonable attorney fees), liabilities, obligations,
taxes, liens, losses and expenses, including those incurred by or awarded to <FONT STYLE="text-transform: uppercase">Third PARTIES
</FONT>with respect to a <FONT STYLE="text-transform: uppercase">Third PARTY Claim</FONT> by reason of any judgment, order, decree,
stipulation or injunction, or any settlement entered into, and all other documented costs and expenses incurred in investigating,
preparing or defending any <FONT STYLE="text-transform: uppercase">Third PARTY</FONT> <FONT STYLE="text-transform: uppercase">Claim
</FONT>litigation or proceeding, commenced or threatened, or in complying with any judgments, orders, decrees, stipulations and
injunctions (including court costs, interest and reasonable fees of attorneys, accountants and other experts).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;MANUFACTURE&rdquo;
or &ldquo;MANUFACTURING&rdquo; means all activities related to the manufacturing of the COMPOUND, <FONT STYLE="text-transform: uppercase">Drug
Substance</FONT> or <FONT STYLE="text-transform: uppercase">ProductS</FONT>, and/or any ingredient thereof, including manufacturing
for commercial sale, in-process and finished product testing, <FONT STYLE="text-transform: uppercase">Fill/Finish</FONT>, <FONT STYLE="text-transform: uppercase">Labeling
and Packaging</FONT>, release of product, quality assurance activities related to manufacturing and release of product and ongoing
stability tests and regulatory activities related to any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;NAKED
VIALS&rdquo; means unlabelled vials [***] of PRODUCT that have undergone FILL/FINISH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;NET
SALES&rdquo; means the gross receipts of all sales of FINAL PRODUCT by or on behalf of FIOCRUZ, less any sales taxes actually
incurred and paid by FIOCRUZ and reasonable out-of-pocket costs of transportation insurance and transportation for such FINAL
PRODUCT actually incurred and paid by FIOCRUZ. A Royalty Payment obligation shall accrue upon the receipt of payment for such
FINAL<FONT STYLE="text-transform: uppercase"> Product</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&quot;OCS&quot;
means the Office of the Chief Scientist of the Israeli Ministry of Trade, Industry and Labor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;ORAL
FORMULATION&rdquo; means an oral formulation of a drug product for the treatment of Gaucher Disease which contains any <FONT STYLE="text-transform: uppercase">Compound
</FONT>as the active pharmaceutical ingredient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PATENT
APPLICATION&rdquo; means any application for a <FONT STYLE="text-transform: uppercase">Patent</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PATENT
RIGHTS&rdquo; means <FONT STYLE="text-transform: uppercase">Patents</FONT> and <FONT STYLE="text-transform: uppercase">Patent
Applications</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PATENTS&rdquo;
means issued patents, whether domestic or foreign, including issued patents granted with respect to all continuations, continuations-in-part,
divisions, provisionals and renewals, patents of addition, supplementary protection certificates, registration or confirmation
patents and all reissues, re-examination and extensions thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PERMITS&rdquo;
means all approvals, authorizations, stamps, registrations, clearances, consents, licenses, permits, certificates, or regulatory
approvals of any <FONT STYLE="text-transform: uppercase">Governmental Authority</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PERSON&rdquo;
means an individual, corporation, partnership, company, joint venture, unincorporated organization, limited liability company
or partnership, sole proprietorship, association, bank, trust company or trust, whether or not legal entities, or any <FONT STYLE="text-transform: uppercase">Governmental
Authority</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PHARMACOVIGILANCE
AGREEMENT&rdquo; means the PHARMACOVIGILANCE Agreement(s) set forth as Appendix VIII, between PROTALIX and FIOCRUZ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PRICE&rdquo;
means the price to be charged by PROTALIX for SUPPLIED MATERIAL manufactured and supplied hereunder as delivered to FIOCRUZ, and
which price is set forth in Article 6, herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PRODUCT&rdquo;
means the pharmaceutical product <I>plant cell expressed recombinant Glucocerebrosidase</I> in any finished dosage form of a drug
product that contains <FONT STYLE="text-transform: uppercase">Drug Substance</FONT> (excluding any ORAL FORMULATION), which is
the object of the TECHNOLOGY TRANSFER under this AGREEMENT, and, as used in this AGREEMENT, refers to any one of PRODUCT 1, PRODUCT
2, PRODUCT 3 and FINAL PRODUCT (and PRODUCTS, as used in this AGREEMENT, refers to all of PRODUCT 1, PRODUCT 2, PRODUCT 3 and
FINAL PRODUCT).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PRODUCT
1&rdquo; shall mean the FINISHED PACKAGED PRODUCT supplied to FIOCRUZ by PROTALIX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&quot;PRODUCT
2&quot; shall mean PRODUCT LABELED AND PACKAGED by FIOCRUZ at the FACILITIES from NAKED VIALS supplied to FIOCRUZ by PROTALIX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PRODUCT
3&rdquo; shall mean PRODUCT FILLED/FINISHED and LABELED AND PACKAGED by FIOCRUZ at the FACILITIES from BULK PRODUCT supplied to
FIOCRUZ by PROTALIX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PRODUCT
MARKS&rdquo; means the names and marks on the labeling and packaging of the FINISHED PACKAGED PRODUCTS supplied to FIOCRUZ hereunder
by PROTALIX.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PROTALIX
PATENT RIGHTS&rdquo; means all <FONT STYLE="text-transform: uppercase">Patent Rights</FONT> owned by PROTALIX or otherwise <FONT STYLE="text-transform: uppercase">Controlled
</FONT>by PROTALIX as of the EFFECTIVE DATE or at any time during the <FONT STYLE="text-transform: uppercase">Term</FONT> that
claim the composition of matter, MANUFACTURE or use of the <FONT STYLE="text-transform: uppercase">Compound</FONT>, <FONT STYLE="text-transform: uppercase">Drug
Substance</FONT> or a drug product that contains <FONT STYLE="text-transform: uppercase">Drug Substance</FONT>, including the
<FONT STYLE="text-transform: uppercase">Patent Rights</FONT> listed in <U>Exhibit B</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PROTALIX
TECHNOLOGY&rdquo; means any <FONT STYLE="text-transform: uppercase">Technology</FONT> possessed or otherwise <FONT STYLE="text-transform: uppercase">Controlled
</FONT>by PROTALIX as of the EFFECTIVE DATE or at any time during <FONT STYLE="text-transform: uppercase">Term</FONT> 1 that is
necessary for the MANUFACTURE of the PRODUCTS as MANUFACTURED by, on behalf of, or under license from, PROTALIX as of the EFFECTIVE
DATE.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;PURCHASE
ORDER&rdquo; means a firm purchase order in written or electronic form submitted by FIOCRUZ in accordance with the terms of this
Agreement to PROTALIX authorizing the manufacture and supply of SUPPLIED MATERIAL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;RATE&rdquo;
shall have the meaning ascribed to such term in Article 9.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;RECIPIENT&rdquo;
shall have the meaning ascribed to such term in Article 11.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;REPORTING
PERIOD&rdquo; shall have the meaning ascribed to such term in Article 9.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;ROYALTY
PAYMENTS&rdquo; shall have the meaning ascribed to such term in Article 9.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;SPECIFICATIONS&rdquo;
means the specifications of the <FONT STYLE="text-transform: uppercase">Drug Substance</FONT>, PRODUCTS, and SUPPLIED MATERIALS
designated by PROTALIX, as initially set forth in Appendix I, which may be updated from time to time by PROTALIX, including with
respect to MANUFACTURING (including standard operating procedures for manufacturing), performance, quality control, release, and
<FONT STYLE="text-transform: uppercase">fill/finish</FONT> specifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;STAGES&rdquo;
shall have the meaning ascribed to such term in Article 5.1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;SUPPLIED
MATERIALS&rdquo; means the FINISHED PACKAGED PRODUCT, <FONT STYLE="text-transform: uppercase">Naked Vials</FONT>, <FONT STYLE="text-transform: uppercase">Bulk
Product</FONT> and any other materials supplied to FIOCRUZ by PROTALIX for the MANUFACTURE and/or COMMERCIALIZATION by FIOCRUZ
of PRODUCTS in the TERRITORY for the FIELD in accordance with this AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;TECHNOLOGY&rdquo;
means all materials, technology, data, results and non-public technical, scientific and clinical information, in any tangible
or intangible form, including know-how, expertise, trade secrets, practices, techniques, methods, processes, developments, specifications,
formulations, formulae, and any intellectual property rights embodying any of the foregoing, but excluding any <FONT STYLE="text-transform: uppercase">Patent
Rights</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;TECHNOLOGY
TRANSFER&rdquo; means the provision to FIOCRUZ of the data and information comprising the <FONT STYLE="text-transform: uppercase">Protalix
Technology</FONT> and the non-exclusive, non-transferable rights to use the <FONT STYLE="text-transform: uppercase">Protalix Technology
</FONT>in the TERRITORY granted to FIOCRUZ hereunder), reasonably necessary to produce the PRODUCT, to be implemented in various
<FONT STYLE="text-transform: uppercase">stages</FONT> as described in Article 5.2 and Appendix II of this AGREEMENT, for the sole
purpose of enabling FIOCRUZ to MANUFACTURE the <FONT STYLE="text-transform: uppercase">ProductS</FONT> for sale within the <FONT STYLE="text-transform: uppercase">Territory
</FONT>for the FIELD, and all data and documentation in PROTALIX's possession or control reasonably necessary for FIOCRUZ to obtain
registration of the PRODUCTS by ANVISA, in accordance with and subject to the terms and conditions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;TERM&rdquo;
shall mean &quot;TERM 1&quot; and &quot;TERM 2&quot;, and such terms shall have the meanings ascribed to such terms in Articles
12.1 and 12.2, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;THIRD
PARTY&rdquo; means any <FONT STYLE="text-transform: uppercase">Person</FONT> other than PROTALIX, FIOCRUZ or any of their respective
<FONT STYLE="text-transform: uppercase">Affiliates</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;THIRD
PARTY CLAIM&rdquo; shall have the meaning ascribed to such term in Article 16.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;THIRD
PARTY LICENSE&rdquo; means each license agreement between PROTALIX and a THIRD PARTY pursuant to which or from which PROTALIX
obtains a license to PROTALIX TECHNOLOGY or PROTALIX PATENT RIGHTS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;TERRITORY&rdquo;
means Brazil.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
                                         where expressly stated otherwise in this AGREEMENT, the following rules of interpretation
                                         apply to this AGREEMENT: (a) &ldquo;include&rdquo;, &ldquo;includes&rdquo; and &ldquo;including&rdquo;
                                         are not limiting and mean include, includes and including, without limitation; (b) definitions
                                         contained in this AGREEMENT are applicable to the singular as well as the plural forms
                                         of such terms; (c) references to an agreement, statute or instrument mean such agreement,
                                         statute or instrument as from time to time amended, modified or supplemented; (d) references
                                         to a <FONT STYLE="text-transform: uppercase">Person</FONT> are also to its permitted
                                         successors and assigns; (e) references to an &ldquo;Article&rdquo;, &ldquo;Section&rdquo;,
                                         &ldquo;Exhibit&rdquo;, &ldquo;Appendix&rdquo; or &ldquo;Schedule&rdquo; refer to an Article
                                         or Section of, or any Exhibit, Appendix or Schedule to, this AGREEMENT unless otherwise
                                         indicated; (f) the word &ldquo;will&rdquo; shall be construed to have the same meaning
                                         and effect as the word &ldquo;shall&rdquo;; and (g) the word &ldquo;any&rdquo; shall
                                         mean &ldquo;any and all&rdquo; unless otherwise indicated by context.<B> </B></FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
2. &#9;AGREEMENT PURPOSE AND SCOPE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         primary purpose and scope of this AGREEMENT is the TECHNOLOGY TRANSFER from PROTALIX
                                         to FIOCRUZ in order to enable FIOCRUZ to produce and supply PRODUCTS in the TERRITORY
                                         for the FIELD, as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">during
                                         the TECHNOLOGY TRANSFER, the sale and supply exclusively by PROTALIX to FIOCRUZ of the
                                         SUPPLIED MATERIALS for the purpose of FIOCRUZ manufacturing PRODUCTS in accordance with
                                         the STAGES and the provisions of Articles 5 and 6 in such quantities as provided herein,
                                         in order to satisfy the requirements of the Brazilian MOH for <I>plant cell expressed
                                         recombinant Glucocerebrosidase</I> during the period of the TECHNOLOGY TRANSFER and until
                                         registration of the FINAL PRODUCT<B><I> </I></B>by ANVISA in FIOCRUZ's name. For the
                                         avoidance of doubt, subject to Section 4.8, sales by FIOCRUZ outside of Brazil will only
                                         apply to FINAL PRODUCT and shall only take place after full completion of the TECHNOLOGY
                                         TRANSFER and in accordance with the terms and conditions of this AGREEMENT;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         supply of all of the, documentation and technical information reasonably necessary for
                                         the manufacturing and releasing of the PRODUCTS;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                         non-exclusive, non-transferable and non-sublicensable license of <FONT STYLE="text-transform: uppercase">Protalix
                                         Patent Rights</FONT> in the TERRITORY for the term of such PATENTS in the TERRITORY,
                                         subject to the terms and conditions of this AGREEMENT; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         provision of TECHNICAL ASSISTANCE by PROTALIX to FIOCRUZ.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
3. &#9;CONDITIONS PRECEDENT<FONT STYLE="font-size: 10pt; font-weight: normal"><U> </U></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
                                         AGREEMENT shall become effective upon the last to occur of (a) the date of written notification
                                         by either PARTY to the other PARTY of approval by INPI of this AGREEMENT, (b) the date
                                         of written notification by either PARTY to the other PARTY of approval by OCS of this
                                         AGREEMENT, and (c) registration of the <FONT STYLE="text-transform: uppercase">Product
                                         </FONT>by ANVISA in the name of PROTALIX or, along with Laborat&oacute;rios Pfizer Ltda.'s
                                         approval to import the PRODUCT into Brazil set forth on Appendix V, in the name of Laborat&oacute;rios
                                         Pfizer Ltda. (the later of (a), (b) and (c), the &ldquo;EFFECTIVE DATE&rdquo;). If for
                                         any reason the supply of the FINISHED PACKAGED PRODUCT by PROTALIX to FIOCRUZ becomes
                                         prohibited under Brazilian LAW, notwithstanding anything to the contrary herein, PROTALIX
                                         shall not be required to supply such FINISHED PACKAGED PRODUCT for so long as such supply
                                         is prohibited and FIOCRUZ shall pay for any FINISHED PACKAGED PRODUCT already shipped
                                         to FIOCRUZ pursuant to the terms of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall, at its sole cost and expense, submit this AGREEMENT to the INPI for approval and
                                         recordation (and take all other actions reasonably necessary to obtain such approval
                                         and recordation) promptly following the EXECUTION DATE and shall promptly notify PROTALIX
                                         of the approval and recordation of this AGREEMENT by INPI. PROTALIX shall, at its sole
                                         cost and expense, submit this AGREEMENT to the OCS for approval (and take all other actions
                                         reasonably necessary to obtain such approval) promptly following the EXECUTION DATE and
                                         shall promptly notify FIOCRUZ of the approval of this AGREEMENT by OCS.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
4. &#9;GRANT OF RIGHTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
                                         to the terms and conditions set forth herein, PROTALIX hereby grants to FIOCRUZ (a) the
                                         non-exclusive, non-transferable rights, as applicable, to use the <FONT STYLE="text-transform: uppercase">Protalix
                                         Technology </FONT>provided to FIOCRUZ hereunder, and (b) the non-exclusive, non-transferable
                                         and non-sublicensable license or sublicense, as applicable, under all PROTALIX PATENT
                                         RIGHTS in the TERRITORY for the duration of such <FONT STYLE="text-transform: uppercase">Patent
                                         Rights</FONT>, solely, with respect to the foregoing (a) and (b), for the purpose of
                                         MANUFACTURING PRODUCTS in the FACILITIES, and the COMMERCIALIZATION of such PRODUCTS,
                                         for sale within the <FONT STYLE="text-transform: uppercase">Territory</FONT> for the
                                         <FONT STYLE="text-transform: uppercase">Field</FONT>, as appropriate for each STAGE,
                                         in accordance with this AGREEMENT. Notwithstanding the foregoing, FIOCRUZ&rsquo;s right
                                         to COMMERCIALIZE the PRODUCTS in the TERRITORY for the FIELD shall be exclusive; <U>provided
                                         </U>that (x) such right shall become non-exclusive in the event that FIOCRUZ fails to
                                         comply with this Article 4.1 or Article 7.2 or is unable to meet demand for the PRODUCTS
                                         in the TERRITORY, and (y) shall not be exclusive with respect to any P<FONT STYLE="text-transform: uppercase">rotalix
                                         </FONT>PATENTS RIGHTS or P<FONT STYLE="text-transform: uppercase">rotalix Technology
                                         </FONT>that is subject to a THIRD PARTY LICENSE that does not provide PROTALIX the rights
                                         to grant exclusive sublicenses thereof. Any sublicense obligations required by a THIRD
                                         PARTY LICENSE to be included in a sublicense shall be deemed to be included in this AGREEMENT
                                         as obligations of FIOCRUZ [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall not directly or indirectly market, promote, supply, distribute, offer for sale,
                                         or sell <FONT STYLE="text-transform: uppercase">Products </FONT>nor any other pharmaceutical
                                         product that contains DRUG SUBSTANCE or is derived from <FONT STYLE="text-transform: uppercase">Protalix
                                         Technology</FONT> or otherwise use or otherwise exploit the PROTALIX PATENTS RIGHTS,
                                         <FONT STYLE="text-transform: uppercase">Protalix Technology</FONT>, or SUPPLIED MATERIALS,
                                         in, for or to territories outside the TERRITORY or a field other than the <FONT STYLE="text-transform: uppercase">Field,
                                         </FONT>in connection with any other pharmaceutical products, or in any manner other than
                                         as expressly permitted hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall not, without the prior written consent of PROTALIX directly or indirectly (a) disclose
                                         or otherwise make available the <FONT STYLE="text-transform: uppercase">Protalix Technology</FONT>,
                                         nor assign, transfer, license, or sublicense any rights obtained by FIOCRUZ hereunder,
                                         to any AFFILIATE or THIRD PARTY, (b) use the <FONT STYLE="text-transform: uppercase">Protalix
                                         Technology </FONT>for research or development, (c) MANUFACTURE or COMMERCIALIZE <FONT STYLE="text-transform: uppercase">ProductS
                                         </FONT>in any facility or plant other than the <FONT STYLE="text-transform: uppercase">Facilities
                                         </FONT>or through any unit of FIOCRUZ other than BIO-MANGUINHOS, nor (d) other than for
                                         the <FONT STYLE="text-transform: uppercase">PRODUCTS</FONT>, use the PROTALIX PATENTS
                                         RIGHTS or <FONT STYLE="text-transform: uppercase">Protalix Technology</FONT> in connection
                                         with any pharmaceutical products (including any successor or alternative delivery, presentations
                                         or dosing regimens of the <FONT STYLE="text-transform: uppercase">Product</FONT>).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         the <FONT STYLE="text-transform: uppercase">Term</FONT>, FIOCRUZ shall not directly or
                                         indirectly market, promote, supply, distribute, offer for sale, sell or otherwise exploit
                                         any other products that, in PROTALIX&rsquo;s good faith judgment may compete with the
                                         PRODUCT.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         the <FONT STYLE="text-transform: uppercase">Technology Transfer</FONT>, PROTALIX shall
                                         make available to FIOCRUZ all <FONT STYLE="text-transform: uppercase">Improvements </FONT>CONTROLLED
                                         by such PARTY that are useful to the MANUFACTURE of the <FONT STYLE="text-transform: uppercase">PRODUCTS</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
                                         for the licenses and other rights granted to FIOCRUZ herein, all right, title and interest
                                         in and to the <FONT STYLE="text-transform: uppercase">Protalix Patent Rights </FONT>and
                                         <FONT STYLE="text-transform: uppercase">Protalix Technology </FONT>shall remain solely
                                         with PROTALIX and its licensors, as applicable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         hereby covenants and agrees not to, directly or indirectly, commence (or assist any other
                                         <FONT STYLE="text-transform: uppercase">Person </FONT>in connection with) any claim,
                                         suit, action or other proceeding (including in front of any court or <FONT STYLE="text-transform: uppercase">Governmental
                                         Authority</FONT>, including any intellectual property office or registry), that challenges
                                         the legality, validity, enforceability, scope or ownership of any PROTALIX <FONT STYLE="text-transform: uppercase">Patent
                                         Right</FONT> or PROTALIX TECHNOLOGY (a &ldquo;CHALLENGE&rdquo;). If FIOCRUZ directly
                                         or indirectly commences (or assists any other <FONT STYLE="text-transform: uppercase">Person
                                         </FONT>in connection with) any <FONT STYLE="text-transform: uppercase">Challenge</FONT>,
                                         PROTALIX shall (a) have the right to immediately terminate this AGREEMENT by written
                                         notice effective upon receipt by FIOCRUZ, and (b) shall be entitled to recover from FIOCRUZ
                                         any and all costs and expenses, including reasonable attorneys&rsquo; fees and expenses
                                         of investigation and defense, incurred by PROTALIX in connection with such <FONT STYLE="text-transform: uppercase">Challenge</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
                                         anything to the contrary herein, following COMPLETION of the TECHNOLOGY TRANSFER, [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         the avoidance of doubt, notwithstanding the license granted hereunder, PROTALIX shall
                                         retain its exclusive right in the TERRITORY to partner with patient advocacy groups,
                                         and provide patient support and medical education services to health care professionals,
                                         during the TERM and thereafter until COMPLETION of the TECHNOLOGY TRANSFER or for so
                                         long as PROTALIX continues to supply PRODUCTS to the TERRITORY.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
                                         time to time throughout the TERM, PROTALIX will provide to FIOCRUZ information regarding
                                         the status of its development programs for the ORAL FORMULATION. Upon FIOCRUZ's reasonable
                                         request in writing (made no more than once per every twelve month period), PROTALIX agrees
                                         to discuss in good faith a possible collaboration with FIOCRUZ, or a license or sale
                                         to FIOCRUZ of rights, with respect to the ORAL FORMULATION. Any agreement resulting from
                                         such discussions relating to the ORAL FORMULATION (including any rights to be granted
                                         with respect to the ORAL FORMULATION) shall be separate and apart from this AGREEMENT.
                                         PROTALIX's obligations and FIOCRUZ's rights set forth in this Article 4.10 shall be PROTALIX's
                                         sole obligations and FIOCRUZ's sole rights hereunder with respect to the ORAL FORMULATION.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: Transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
5. &#9;TECHNOLOGY TRANSFER</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>5.1
General</U>.&nbsp; The TECHNOLOGY TRANSFER shall commence upon the EFFECTIVE DATE and shall be implemented as set forth in the
following chart (and as set forth in this Article 5 and Appendix II):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Estimated
Time Table of Milestones in Product Production and Supply, </B><BR>
<B>as a Result of Technology Transfer As Specified In Appendix II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 47%; text-align: left; border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stages</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 19%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplied&nbsp;by<BR>
    PROTALIX&nbsp;for<BR>
    PRODUCT&nbsp;supply&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 17%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ&nbsp;activity</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 14%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stages&nbsp;Quantity</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stage
    0 &ndash;&nbsp;&nbsp;&nbsp; Immediately after the EFFECTIVE DATE</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;[***]</FONT></P></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;[***]</FONT></P></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stage
    1 &ndash;&nbsp; Immediately after registration by ANVISA of PRODUCT 2 in FIOCRUZ's name</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stage
    2 - After validation of FIOCRUZ new FILL AND FINISH facility</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stage
    3 - After construction and validation of FIOCRUZ Plant Cell culturing facility and registration by ANVISA of FINAL PRODUCT
    in FIOCRUZ's name</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD>
    <TD STYLE="text-align: justify; background-color: white; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0.1in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="5" STYLE="text-align: justify; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">TOTAL
    QUANTITY: [***] vials (or equivalent depending on PRODUCT type)</FONT></TD>
    <TD STYLE="text-align: justify; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-top: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note:
The FIOCRUZ activity set forth in each STAGE in the above chart (other than STAGE 0) shall only commence following the TECHNOLOGY
TRANSFER by PROTALIX for, and the COMPLETION of, the prior STAGE, as set forth in Appendix II (so that FIOCRUZ is able to properly
perform such activity). COMMERCIALIZATION of the FINAL PRODUCT shall only occur following COMPLETION of the TECHNOLOGY TRANSFER.
During each STAGE, as applicable, PROTALIX shall use commercially reasonable efforts to provide, at FIOCRUZ's cost, any proprietary
or non-commercial reagents and standards to FIOCRUZ that are required by FIOCRUZ in connection with its responsibilities for such
STAGE, and use commercially reasonable efforts to help FIOCRUZ to become self-sufficient to produce or obtain such materials or
reagents on its own.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
                                         to the terms and conditions hereof, PROTALIX shall make available to FIOCRUZ at and for
                                         the FACILITIES, on a STAGE by STAGE basis, all <FONT STYLE="text-transform: uppercase">Protalix
                                         Technology</FONT> that is necessary for such STAGE and for the related MANUFACTURING,
                                         quality control and registration by ANVISA of the <FONT STYLE="text-transform: uppercase">PRODUCTS
                                         </FONT>by FIOCRUZ (including or as reasonable necessary for obtaining requisite GOVERNMENTAL
                                         APPROVALS) in accordance with this AGREEMENT. All PROTALIX TECHNOLOGY shall be provided
                                         in the English language. FIOCRUZ may translate any such documents at its own risk, cost
                                         and expense. Notwithstanding anything to the contrary herein, PROTALIX will transfer
                                         the PROTALIX TECHNOLOGY relating to [***] as the last step of STAGE 3 of the TECHNOLOGY
                                         TRANSFER only following positive completion by FIOCRUZ of clinical trials for the FINAL
                                         PRODUCT and registration by ANVISA of the FINAL PRODUCT in FIOCRUZ's name (as well as
                                         the other steps of STAGE 3 [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         PARTIES hereby agree that the TECHNOLOGY TRANSFER will be implemented in sequential stages
                                         (the &ldquo;STAGES&rdquo;) as set forth in Article 5.1, Article 5.2 and Appendix II.
                                         Each STAGE will take the time required to achieve the COMPLETION of such STAGE as provided
                                         by Article 5.2 and Appendix II. The beginning of each STAGE following STAGE 0 will be
                                         subject to the achievement of the COMPLETION REQUIREMENTS of the previous STAGE, as specified
                                         in Article 5.2 and Appendix II. FIOCRUZ will purchase the quantity of PRODUCTS set forth
                                         for each STAGE in the STAGES chart in Section 5.1, in order for COMPLETION of each such
                                         STAGE and commencement of the following STAGE (in addition to COMPLETING the other COMPLETION
                                         REQUIREMENTS), emphasizing that, notwithstanding anything to the contrary herein, proceeding
                                         to the STAGE 3 will only occur with the total purchase by FIOCRUZ of the estimated quantities
                                         for the STAGES 0, 1 and 2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         and FIOCRUZ shall each appoint, no later than thirty (30) calendar days after the EXECUTION
                                         DATE, its respective Technical Project Managers (whose duties are set forth in Articles
                                         5.3 and 5.4 below) and prepare a coordination plan that will set forth and coordinate
                                         the activities of the PARTIES to take place during the period of the TECHNOLOGY TRANSFER.
                                         The coordination plan will take into account the contractual obligations of the PARTIES
                                         and shall include clauses such as addresses, correspondence, numbers, numbers of copies
                                         to be released, scheduling of activities, persons in charge, standards to be used for
                                         equipment and construction and other matters required or useful for the successful implementation
                                         of the TECHNOLOGY TRANSFER. Each of FIOCRUZ and PROTALIX shall notify the other in writing,
                                         at least thirty (30) days prior to replacing any of its Technical Project Managers and,
                                         in such case, shall cause both the replaced Technical Project Manager and the replacement
                                         Technical Project Manager to work together during a transition term of at least thirty
                                         (30) days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         all STAGES, FIOCRUZ shall, at its own cost and expense, be responsible for (a) obtaining
                                         all GOVERNMENTAL APPROVALS required to MANUFACTURE and COMMERCIALIZE the PRODUCTS MANUFACTURED
                                         in the FACILITY in the <FONT STYLE="text-transform: uppercase">Territory </FONT>in accordance
                                         with the applicable STAGE, and (b) the construction, validation, maintenance and operation
                                         of the FACILITIES (including the new lyophilization suite, bioreactor facility and purification
                                         suites). FIOCRUZ shall be permitted to conduct any clinical trials approved by ANVISA
                                         required to obtain GOVERNMENTAL APPROVALS in the TERRITORY for the PRODUCTS entirely
                                         MANUFACTURED by FIOCRUZ at the FACILITY for the FIELD; <U>provided</U> FIOCRUZ provides
                                         PROTALIX prior written notice thereof and reasonably consults with PROTALIX upon PROTALIX&rsquo;s
                                         request.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
                                         Article 5.1.4, and for the avoidance of doubt, (a) FIOCRUZ acknowledges and agrees that
                                         PROTALIX shall be permitted to obtain and maintain, and take all actions necessary to
                                         obtain and maintain its own GOVERNMENTAL APPROVALS for the PRODUCTS or similar pharmaceutical
                                         products in the TERRITORY, and (b) the PARTIES acknowledge and agree that until FIOCRUZ
                                         obtains its own GOVERNMENTAL APPROVAL for the <FONT STYLE="text-transform: uppercase">ProductS</FONT>,
                                         FIOCRUZ shall COMMERCIALIZE the FINISHED PACKAGED PRODUCT supplied by PROTALIX under
                                         the GOVERNMENTAL APPROVALS obtained prior to the <FONT STYLE="text-transform: uppercase">Effective
                                         Date</FONT> by PROTALIX for the <FONT STYLE="text-transform: uppercase">Territory</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         purchase by and supply to FIOCRUZ of SUPPLIED MATERIALS during each STAGE of TECHNOLOGY
                                         TRANSFER shall occur in accordance with Article 6. As part of the TECHNOLOGY TRANSFER,
                                         PROTALIX may supply specific SUPPLIED MATERIALS to FIOCRUZ for the sole purpose of testing,
                                         validation and training, and for preparation for the following STAGE. FIOCRUZ shall utilize
                                         such SUPPLIED MATERIALS solely for such purpose and not for any commercial use.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><U>STAGEs</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.
                                         The TECHNOLOGY TRANSFER will be implemented in the sequential STAGES set forth in Appendix
                                         II, subject to and in accordance with the terms hereof, including Appendix II.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Responsibilities
                                         of PROTALIX</U>. The sole obligations of PROTALIX relating to the TECHNOLOGY TRANSFER
                                         are set forth in this Article 5 and FIOCRUZ agrees that PROTALIX shall have no other
                                         obligations, express or implied, with respect thereto.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         PROTALIX Project Technical Manager will represent PROTALIX with respect to the implementation
                                         of the TECHNOLOGY TRANSFER. The PROTALIX Project Technical Manager will coordinate all
                                         activities of PROTALIX in relation to the TECHNOLOGY TRANSFER in cooperation with the
                                         FIOCRUZ Project Technical Manager. The PROTALIX Project Technical Manager shall not be
                                         responsible for the responsibilities of FIOCRUZ nor for management of FIOCRUZ&rsquo;s
                                         employees or other personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Following
                                         [***], in the event that FIOCRUZ's CELL BANK is damaged or otherwise becomes defective,
                                         PROTALIX shall utilize its own CELL BANK to provide a new CELL BANK to FIOCRUZ.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                         of PROTALIX&rsquo;s obligations under this Article 5 shall (a) be conditioned on FIOCRUZ&rsquo;s
                                         cooperation in connection therewith and compliance with this AGREEMENT (including fulfillment
                                         of its responsibilities set forth in this Article 5), and (b) cease upon <FONT STYLE="text-transform: uppercase">Completion
                                         </FONT>of the final STAGE of the TECHNOLOGY TRANSFER.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Responsibilities
                                         of FIOCRUZ</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         FIOCRUZ Project Technical Manager will represent FIOCRUZ with respect to the implementation
                                         of the TECHNOLOGY TRANSFER. The FIOCRUZ Project Technical Manager of FIOCRUZ will coordinate
                                         all activities of FIOCRUZ in relation to the TECHNOLOGY TRANSFER in cooperation with
                                         the PROTALIX Project Technical Manager. The FIOCRUZ Project Technical Manager shall not
                                         be responsible for the responsibilities of PROTALIX nor for management of PROTALIX&rsquo;s
                                         employees or other personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]
                                         in the event that PROTALIX's CELL BANK is damaged or otherwise becomes defective, FIOCRUZ
                                         shall utilize its own CELL BANK to provide a new CELL BANK to PROTALIX.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall take all necessary steps to ensure the FACILITY is constructed, maintained and
                                         operated in a manner that enables the safe and proper use of the PROTALIX TECHNOLOGY
                                         solely for the MANUFACTURE of the PRODUCTS in accordance with this AGREEMENT. FIOCRUZ
                                         will be responsible for the construction, validation, maintenance and operation of the
                                         FACILITIES during the term of this AGREEMENT and those FACILITIES shall at all times
                                         be (a) approved by ANVISA, (b) appropriate and adequate for implementing the then-current
                                         STAGE, and (c) in compliance with all the applicable LAWS, SPECIFICATIONS and GMP. The
                                         MANUFACTURING, COMMERCIALIZATION and storage operations, procedures and processes used
                                         by FIOCRUZ in connection with the MANUFACTURE of PRODUCTS hereunder (including any FACILITY)
                                         shall be in full compliance with all applicable SPECIFICATIONS and LAWS, including GMP
                                         and health and safety LAWS.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                         costs and expenses related to the FACILITIES, including their construction, operation,
                                         maintenance and validation, shall be borne by FIOCRUZ. FIOCRUZ shall staff the FACILITIES
                                         with qualified personnel to perform all STAGES of the production and operation process
                                         and obtain the required GOVERNMENTAL APPROVALS therefor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
                                         as otherwise expressly set forth herein, FIOCRUZ shall be responsible for the production
                                         and acquisition, at its own cost and expense, of all necessary materials. FIOCRUZ shall
                                         be responsible for the ensuring the quality of all such materials, including that such
                                         materials meet all requirements of applicable Brazilian LAWS.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>ADVISORY
                                         COMMITTEE</U>. PROTALIX and FIOCRUZ shall establish an ADVISORY COMMITTEE as of the EFFECTIVE
                                         DATE composed of three (3) senior members of each of PROTALIX and FIOCRUZ. The members
                                         of the ADVISORY COMMITTEE may be represented at any meeting by a designee appointed by
                                         such member for such meeting. The chairperson of the ADVISORY COMMITTEE shall be designated
                                         by PROTALIX. FIOCRUZ shall designate one of its representative members as secretary to
                                         the ADVISORY COMMITTEE. Each such PARTY shall be free to change its representative members
                                         by notice to the other such PARTY.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Responsibilities.
                                         The ADVISORY COMMITTEE shall be responsible for advising on and monitoring the implementation
                                         of the TECHNOLOGY TRANSFER, including clinical development work and regulatory activities
                                         in relation to PRODUCTS in a manner which is consistent with the terms and conditions
                                         of this AGREEMENT.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Meetings.
                                         The ADVISORY COMMITTEE shall meet at least twice every calendar year, (and more frequently
                                         should PROTALIX and FIOCRUZ agree to such more frequent meetings), on such dates and
                                         at such times as PROTALIX and FIOCRUZ shall agree. Additional meetings may also be called
                                         by either PROTALIX or FIOCRUZ as reasonably required, on forty (40) calendar days written
                                         notice to the other, unless such notice is waived by such other PARTY. The meetings shall
                                         alternate between the offices of PROTALIX and FIOCRUZ, unless the PARTIES otherwise agree.
                                         The chairperson shall be responsible for sending notices of meetings to all members.
                                         The ADVISORY COMMITTEE may also convene or be polled or consulted from time to time by
                                         means of telecommunications, video conferences or correspondence, as deemed necessary
                                         or appropriate. Fifteen (15) calendar days prior to each ADVISORY COMMITTEE meetings
                                         described above, an English summary of progress under the TECHNOLOGY TRANSFER shall be
                                         provided by FIOCRUZ to the members of the ADVISORY COMMITTEE, including detailed accounting
                                         of the expenditures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Decisions.
                                         All decisions of the ADVISORY COMMITTEE shall be made by unanimous consent of the members
                                         present in person or by telephone or teleconferences/videoconferences at any meeting,
                                         with FIOCRUZ members cumulatively having one (1) vote and PROTALIX members cumulatively
                                         having one (1) vote. A quorum for a meeting shall require at least one (1) representative
                                         from FIOCRUZ and at least one (1) representative from PROTALIX.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         the event that unanimity cannot be reached by the ADVISORY COMMITTEE with respect to
                                         a matter that is subject to its decision-making authority, then the matter shall be referred
                                         for further review and resolution to the President of PROTALIX or such other similar
                                         position designated by PROTALIX from time to time, and the President of FIOCRUZ, or such
                                         other similar position designated by FIOCRUZ from time to time. The designated persons
                                         at each of PROTALIX and FIOCRUZ shall use reasonable efforts to resolve the matter within
                                         thirty (30) days after the matter is referred to them. In the event that the designated
                                         officers fail to resolve the matter during such time period, PROTALIX and FIOCRUZ agree
                                         to submit the matter to be resolved with the assistance of a suitably qualified independent
                                         mediator or expert. In the event that the matter is still not resolved within fifty (50)
                                         days after the matter was referred to the designated persons at each of PROTALIX and
                                         FIOCRUZ the proposal or determination of PROTALIX&rsquo;s President shall prevail (provided
                                         such proposal or determination shall be made in good faith).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Minutes.
                                         Within fifteen (15) BUSINESS DAYS after each ADVISORY COMMITTEE meeting, the secretary
                                         of the ADVISORY COMMITTEE shall prepare and distribute minutes of the meeting, which
                                         shall provide a description in reasonable detail of the discussions held at that meeting
                                         and a list of any actions, decisions and/or determinations approved by the ADVISORY COMMITTEE.
                                         The secretary shall be responsible for circulation of all drafts and final minutes. Draft
                                         minutes shall be first circulated to the chairperson, edited and approved by the chairperson
                                         and then circulated in final draft form to all members of the ADVISORY COMMITTEE sufficiently
                                         in advance of the next meeting to allow adequate review and comment prior to the meeting.
                                         Minutes shall be approved or disapproved, and revised as necessary, at the next meeting.
                                         Final minutes shall be distributed to the members of the ADVISORY COMMITTEE.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expenses.
                                         Each PARTY shall be responsible for all travel and related costs for its representatives
                                         to attend meetings of, and otherwise participate on, the ADVISORY COMMITTEE.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         the term of this AGREEMENT, the ADVISORY COMMITTEE shall be assisted by specific task
                                         forces (&ldquo;TASK FORCES&rdquo;) which shall be responsible for advising the ADVISORY
                                         COMMITTEE within their area of responsibilities and implementing the decisions made by
                                         the ADVISORY COMMITTEE to the extent such decisions are within the competence of the
                                         TASK FORCES. The following TASK FORCES shall be organized:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                         technical TASK FORCE;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                         clinical and regulatory TASK FORCE;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                         manufacturing TASK FORCE; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">other
                                         TASK FORCES may be established upon the decision of the ADVISORY COMMITTEE.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
composition and numbers of representatives of each PARTY on each TASK FORCE shall be decided by both PROTALIX and FIOCRUZ on an
ad hoc basis. Each of PROTALIX and FIOCRUZ shall be responsible for all travel and related costs for its representatives to attend
TASK FORCE meetings.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
6. &#9;PURCHASE AND SUPPLY OF SUPPLIED MATERIALS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Agreement
                                         to Supply</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commencing
                                         on the EFFECTIVE DATE and continuing until the COMPLETION of the TECHNOLOGY TRANSFER,
                                         PROTALIX will supply and FIOCRUZ will purchase SUPPLIED MATERIALS, in the form (<U>e.g.</U>,
                                         FINISHED PACKAGED PRODUCT, NAKED VIALS, BULK PRODUCT, etc.) appropriate for the then-current
                                         STAGE, that are necessary for FIOCRUZ to MANUFACTURE and/or COMMERCIALIZE the PRODUCTS
                                         in the TERRITORY for the FIELD, at the pricing set forth herein. [***]</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commercial
                                         supply will commence as soon as commercially reasonable, following the receipt of ANVISA
                                         approval for the PRODUCT.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commencing
                                         on the EFFECTIVE DATE and continuing until the later of COMPLETION of the TECHNOLOGY
                                         TRANSFER, FIOCRUZ shall purchase the SUPPLIED MATERIALS from PROTALIX on an exclusive
                                         basis.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         the TECHNOLOGY TRANSFER, if FIOCRUZ is unable to MANUFACTURE the PRODUCTS in accordance
                                         with the then-current STAGE, then FIOCRUZ shall, in accordance with this Article 6, submit
                                         to PROTALIX orders for, and PROTALIX shall use commercially reasonable efforts to fulfill
                                         such orders for, SUPPLIED MATERIALS in the form required by FIOCRUZ to MANUFACTURE and/or
                                         COMMERCIALIZE the PRODUCTS (<U>e.g.</U>, if, during STAGE 3, FIOCRUZ cannot adequately
                                         FILL/FINISH the BULK PRODUCT to create PRODUCTS, then PROTALIX shall use commercially
                                         reasonable efforts to supply [***] ordered by FIOCRUZ); <U>provided</U> that FIOCRUZ
                                         provides PROTALIX sixty (60) days advance notice thereof.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FINISHED
                                         PACKAGED PRODUCT will be provided with a minimum [***] remaining shelf life and NAKED
                                         VIALS will be provided with a minimum [***] remaining shelf life.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Forecasts
                                         and Purchase Orders</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                         the EFFECTIVE DATE, or such later date that is at least ninety (90) days preceding the
                                         first requested delivery date for SUPPLIED MATERIALS, FIOCRUZ shall deliver to PROTALIX,
                                         FIOCRUZ&rsquo;s quarterly projection of the quantities of SUPPLIED MATERIALS that FIOCRUZ
                                         anticipates ordering from PROTALIX for the four (4) calendar quarters commencing with
                                         the first quarter that includes the first requested delivery date (the &ldquo;INITIAL
                                         FORECAST&rdquo;), together with a Purchase Order for SUPPLIED MATERIALS for the first
                                         two (2) calendar quarters covered by such Initial Forecast. The quantities of SUPPLIED
                                         MATERIALS specified for the remaining quarters of such Initial Forecast shall be non-binding.
                                         Thereafter, ninety (90) days prior to the first business day of each subsequent calendar
                                         quarter during the Term, FIOCRUZ shall deliver to PROTALIX a rolling four (4) calendar
                                         quarter forecast updating the prior forecast (together with the Initial Forecast, each
                                         a &ldquo;FORECAST&rdquo;), together with a Purchase Order for the first two (2) calendar
                                         quarters of such Forecast. The quantities of SUPPLIED MATERIALS specified for the remaining
                                         two (2) quarters of such Forecast shall be non-binding. Unless agreed separately between
                                         the PARTIES, each Purchase Order shall specify no more than three (3) delivery dates
                                         for the SUPPLIED MATERIALS in each calendar quarter. Purchase Orders shall be in writing,
                                         and no verbal communications or e-mail shall be construed to mean a commitment to purchase
                                         or sell. PROTALIX shall confirm receipt of any valid Purchase Order as soon as reasonably
                                         practicable after receipt. Subject to Sections 6.2.2, PROTALIX shall provide SUPPLIED
                                         MATERIALS to FIOCRUZ pursuant to valid Purchase Orders issued by FIOCRUZ to PROTALIX.
                                         FIOCRUZ shall provide PROTALIX with a written acknowledgment of receipt of SUPPLIED MATERIALS
                                         within three (3) BUSINESS DAYS of its receipt of SUPPLIED MATERIALS. This written acknowledgment
                                         shall confirm the quantity of SUPPLIED MATERIALS delivered and the date of delivery.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
                                         otherwise agreed in writing by PROTALIX, in no event shall PROTALIX be obligated to deliver
                                         quantities of SUPPLIED MATERIALS specified in a Purchase Order for a quarter which exceed
                                         [***] of the quantities specified by FIOCRUZ for the same period in the Forecast delivered
                                         in the prior calendar quarter. PROTALIX shall, however, use commercially reasonable efforts,
                                         but will be under no obligation, to supply SUPPLIED MATERIALS in excess of [***] of such
                                         quantities specified in such Forecast. Without limitation to the foregoing, in no event
                                         shall PROTALIX be required to supply quantities of SUPPLIED MATERIALS in excess of those
                                         commercially reasonable for PROTALIX to supply for any given period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject
                                         to Section 6.2.2, FIOCRUZ shall purchase all SUPPLIED MATERIALS ordered and specified
                                         in a Purchase Order. Purchase Orders may be delivered electronically or by other means
                                         to such location and in such manner as the PARTIES shall agree All Purchase Orders, confirmations
                                         of receipt of Purchase Orders and other notices contemplated under this Section 6.2 shall
                                         be sent to the attention of such persons as each party may identify to the other in writing
                                         from time to time in accordance with Section 20.9.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Forecasts shall show demand for SUPPLIED MATERIALS on a monthly basis, and for the first
                                         three months of any such Forecast shall state the dates of required delivery for such
                                         SUPPLIED MATERIAL.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                         Forecasts and Purchase Orders shall set forth the presentation of such SUPPLIED MATERIALS
                                         (e.g., FINISHED PACKAGED PRODUCT, NAKED VIALS, BULK PRODUCT).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall not submit Purchase Orders for, and PROTALIX shall not be required to supply, any
                                         single delivery of SUPPLIED MATERIALS of less than [***] of SUPPLIED MATERIALS (or the
                                         equivalent thereof with respect to DRUG SUBSTANCE). For the avoidance of doubt, all vials
                                         supplied hereunder shall be [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         shall use commercially reasonable efforts to meet FIOCRUZ requests for additional quantities
                                         beyond those set forth in Purchase Orders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Delivery;
                                         Risk of Loss</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         shall ship SUPPLIED MATERIALS ordered by FIOCRUZ as set forth in the applicable Purchase
                                         Order, in accordance with the terms hereof. PROTALIX shall deliver SUPPLIED MATERIALS
                                         to FIOCRUZ by the delivery date set forth in the applicable Purchase Order, or such other
                                         date as may be agreed to in writing by the PARTIES from time to time. PROTALIX shall
                                         deliver SUPPLIED MATERIALS to FIOCRUZ FCA Protalix airport, customs cleared at shipping
                                         point, as per Incoterms 2000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         shall include certificates of analysis with all shipments of SUPPLIED MATERIAL.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title
                                         to SUPPLIED MATERIAL shall pass to FIOCRUZ when the SUPPLIED MATERIAL has been delivered
                                         to FIOCRUZ pursuant to Article 6.3.1 above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         is responsible for acquiring import permits, letters of credit, customs clearance in
                                         Brazil and local transportation and distribution necessary for the supply and receipt
                                         of SUPPLIED MATERIALS to be supplied to FIOCRUZ hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Price;
                                         Payment; Taxes</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         the event the TECHNOLOGY TRANSFER is not COMPLETED by the end of the initial seven (7)
                                         year period, FIOCRUZ shall continue to obtain from PROTALIX its requirements of PROTALIX
                                         BULK PRODUCT for production of the PRODUCT at the same terms and conditions as described
                                         above and, for the renewal periods in TERM 1, PROTALIX shall provide [***]% discount
                                         over the last price of BULK PRODUCT as described in table below (6.4.2).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         TERM 1, the pricing for the SUPPLIED MATERIALS shall be as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 39%; text-align: left; text-indent: 0in; border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Year</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: left; text-indent: 0in; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-indent: 0in; vertical-align: bottom; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FINISHED&nbsp;PACKAGED</B><BR>
    <B>PRODUCT&nbsp;PRICE&nbsp;</B>[***]</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; text-indent: 0in; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; text-indent: 0in; vertical-align: bottom; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NAKED&nbsp;VIALS</B><BR>
    <B>PRICE&nbsp;</B>[***]</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; text-indent: 0in; padding-bottom: 1pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; text-align: left; text-indent: 0in; border-bottom: Black 1pt solid; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>BULK</B><BR>
    <B>PRODUCT</B><BR>
    <B>PRICE&nbsp;</B>[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
    the EFFECTIVE DATE until one (1) year after the EFFECTIVE DATE.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
    the end of the foregoing period until two (2) years after the EFFECTIVE DATE.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
    the end of the foregoing period until three (3) years after the EFFECTIVE DATE.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
    the end of the foregoing period until four (4) years after the EFFECTIVE DATE.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
    the end of the foregoing period until five (5) years after the EFFECTIVE DATE.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
    the end of the foregoing period until six (6) years after the EFFECTIVE DATE.</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
    the end of the foregoing period until the COMPLETION of the TECHNOLOGY TRANSFER</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; padding-top: 0.11in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    [***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Invoices
                                         and Payment</U>. PROTALIX shall submit invoices to FIOCRUZ upon shipment of SUPPLIED
                                         MATERIALS to the address in the TERRITORY set forth in the applicable Purchase Order.
                                         FIOCRUZ shall pay all amounts due in U.S. Dollars within [***] from the date of receipt
                                         of the invoice by FIOCRUZ.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Taxes</U>.
                                         Subject to Article 9.5 of this Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify; text-indent: -9pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 84.6pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">I.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                         Price includes all taxes except such sales, value-added and use taxes which PROTALIX
                                         is required by law to collect from FIOCRUZ;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify; text-indent: -9pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 84.6pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">II.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">such
                                         taxes, if any, will be separately stated in PROTALIX's invoice and will be paid by FIOCRUZ
                                         to PROTALIX, unless FIOCRUZ provides an exemption to PROTALIX, and subject to receipt
                                         of a valid receipt or invoice to FIOCRUZ in the form and manner required by LAW to allow
                                         FIOCRUZ to recover such taxes to the extent allowable by LAW; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.3in; text-align: justify; text-indent: -9pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 84.6pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">III.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         shall be solely responsible for the timely payment of all such taxes to the applicable
                                         GOVERNMENTAL AUTHORITY.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Purchase
                                         Order Effective Upon Anvisa Approval; Letter of Credit</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
                                         anything to the contrary herein, (i) the PURCHASE ORDER set forth in Appendix IV for
                                         the first delivery, for [***], of PRODUCT for STAGE 0 of the Agreement shall be deemed
                                         to be delivered by FIOCRUZ to PROTALIX concurrently upon the EFFECTIVE DATE, and (ii)
                                         the PURCHASE ORDER for [***] of PRODUCT for completion of STAGE 0 of the AGREEMENT, shall
                                         be deemed to be delivered by FIOCRUZ to PROTALIX [***]. As security for payment of the
                                         PRICE for the PRODUCT to be ordered pursuant to such PURCHASER ORDER for the first delivery
                                         of STAGE 0, concurrently with the execution and delivery of this Agreement, FIOCRUZ shall
                                         execute and deliver to PROTALIX the letter of credit attached hereto as Appendix VI.&nbsp;
                                         For the avoidance of doubt, the quantity of PRODUCT purchased pursuant to such PURCHASE
                                         ORDER shall count towards and satisfy the first delivery requirement for STAGE 0 set
                                         forth in Section 5.1. As security for payment of the PRICE for the PRODUCT to be ordered
                                         pursuant to PURCHASE ORDERS, (a) concurrently with the execution and delivery of this
                                         AGREEMENT, FIOCRUZ shall request an irrevocable letter of credit to be confirmed by a
                                         first class USA bank covering the PURCHASE ORDER for the first delivery of STAGE 0 of
                                         this AGREEMENT, in the form of the request attached hereto as Appendix VI, (b) within
                                         thirty (30) days of the execution and delivery of this AGREEMENT, FIOCRUZ shall provide
                                         to PROTALIX a fully executed and effective irrevocable letter of credit confirmed by
                                         a first class USA bank covering the PURCHASE ORDER for the first delivery of STAGE 0
                                         of this AGREEMENT, in a form reasonably acceptable to PROTALIX, and (c) on or prior to
                                         submission of each subsequent PURCHASE ORDER [***] FIOCRUZ shall execute and deliver
                                         other irrevocable letters of credit confirmed by a first class USA bank covering the
                                         PURCHASE ORDER for such delivery under the AGREEMENT (in the same form as the letter
                                         of credit provided by FIOCRUZ for the first delivery of STAGE 0 of this AGREEMENT), together
                                         covering the total amount of the AGREEMENT, along the duration of the AGREEMENT.&nbsp;
                                         [***]&nbsp; Notwithstanding anything to the contrary herein, PROTALIX shall have no obligation
                                         to ship any PRODUCT for any year of this AGREEMENT until a fully executed and effective
                                         letter of credit for such PURCHASE ORDER of the AGREEMENT (that complies with the terms
                                         of this Section 6.5.1) is delivered to PROTALIX.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         the event that COMPLETION of the TECHNOLOGY TRANSFER is not achieved prior to the date
                                         occurring seven (7) years following the EFFECTIVE DATE, this AGREEMENT may be renewed,
                                         pursuant to and in accordance with Section 12.1; <U>provided</U> that, for each such
                                         renewal period, PURCHASE ORDERS and a letter of credit equivalent to those provided for
                                         in Section 6.5.1 are executed by FIOCRUZ and delivered to PROTALIX prior to such renewal</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
7. &#9;MANUFACTURE; COMMERCIALIZATION AND QUALITY CONTROL</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Manufacture</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         the TERM following the EFFECTIVE DATE, FIOCRUZ shall perform the applicable MANUFACTURING
                                         steps with respect to the PRODUCTS solely in the FACILITY and solely from the SUPPLIED
                                         MATERIALS supplied by PROTALIX to FIOCRUZ.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall employ only the MANUFACTURING and other processes, and shall comply with the quality
                                         control standards, included in the PROTALIX TECHNOLOGY provided to FIOCRUZ and shall
                                         ensure that the PRODUCTS complies with the SPECIFICATIONS, GMP standards and all applicable
                                         Brazilian LAWS. There shall be no changes made to such processes, standards, or SPECIFICATIONS
                                         without PROTALIX&rsquo;s prior written consent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         represents and warrants that the FACILITIES and FIOCRUZ&rsquo;s MANUFACTURING practices
                                         at the FACILITIES shall at all times comply with all applicable Brazilian LAWS, SPECIFICATIONS
                                         and GMP standards.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall use the PROTALIX TECHNOLOGY and SPECIFICATIONS (including any items provided pursuant
                                         to the TECHNOLOGY TRANSFER, such as the bioreactors, growth media, and cell banks) solely
                                         for the purposes of MANUFACTURING the PRODUCTS in the FACILITY, pursuant to and in accordance
                                         with this AGREEMENT, and not in connection with any other pharmaceutical products unless
                                         agreed to by the PARTIES in writing in advance.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         may, in its sole discretion, modify the SPECIFICATIONS upon written notice to FIOCRUZ.
                                         PROTALIX shall use commercially reasonable efforts to provide written justification of
                                         such changes (which shall include information and data supporting such change) to FIOCRUZ
                                         in a reasonably prompt manner so that FIOCRUZ may update the PRODUCT registration in
                                         ANVISA held by FIOCRUZ.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Commercialization</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall use its best efforts to diligently COMMERCIALIZE the PRODUCTS in accordance with
                                         this AGREEMENT.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         represents and warrants that FIOCRUZ&rsquo;s COMMERCIALIZATION shall at all times comply
                                         with all applicable Brazilian LAWS and the highest commercial and ethical standards.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ&rsquo;s
                                         COMMERCIALIZATION, including with respect to the marketing and promotion, of the PRODUCTS
                                         shall only be for the approved indications, dosage forms and strengths included in the
                                         FIELD.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Access
                                         to the <FONT STYLE="text-transform: uppercase">Facilities </FONT>and Technical Visits;
                                         Payment for Technical Assistance</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         the TECHNOLOGY TRANSFER, PROTALIX shall have the right to enter the FACILITIES, during
                                         normal business hours to check and verify the FACILITY, DRUG SUBSTANCES, PRODUCTS, SUPPLIED
                                         MATERIALS and any MANUFACTURING processes, quality control standards and other activities
                                         relating to the foregoing or this AGREEMENT that are performed at the FACILITY to ensure
                                         compliance with this AGREEMENT (including compliance with the SPECIFICATIONS, GMP standards,
                                         and applicable Brazilian LAW and achievement of COMPLETION REQUIREMENTS). FIOCRUZ shall
                                         implement any mitigation plan reasonably identified by PROTALIX to address any such findings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall allow PROTALIX and/or its representatives/designees reasonable access to the FACILITIES
                                         and to its records in order to enable PROTALIX to conduct periodic reviews during normal
                                         business hours of the health and safety practices and performance of the FACILITIES.
                                         In connection with such audit or evaluation, FIOCRUZ shall cooperate in the completion
                                         of a Health &amp; Safety survey by PROTALIX or in the scheduling of a Health &amp; Safety
                                         audit of any FACILITY, as applicable. FIOCRUZ shall correct, at its own cost and expense,
                                         any material deficiencies in its health and safety management practices that are identified
                                         to it. FIOCRUZ acknowledges that such reviews and evaluations conducted by PROTALIX are
                                         for the benefit of PROTALIX only and are not a substitute for FIOCRUZ&rsquo;s own health
                                         and safety management obligations under this AGREEMENT and, accordingly, FIOCRUZ may
                                         not rely upon them.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Quality
                                         Control Testing/Validation</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         each STAGE of the TECHNOLOGY TRANSFER, FIOCRUZ shall be responsible for validation of
                                         the MANUFACTURING and operating processes and quality control testing as conducted by
                                         FIOCRUZ at the FACILITIES. During the TECHNOLOGY TRANSFER, upon PROTALIX&rsquo;s request,
                                         FIOCRUZ shall, at FIOCRUZ&rsquo;s sole cost and expense, (a) submit a sample of any production
                                         batch of the PRODUCTS for parallel quality control testing to be performed by PROTALIX
                                         or representatives/designees, (b) make available to PROTALIX any books and records relating
                                         to the MANUFACTURING and operating processes, quality control testing, DRUG SUBSTANCE,
                                         SUPPLIED MATERIALS and the PRODUCTS, and (c) provide to PROTALIX all documentation reasonably
                                         necessary to evidence that the PROTALIX TECHNOLOGY and SUPPLIED MATERIALS have been used
                                         only in accordance with this AGREEMENT.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
                                         the TERM of the AGREEMENT, in accordance with Section 7.4.1(a), FIOCRUZ will supply with
                                         each sample supplied to PROTALIX, a certificate of analysis duly signed by an individual
                                         qualified and authorized with respect to the PRODUCTS in sufficient detail to demonstrate
                                         conformity with the SPECIFICATIONS. If any delivery consists of the PRODUCTS of more
                                         than one production batch, FIOCRUZ shall provide a certificate of analysis for each such
                                         batch.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         the event that the results of the quality control tests of PROTALIX and FIOCRUZ are not
                                         consistent, FIOCRUZ shall, and PROTALIX, shall have the right but not the obligation
                                         to, repeat such tests, at FIOCRUZ&rsquo;s sole cost and expense. In the event PROTALIX
                                         and FIOCRUZ repeated such tests and such inconsistency remains, an independent laboratory
                                         having a confirmed experience in <I>Recombinant Enzyme</I> testing agreed upon by both
                                         PROTALIX and FIOCRUZ in good faith shall be requested to perform the test and such test
                                         shall determine whether a batch can be released or not. The costs of such test by the
                                         laboratory shall be borne by FIOCRUZ. Any batch that has been finally rejected shall
                                         be destroyed at FIOCRUZ&lsquo; expense and FIOCRUZ shall provide PROTALIX with destruction
                                         certificates. In case FIOCRUZ experiences, during the TECHNOLOGY TRANSFER, problems in
                                         meeting the quality of SPECIFICATIONS of PRODUCTS, the PARTIES will define corrective
                                         measures to ensure quality and carry out validation of such measures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall be responsible for and reimburse PROTALIX for costs and reasonably agreed upon
                                         expenses incurred to provide technical assistance or training to FIOCRUZ, including all
                                         costs and expenses relating to travel (business class tickets for all flights), local
                                         transportation, hotel, food, and reasonable per diem expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         accordance with the payment terms in Article 9, FIOCRUZ shall pay PROTALIX for the technical
                                         assistance and training provided by PROTALIX to FIOCRUZ (as agreed upon by PROTALIX and
                                         FIOCRUZ), at the following rates:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 46%; padding-left: 1.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Employee
    (other than Supervisors, Managers or Directors)</FONT></TD>
    <TD STYLE="width: 54%; text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]
    U.S. dollars per hour</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 1.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supervisor:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***] U.S. dollars per hour</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 1.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Manager:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***] U.S. dollars per hour</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-left: 1.8pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Senior Manager
    or Director</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***] U.S. dollars per hour</FONT></TD></TR>
</TABLE>
<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: Transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
8. &#9;USE OF NAMES AND MARKS; PATENT RIGHTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Product
                                         Mark License to FIOCRUZ</U>. PROTALIX hereby grants to FIOCRUZ, during the <FONT STYLE="text-transform: uppercase">Term</FONT>,
                                         a non-exclusive, non-transferable, non-sublicensable, limited license to use the <FONT STYLE="text-transform: uppercase">Product
                                         Marks</FONT> as they exist on the labeling and packaging of the FINISHED PACKAGED <FONT STYLE="text-transform: uppercase">Product
                                         </FONT>at the time such FINISHED PACKAGED PRODUCT is supplied to FIOCRUZ by PROTALIX
                                         hereunder in connection with COMMERCIALIZATION of such PRODUCT within the <FONT STYLE="text-transform: uppercase">Territory
                                         </FONT>for the <FONT STYLE="text-transform: uppercase">Field</FONT> in accordance with
                                         the terms and conditions of this AGREEMENT. For the avoidance of doubt, FIOCRUZ is not
                                         granted any rights to display the PRODUCT MARKS other than on the labeling and packaging
                                         of such FINISHED PACKAGED PRODUCT as such PRODUCT MARKS are already displayed thereon.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Quality
                                         Control</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall not alter, remove, cover or otherwise modify the labeling or packaging of any FINISHED
                                         PACKAGED PRODUCT (or any PRODUCT MARK thereon). The quality of the FINISHED PACKAGED
                                         PRODUCT sold or otherwise distributed by FIOCRUZ must be of the same quality as the FINISHED
                                         PACKAGED PRODUCT at the time it was supplied to FIOCRUZ hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall (a) comply with all applicable Brazilian <FONT STYLE="text-transform: uppercase">Laws
                                         </FONT>pertaining to the proper use and designation of the <FONT STYLE="text-transform: uppercase">Product
                                         Marks</FONT>, (b) modify the labeling and packaging of any FINISHED PACKAGED PRODUCT
                                         as directed by PROTALIX, (c) not use any <FONT STYLE="text-transform: uppercase">Product
                                         Mark</FONT> as a corporate name, business name, or trade name, (d) not use the PRODUCT
                                         MARKS in connection with any SUPPLIED MATERIALS or PRODUCTS other than the FINISHED PACKAGED
                                         PRODUCT or in any manner not expressly permitted hereunder, and (e) not use any <FONT STYLE="text-transform: uppercase">Product
                                         Mark</FONT> in a manner that would reasonably be expected to materially impair the validity,
                                         reputation, or distinctiveness of any <FONT STYLE="text-transform: uppercase">Product
                                         Mark</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Prosecution
                                         and Maintenance of <FONT STYLE="text-transform: uppercase">Product Marks</FONT></U>.
                                         PROTALIX (or its licensors) shall have the sole right, but not the obligation, through
                                         counsel of its choosing, to prosecute and maintain the <FONT STYLE="text-transform: uppercase">Product
                                         Marks</FONT> in and outside the <FONT STYLE="text-transform: uppercase">Territory</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Enforcement
                                         of <FONT STYLE="text-transform: uppercase">Product Marks</FONT></U>. FIOCRUZ shall promptly
                                         notify PROTALIX in the event of any actual, potential or suspected infringement of a
                                         <FONT STYLE="text-transform: uppercase">Product Mark</FONT> by any <FONT STYLE="text-transform: uppercase">Third
                                         PARTY</FONT>. [***] shall have the sole right, but not the obligation, to institute litigation
                                         or take other remedial measures in connection with <FONT STYLE="text-transform: uppercase">Third
                                         PARTY </FONT>infringement of <FONT STYLE="text-transform: uppercase">Product Marks</FONT>.
                                         [***] shall be solely entitled to any and all recoveries from THIRD PARTIES resulting
                                         from such litigation or other appropriate action, after reimbursement from such recoveries
                                         of [***] costs and expenses in enforcing the PRODUCT MARKS in such litigation or other
                                         action [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Use
                                         of Names</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.5.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
                                         right, expressed or implied, is granted by this AGREEMENT to FIOCRUZ to use in any manner
                                         the name or any other trade name of PROTALIX or its <FONT STYLE="text-transform: uppercase">Affiliates</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
                                         the foregoing Article 8.5.1, FIOCRUZ shall have the right to use the PROTALIX corporate
                                         name, subject to PROTALIX&rsquo;s trademark usage guidelines provided to FIOCRUZ from
                                         time to time, on package inserts, packaging or trade packaging associated with the <FONT STYLE="text-transform: uppercase">ProductS
                                         </FONT>in the <FONT STYLE="text-transform: uppercase">Territory</FONT> solely to the
                                         extent required by applicable <FONT STYLE="text-transform: uppercase">Laws</FONT>. FIOCRUZ
                                         will submit for PROTALIX&rsquo;s prior written approval a sample of each such proposed
                                         use of the PROTALIX corporate name prior to any use thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>FIOCRUZ
                                         Covenants</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
                                         than as expressly permitted in this Article 8, FIOCRUZ shall not (a) use, register, or
                                         apply to register any name, mark, domain name, or logo that consists of or is confusingly
                                         similar to any name, mark, domain name, or logo owned or controlled by PROTALIX or its
                                         AFFILIATES; (b) use any name, mark, domain name, or logo owned or controlled<FONT STYLE="text-transform: uppercase">
                                         </FONT>by PROTALIX or its AFFILIATES together with any other mark or name, without prior
                                         written consent from such PARTY; or (c) take any action whereby any name, mark, domain
                                         name, or logo owned or controlled<FONT STYLE="text-transform: uppercase"> </FONT>by PROTALIX
                                         or its AFFILIATES becomes invalid, unenforceable, generic or otherwise impaired.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.3pt; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 58.5pt"></TD><TD STYLE="width: 28.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall not take any action that in any way might tend to disparage, diminish, or reflect
                                         negatively upon the goodwill, reputation or value of PROTALIX, the PRODUCT, FIOCRUZ or
                                         any name, mark domain name or logo owned or controlled<FONT STYLE="text-transform: uppercase">
                                         </FONT>by PROTALIX or its AFFILIATES.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Prosecution
                                         and Maintenance of PROTALIX PATENT RIGHTS</U>. PROTALIX shall have the sole right, but
                                         not the obligation, through counsel of its choosing, to prosecute and maintain the PROTALIX
                                         PATENT RIGHTS in and outside the TERRITORY.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Enforcement
                                         of PROTALIX PATENT RIGHTS</U>. FIOCRUZ shall promptly notify PROTALIX in the event of
                                         any actual, potential or suspected infringement of a PROTALIX PATENT RIGHT by any <FONT STYLE="text-transform: uppercase">Third
                                         PARTY</FONT>. PROTALIX shall have the sole right, but not the obligation, to institute
                                         litigation or take other remedial measures in connection with <FONT STYLE="text-transform: uppercase">Third
                                         PARTY</FONT> infringement of PROTALIX PATENT RIGHTS. FIOCRUZ shall[***] cooperate with
                                         PROTALIX in any such litigation or other remedial measure, including by being named as
                                         a party if necessary to institute or maintain such litigation or other remedial measure.
                                         If FIOCRUZ is so named, it may hire its own counsel at its sole cost and expense to participate
                                         in such litigation or other remedial measure, provided that PROTALIX and its counsel
                                         shall at all times and in all cases control such litigation or other remedial measure.
                                         [***][***] shall be entitled to any and all recoveries from THIRD PARTIES resulting from
                                         such litigation or other remedial action, after reimbursement from such amount of [***]
                                         costs and expenses in enforcing the PROTALIX PATENT RIGHTS in such litigation or action
                                         [***].<B> </B></FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: Transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
9. &#9;ROYALTY, REPORTING AND PAYMENT TERMS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Royalties</U>.
                                         Commencing upon FIOCRUZ&rsquo;s completion of a Phase III clinical trial and obtaining
                                         a GOVERNMENTAL APPROVAL from ANVISA for the MANUFACTURE entirely by FIOCRUZ of the FINAL
                                         PRODUCT in the TERRITORY, FIOCRUZ shall pay to PROTALIX for the exploitation of the PROTALIX
                                         <FONT STYLE="text-transform: uppercase">patent RIGHTs</FONT> and the PROTALIX TECHNOLOGY
                                         in the TERRITORY a running royalty of [***] of <FONT STYLE="text-transform: uppercase">Net
                                         Sales (</FONT>the &ldquo;ROYALTY PAYMENTS&rdquo;), on a quarterly basis in the manner
                                         described in this Article 9. For the avoidance of doubt, (i) FIOCRUZ shall not COMMERCIALIZE
                                         the FINAL PRODUCT until completion of a Phase III clinical trial and obtaining a GOVERNMENTAL
                                         APPROVAL from ANVISA for the MANUFACTURE entirely by FIOCRUZ of the FINAL PRODUCT in
                                         the TERRITORY, and (ii) the requirement to pay ROYALTY PAYMENTS shall survive any termination
                                         or expiration of this AGREEMENT until the expiration of the last to expire PROTALIX patent
                                         in Brazil.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Royalty
                                         Reporting and Payment</U>. Not later than thirty (30) days after the end of each calendar
                                         quarter during the <FONT STYLE="text-transform: uppercase">Term </FONT>(a &ldquo;REPORTING
                                         PERIOD&rdquo;), FIOCRUZ shall (a) submit to PROTALIX a written report setting forth in
                                         reasonable detail (i) gross sales of FINAL <FONT STYLE="text-transform: uppercase">Product
                                         </FONT>during the <FONT STYLE="text-transform: uppercase">Reporting Period</FONT>, (ii)
                                         <FONT STYLE="text-transform: uppercase">Net Sales</FONT> and number of units of FINAL
                                         <FONT STYLE="text-transform: uppercase">Product</FONT> sold or distributed during the
                                         <FONT STYLE="text-transform: uppercase">Reporting Period</FONT>, as well as the computation
                                         of such <FONT STYLE="text-transform: uppercase">Net Sales</FONT> amounts, (iii) inventory
                                         of FINAL <FONT STYLE="text-transform: uppercase"> PRODUCT</FONT> at the beginning and
                                         end of such <FONT STYLE="text-transform: uppercase">Reporting Period</FONT>, and (iv)
                                         all other information related to the business of FIOCRUZ during such <FONT STYLE="text-transform: uppercase">Reporting
                                         Period</FONT> to the extent necessary to enable the calculation of amounts payable hereunder
                                         to be verified, and (b) pay PROTALIX all amounts due for such <FONT STYLE="text-transform: uppercase">Reporting
                                         Period</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Other
                                         Payments</U>. Other than the Royalty Payments, which are subject to Article 9.2, all
                                         other payments (including any reimbursements) arising hereunder shall, unless otherwise
                                         set forth herein, be paid not later than [***] of receipt of an invoice or notice therefor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Interest
                                         and other Charges</U>. In the event that PROTALIX does not receive on or prior to the
                                         date when due hereunder all amounts owed by FIOCRUZ to PROTALIX, such unpaid amount shall
                                         be automatically subject to a flat penalty of [***] and monthly adjustment for inflation
                                         based on the positive variation of the [IGP-M/FGV] in the period. Any such amount (as
                                         increased by the penalty and the monetary correction mentioned above) shall bear default
                                         interest from the due date until payment is received by such PARTY at a rate of [***]
                                         per month (the &ldquo;RATE&rdquo;). The above additional charges shall be in addition
                                         to, and not in lieu of, any other remedy available to PROTALIX hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Taxes
                                         and Other Charges</U>. FIOCRUZ represents and warrants to PROTALIX that, as of the EXECUTION
                                         DATE, there are no Brazilian taxes, customs, duties, assessments, excises, registration
                                         fees, surtax, stamp duties, or any other charges that are required to be levied upon
                                         or withheld from the importation of or assessed against the material furnished or rights
                                         licensed by PROTALIX hereunder, or for or on account of the operation of the FACILITY,
                                         the purchase, MANUFACTURE, COMMERCIALIZATION by or on behalf of FIOCRUZ of the SUPPLIED
                                         MATERIALS and PRODUCTS, or other business of FIOCRUZ contemplated under this AGREEMENT,
                                         including any withholding taxes or any such payments related to the registration or recording
                                         of this AGREEMENT, or any related documents (not including any ANVISA registration fees)
                                         (collectively &quot;TAXES AND FEES&quot;), other than as set forth in Exhibit C (which
                                         shall include details regarding applicable percentages and amounts if any such TAXES
                                         AND FEES, and the PARTY to be responsible therefore). If there are any TAXES AND FEES
                                         under Brazilian LAW that are not set forth on Exhibit C and are, or during the TERM become,
                                         in effect (whether as a result of any change in, or amendment to, Brazilian LAWS or otherwise),
                                         and such TAXES AND FEES materially change the dollar amount or timing of payments expected
                                         to be received by PROTALIX hereunder, then (i) the PARTIES shall discuss in good faith
                                         how to address such change in a mutually acceptable manner to compensate PROTALIX for
                                         such change (e.g., by an increase in pricing of PRODUCT, an increase in amount of PRODUCT
                                         to be purchased, etc.), and (ii) if the PARTIES do not come to an agreement in writing
                                         with respect thereto within thirty (30) calendar days, PROTALIX shall have the right
                                         to terminate this AGREEMENT immediately upon written notice to FIOCRUZ.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Currency
                                         and Mode of Payment</U>. All payments to be made hereunder by one PARTY to another PARTY
                                         shall be paid in United States dollars, by electronic transfer in immediately available
                                         funds via either a bank wire transfer, an electronic funds transfer mechanism, at the
                                         paying PARTY&rsquo;s election, to the bank account designated in Appendix VII or otherwise
                                         designated by the PARTY entitled to receive such payment. ROYALTY PAYMENTS and other
                                         payments due hereunder shall be converted into U.S. dollars at the exchange rate quoted
                                         by Brazilian Central Bank (or its successor in interest) at its market rate for the purchase
                                         of U.S. dollars with the applicable currency that needs to be converted (e.g., the currency
                                         of the <FONT STYLE="text-transform: uppercase">Net Sales</FONT> received) and applied
                                         by that bank on the day such payment is made.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Permits</U>.
                                         FIOCRUZ assumes the sole responsibility of procuring <FONT STYLE="text-transform: uppercase">Permits
                                         </FONT>for the export of funds as may be required in the <FONT STYLE="text-transform: uppercase">Territory</FONT>;
                                         <U>provided</U>, <U>however</U>, that to the extent that it is impossible to make such
                                         payments due to the &ldquo;blocking&rdquo; of funds by LAW, such &ldquo;blocked&rdquo;
                                         funds shall be deposited to the credit of PROTALIX, in such depository as PROTALIX designates
                                         or, at the option of PROTALIX, paid directly to a Brazilian entity designated by PROTALIX.
                                         Other than as set forth on Exhibit C, there shall be no deduction or offset from, nor
                                         shall FIOCRUZ have any right to hold back any payment of, any payments owed by FIOCRUZ
                                         hereunder for any reason, including for any uncollectible accounts or other TAXES AND
                                         FEES for which FIOCRUZ is responsible hereunder, or for any banking cost or cost of exchange
                                         or expense of transmitting said funds. FIOCRUZ shall not conduct its business in any
                                         manner intended to reduce the ROYALTY PAYMENTS required to be paid by FIOCRUZ hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: Transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
10. &#9;OWNERSHIP OF ENHANCEMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
                                         invention made, conceived or reduced to practice by PROTALIX in connection with the performance
                                         of the obligations of this AGREEMENT relating to: (i) a pharmaceutical product with the
                                         same chemical composition as the PRODUCT or (ii) an IMPROVEMENT to the PRODUCT or (iii)
                                         an IMPROVEMENT to the process or specifications provided by PROTALIX to FIOCRUZ, shall
                                         be the exclusive property of PROTALIX. PROTALIX, in its sole discretion, may file for
                                         patent protection in its own name for any such invention. PROTALIX shall, and hereby
                                         does, grant to FIOCRUZ a non-exclusive, irrevocable, perpetual, worldwide, royalty-free
                                         license to use, sublicense, practice and otherwise exploit in any manner any such invention
                                         and any patent or other intellectual property or proprietary rights therein throughout
                                         the world.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
11. &#9;CONFIDENTIALITY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
                                         non-public information, which is received or made available by or on behalf of PROTALIX
                                         or FIOCRUZ (each, in such capacity, the &ldquo;RECIPIENT&rdquo;) from or on behalf of
                                         the other (in such capacity, the &ldquo;DISCLOSING PARTY&rdquo;) prior to or during the
                                         <FONT STYLE="text-transform: uppercase">Term</FONT> of this AGREEMENT in connection with
                                         this AGREEMENT or relating hereto, including without limitation, relating to the PRODUCT
                                         or any other pharmaceutical product that contains DRUG SUBSTANCE (&ldquo;CONFIDENTIAL
                                         INFORMATION&rdquo;) shall be maintained in confidence and shall not be disclosed to any
                                         <FONT STYLE="text-transform: uppercase">Third PARTY </FONT>nor used for purposes other
                                         than as set forth herein, without the prior written consent of the DISCLOSING PARTY,
                                         except to the extent that the CONFIDENTIAL INFORMATION: (a) is known to the RECIPIENT
                                         prior to disclosure by the DISCLOSING PARTY to the RECIPIENT through no wrongful act
                                         of the RECIPIENT, provided that the RECIPIENT is able to provide competent proof of such
                                         prior knowledge; (b) is obtained by the RECIPIENT in a lawful manner from a source other
                                         than the DISCLOSING PARTY, which source (i) was not required to hold such secrets or
                                         information in confidence, and (ii) was not limited or restricted in its disclosure thereof,
                                         (c) has become public knowledge other than through the fault of the RECIPIENT; (d) has
                                         been developed by the RECIPIENT independently of the information received as established
                                         by written records. The PROTALIX TECHNOLOGY, SPECIFICATIONS and all other information
                                         relating thereto or to the business, operations, research or development of PROTALIX,
                                         shall be deemed included in the CONFIDENTIAL INFORMATION of PROTALIX.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
                                         the foregoing, RECIPIENT shall be entitled to disclose CONFIDENTIAL INFORMATION to the
                                         extent disclosure by the RECIPIENT is required: (a) to submit applications by the RECIPIENT
                                         for GOVERNMENTAL APPROVALS (i) in the case of FIOCRUZ as RECIPIENT, to MANUFACTURE and
                                         COMMERCIALIZE the <FONT STYLE="text-transform: uppercase">Product </FONT>in accordance
                                         with the terms and conditions of this AGREEMENT, or (ii) in the case of PROTALIX as the
                                         RECIPIENT, in relation to the COMPOUND, DRUG SUBSTANCE, or PRODUCT, (b) in the case of
                                         PROTALIX as the RECIPIENT, in connection with filing or prosecution of the PROTALIX PATENT
                                         RIGHTS or the PRODUCT MARKS, prosecuting or defending litigation relating thereto or
                                         to the PROTALIX TECHNOLOGY, or (c) by LAW or by any THIRD PARTY LICENSE; <U>provided
                                         </U>that the RECIPIENT shall use commercially reasonable efforts to obtain confidential
                                         treatment of any CONFIDENTIAL INFORMATION to the extent applicable and, if reasonably
                                         practicable under the circumstances, provide the DISCLOSING PARTY with sufficient advance
                                         notice of such intended disclosure so that the DISCLOSING PARTY will have the opportunity
                                         to seek, at its own cost, an appropriate protective order or other remedy, to the extent
                                         applicable, or waive compliance with the provisions of this AGREEMENT. If the DISCLOSING
                                         PARTY seeks a protective order, the RECIPIENT will cooperate. If the DISCLOSING PARTY
                                         fails to obtain a protective order or waive compliance with the relevant portions of
                                         this AGREEMENT, the RECIPIENT will disclose only that portion of information concerning
                                         the COMPOUND or PRODUCT which its legal counsel determines it is required to disclose.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         the avoidance of doubt, the [***] shall be deemed included in the CONFIDENTIAL INFORMATION
                                         of PROTALIX. In addition to the obligations set forth in Article 11.1 and 11.2, FIOCRUZ
                                         agrees to (i) treat the [***] with the utmost confidence and in a manner at least as
                                         protective as the manner in which FIOCRUZ protects its own most highly sensitive confidential
                                         information, trade secrets and know-how, (ii) not use such [***] for any purpose other
                                         than for the MANUFACTURING of the FINAL PRODUCT, and (iii) not disclose the information
                                         to any PERSON, other than as permitted pursuant to Article 11.2 to PERSONS (a) who have
                                         a need to know such information for the purpose of MANUFACTURING the FINAL PRODUCT, (b)
                                         who are informed by FIOCRUZ of the confidential nature thereof and the obligations under
                                         this AGREEMENT with respect thereto, and (c) who agree in writing with PROTALIX to comply
                                         with the obligations of FIOCRUZ under this Article 11 with respect thereto.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         confidentiality obligations set forth in this Article 11 shall survive the termination
                                         or expiration of this AGREEMENT until fifteen (15) years from the EFFECTIVE DATE. Notwithstanding
                                         anything to the contrary herein, FIOCRUZ's obligations under this Article 11 with respect
                                         to the [***] shall survive the termination or expiration of this AGREEMENT for no less
                                         than fifteen (15) years from the completion of the transfer of such [***] to FIOCRUZ.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
12. &#9;TERM AND TERMINATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
                                         AGREEMENT shall come into force and effect as of the EFFECTIVE DATE, and shall remain
                                         in force for seven (7) years following the EFFECTIVE DATE, and may be renewed upon the
                                         written agreement of FIOCRUZ and PROTALIX, if INPI authorizes such renewal, for additional
                                         five (5) years periods. If in the end of the initial seven (7) year period or any such
                                         renewal period the TECHNOLOGY TRANSFER has not been COMPLETED, the PARTIES may renew
                                         the AGREEMENT for the period needed for the COMPLETION of the TECHNOLOGY TRANSFER in
                                         accordance with the foregoing sentence (the initial period and any such renewal periods,
                                         collectively, &quot;TERM 1&quot;), and upon COMPLETION of the TECHNOLOGY TRANSFER TERM
                                         1 shall immediately and automatically expire and TERM 2 shall immediately and automatically
                                         commence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall pay royalties hereunder to PROTALIX for the PROTALIX PATENT RIGHTS for the period
                                         of time beginning on the completion of TERM 1 until the later of expiration of the last
                                         to expire PROTALIX patent in Brazil in accordance with ARTICLE 9 (&quot;TERM 2&quot;).
                                         The TERM 2 is valid only for the purpose of royalties payment, any terms and conditions
                                         relating to PROTALIX PATENT RIGHTS or PRODUCT MARKS in any way (including, for the avoidance
                                         of doubt, all license rights and restrictions), and any other obligations that survive
                                         termination or expiration of this AGREEMENT. The other obligations of this AGREEMENT
                                         (i.e., those obligations not referenced in the foregoing sentence) shall expire with
                                         the end of TERM 1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Without
                                         limiting any other provision of this AGREEMENT, this AGREEMENT may be terminated by PROTALIX
                                         as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         FIOCRUZ materially breaches its representations or warranties made in this AGREEMENT,
                                         or materially breaches or materially defaults in the performance or observance of any
                                         of its obligations under this AGREEMENT, and such breach or default is not cured within
                                         [***] after the giving of written notice by PROTALIX, specifying such breach or default,
                                         then PROTALIX shall have the right to terminate this AGREEMENT by providing FIOCRUZ written
                                         notice following the expiration of such [***][***] period (such termination to be effective
                                         upon receipt of such termination notice);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">immediately
                                         upon written notice to FIOCRUZ if any GOVERNMENTAL AUTHORITY announces plans to privatize
                                         FIOCRUZ and a competitor of PROTALIX acquires FIOCRUZ or any part of FIOCRUZ that is
                                         responsible for the MANUFACTURE or COMMERCIALIZATION of PRODUCTS;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         FIOCRUZ fails to make any payment when due in accordance with the terms and conditions
                                         of this AGREEMENT and such failure to pay is not cured within [***] after the giving
                                         of written notice by PROTALIX of such failure, then PROTALIX shall have the right to
                                         terminate this AGREEMENT by providing FIOCRUZ written notice following the expiration
                                         of such [***] period (such termination to be effective upon receipt of such termination
                                         notice);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">immediately
                                         upon written notice if FIOCRUZ undergoes a change of control (as such term is defined
                                         in the definition of AFFILIATE);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">immediately
                                         upon written notice if FIOCRUZ orders, purchases, accepts or otherwise imports from a
                                         third party any product that is a therapy for the treatment of Gaucher Disease;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">immediately
                                         upon written notice in the event of: (i) FIOCRUZ&rsquo;s insolvency or bankruptcy, (ii)
                                         a liquidation committee or team being formed pursuant to the liquidation rules or <FONT STYLE="text-transform: uppercase">Laws
                                         </FONT>of any applicable jurisdiction with respect to FIOCRUZ, or substantially all of
                                         the property or assets of FIOCRUZ is under custody by the liquidation committee under
                                         the provisions of any bankruptcy, insolvency, or similar LAW, (iv) FIOCRUZ making an
                                         assignment for the benefit of its creditors, or (v) FIOCRUZ being dissolved; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         purchase by and supply to FIOCRUZ of SUPPLIED MATERIALS during each STAGE in order to
                                         proceed to the subsequent STAGE of TECHNOLOGY TRANSFER shall occur subject to [***] and
                                         PROTALIX&rsquo;s prior written approval of such quantities. In the event that (i) PROTALIX
                                         does not agree in advance in writing with such quantities proposed by the Brazilian MOH
                                         or (ii) the [***] and corresponding PURCHASE ORDERS issued by FIOCRUZ to PROTALIX for
                                         any year are less than the amount set forth in the following chart for any given year,
                                         PROTALIX shall have the right to terminate this AGREEMENT immediately upon providing
                                         FIOCRUZ written notice:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Yearly
Termination Threshold</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 52%; text-align: left; text-indent: 0in; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Year</B></FONT></TD>
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 39%; text-align: left; text-indent: 0in; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Termination
    Threshold</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From January 1, 2014
    until July 31, 2015</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From August1, 2015
    until July 31, 2016</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From August 1, 2016
    until July 31, 2017</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From August 1, 2017
    until July 31, 2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From August 1, 2018
    until July 31, 2019</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From August 1, 2019
    until July 31, 2020</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Without
                                         limiting any other provision of this AGREEMENT, this AGREEMENT may be terminated by FIOCRUZ
                                         as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         PROTALIX materially breaches its representations or warranties made in this AGREEMENT,
                                         or materially breaches or defaults in the performance or observance of any of its respective
                                         obligations under, this AGREEMENT, and such breach or default is not cured within [***]
                                         after the giving of written notice by FIOCRUZ to PROTALIX specifying such breach or default,
                                         then FIOCRUZ shall have the right to terminate this AGREEMENT by providing PROTALIX written
                                         notice following the expiration of such [***] period (such termination to be effective
                                         upon receipt of such termination notice);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">immediately
                                         upon notice to PROTALIX if FIOCRUZ due to any change in Brazilian LAW is unable to maintain
                                         compliance with this AGREEMENT; <U>provided</U> FIOCRUZ used its best efforts to prevent
                                         any of the foregoing events from occurring and to mitigate or cure any effects thereof
                                         prior to exercising such termination right; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                         the pharmaceutical product <I>plant cell expressed recombinant Glucocerebrosidase</I>
                                         in a finished dosage form of a drug product that contains DRUG SUBSTANCE (excluding any
                                         ORAL FORMULATION) is recalled by both ANVISA and the United States Food and Drug Administration
                                         in a manner that is not curable within [***]. In the case of termination pursuant to
                                         this Section 12.4(c), FIOCRUZ shall not be required to pay any outstanding payment obligations
                                         incurred prior to the effective date of such termination under this AGREEMENT for any
                                         PRODUCT batches subject to such recall.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall notify PROTALIX at least twenty (20) days prior to the occurrence of any of the
                                         events or scenarios described in Articles 12.3(b) and (d) and 12.4(b), or, if not possible
                                         on such time frame, as soon as possible prior to such occurrence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Termination
                                         of this AGREEMENT shall be in addition to, and not in lieu of, any other rights or remedies
                                         available to the terminating PARTY under this AGREEMENT or applicable Brazilian LAW.
                                         Termination of this AGREEMENT in accordance with the terms hereof shall not be the basis
                                         for any compensation or other claim for damages resulting therefrom (including any lost
                                         profits due to such termination), other than as set forth in Section 12.7.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Termination
                                         of this AGREEMENT for any reason (a) shall be without prejudice to and shall not impair
                                         or limit in any manner PROTALIX&rsquo;s right to receive payment from FIOCRUZ in respect
                                         of any payment obligations incurred prior to the effective date<FONT STYLE="text-transform: uppercase">
                                         </FONT>of such termination, whether or not the due date for such payment is after such
                                         effective date of termination and (b) shall not release a PARTY hereto from any indebtedness,
                                         liability, payment or other obligation incurred hereunder (including liability for breach
                                         of this AGREEMENT) by such PARTY prior to the effective date of such termination.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
13. &#9;EFFECTS OF TERMINATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
                                         as expressly provided for hereunder, upon the effective date of termination of this AGREEMENT
                                         in accordance with this AGREEMENT, all licenses and rights granted to FIOCRUZ herein
                                         shall automatically and immediately terminate and FIOCRUZ shall immediately cease all
                                         use of the PROTALIX TECHNOLOGY, PROTALIX PATENTS, SPECIFICATIONS and any other CONFIDENTIAL
                                         INFORMATION provided to FIOCRUZ hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall, promptly after termination of this AGREEMENT, provide to PROTALIX or its designee
                                         (or upon PROTALIX&rsquo;s direction with respect to specific items, destroy) all documents,
                                         data, reports, records, regulatory correspondence and other materials and information
                                         (and any copies thereof) that contain or are related to the PROTALIX TECHNOLOGY, CONFIDENTIAL
                                         INFORMATION disclosed by PROTALIX, and the COMPOUNDS, DRUG SUBSTANCES, CELL BANK, reagents,
                                         and PRODUCTS (including and GOVERNMENTAL APPROVALS and regulatory filings with respect
                                         thereto) in a form and format useable by PROTALIX. Upon such termination, FIOCRUZ shall
                                         assign and transfer to PROTALIX or its designee all of FIOCRUZ&rsquo;s right, title and
                                         interest in and to all GOVERNMENTAL APPROVALS for or related to the PRODUCTS, COMPOUND
                                         or DRUG SUBSTANCE in the <FONT STYLE="text-transform: uppercase">Territory </FONT>and
                                         any related data and other materials transferred or delivered or deliverable by FIOCRUZ
                                         pursuant to this Article 13.2. FIOCRUZ shall execute and deliver to PROTALIX such documents,
                                         and take such other actions requested by PROTALIX that are necessary or appropriate to
                                         carry out the intent and purposes of this Article 13.2 and to perfect and confirm such
                                         assignment, including submitting letters to the GOVERNMENTAL AUTHORITIES in forms reasonably
                                         acceptable to PROTALIX.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Following
                                         termination of this AGREEMENT, upon a PARTY&rsquo;s reasonable request and at such requesting
                                         PARTY&rsquo;s cost, the other PARTY shall reasonably cooperate with the requesting PARTY
                                         (including by providing relevant information and data) in connection with any requests
                                         or investigations of a regulatory authority, any <FONT STYLE="text-transform: uppercase">Third
                                         PARTY</FONT> claims against the requesting PARTY, or such requesting PARTY&rsquo;s efforts
                                         to comply with <FONT STYLE="text-transform: uppercase">Laws</FONT>, relating to the PRODUCTS,
                                         COMPOUND, DRUG SUBSTANCE, PROTALIX TECHNOLOGY, or SPECIFICATIONS.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
                                         termination of this AGREEMENT, FIOCRUZ shall terminate the MANUFACTURE and COMMERCIALIZATION
                                         of any COMPOUND, DRUG SUBSTANCE, or PRODUCTS and, at PROTALIX&rsquo;s sole option, shall
                                         (a) only in the event of termination by PROTALIX pursuant to Article 12.3, arrange the
                                         sale to PROTALIX or its designee at FIOCRUZ&rsquo;s cost of all (or at PROTALIX&rsquo;s
                                         option, a portion of the) SUPPLIED MATERIAL, DRUG SUBSTANCES and PRODUCTS in FIOCRUZ&rsquo;s
                                         inventory, and/or (b) dispose of all (or at PROTALIX&rsquo;s option, a portion of the)
                                         SUPPLIED MATERIAL, DRUG SUBSTANCES and PRODUCTS in FIOCRUZ&rsquo;s inventory.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">13.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
                                         termination of this AGREEMENT, FIOCRUZ shall cooperate with PROTALIX to effect a cancellation
                                         or termination of any recordation of this AGREEMENT with the appropriate <FONT STYLE="text-transform: uppercase">Governmental
                                         Authorities</FONT> in the <FONT STYLE="text-transform: uppercase">Territory</FONT>, and
                                         the FIOCRUZ will grant, and hereby does grant, to PROTALIX an irrevocable power of attorney
                                         coupled with an interest to effect such cancellation within twenty (20) days after the
                                         termination of this AGREEMENT.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
14. &#9;BOOKS AND RECORDS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall keep and maintain during the TERM and for one (1) years after the termination of
                                         this AGREEMENT, accurate and correct books and records setting forth gross sales of the
                                         <FONT STYLE="text-transform: uppercase">PRODUCTS</FONT>, <FONT STYLE="text-transform: uppercase">Net
                                         Sales</FONT>, number of units of <FONT STYLE="text-transform: uppercase">PRODUCT </FONT>sold,
                                         inventory of <FONT STYLE="text-transform: uppercase">PRODUCT</FONT> and all other information
                                         related to the business of FIOCRUZ necessary to enable the calculation of amounts payable
                                         hereunder to be verified and the confirmation of FIOCRUZ&rsquo;s compliance with this
                                         AGREEMENT. PROTALIX shall have the right to request that an independent accountant reasonably
                                         selected by it examine FIOCRUZ&rsquo;s books and records at any reasonable time, upon
                                         reasonable notice and at the <FONT STYLE="text-transform: uppercase">Facilities </FONT>or
                                         other <FONT STYLE="text-transform: uppercase">facilities</FONT> where such books and
                                         records are normally kept. The opinion of such independent accountants regarding such
                                         payments shall be binding on the PARTIES, other than in the case of manifest error. Except
                                         as set forth below, the auditing PARTY shall bear the cost of any such examination and
                                         review.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
                                         the review of FIOCRUZ&rsquo;s records reveals that FIOCRUZ failed to accurately report
                                         information pursuant to Article 9.2 or otherwise underpaid any amounts due hereunder,
                                         then FIOCRUZ&rsquo;s shall promptly pay PROTALIX the amount of any underpayment due hereunder,
                                         which shall be subject to all additional charges mentioned in Article 9.4 above, including
                                         the default interest at the <FONT STYLE="text-transform: uppercase">Rate. </FONT>If such
                                         discrepancy is greater than five percent (5%) of the amount due, FIOCRUZ shall promptly
                                         reimburse all costs incurred by PROTALIX in connection with such examination.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
15. &#9;GOVERNING LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         PARTIES agree that this AGREEMENT shall be governed by and construed in accordance with
                                         the laws of Brazil and the courts of Brazil shall have jurisdiction over any disputes
                                         arising in connection with this AGREEMENT. It is acknowledged that PROTALIX and FIOCRUZ
                                         shall not be excluded from adjudicating and enforcing their rights under this AGREEMENT
                                         as relate to countries other than Brazil (including but not limited to enforcing any
                                         restriction on a PARTY outside the TERRITORY) in courts other than the courts of Brazil.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
16. &#9;INDEMNIFICATION; DISCLAIMER; LIMITATION OF LIABILITY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall indemnify, defend and hold PROTALIX and its AFFILIATES and their respective directors,
                                         officers, shareholders, representatives, agents, successors, assigns, licensors and employees
                                         harmless from and against all <FONT STYLE="text-transform: uppercase">Losses</FONT>,
                                         in each case to the extent arising out of (a) any acts or omissions of FIOCRUZ or any
                                         of its <FONT STYLE="text-transform: uppercase">Affiliates</FONT>, agents, consultants
                                         or contractors in connection with its activities under this AGREEMENT, including MANUFACTURE,
                                         use or sale of the SUPPLIED MATERIALS, COMPOUND, <FONT STYLE="text-transform: uppercase">Drug
                                         Substance</FONT> and/or <FONT STYLE="text-transform: uppercase">ProductS</FONT>, unless
                                         such <FONT STYLE="text-transform: uppercase">Losses</FONT> are for <FONT STYLE="text-transform: uppercase">Losses
                                         </FONT>to which FIOCRUZ is entitled to indemnification pursuant to Article 16.2, as applicable,
                                         (b) the breach of any covenant, warranty or representation made by FIOCRUZ under this
                                         AGREEMENT, or (c) the negligence, recklessness, or willful misconduct of, or violation
                                         of Brazilian LAW by, FIOCRUZ or any of its <FONT STYLE="text-transform: uppercase">Affiliates</FONT>,
                                         agents, consultants or contractors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         shall indemnify, defend and hold FIOCRUZ and its AFFILIATES and their respective directors,
                                         officers, shareholders, representatives, agents, successors, assigns, and employees harmless
                                         from and against all <FONT STYLE="text-transform: uppercase">Losses</FONT> arising from
                                         <FONT STYLE="text-transform: uppercase">Third PARTY</FONT> <FONT STYLE="text-transform: uppercase">Claims
                                         </FONT>that the MANUFACTURE and sale of the PRODUCTS by FIOCRUZ within the <FONT STYLE="text-transform: uppercase">Territory
                                         </FONT>for the <FONT STYLE="text-transform: uppercase">Field</FONT> in accordance with
                                         the terms and conditions hereof, infringes any <FONT STYLE="text-transform: uppercase">Patent
                                         Rights</FONT> of any THIRD PARTY.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
                                         purposes of this AGREEMENT, &ldquo;THIRD PARTY CLAIM&rdquo; means a claim asserted by
                                         a <FONT STYLE="text-transform: uppercase">Third PARTY</FONT> (in no event to include
                                         any <FONT STYLE="text-transform: uppercase">Affiliate </FONT>of either PARTY) against
                                         a PARTY or any of its <FONT STYLE="text-transform: uppercase">Affiliates</FONT>, or any
                                         of their respective directors, officers, shareholders, representatives, agents, successors,
                                         assigns, licensors or employees. In the event a <FONT STYLE="text-transform: uppercase">Third
                                         PARTY Claim</FONT> is asserted or LOSSES are incurred with respect to any matter for
                                         which a PARTY or any of its <FONT STYLE="text-transform: uppercase">Affiliates</FONT>,
                                         or any of their respective directors, officers, shareholders, representatives, agents,
                                         successors, assigns, licensors and employees (the &ldquo;INDEMNIFIED PARTY&rdquo;) is
                                         entitled to indemnification hereunder, then the <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT> shall promptly notify in writing the PARTY obligated to indemnify the <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT> (the &ldquo;INDEMNIFYING PARTY&rdquo;) thereof; <U>provided</U>, however,
                                         that no delay on the part of the <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT> in notifying the <FONT STYLE="text-transform: uppercase">Indemnifying PARTY
                                         </FONT>shall relieve the <FONT STYLE="text-transform: uppercase">Indemnifying PARTY</FONT>
                                         from any obligation hereunder unless (and then only to the extent that) the <FONT STYLE="text-transform: uppercase">Indemnifying
                                         PARTY</FONT> is prejudiced thereby.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         <FONT STYLE="text-transform: uppercase">Indemnifying PARTY</FONT> shall assume direction
                                         and control of the defense, litigation, settlement, appeal or other disposition of the
                                         <FONT STYLE="text-transform: uppercase">Third PARTY Claim</FONT> (including the right
                                         to settle the claim solely for monetary consideration) with counsel selected by the <FONT STYLE="text-transform: uppercase">Indemnifying
                                         PARTY </FONT>and reasonably acceptable to the <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT>. The <FONT STYLE="text-transform: uppercase">Indemnified PARTY</FONT> shall
                                         have the right to join in (including the right to conduct discovery, interview and examine
                                         witnesses and participate in all settlement conferences), but not control, at its own
                                         expense, the defense of any <FONT STYLE="text-transform: uppercase">Third PARTY Claim
                                         </FONT>that the <FONT STYLE="text-transform: uppercase">Indemnifying PARTY</FONT> is
                                         defending as provided in this AGREEMENT. Notwithstanding anything to the contrary contained
                                         herein, an <FONT STYLE="text-transform: uppercase">Indemnified PARTY</FONT> shall be
                                         entitled to assume the defense of any <FONT STYLE="text-transform: uppercase">Third PARTY
                                         Claim</FONT> with respect to the <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT>, (i) upon written notice to the <FONT STYLE="text-transform: uppercase">Indemnifying
                                         PARTY</FONT>, in which case the <FONT STYLE="text-transform: uppercase">Indemnifying
                                         PARTY</FONT> shall be relieved of liability under Article 16.1 or 16.2, as applicable,
                                         solely for such <FONT STYLE="text-transform: uppercase">Third PARTY Claim</FONT> and
                                         related <FONT STYLE="text-transform: uppercase">Losses, </FONT>or (ii) in the event the
                                         INDEMNIFYING PARTY refuses or fails to assume the defense as required hereunder, in which
                                         case the <FONT STYLE="text-transform: uppercase">Indemnifying PARTY</FONT> shall not
                                         be relieved of liability under Article 16.1 or 16.2, as applicable, solely for such <FONT STYLE="text-transform: uppercase">Third
                                         PARTY Claim</FONT> and related <FONT STYLE="text-transform: uppercase">Losses</FONT>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         will not enter into any settlement of any THIRD PARTY CLAIM for which PROTALIX or any
                                         of its <FONT STYLE="text-transform: uppercase">Affiliates</FONT>, or any of their respective
                                         directors, officers, shareholders, representatives, agents, successors, assigns, licensors
                                         or employees is entitled to indemnification hereunder involving PROTALIX TECHNOLOGY,
                                         PROTALIX PATENT RIGHTS, CONFIDENTIAL INFORMATION of PROTALIX, PRODUCT MARKS, COMPOUND,
                                         <FONT STYLE="text-transform: uppercase">Drug Substance</FONT>, <FONT STYLE="text-transform: uppercase">PRODUCTS
                                         </FONT>or SUPPLIED MATERIALS, without such <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT>&rsquo;s prior written consent. Without limiting the foregoing, FIOCRUZ shall
                                         not, without the written consent of the <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT> (which consent shall not be unreasonably withheld), effect any settlement
                                         of any pending or threatened litigation in which the <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT> has sought indemnification hereunder by FIOCRUZ, unless such settlement
                                         involves solely monetary damages and includes an unconditional release of the <FONT STYLE="text-transform: uppercase">Indemnified
                                         PARTY</FONT> from all liability on claims that are the subject matter of such litigation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IN
                                         NO EVENT SHALL EITHER PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER THIS
                                         AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT,
                                         WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING LOSS OF PROFITS
                                         OR REVENUE, SUFFERED BY PROTALIX, FIOCRUZ OR ANY OF THEIR RESPECTIVE AFFILIATES. THE
                                         FOREGOING SENTENCE SHALL NOT LIMIT (A) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE
                                         OTHER PARTY AS PROVIDED HEREUNDER, (B) ANY LIABILITIES RESULTING FROM A BREACH OF THE
                                         CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 11 OR FROM USE OF ANY INTELLECTUAL PROPERTY
                                         OTHER THAN IN ACCORDANCE WITH THE LICENSE GRANTED PURSUANT TO ARTICLE 4, OR (C) ANY PAYMENT
                                         OBLIGATIONS UNDER THIS AGREEMENT. <FONT STYLE="font-size: 10pt">EXCEPT FOR LOSSES TO
                                         THE EXTENT RESULTING FROM PROTALIX'S GROSS NEGLIGENCE, FRAUD OR WILLFUL MISCONDUCT, IN
                                         NO EVENT SHALL PROTALIX'S TOTAL LIABILITY TO FIOCRUZ ARISING IN CONNECTION WITH THE SUPPLY
                                         OF SUPPLIED MATERIALS PURSUANT TO SECTION 6 HEREOF EXCEED, ON A SUPPLIED MATERIAL-BY-SUPPLIED
                                         MATERIAL BASIS, THE TOTAL AMOUNT PAID BY FIOCRUZ FOR SUCH SUPPLIED MATERIAL.</FONT><B>
                                         </B></FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
17. &#9;WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
                                         PARTY hereby represents and warrants as of the EXECUTION DATE and the <FONT STYLE="text-transform: uppercase">Effective
                                         Date </FONT>that such PARTY has the requisite corporate power and authority to execute
                                         and deliver this AGREEMENT and to perform its obligations hereunder, and that the execution,
                                         delivery and performance of this AGREEMENT by such PARTY has been duly and validly authorized
                                         and approved by proper corporate action on the part of such PARTY, and such PARTY has
                                         taken all other action required by LAW, its certificate of incorporation, by-laws or
                                         other organizational documents, required to authorize such execution, delivery and performance.
                                         Assuming due authorization, execution and delivery on the part of the other PARTY, each
                                         PARTY represents and warrants as of the EFFECTIVE DATE that this AGREEMENT constitutes
                                         a legal, valid and binding obligation of such PARTY, enforceable against such PARTY in
                                         accordance with its terms.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         hereby represents and warrants to PROTALIX as of the EXECUTION DATE and the EFFECTIVE
                                         DATE, and covenants to PROTALIX, as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                         connection with the COMPOUND, <FONT STYLE="text-transform: uppercase">Drug Substance
                                         </FONT>and <FONT STYLE="text-transform: uppercase">ProductS Manufactured</FONT> by, or
                                         under authority of, FIOCRUZ: (i) any FACILITY and all equipment, tooling and molds utilized
                                         in the <FONT STYLE="text-transform: uppercase">Manufacture </FONT>hereunder by FIOCRUZ
                                         shall be maintained in good operating condition and shall be maintained and operated
                                         in accordance with all applicable Brazilian <FONT STYLE="text-transform: uppercase">Laws
                                         </FONT>and GMP, (ii) the <FONT STYLE="text-transform: uppercase">Manufacturing, COMMERCIALIZATION
                                         </FONT>and storage operations, procedures and processes utilized by FIOCRUZ hereunder
                                         (including any F<FONT STYLE="text-transform: uppercase">acility</FONT>) shall be in full
                                         compliance with all applicable Brazilian<FONT STYLE="text-transform: uppercase"> Laws</FONT>,
                                         including GMP and Brazilian health and safety <FONT STYLE="text-transform: uppercase">Laws</FONT>,
                                         (iii) FIOCRUZ shall hold all <FONT STYLE="text-transform: uppercase">Permits</FONT> required
                                         by any <FONT STYLE="text-transform: uppercase">Governmental Authority</FONT> for it to
                                         <FONT STYLE="text-transform: uppercase">ManufacturE, COMMERCIALIZE </FONT>and otherwise
                                         distribute the COMPOUND, <FONT STYLE="text-transform: uppercase">Drug Substance</FONT>
                                         and PRODUCTS in accordance with this AGREEMENT (subject to Article 5.1.5), and (iv) the
                                         PRODUCTS, or its containers, shall be marked by FIOCRUZ in accordance with the applicable
                                         patent marking LAWS.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         COMPOUND, <FONT STYLE="text-transform: uppercase">Drug Substance</FONT> and <FONT STYLE="text-transform: uppercase">ProductS</FONT>,
                                         as applicable, shall be <FONT STYLE="text-transform: uppercase">Manufactured</FONT>,
                                         COMMERCIALIZED, packaged, labeled, handled, stored and shipped by FIOCRUZ, in accordance
                                         with the SPECIFICATIONS and in compliance with all applicable Brazilian <FONT STYLE="text-transform: uppercase">Laws
                                         </FONT>and GMP, and in accordance with the <FONT STYLE="text-transform: uppercase">PHARMACOVIGILANCE
                                         AGREEMENT</FONT> and any other quality assurance requirements provided in writing to
                                         FIOCRUZ by PROTALIX, and this AGREEMENT.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall not allow the introduction into the <FONT STYLE="text-transform: uppercase">Drug
                                         SUBSTANCE</FONT> or PRODUCTS of (i) any material that has not been used, handled or stored
                                         in accordance with the <FONT STYLE="text-transform: uppercase">Specifications</FONT>,
                                         all applicable Brazilian<FONT STYLE="text-transform: uppercase"> Laws</FONT>, GMP, the
                                         <FONT STYLE="text-transform: uppercase">PHARMACOVIGILANCE AGREEMENT,</FONT> (ii) any
                                         material that would cause the <FONT STYLE="text-transform: uppercase">Drug Substance
                                         </FONT>or <FONT STYLE="text-transform: uppercase"> ProductS</FONT> to be adulterated
                                         or misbranded within the meaning of any Brazilian<FONT STYLE="text-transform: uppercase">
                                         Laws</FONT>, and (iii) any defects in material and workmanship.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
                                         PARTY does not, to such PARTY's knowledge, currently employ and will not knowingly employ
                                         during the <FONT STYLE="text-transform: uppercase">Term</FONT>, and does not, to such
                                         PARTY's knowledge, use as a subcontractor and will not knowingly use as a subcontractor
                                         during the <FONT STYLE="text-transform: uppercase">Term</FONT>, and such subcontractors
                                         do not, to such PARTY's knowledge, currently employ and will not employ or engage during
                                         the <FONT STYLE="text-transform: uppercase">Term</FONT>, any <FONT STYLE="text-transform: uppercase">Person
                                         </FONT>that has been debarred or has otherwise been disqualified or suspended from performing
                                         scientific or clinical investigations or otherwise subjected to any restrictions or sanctions
                                         by the ANVISA or any other <FONT STYLE="text-transform: uppercase">Governmental Authority
                                         </FONT>or professional body with respect to the performance of scientific or clinical
                                         investigations, or any <FONT STYLE="text-transform: uppercase">Person</FONT> finally
                                         convicted of a criminal offense, with no existing rights to appeal such conviction, in
                                         relation to: (i) the development or approval (including the process for development or
                                         approval) of an abbreviated drug application, (ii) the development or approval of any
                                         drug product or otherwise relating to the regulation of any drug product, or (iii) bribery,
                                         payment of illegal gratuities, fraud, perjury, racketeering, blackmail, extortion, falsification
                                         or destruction of records or interference with, obstruction of an investigation into
                                         a prosecution of any criminal offense.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall operate and maintain all equipment used at the <FONT STYLE="text-transform: uppercase">Facilities
                                         </FONT>in a safe manner and provide adequate employee training with respect thereto.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
                                         PARTY has not, to such PARTY's knowledge, and will not knowingly offer or pay, or authorize
                                         such offer or payment, of any money or anything of value or improperly seek to influence
                                         any <FONT STYLE="text-transform: uppercase">Government Official</FONT> in connection
                                         with this AGREEMENT. For purposes of this Article, a &ldquo;GOVERNMENT OFFICIAL&rdquo;
                                         is defined as and includes: (i) any elected or appointed government official (e.g., a
                                         member of a ministry of health); (ii) any employee or person acting for or on behalf
                                         of a government official, agency, or enterprise performing a governmental function; (iii)
                                         any political party, officer, employee, or person acting for or on behalf of a political
                                         party or candidate for public office; (iv) an employee or person acting for or on behalf
                                         of a public international organization; or (v) any person otherwise categorized as a
                                         <FONT STYLE="text-transform: uppercase">Government Official</FONT> under local law where
                                         &ldquo;government&rdquo; includes all levels and subdivisions of non-U.S. governments
                                         (i.e., local, regional, or national and administrative, legislative, or executive).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FIOCRUZ
                                         shall (i) not use, sell or distribute the <FONT STYLE="text-transform: uppercase">PRODUCTS
                                         </FONT>or any other product that contains the DRUG SUBSTANCE, for any purpose other than
                                         as set forth herein, (ii) use the SUPPLIED MATERIALS and PROTALIX TECHNOLOGY solely for
                                         the purpose of converting such SUPPLIED MATERIALS into the PRODUCTS for sale within the
                                         <FONT STYLE="text-transform: uppercase">Territory </FONT>in the <FONT STYLE="text-transform: uppercase">Field,
                                         </FONT>in accordance with this AGREEMENT, (iii) not source materials for inclusion in
                                         the PRODUCTS other than through PROTALIX, and (iv) not sell, distribute or use a <FONT STYLE="text-transform: uppercase">Product
                                         </FONT>if it does not conform with the SPECIFICATIONS.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         hereby represents and warrants to FIOCRUZ that, to its knowledge, as of the EXECUTION
                                         DATE and the <FONT STYLE="text-transform: uppercase">Effective Date</FONT>:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         COMPOUND, DRUG SUBSTANCE, BULK PRODUCT, NAKED VIAL, CELL BANK and the FINISHED PACKAGED
                                         PRODUCT supplied by PROTALIX to FIOCRUZ hereunder is in full compliance with all applicable
                                         Brazilian <FONT STYLE="text-transform: uppercase">Laws</FONT>, including GMP and Brazilian
                                         health and safety <FONT STYLE="text-transform: uppercase">Laws.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.4in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.6in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         PROTALIX PATENT RIGHTS, PROTALIX TECHNOLOGY, PRODUCT MARKS or CONFIDENTIAL INFORMATION
                                         does not infringe any THIRD PARTY rights.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
                                         hereby covenants to FIOCRUZ that the COMPOUND, DRUG SUBSTANCE, BULK PRODUCT, NAKED VIAL,
                                         CELL BANK and the FINISHED PACKAGED PRODUCT supplied by PROTALIX to FIOCRUZ hereunder
                                         shall be in full compliance with GMP.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Disclaimer
                                         of Warranty</U>. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY
                                         MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE COMPOUND, DRUG SUBSTANCE,
                                         THE PRODUCT, PROTALIX PATENT RIGHTS, PROTALIX TECHNOLOGY, PRODUCT MARKS OR CONFIDENTIAL
                                         INFORMATION. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, EACH PARTY EXPRESSLY
                                         DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY,
                                         FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: left; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: left; text-indent: -1in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: left; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
18. &#9;PHARMACOVIGILANCE AGREEMENT/QUALITY AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         PARTIES agree to comply with the terms and conditions of the Pharmacovigilance Agreement
                                         set forth as Appendix VIII.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         PARTIES agree in good faith to establish&nbsp;mutually agreeable quality guidelines&nbsp;following
                                         the EXECUTION DATE and prior to distribution of PRODUCT by FIOCRUZ, which shall cover,
                                         amongst other matters, delivery and storage of PRODUCT by FIOCRUZ.&nbsp; The PARTIES
                                         agree to comply with such quality guidelines during the TERM.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
19. &#9;APPROVALS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
                                         where expressly stated otherwise herein, all approvals and consent rights of a PARTY
                                         under this AGREEMENT shall be in such PARTY&rsquo;s sole and absolute but good faith
                                         discretion. Any approval or consent may be subject to such conditions as such PARTY deems
                                         appropriate or be granted on a &ldquo;test&rdquo; or temporary basis, in each case to
                                         the extent identified to the PARTY requesting such approval or consent. If a PARTY does
                                         not grant any required approval or consent within ten (10) <FONT STYLE="text-transform: uppercase">business
                                         Days</FONT> of any submission or request for approval or consent, such submission or
                                         request shall be deemed to be disapproved.</FONT></TD></TR></TABLE>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.1pt; text-align: justify; text-indent: -1in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ARTICLE
20. &#9;MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Force
                                         Majeure</U>. Neither PARTY shall be liable to the other PARTY for any losses or damages
                                         attributable to a default under or breach of this AGREEMENT that is the result of war
                                         (whether declared or undeclared), acts of God, revolution, acts of terror, fire, earthquake,
                                         flood, pestilence, riot, enactment or change of LAW (following the <FONT STYLE="text-transform: uppercase">EXECUTION
                                         Date</FONT>) making performance of this AGREEMENT by such PARTY impossible, accident(s),
                                         labor trouble, shortage of or inability to obtain material equipment or transport or
                                         any other cause beyond the reasonable control of such PARTY (each, a &ldquo;FORCE MAJEURE
                                         EVENT&rdquo;); <U>provided </U>that if such a cause occurs, then the PARTY affected will
                                         promptly notify the other PARTY of the nature and likely result and duration (if known)
                                         of such cause and use its commercially reasonable efforts to avoid or remove such causes
                                         of nonperformance as soon as is reasonably practicable. Upon termination of the <FONT STYLE="text-transform: uppercase">Force
                                         Majeure Event</FONT>, the performance of any suspended obligation or duty shall promptly
                                         recommence. If the event lasts for a period of longer than one (1) month, the PARTIES
                                         shall meet and work diligently to implement appropriate remedial measures. Notwithstanding
                                         anything to the contrary herein, despite the existence of any such <FONT STYLE="text-transform: uppercase">Force
                                         Majeure Event</FONT> affecting FIOCRUZ's ability to pay all monies due hereunder for
                                         PRODUCTS delivered or services or licenses provided hereunder, FIOCRUZ shall pay any
                                         such amounts immediately upon the termination of such FORCE MAJEURE EVENT without penalty
                                         for any such delay during the continuance of the FORCE MAJEURE EVENT, in accordance with
                                         the terms hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Severability</U>.
                                         If and solely to the extent that any provision of this AGREEMENT shall be invalid or
                                         unenforceable, such offending provision shall be of no effect and shall not affect the
                                         enforceability or validity of the remainder of this AGREEMENT or any of its provisions;
                                         <U>provided, however</U>, the PARTIES shall use their respective reasonable efforts to
                                         mutually agree to replace the invalid provisions in a manner that best accomplishes the
                                         original intentions of the PARTIES.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Waivers</U>.
                                         Any term or condition of this AGREEMENT may be waived at any time by the PARTY that is
                                         entitled to the benefit thereof, but no such waiver shall be effective unless set forth
                                         in a written instrument duly executed by or on behalf of the PARTY waiving such term
                                         or condition. Neither the waiver by any PARTY of any term or condition of this AGREEMENT
                                         nor the failure on the part of any PARTY, in one or more instances, to enforce any of
                                         the provisions of this AGREEMENT or to exercise any right or privilege, shall be deemed
                                         or construed to be a waiver of such term or condition for any similar instance in the
                                         future or of any subsequent breach hereof. All rights, remedies, undertakings, obligations
                                         and agreements contained in this AGREEMENT shall be cumulative and none of them shall
                                         be a limitation of any other remedy, right, undertaking, obligation or agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Entire
                                         Agreement; Amendments</U>. This AGREEMENT (together with any agreements between the PARTIES
                                         expressly contemplated to be entered into by this AGREEMENT) sets forth the entire agreement
                                         and understanding between the PARTIES as to the subject matter hereof and supersedes
                                         all agreements or understandings, verbal or written, made between FIOCRUZ and PROTALIX
                                         before the EXECUTION DATE with respect to the subject matter hereof. <B><I> </I></B>All
                                         <FONT STYLE="text-transform: uppercase">Confidential Information</FONT> disclosed between
                                         FIOCRUZ and PROTALIX prior to the <FONT STYLE="text-transform: uppercase">Effective Date
                                         </FONT>will be deemed to have been disclosed pursuant to and under this AGREEMENT. None
                                         of the terms of this AGREEMENT shall be amended, supplemented or modified except in writing
                                         signed by the PARTIES.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Survival</U>.
                                         The provisions of Articles 1, 4.3, 4.6, 4.7, 8.6, 9 (for any payment obligations incurred
                                         during the TERM until the date of termination), 10, 11, 12.6, 12.7, 13, 14, 15, 16, 17,
                                         19 and 20, as well as (i) any other Articles, Exhibits, Schedules or Appendices or defined
                                         terms referred to in such Articles necessary to give them effect and (ii) any other provision
                                         that by its terms expressly survives termination of this AGREEMENT, shall survive termination
                                         of this AGREEMENT and remain in force until discharged in full. Furthermore, any other
                                         provisions required to interpret and enforce the PARTIES&rsquo; rights and obligations
                                         or to wind up their outstanding obligations under this AGREEMENT shall survive to the
                                         extent required, including any payment obligations incurred during the <FONT STYLE="text-transform: uppercase">Term
                                         </FONT>or pursuant to any surviving Article.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Assignment;
                                         Binding Effect</U>. Neither this AGREEMENT nor any rights or obligations of FIOCRUZ in,
                                         to or under this AGREEMENT may be assigned or otherwise transferred by FIOCRUZ without
                                         the prior written consent of PROTALIX. For purposes of this AGREEMENT, an &ldquo;assignment&rdquo;
                                         includes any change of control of FIOCRUZ (as such term is defined in the definition
                                         of AFFILIATES) or assignment by operation of LAW. PROTALIX may assign this AGREEMENT
                                         or any of its rights or obligations hereunder, in whole or in part, with the prior consent
                                         of FIOCRUZ (such consent not to be unreasonably withheld or delayed); <U>provided</U>
                                         that, for the avoidance of doubt, no such consent of FIOCRUZ shall be required for an
                                         assignment in connection with a change of control (as such term is defined in the definition
                                         of AFFILIATES), merger or reorganization of PROTALIX or any of its AFFILIATES, or a sale
                                         or other transfer by PROTALIX or any of its AFFILIATES of all or substantially all of
                                         the assets or business to which this AGREEMENT relates. Subject to the foregoing, this
                                         AGREEMENT shall be binding upon and inure to the benefit of the PARTIES and their successors,
                                         respective heirs, and legal representatives. Any purported assignment in violation of
                                         this Article 20.6 shall be void <I>ab initio</I>. Any permitted assignee shall assume
                                         all obligations of its assignor under this AGREEMENT. Notwithstanding the foregoing,
                                         should Bio-Manguinhos become a company controlled by FIOCRUZ (Empresa Brasileira de Biotecnologia
                                         em Sa&uacute;de - Bio-Manguinhos), both parties consent that this agreement may be transferred
                                         to such company at FIOCRUZ's sole discretion without <FONT STYLE="text-transform: uppercase">Protalix
                                         </FONT>written consent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Independent
                                         Contractor</U>. The relationship between the PARTIES is that of independent contractors.
                                         The PARTIES are not joint venturers, partners, principal and agent, employer and employee,
                                         and have no other relationship other than independent contracting parties. Neither PARTY
                                         has the authorization or right hereunder to make any representations, enter into any
                                         agreements or assume any other obligations on behalf of the other PARTY.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Publicity</U>.
                                         FIOCRUZ shall not make (and shall cause its <FONT STYLE="text-transform: uppercase">Affiliates
                                         </FONT>not to make) any press release or public statement (written or oral) concerning
                                         the terms of, or events related to, this AGREEMENT or concerning PROTALIX, the <FONT STYLE="text-transform: uppercase">PRODUCT</FONT>,
                                         COMPOUND, DRUG SUBSTANCE, SUPPLIED MATERIALS, or PROTALIX TECHNOLOGY, without the prior
                                         written approval of PROTALIX, except where such statement is required by Brazilian LAW.
                                         In the case of any press release or public statement (written or oral) that is required
                                         by Brazilian LAW, FIOCRUZ shall use all reasonable efforts to give PROTALIX sufficient
                                         advance notice of the text of any such public statement, so that PROTALIX will have the
                                         opportunity to comment upon the statement, and give due consideration to any of PROTALIX's
                                         comments on such text.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notices</U>.
                                         All notices, consents, approvals, requests or other communications required hereunder
                                         given by one PARTY to the other hereunder shall be in writing and made by registered
                                         or certified air mail, facsimile, express overnight courier or delivered personally to
                                         the following addresses of the respective PARTIES:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 18%; padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
    to PROTALIX:</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 77%; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Protalix
    Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2
    Snunit Street</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Science
    Park</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">P.O.B
    455</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carmiel
    20100, Israel</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention:&nbsp;&nbsp;&nbsp;Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Facsimile:&nbsp;&nbsp;972-4-988-9489</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to FIOCRUZ:</FONT></TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 77%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fiocruz</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bio-Manguinhos</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pavilh&atilde;o Rocha Lima &ndash;
    6 andar</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Avenida Brasil, 4365, Manguinhos</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rio de Janeiro, CEP: 21040-360</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Brazil</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention: Bio-Manguinhos Director</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Facsimile:<B> </B>+ 55 21 3882-7176</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notices
hereunder shall be deemed to be effective (a) upon receipt if personally delivered, (b) on the tenth (10th) <FONT STYLE="text-transform: uppercase">Business
Day</FONT> following the date of mailing if sent by registered or certified air mail and (c) on the first (1st) <FONT STYLE="text-transform: uppercase">Business
Day</FONT> following the date of transmission or delivery to the overnight courier if sent by facsimile or overnight courier.
A PARTY may change its address listed above by sending notice to the other PARTY in accordance with this Article 20.9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Third
                                         Party Beneficiaries</U>. Except for the rights of PERSONS not a PARTY to this AGREEMENT
                                         to indemnification pursuant to Article 16 (which is intended to benefit such PERSONS),
                                         none of the provisions of this AGREEMENT shall be for the benefit of or enforceable by
                                         any <FONT STYLE="text-transform: uppercase">Third PARTY</FONT>, including any creditor
                                         of any PARTY. No <FONT STYLE="text-transform: uppercase">Third PARTY</FONT> shall obtain
                                         any right under any provision of this AGREEMENT or shall by reason of any such provision
                                         make any claim in respect of any debt, liability or obligation (or otherwise) against
                                         any PARTY.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.11</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Subcontractors</U>.
                                         FIOCRUZ shall not use any subcontractors to perform its obligations or exercise its rights
                                         hereunder, without the prior written consent of PROTALIX. PROTALIX may use one or more
                                         of its <FONT STYLE="text-transform: uppercase">Affiliates </FONT>or any reasonably able
                                         <FONT STYLE="text-transform: uppercase">Third PARTIES</FONT> to exercise its rights or
                                         perform its obligations hereunder (including each other). Despite any such subcontracting
                                         the PARTIES shall remain liable hereunder for the performance of all of its obligations
                                         hereunder (including the payment of any amounts due hereunder).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.12</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Headings</U>.
                                         Headings in this AGREEMENT are included herein for ease of reference only and shall have
                                         no legal effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">20.13</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Language.
                                         </U>This AGREEMENT has been prepared in the English language and has been translated
                                         into the Portuguese language and the Portuguese language version shall control all questions
                                         of interpretation and performance hereof. If there is any difference in meaning between
                                         any portion of the English version and any other version, the Portuguese version shall
                                         prevail. Unless otherwise specifically required by Brazilian LAW or by written agreement
                                         of the PARTIES or as otherwise provided herein, all notices and other communications
                                         required or permitted under this AGREEMENT shall be made in the English language.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: center; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: center; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: center; text-indent: -0.5in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">IN
WITNESS WHEREOF the PARTIES hereto have caused this AGREEMENT to be executed by their duly authorized officers upon the date set
out below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Funda&ccedil;&atilde;o
    Oswaldo Cruz</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(on behalf of itself
    and the Immunobiological</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Technology Institute
    (Bio-Manguinhos))</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 7%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 23%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 70%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Paulo
    Gadelha</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Paulo Gadelha</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Protalix Ltd.</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ David
    Aviezer</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">David Aviezer</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and CEO</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>[Signature
Page to Technology Transfer and Supply Agreement]</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>APPENDIX
I</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>PROTALIX
TECHNOLOGY (INCLUDING SPECIFICATIONS)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Appendix <!-- Field: Sequence; Type: UpperRoman; Name: PageNo -->I<!-- Field: /Sequence -->]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>APPENDIX
II</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>TECHNOLOGY
TRANSFER</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Appendix <!-- Field: Sequence; Type: UpperRoman; Name: PageNo -->II<!-- Field: /Sequence -->]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">APPENDIX
III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>FORM
OF ACCEPTANCE CERTIFICATE</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>ACCEPTANCE
CERTIFICATE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[DATE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">RE:&#9;Completion
of Technology Transfer Stage [#]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reference
is hereby made to the Technology Transfer Agreement by and between PROTALIX LTD., a limited liability company incorporated under
the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B 455, Carmiel 20100, Israel (&ldquo;Protalix&rdquo;)
and FUNDA&Ccedil;&Atilde;O OSWALDO CRUZ, an agency of the Brazilian Ministry of Health organized under the laws of Brazil, including
its manufacturing unit &ldquo;BIO-MANGUINHOS&rdquo;, with registered offices at Avenida Brasil, 4365, Manguinhos, Rio de Janeiro,
RJ, Cep 21045-900, Brazil, CGC NI 33.781.055/0001-35 (the &ldquo;Agreement&rdquo;). All capitalized terms contained herein shall
have the meaning ascribed to such terms in the Agreement. Pursuant to the Agreement, PROTALIX and FIOCRUZ hereby acknowledge and
agree that (i) the COMPLETION REQUIREMENTS of STAGE [X] of the TECHNOLOGY TRANSFER have been achieved, (ii) PROTALIX has fulfilled
its obligations with respect to STAGE [X], including the TECHNOLOGY TRANSFER, supply of the SUPPLIED MATERIALS, and any technical
assistance and training for such STAGE, and (iii) STAGE [X] is now complete and the Parties can proceed to STAGE [X+1].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">PROTALIX
    LTD.</FONT></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FUNDA&Ccedil;&Atilde;O
    OSWALDO CRUZ</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:
    &#9;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Print
    Name:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Print
    Name:&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Appendix <!-- Field: Sequence; Type: UpperRoman; Name: PageNo -->III<!-- Field: /Sequence -->]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: center; text-indent: -2in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: center; text-indent: -2in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>APPENDIX
IV &ndash; PURCHASE ORDER</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left; text-indent: -2in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left; text-indent: -2in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Appendix <!-- Field: Sequence; Type: UpperRoman; Name: PageNo -->IV<!-- Field: /Sequence -->]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>APPENDIX
V</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>PFIZER
APPROVAL</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>To
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Ag&ecirc;ncia
Nacional de Vigil&acirc;ncia Sanit&aacute;ria (ANVISA/MS)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -7.1pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DECLARATION
OF IMPORT AUTHORIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">BY
LEGAL ENTITY WHICH DOES NOT HOLD REGULARIZATION BEFORE ANVISA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Legal
Basis: RDC N&ordm; 81/08 &ndash; CHAPTER VII &ndash; ITEM 7B)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -7.1pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>REFERENCE:
Import License/IL n&ordm;</B> _____/_________________-________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
company Laborat&oacute;rios PFIZER Ltda., with (address), duly regularized before ANVISA &ndash; Ag&ecirc;ncia Nacional de Vigil&acirc;ncia
Sanit&aacute;ria under N&ordm; ___________, represented by its Legal Representative ______________________________ and Legal Responsible
______________________________, and by its Technical Responsible _______________________________, undersigned, grants authorization
to import, directly from its supplier Protalix Ltd., the product indicated below, and which holds the regularization document
before Minist&eacute;rio da Sa&uacute;de/Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Authorized
    Importer:</B></FONT></TD>
    <TD STYLE="width: 71%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fiocruz
                                         &ndash; Instituto de Tecnologia em Imunobiol&oacute;gicos, Bio-Manguinhos</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">CNPJ
        n&ordm; 33.781.055/0015-30</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 49%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Description
    of the health product:</B></FONT></TD>
    <TD STYLE="width: 31%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
    n&ordm; at ANVISA</B></FONT></TD>
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Term</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">____________________________________</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">_________________________</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">________________</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
compliance with the determination of RDC n&ordm; 81/08, we authorize exclusively the importer mentioned above to use the abovementioned
register, and, therefore, its transfer is prohibited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expressly assume the commitment to and compliance with the standards and procedures of health legislation, as well as the science
of the penalties to which we will be subject, pursuant to Law No. 6437, August 1977.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
Representative: ___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal
Responsible:___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Technical
Responsible: ___________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valid
for 90 days from issuance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rio
de Janeiro, __________________________.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Representative
    </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Responsible</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">_____________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Technical
Responsible</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Appendix <!-- Field: Sequence; Type: UpperRoman; Name: PageNo -->V<!-- Field: /Sequence -->]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>APPENDIX
VI - LETTER OF CREDIT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Appendix <!-- Field: Sequence; Type: UpperRoman; Name: PageNo -->VI<!-- Field: /Sequence -->]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>APPENDIX
VII</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">ACCOUNT
INFORMATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Appendix <!-- Field: Sequence; Type: UpperRoman; Name: PageNo -->VII<!-- Field: /Sequence -->]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>APPENDIX
VIII</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">PHARMACOVIGILANCE
AGREEMENT</FONT></P>

<P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">[***]</FONT></P>

<P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Appendix <!-- Field: Sequence; Type: UpperRoman; Name: PageNo -->VIII<!-- Field: /Sequence -->]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>EXHIBIT
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>AMINO
ACID SEQUENCE FOR DRUG SUBSTANCE</U></FONT></P>

<P STYLE="font: 10pt Courier; margin: 0pt 0; text-align: left; text-indent: 27pt; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 16%; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 14%; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EFARPCIPKS</FONT></TD>
    <TD STYLE="width: 14%; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FGYSSVVCVC</FONT></TD>
    <TD STYLE="width: 14%; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NATYCDSFDP</FONT></TD>
    <TD STYLE="width: 14%; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PTFPALGTFS</FONT></TD>
    <TD STYLE="width: 14%; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RYESTRSGRR</FONT></TD>
    <TD STYLE="width: 14%; text-align: left; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MELSMGPIQA</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">61</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NHTGTGLLLT</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LQPEQKFQKV</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">KGFGGAMTDA</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AALNILALSP</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PAQNLLLKSY</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FSEEGIGYNI</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">121</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IRVPMASCDF</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SIRTYTYADT</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PDDFQLHNFS</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LPEEDTKLKI</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLIHRALQLA</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">QRPVSLLASP</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">181</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WTSPTWLKTN</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GAVNGKGSLK</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GQPGDIYHQT</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">WARYFVKFLD</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AYAEHKLQFW</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AVTAENEPSA</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">241</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GLLSGYPFQC</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LGFTPEHQRD</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FIARDLGPTL</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ANSTHHNVRL</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LMLDDQRLLL</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PHWAKVVLTD</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">301</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PEAAKYVHGI</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AVHWYLDFLA</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PAKATLGETH</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RLFPNTMLFA</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SEACVGSKFW</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EQSVRLGSWD</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">361</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RGMQYSHSII</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TNLLYHVVGW</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TDWNLALNPE</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GGPNWVRNFV</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DSPIIVDITK</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DTFYKQPMFY</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">421</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">HLGHFSKFIP</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EGSQRVGLVA</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SQKNDLDAVA</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LMHPDGSAVV</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">VVLNRSSKDV</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLTIKDPAVG</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">481</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FLETISPGYS</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IHTYLWHRQD</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">LLVDTM</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">[Exhibit A]</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>EXHIBIT
B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>PROTALIX
PATENT SCHEDULE</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXHIBIT
C</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>APPLICABLE
TAXES AND FEES</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
[***]% tax will be withheld from payments for services made by FIOCRUZ pursuant to Section 7.4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are no withholding or other taxes applicable to any payments required to be made by FIOCRUZ under this AGREEMENT, including those
made for the purchase of PRODUCTS during each STAGE of the TECHNOLOGY TRANSFER.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 50; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>v376666_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, David Aviezer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-left: 12pt; text-indent: -12pt">Date: May 8, 2014</TD>
    <TD STYLE="width: 60%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ David Aviezer</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">David Aviezer, Ph.D.</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>v376666_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">Date: May 8, 2014</TD>
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Chief Financial Officer, Treasurer </TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>v376666_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2014 as filed with the Securities and Exchange Commission
(the &ldquo;Report&rdquo;), I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify as of the date
hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">Date: May 8, 2014</TD>
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ David Aviezer</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">David Aviezer, Ph.D.</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>v376666_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2014 as filed with the Securities and Exchange Commission
(the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify as of the
date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best of
my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">Date: May 8, 2014</TD>
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Vice President and Chief Financial Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>plx-20140331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2014-05-07 @ 12:05 PM-->
<xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plx="http://www.protalix.com/20140331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20140331.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">2014-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.7928.0.0.0.0.0.0" contextRef="as-of-2014-05-01.7928.0.0.0.0.0.0.0" unitRef="shares" decimals="0">93606460</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory id="EntityFilerCategory.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="EntityRegistrantName.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:TradingSymbol id="TradingSymbol.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">PLX</dei:TradingSymbol>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12000</plx:CashlessExerciseOfStockOptions>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">28000</plx:CashlessExerciseOfStockOptions>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.7924.23598.5386.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.23598.5386.0.0.0.0" unitRef="pure" decimals="1">0.4</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.7924.23596.5386.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.23596.5386.0.0.0.0" unitRef="pure" decimals="1">0.6</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">828000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">926000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement id="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">19000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2085000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2431000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">138000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">815000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits id="LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.7935.27186.5386.0.0.0.0" contextRef="from-2013-06-01-to-2013-06-18.7935.0.27186.5386.0.0.0.0" unitRef="USD" decimals="-3">12500000</plx:LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits>
  <plx:MilestonePayment id="MilestonePayment.7937.23602.5162.0.0.0.0" contextRef="from-2012-01-01-to-2012-06-30.7937.0.23602.5162.0.0.0.0" unitRef="USD" decimals="-3">25000000</plx:MilestonePayment>
  <plx:NatureOfOperationsPolicyTextBlock id="NatureOfOperationsPolicyTextBlock.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-BOTTOM: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. ("Pfizer"), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the "Pfizer Agreement"). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Funda&amp;ccedil;&amp;atilde;o Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO&lt;sup&gt;TM&lt;/sup&gt;. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil agreement became effective during the first quarter of 2014.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; During the three months ended March 31, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.&amp;#39;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:NumberOfSubsidiaries id="NumberOfSubsidiaries.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="pure" decimals="0">2</plx:NumberOfSubsidiaries>
  <plx:OtherGainsLosses id="OtherGainsLosses.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">687000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">400000</plx:OtherGainsLosses>
  <plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights id="PurchaseAmountToBeSatisfiedToReceiveEntitledRights.7936.27186.5386.0.0.0.0" contextRef="as-of-2013-06-18.7936.0.27186.5386.0.0.0.0" unitRef="USD" decimals="-3">280000000</plx:PurchaseAmountToBeSatisfiedToReceiveEntitledRights>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6067000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5323000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7926.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7927.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7926.485.5169.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">508000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7927.485.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">1020000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7926.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7927.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">508000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1020000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.7926.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.1087.5169.0.0.0.0" unitRef="shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares id="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.7927.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.1087.5169.0.0.0.0" unitRef="shares" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:SupplyCommitmentPerYear id="SupplyCommitmentPerYear.7936.27186.5386.0.0.0.0" contextRef="as-of-2013-06-18.7936.0.27186.5386.0.0.0.0" unitRef="USD" decimals="-3">40000000</plx:SupplyCommitmentPerYear>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14533000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12073000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4639000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5254000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1735000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2091000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7926.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7927.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7926.485.5169.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">162000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7927.485.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">162000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7926.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.7927.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7926.4573.2652.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">428000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7927.4573.2652.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.4573.2652.0.0.0.0" unitRef="USD" decimals="-3">870000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7926.2476.2652.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">242000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.7927.2476.2652.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.2476.2652.0.0.0.0" unitRef="USD" decimals="-3">497000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCosts id="AmortizationOfFinancingCosts.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">109000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCosts id="AmortizationOfFinancingCosts.7927.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="shares" decimals="0">18913153</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="shares" decimals="0">7471571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets id="Assets.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">103416000</us-gaap:Assets>
  <us-gaap:Assets id="Assets.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">113333000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">88561000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">97903000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="BasisOfAccountingPolicyPolicyTextBlock.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. ("Pfizer"), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the "Pfizer Agreement"). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Funda&amp;ccedil;&amp;atilde;o Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO&lt;sup&gt;TM&lt;/sup&gt;. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil agreement became effective during the first quarter of 2014.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; During the three months ended March 31, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.&amp;#39;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Diluted LPS does not include 7,471,571 and 18,913,153 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the three months ended March 31, 2013 and 2014, respectively, because the effect would be anti-dilutive.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">77690000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">86398000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.7931.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7931.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">52035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.7932.0.0.0.0.0.0" contextRef="as-of-2013-03-31.7932.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">41870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8708000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-10165000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.7924.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.7925.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.7932.0.0.0.0.0.0" contextRef="as-of-2013-03-31.7932.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="shares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.7932.0.0.0.0.0.0" contextRef="as-of-2013-03-31.7932.0.0.0.0.0.0.0" unitRef="shares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ConvertibleDebtNoncurrent id="ConvertibleDebtNoncurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">67151000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent id="ConvertibleDebtNoncurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">67048000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:CostOfRevenue id="CostOfRevenue.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4073000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">971000</us-gaap:CostOfRevenue>
  <us-gaap:DeferredCosts id="DeferredCosts.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">135000</us-gaap:DeferredCosts>
  <us-gaap:DeferredCosts id="DeferredCosts.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">141000</us-gaap:DeferredCosts>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7609000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9369000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">40655000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">41796000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1622000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1578000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.05</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="EarningsPerSharePolicyTextBlock.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"&gt; Diluted LPS does not include 7,471,571 and 18,913,153 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the three months ended March 31, 2013 and 2014, respectively, because the effect would be anti-dilutive.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-29000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">110000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:FairValueDisclosuresTextBlock id="FairValueDisclosuresTextBlock.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;NOTE 3 - FAIR VALUE MEASUREMENT&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"&gt; The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-14000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">78000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:GrossProfit id="GrossProfit.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3310000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2997000</us-gaap:GrossProfit>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-450000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3005000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">744000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">42000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2901000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2740000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1430000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1734000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="IncreaseDecreaseInRestrictedCash.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">57000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="IncreaseDecreaseInRestrictedCash.7927.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InventoryDisclosureTextBlock id="InventoryDisclosureTextBlock.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;NOTE 2 - INVENTORIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"&gt; Inventory at March 31, 2014 and December&amp;nbsp;31, 2013 consisted of the following:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;March 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2014&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="WIDTH: 76%; TEXT-ALIGN: left"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="WIDTH: 9%; TEXT-ALIGN: right"&gt;2,076&lt;/td&gt; &lt;td style="WIDTH: 1%; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="WIDTH: 9%; TEXT-ALIGN: right"&gt;2,342&lt;/td&gt; &lt;td style="WIDTH: 1%; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;170&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;92&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4,281&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 5,523&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 6,527&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,957&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"&gt; During the three months ended March 31, 2014, the Company recorded approximately $1.1 million for write-down of inventory under cost of revenues.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="InventoryFinishedGoodsNetOfReserves.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4281000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="InventoryFinishedGoodsNetOfReserves.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5523000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet id="InventoryNet.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6527000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="InventoryNet.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7957000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="InventoryRawMaterialsNetOfReserves.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2076000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="InventoryRawMaterialsNetOfReserves.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2342000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="InventoryWorkInProcessNetOfReserves.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">170000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="InventoryWorkInProcessNetOfReserves.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">92000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWriteDown id="InventoryWriteDown.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1100000</us-gaap:InventoryWriteDown>
  <us-gaap:Liabilities id="Liabilities.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">136994000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">140279000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">103416000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">113333000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26781000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26696000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">110213000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">113583000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.7924.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2371000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">31000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.7927.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-370000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-689000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8340000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-9586000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-7345000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-4321000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7926.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7927.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7926.485.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.485.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7927.485.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.485.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7926.4652.5169.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-7345000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.7927.4652.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-4321000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense id="NonoperatingIncomeExpense.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-877000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="NonoperatingIncomeExpense.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">108000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-6468000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-4429000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">915000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="OtherNonoperatingExpense.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">14000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingIncome id="OtherNonoperatingIncome.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">38000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="OtherNonoperatingIncome.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">122000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2609000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1457000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">47000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">263000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">642000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2407000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2368000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">60000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.8126.0.0.0.0.0.0" contextRef="from-2009-10-01-to-2009-12-31.8126.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">60000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.8126.23603.5162.0.0.0.0" contextRef="from-2009-10-01-to-2009-12-31.8126.0.23603.5162.0.0.0.0" unitRef="USD" decimals="-3">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromSaleOfOtherAssets1 id="ProceedsFromSaleOfOtherAssets1.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3500000</us-gaap:ProceedsFromSaleOfOtherAssets1>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">31000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.7927.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.7926.23589.3709.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.23589.3709.0.0.0.0" unitRef="USD" decimals="-3">43000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">13098000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">13711000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8152000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7754000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:Revenues id="Revenues.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6696000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3568000</us-gaap:Revenues>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="ScheduleOfInventoryCurrentTableTextBlock.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"&gt; Inventory at March 31, 2014 and December&amp;nbsp;31, 2013 consisted of the following:&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;March 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2014&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2"&gt;2013&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="WIDTH: 76%; TEXT-ALIGN: left"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="WIDTH: 9%; TEXT-ALIGN: right"&gt;2,076&lt;/td&gt; &lt;td style="WIDTH: 1%; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%; TEXT-ALIGN: left"&gt;$&lt;/td&gt; &lt;td style="WIDTH: 9%; TEXT-ALIGN: right"&gt;2,342&lt;/td&gt; &lt;td style="WIDTH: 1%; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;170&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;92&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 4,281&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 5,523&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 6,527&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 7,957&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="SellingGeneralAndAdministrativeExpense.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3711000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="SellingGeneralAndAdministrativeExpense.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2103000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">670000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1367000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharesOutstanding id="SharesOutstanding.7924.1087.5169.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">93606460</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.7925.1087.5169.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">93551098</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.7931.1087.5169.0.0.0.0" contextRef="as-of-2012-12-31.7931.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">93489809</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.7932.1087.5169.0.0.0.0" contextRef="as-of-2013-03-31.7932.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">93502230</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7924.0.0.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-33578000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7925.0.0.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-26946000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7931.0.0.0.0.0.0" contextRef="as-of-2012-12-31.7931.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3357000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7932.0.0.0.0.0.0" contextRef="as-of-2013-03-31.7932.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-6283000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7924.1087.5169.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7925.1087.5169.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7931.1087.5169.0.0.0.0" contextRef="as-of-2012-12-31.7931.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7932.1087.5169.0.0.0.0" contextRef="as-of-2013-03-31.7932.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7924.485.5169.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">185058000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7925.485.5169.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">184345000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7931.485.5169.0.0.0.0" contextRef="as-of-2012-12-31.7931.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">180145000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7932.485.5169.0.0.0.0" contextRef="as-of-2013-03-31.7932.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">181539000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7924.4652.5169.0.0.0.0" contextRef="as-of-2014-03-31.7924.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-218730000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7925.4652.5169.0.0.0.0" contextRef="as-of-2013-12-31.7925.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-211385000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7931.4652.5169.0.0.0.0" contextRef="as-of-2012-12-31.7931.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-183595000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.7932.4652.5169.0.0.0.0" contextRef="as-of-2013-03-31.7932.0.4652.5169.0.0.0.0" unitRef="USD" decimals="-3">-187916000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;NOTE 4 - STOCK TRANSACTIONS&lt;/strong&gt;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal"&gt; During the three months ended March 31, 2014, the Company issued a total of 55,362 shares of Common Stock in connection with the exercise of a total of 56,122 options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $43,000.&lt;/p&gt; &lt;p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="StockIssuedDuringPeriodSharesShareBasedCompensation.7926.23589.3709.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.23589.3709.0.0.0.0" unitRef="shares" decimals="0">56122</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7926.1087.5169.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">55362</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7927.1087.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.1087.5169.0.0.0.0" unitRef="shares" decimals="0">12421</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.7926.23589.3709.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.23589.3709.0.0.0.0" unitRef="shares" decimals="0">55362</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7926.1087.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.1087.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7927.1087.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.1087.5169.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7926.485.5169.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7927.485.5169.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.485.5169.0.0.0.0" unitRef="USD" decimals="-3">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7926.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2014-01-01-to-2014-03-31.7926.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7927.4652.5169.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.7927.0.4652.5169.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">43000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">28000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.7926.0.0.0.0.0.0" contextRef="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0" unitRef="shares" decimals="0">92686638</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.7927.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0" unitRef="shares" decimals="0">92184220</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD_per_share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2014-01-01-to-2014-03-31.7926.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2014-01-01-to-2014-03-31.7926.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2014-01-01-to-2014-03-31.7926.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2014-01-01-to-2014-03-31.7926.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2014-01-01-to-2014-03-31.7926.0.23589.3709.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2014-01-01-to-2014-03-31.7926.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2014-01-01-to-2014-03-31.7926.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-06-01-to-2013-06-18.7935.0.27186.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-06-01</xbrli:startDate>
      <xbrli:endDate>2013-06-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.7927.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.7927.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.7927.0.4573.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.7927.0.2476.2652.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.7927.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.7927.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-06-30.7937.0.23602.5162.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-10-01-to-2009-12-31.8126.0.23603.5162.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-10-01-to-2009-12-31.8126.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-10-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2014-05-01.7928.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2014-03-31.7924.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2014-03-31.7924.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2014-03-31.7924.0.23598.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2014-03-31.7924.0.23596.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2014-03-31.7924.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2014-03-31.7924.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-12-31.7925.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-12-31.7925.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-12-31.7925.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-12-31.7925.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-06-18.7936.0.27186.5386.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-06-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.7932.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.7932.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.7932.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.7932.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7931.0.485.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7931.0.4652.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7931.0.1087.5169.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.7931.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:footnote xlink:type="resource" xlink:label="Footnote_538_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Represents an amount less than $1.</link:footnote>
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodValueStockOptionsExercised.7926.1087.5169.0.0.0.0" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised.7926.1087.5169.0.0.0.0_loc" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised.7926.1087.5169.0.0.0.0_loc" xlink:to="Footnote_538_lbl" order="1.0" />
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>plx-20140331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2014-05-07 @ 12:05 PM-->
<xsd:schema targetNamespace="http://www.protalix.com/20140331" elementFormDefault="qualified" xmlns:plx="http://www.protalix.com/20140331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="plx-20140331_cal.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="plx-20140331_def.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="plx-20140331_lab.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="plx-20140331_pre.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" id="plx-ccbs" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" id="plx-ccsocf" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" id="plx-ccsocicd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" id="plx-ccsocicdp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY  (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" id="plx-ccsoo" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="plx-ccsoop" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" id="plx-daei" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/FairValueMeasurement" id="plx-fvm" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>103 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/Inventories" id="plx-i" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>102 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" id="plx-isoicd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesTables" id="plx-it" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>302 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" id="plx-sap" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" id="plx-sapd1" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" id="plx-sapp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StockTransactions" id="plx-st" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>104 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StockTransactionsDetails" id="plx-std" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40401 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CollaborativeArrangementProfitSharePercentage" id="plx_CollaborativeArrangementProfitSharePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="DepreciationAmortizationAndAssetImpairment" id="plx_DepreciationAmortizationAndAssetImpairment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="EmployeeAndNonemployeeMember" id="plx_EmployeeAndNonemployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="EmployeeMember" id="plx_EmployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="GrantsAndReimbursementsReceivedOrReceivable" id="plx_GrantsAndReimbursementsReceivedOrReceivable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" id="plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="MilestonePayment" id="plx_MilestonePayment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" id="plx_NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="NumberOfSubsidiaries" id="plx_NumberOfSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element name="OtherGainsLosses" id="plx_OtherGainsLosses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="PfizerIncorporationMember" id="plx_PfizerIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" id="plx_ProtalixBioTherapeuticsIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProtalixLtdMember" id="plx_ProtalixLtdMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="PurchaseAmountToBeSatisfiedToReceiveEntitledRights" id="plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ScenarioFourMember" id="plx_ScenarioFourMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioOneMember" id="plx_ScenarioOneMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioThreeMember" id="plx_ScenarioThreeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioTwoMember" id="plx_ScenarioTwoMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="plx_SignificantAccountingPoliciesLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="plx_SignificantAccountingPoliciesTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="StockOptionsAndRestrictedSharesMember" id="plx_StockOptionsAndRestrictedSharesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SupplyCommitmentPerYear" id="plx_SupplyCommitmentPerYear" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>plx-20140331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2014-05-07 @ 12:05 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20140331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20140331.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20140331.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:href="plx-20140331.xsd#plx-ccsocicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" xlink:href="plx-20140331.xsd#plx-ccsocicdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20140331.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20140331.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20140331.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20140331.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20140331.xsd#plx-isoicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20140331.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20140331.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20140331.xsd#plx-sapd1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20140331.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20140331.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20140331.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurement" xlink:href="plx-20140331.xsd#plx-fvm" xlink:type="simple" />
  <link:calculationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_Assets.6057.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:loc xlink:label="loc_AssetsCurrent.6084.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_AssetsCurrent.6084.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_AccountsReceivableNetCurrent.5665.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_PropertyPlantAndEquipmentNet.15211.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCosts.7792.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.6057.14.6" xlink:to="loc_DeferredCosts.7792.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13867.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_OtherReceivablesNetCurrent.13867.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryNet.11816.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.6084.14.6" xlink:to="loc_InventoryNet.11816.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5660.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_AccountsPayableTradeCurrent.5660.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5690.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_AccountsPayableOtherCurrent.5690.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.12126.14.6" xlink:to="loc_DeferredRevenueCurrent.7937.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_StockholdersEquity.17302.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Liabilities.12166.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_Liabilities.12166.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.14.6" xlink:to="loc_CommitmentsAndContingencies.7121.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.12165.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.12165.14.6" xlink:to="loc_DeferredRevenueNoncurrent.7950.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12757.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.12165.14.6" xlink:to="loc_LongTermDebtNoncurrent.12757.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.12165.14.6" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_LiabilitiesNoncurrent.12165.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_Liabilities.12166.14.6" xlink:to="loc_LiabilitiesCurrent.12126.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ConvertibleDebtNoncurrent.7358.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.12165.14.6" xlink:to="loc_ConvertibleDebtNoncurrent.7358.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_NetIncomeLoss.13265.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_ShareBasedCompensation.16900.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.14.6" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.14.6" xlink:href="plx-20140331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.23586.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.14.6" order="4.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.14426.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.14426.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AmortizationOfFinancingCosts.5974.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_AmortizationOfFinancingCosts.5974.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.11341.14.6" order="7.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.11237.14.6" order="8.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.11367.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_IncreaseDecreaseInInventories.11367.14.6" order="9.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.14.6" order="10.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.14.6" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.14.6" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.14.6" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.14.6" xlink:href="plx-20140331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.14.6" xlink:to="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.14.6" order="11.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11462.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.14.6" xlink:to="loc_IncreaseDecreaseInRestrictedCash.11462.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_GrossProfit.10776.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.16160.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10776.14.6" xlink:to="loc_Revenues.16160.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherGainsLosses.23595.14.6" xlink:href="plx-20140331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10776.14.6" xlink:to="loc_OtherGainsLosses.23595.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfRevenue.7431.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10776.14.6" xlink:to="loc_CostOfRevenue.7431.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.13265.14.6" xlink:to="loc_OperatingIncomeLoss.13592.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NonoperatingIncomeExpense.13395.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.13265.14.6" xlink:to="loc_NonoperatingIncomeExpense.13395.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherNonoperatingExpense.13989.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NonoperatingIncomeExpense.13395.14.6" xlink:to="loc_OtherNonoperatingExpense.13989.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13592.14.6" xlink:to="loc_GrossProfit.10776.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.14.6" xlink:href="plx-20140331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13592.14.6" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.14.6" xlink:to="loc_ResearchAndDevelopmentExpense.15880.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.14.6" xlink:href="plx-20140331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.14.6" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_SellingGeneralAndAdministrativeExpense.16773.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13592.14.6" xlink:to="loc_SellingGeneralAndAdministrativeExpense.16773.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherNonoperatingIncome.14001.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NonoperatingIncomeExpense.13395.14.6" xlink:to="loc_OtherNonoperatingIncome.14001.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)" xlink:role="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryNet.11816.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11840.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11816.14.6" xlink:to="loc_InventoryRawMaterialsNetOfReserves.11840.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11877.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11816.14.6" xlink:to="loc_InventoryWorkInProcessNetOfReserves.11877.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11837.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11816.14.6" xlink:to="loc_InventoryFinishedGoodsNetOfReserves.11837.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>plx-20140331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2014-05-07 @ 12:05 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20140331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20140331.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20140331.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:href="plx-20140331.xsd#plx-ccsocicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" xlink:href="plx-20140331.xsd#plx-ccsocicdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20140331.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20140331.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20140331.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20140331.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20140331.xsd#plx-isoicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20140331.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20140331.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20140331.xsd#plx-sapd1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20140331.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20140331.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20140331.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurement" xlink:href="plx-20140331.xsd#plx-fvm" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:title="005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1873.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1087.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1873.7.6" xlink:to="loc_CommonStockMember.1087.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.485.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1873.7.6" xlink:to="loc_AdditionalPaidInCapitalMember.485.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4652.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1873.7.6" xlink:to="loc_RetainedEarningsMember.4652.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementTable.5163.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementTable.5163.5.6" xlink:to="loc_StatementEquityComponentsAxis.5169.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.5164.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.5163.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.9.6" xlink:to="loc_StatementTable.5163.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.5164.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockholdersEquity.17302.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharesOutstanding.17056.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_SharesOutstanding.17056.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.17285.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.17271.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_NetIncomeLoss.13265.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.7.6" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.7.6" order="6.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1873.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.5169.6.6" xlink:to="loc_EquityComponentDomain.1873.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1873.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.5169.8.6" xlink:to="loc_EquityComponentDomain.1873.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.7.6" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.5164.7.6" xlink:to="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.7.6" order="7.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.9.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.7.6" xlink:to="loc_AllocatedShareBasedCompensationExpense.5919.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationAxis.2652.8.6" xlink:to="loc_IncomeStatementLocationDomain.2671.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationAxis.2652.6.6" xlink:to="loc_IncomeStatementLocationDomain.2671.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationDomain.2671.7.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4573.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationDomain.2671.7.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2476.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.5.6" xlink:to="loc_IncomeStatementLocationAxis.2652.5.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfSalesMember.1254.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_IncomeStatementLocationDomain.2671.7.6" xlink:to="loc_CostOfSalesMember.1254.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.7.6" xlink:href="plx-20140331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.23598.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.7.6" xlink:href="plx-20140331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_PfizerIncorporationMember.23596.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.7.6" xlink:href="plx-20140331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.582.7.6" xlink:to="loc_StockOptionsAndRestrictedSharesMember.23606.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.6.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.582.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.8.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.582.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.7.6" xlink:href="plx-20140331.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.7.6" xlink:to="loc_ProtalixLtdMember.27186.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.7.6" xlink:href="plx-20140331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioTwoMember.23603.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioOneMember.23601.7.6" xlink:href="plx-20140331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioOneMember.23601.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.7.6" xlink:href="plx-20140331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioThreeMember.23602.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioFourMember.23600.7.6" xlink:href="plx-20140331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.7.6" xlink:to="loc_ScenarioFourMember.23600.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.5162.6.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.5162.8.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TypeOfArrangementAxis.5386.8.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TypeOfArrangementAxis.5386.6.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.5.6" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.5.6" xlink:to="loc_StatementScenarioAxis.5162.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.5.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.9.6" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.9.6" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.9.6" xlink:to="loc_SignificantAccountingPoliciesTable.23605.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.7.6" xlink:href="plx-20140331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_NumberOfSubsidiaries.23594.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14867.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_ProceedsFromCollaborators.14867.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePayment.23592.7.6" xlink:href="plx-20140331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_MilestonePayment.23592.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.7.6" xlink:href="plx-20140331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.23585.7.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_CommonStockParOrStatedValuePerShare.7131.7.6" order="12.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.7.6" order="13.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.5.6" xlink:to="loc_TypeOfArrangementAxis.5386.5.6" order="3.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.7.6" xlink:href="plx-20140331.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.7.6" xlink:href="plx-20140331.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfOtherAssets1.14865.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_ProceedsFromSaleOfOtherAssets1.14865.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.49211.7.6" xlink:href="plx-20140331.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.7.6" xlink:to="loc_SupplyCommitmentPerYear.49211.7.6" order="4.65625" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40401 - Disclosure - STOCK TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/StockTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4895.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.1018.9.6" xlink:to="loc_ScheduleOfStockByClassTable.4895.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.1018.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.1018.7.6" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.1018.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.7.6" order="7.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3709.6.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3712.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3709.8.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3712.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.7.6" xlink:href="plx-20140331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.7.6" xlink:to="loc_EmployeeAndNonemployeeMember.23588.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeMember.23589.7.6" xlink:href="plx-20140331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.7.6" xlink:to="loc_EmployeeMember.23589.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4895.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfStockByClassTable.4895.5.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3709.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>plx-20140331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2014-05-07 @ 12:05 PM-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2012" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#changeLabel2012" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentDocumentation" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#fragmentDocumentation" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentLabel" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#fragmentLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2013" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-roles-2013-01-31.xsd#changeLabel2013" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedDateLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedDateLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.11.7" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.205573" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.205573" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145.205573">Accounts payable and accruals:</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.11.6" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.205572" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.205572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364.205572">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5690.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5690.11.7" xlink:to="lab_AccountsPayableOtherCurrent.138148.205575" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.138148.205575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.138148.205575">Other</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5690.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5690.11.6" xlink:to="lab_AccountsPayableOtherCurrent.376.205574" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.376.205574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.376.205574">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5660.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5660.11.7" xlink:to="lab_AccountsPayableTradeCurrent.138147.205577" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.138147.205577" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.138147.205577">Trade</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5660.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5660.11.6" xlink:to="lab_AccountsPayableTradeCurrent.402.205576" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.402.205576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.402.205576">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5665.11.7" xlink:to="lab_AccountsReceivableNetCurrent.138137.205579" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.138137.205579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.138137.205579">Accounts receivable- Trade</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5665.11.6" xlink:to="lab_AccountsReceivableNetCurrent.390.205578" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.390.205578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.390.205578">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:label="loc_Assets.6057.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.6057.11.6" xlink:to="lab_Assets.1134.205580" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.1134.205580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Assets.1134.205580">Assets</link:label>
    <link:loc xlink:label="loc_Assets.6057.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.6057.11.9" xlink:to="lab_Assets.138141.205581" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.138141.205581" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Assets.138141.205581">Total assets</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.620.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.620.11.6" xlink:to="lab_AssetsAbstract.1105.205582" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.1105.205582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.1105.205582">Assets [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.620.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.620.11.7" xlink:to="lab_AssetsAbstract.138133.205583" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.138133.205583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.138133.205583">ASSETS</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.6084.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.6084.11.6" xlink:to="lab_AssetsCurrent.1123.205584" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.1123.205584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.1123.205584">Assets, Current</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.6084.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.6084.11.9" xlink:to="lab_AssetsCurrent.138142.205585" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.138142.205585" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.138142.205585">Total current assets</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.616.11.6" xlink:to="lab_AssetsCurrentAbstract.1099.205586" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.1099.205586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.1099.205586">Assets, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.616.11.7" xlink:to="lab_AssetsCurrentAbstract.138132.205587" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.138132.205587" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.138132.205587">CURRENT ASSETS:</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.7" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.138135.205589" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.138135.205589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.138135.205589">Cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.6" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.2187.205588" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.2187.205588" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.2187.205588">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.7121.11.7" xlink:to="lab_CommitmentsAndContingencies.138162.205591" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.138162.205591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.138162.205591">COMMITMENTS</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.7121.11.6" xlink:to="lab_CommitmentsAndContingencies.2677.205590" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.2677.205590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.2677.205590">Commitments and Contingencies</link:label>
    <link:loc xlink:label="loc_ConvertibleDebtNoncurrent.7358.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConvertibleDebtNoncurrent.7358.11.6" xlink:to="lab_ConvertibleDebtNoncurrent.3221" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConvertibleDebtNoncurrent.3221" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ConvertibleDebtNoncurrent.3221">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:label="loc_ConvertibleDebtNoncurrent.7358.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ConvertibleDebtNoncurrent.7358.11.7" xlink:to="lab_ConvertibleDebtNoncurrent.150607.275819" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ConvertibleDebtNoncurrent.150607.275819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ConvertibleDebtNoncurrent.150607.275819">Convertible notes</link:label>
    <link:loc xlink:label="loc_DeferredCosts.7792.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCosts.7792.11.6" xlink:to="lab_DeferredCosts.3861" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCosts.3861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCosts.3861">Deferred Costs, Noncurrent</link:label>
    <link:loc xlink:label="loc_DeferredCosts.7792.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCosts.7792.11.7" xlink:to="lab_DeferredCosts.141685.275818" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCosts.141685.275818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCosts.141685.275818">DEFERRED CHARGES</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7937.11.7" xlink:to="lab_DeferredRevenueCurrent.138149.205593" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.138149.205593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.138149.205593">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7937.11.6" xlink:to="lab_DeferredRevenueCurrent.3980.205592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.3980.205592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.3980.205592">Deferred Revenue, Current</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7950.11.7" xlink:to="lab_DeferredRevenueNoncurrent.138153.205595" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.138153.205595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.138153.205595">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7950.11.6" xlink:to="lab_DeferredRevenueNoncurrent.3963.205594" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.3963.205594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.3963.205594">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.11.7" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.205597" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.205597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140.205597">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.11.6" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.205596" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.205596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362.205596">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</link:label>
    <link:loc xlink:label="loc_InventoryNet.11816.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11816.11.7" xlink:to="lab_InventoryNet.138139.205599" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138139.205599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138139.205599">Inventories</link:label>
    <link:loc xlink:label="loc_InventoryNet.11816.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11816.11.6" xlink:to="lab_InventoryNet.9655.205598" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.9655.205598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.9655.205598">Inventory, Net</link:label>
    <link:loc xlink:label="loc_Liabilities.12166.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.12166.11.6" xlink:to="lab_Liabilities.10148.205600" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.10148.205600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.10148.205600">Liabilities</link:label>
    <link:loc xlink:label="loc_Liabilities.12166.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.12166.11.9" xlink:to="lab_Liabilities.138159.205601" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.138159.205601" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.138159.205601">Total liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquity.10196.205602" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.10196.205602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.10196.205602">Liabilities and Equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.12135.11.9" xlink:to="lab_LiabilitiesAndStockholdersEquity.138166.205603" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.138166.205603" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.138166.205603">Total liabilities net of capital deficiency</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.10173.205604" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.10173.205604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.10173.205604">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.11.7" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.138143.205605" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.138143.205605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.138143.205605">LIABILITIES NET OF CAPITAL DEFICIENCY</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.12126.11.6" xlink:to="lab_LiabilitiesCurrent.10094.205606" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.10094.205606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.10094.205606">Liabilities, Current</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.12126.11.9" xlink:to="lab_LiabilitiesCurrent.138151.205607" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.138151.205607" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.138151.205607">Total current liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.11.6" xlink:to="lab_LiabilitiesCurrentAbstract.10147.205608" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.10147.205608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.10147.205608">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.11.7" xlink:to="lab_LiabilitiesCurrentAbstract.138144.205609" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.138144.205609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.138144.205609">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.12165.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.12165.11.6" xlink:to="lab_LiabilitiesNoncurrent.10143.205610" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.10143.205610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.10143.205610">Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.12165.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.12165.11.9" xlink:to="lab_LiabilitiesNoncurrent.138158.205611" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.138158.205611" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.138158.205611">Total long term liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.3062.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.11.6" xlink:to="lab_LiabilitiesNoncurrentAbstract.10151.205612" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.10151.205612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.10151.205612">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.3062.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.11.7" xlink:to="lab_LiabilitiesNoncurrentAbstract.138152.205613" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.138152.205613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.138152.205613">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12757.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12757.11.6" xlink:to="lab_LongTermDebtNoncurrent.11025.205614" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.11025.205614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.11025.205614">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12757.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12757.11.7" xlink:to="lab_LongTermDebtNoncurrent.138155.205615" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.138155.205615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.138155.205615">Liability in connection with collaboration operation</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13867.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13867.11.6" xlink:to="lab_OtherReceivablesNetCurrent.12515.205616" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.12515.205616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.12515.205616">Other Receivables, Net, Current</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13867.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13867.11.7" xlink:to="lab_OtherReceivablesNetCurrent.138138.205617" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.138138.205617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.138138.205617">Other assets</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.11.6" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.205618" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.205618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684.205618">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.11.7" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.205619" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.205619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157.205619">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.15211.11.7" xlink:to="lab_PropertyPlantAndEquipmentNet.134116.205621" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.134116.205621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.134116.205621">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.15211.11.6" xlink:to="lab_PropertyPlantAndEquipmentNet.14913.205620" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.14913.205620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.14913.205620">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.5171.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.11.6" xlink:to="lab_StatementOfFinancialPositionAbstract.138129.205622" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfFinancialPositionAbstract.138129.205622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfFinancialPositionAbstract.138129.205622">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.7" xlink:to="lab_StockholdersEquity.138164.205624" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138164.205624" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138164.205624">CAPITAL DEFICIENCY</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.6" xlink:to="lab_StockholdersEquity.18029.205623" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.18029.205623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.18029.205623">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.7" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.205690" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.205690" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020.205690">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.11.6" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.205689" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.205689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726.205689">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_AmortizationOfFinancingCosts.5974.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfFinancingCosts.5974.11.6" xlink:to="lab_AmortizationOfFinancingCosts.943" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmortizationOfFinancingCosts.943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmortizationOfFinancingCosts.943">Amortization of Financing Costs</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.10" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139058.205691" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139058.205691" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139058.205691">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6843.11.11" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139059.205692" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139059.205692" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139059.205692">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.9" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.205694" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.205694" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056.205694">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.11.6" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.205693" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.205693" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245.205693">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.23584.11.6" xlink:href="plx-20140331.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.23584.11.6" xlink:to="lab_CashlessExerciseOfStockOptions.145608.205695" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145608.205695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145608.205695">Cashless Exercise Of Stock Options</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.23584.11.12" xlink:href="plx-20140331.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.23584.11.12" xlink:to="lab_CashlessExerciseOfStockOptions.145610.205697" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145610.205697" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145610.205697">Cash due from broker assisted exercises of employee stock options.</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.23584.11.7" xlink:href="plx-20140331.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.23584.11.7" xlink:to="lab_CashlessExerciseOfStockOptions.145611.205696" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145611.205696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145611.205696">Exercise of options granted to employees</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.11.6" xlink:href="plx-20140331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.23586.11.6" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139023.205698" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139023.205698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139023.205698">Depreciation Amortization And Asset Impairment</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.11.12" xlink:href="plx-20140331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.23586.11.12" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139026.205700" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139026.205700" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139026.205700">The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.11.7" xlink:href="plx-20140331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.23586.11.7" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139027.205699" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139027.205699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139027.205699">Depreciation and write down of fixed assets</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.7" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.205702" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.205702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055.205702">EFFECT OF EXCHANGE RATE CHANGES ON CASH</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.11.6" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.205701" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.205701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445.205701">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.11.52" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.205704" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.205704" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.139028.205704">Financial expenses (income), net (mainly exchange differences)</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.205703" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.205703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.7370.205703">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:label="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.11.6" xlink:href="plx-20140331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.11.6" xlink:to="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.406716" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.406716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.406716">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:loc xlink:label="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.11.12" xlink:href="plx-20140331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.11.12" xlink:to="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement12.406717" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement12.406717" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement12.406717">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:loc xlink:label="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.11.52" xlink:href="plx-20140331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.11.52" xlink:to="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement52.406718" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement52.406718" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement52.406718">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.7" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.205708" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.205708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038.205708">Decrease in accounts payable and accruals (including long term )</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.11.6" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.205707" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.205707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810.205707">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.11237.11.6" xlink:to="lab_IncreaseDecreaseInAccountsReceivable.8785.205709" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable.8785.205709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable.8785.205709">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.11237.11.52" xlink:to="lab_IncreaseDecreaseInAccountsReceivable42.139035.205710" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable42.139035.205710" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable42.139035.205710">Increase in accounts receivable and other assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.11341.11.7" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.139034.205712" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.139034.205712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.139034.205712">Decrease in deferred revenues (including non-current portion)</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.11341.11.6" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.8782.205711" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.8782.205711" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.8782.205711">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.11367.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.11367.11.6" xlink:to="lab_IncreaseDecreaseInInventories.8903.205713" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories.8903.205713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories.8903.205713">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.11367.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.11367.11.52" xlink:to="lab_IncreaseDecreaseInInventories42.139036.205714" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories42.139036.205714" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories42.139036.205714">Decrease (increase) in inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.7" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.205716" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.205716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033.205716">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.11.6" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.205715" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.205715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850.205715">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11462.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCash.11462.11.6" xlink:to="lab_IncreaseDecreaseInRestrictedCash.9400" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCash.9400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCash.9400">Increase (Decrease) in Restricted Cash</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11462.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInRestrictedCash.11462.11.52" xlink:to="lab_IncreaseDecreaseInRestrictedCash.146550.406719" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInRestrictedCash.146550.406719" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInRestrictedCash.146550.406719">Investment in restricted deposit</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.6" xlink:href="plx-20140331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.6" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.205717" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.205717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065.205717">Increase In Liabilities For Property Plant And Equipment</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.12" xlink:href="plx-20140331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.12" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.205719" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.205719" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067.205719">Increase in liabilities for property, plant and equipment.</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.7" xlink:href="plx-20140331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.11.7" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.205718" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.205718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070.205718">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.205722" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.205722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763.205722">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.11.7" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.205723" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.205723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046.205723">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.12278" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.12278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.12278">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.11.9" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.406713" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.406713" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.406713">Net cash provided by financing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.205726" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.205726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840.205726">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.11.7" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.205727" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.205727" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040.205727">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.12298" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.12298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.12298">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.11.9" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.406714" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.406714" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.406714">Net cash used in investing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.205730" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.205730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842.205730">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.11.7" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.205731" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.205731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996.205731">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.12234" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.12234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.12234">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.11.9" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.406715" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.406715" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.406715">Net cash used in operating activities</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.6" xlink:to="lab_NetIncomeLoss.11860.205732" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.11860.205732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.11860.205732">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.20" xlink:to="lab_NetIncomeLoss.537619.237449" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.537619.237449" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.537619.237449">Net loss</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.11.6" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.205734" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.205734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.13356.205734">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.11.52" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.205735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.205735" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.139042.205735">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.11.6" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.205736" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.205736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519.205736">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.11.52" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.205737" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.205737" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041.205737">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.14426.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.14426.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.13676.205740" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.13676.205740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.13676.205740">Pension and Other Postretirement Benefit Expense</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.14426.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.14426.11.7" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.139030.205741" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.139030.205741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.139030.205741">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.15050.11.8" xlink:to="lab_ProceedsFromStockOptionsExercised.139052.205748" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.139052.205748" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.139052.205748">Exercise of options</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.15050.11.6" xlink:to="lab_ProceedsFromStockOptionsExercised.14691.205747" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.14691.205747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.14691.205747">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16900.11.6" xlink:to="lab_ShareBasedCompensation.17402.205749" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation.17402.205749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation.17402.205749">Share-based Compensation</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16900.11.7" xlink:to="lab_ShareBasedCompensation7.138110.205750" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation7.138110.205750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation7.138110.205750">Share based compensation</link:label>
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.11.6" xlink:to="lab_StatementOfCashFlowsAbstract.138995.205751" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfCashFlowsAbstract.138995.205751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfCashFlowsAbstract.138995.205751">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.11.6" xlink:to="lab_SupplementalCashFlowInformationAbstract.519401.205752" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalCashFlowInformationAbstract.519401.205752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalCashFlowInformationAbstract.519401.205752">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.11.7" xlink:to="lab_SupplementalCashFlowInformationAbstract.522041.205753" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalCashFlowInformationAbstract.522041.205753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalCashFlowInformationAbstract.522041.205753">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:label="loc_AmortizationOfFinancingCosts.5974.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmortizationOfFinancingCosts.5974.11.7" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl.279050" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl.279050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCosts_lbl.279050">Amortization of debt issuance costs and debt discount</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.485.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalMember.485.11.7" xlink:to="lab_AdditionalPaidInCapitalMember.133985.275821" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalMember.133985.275821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalMember.133985.275821">Additional paid-in Capital [Member]</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.485.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalMember.485.11.6" xlink:to="lab_AdditionalPaidInCapitalMember.681.205654" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalMember.681.205654" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalMember.681.205654">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.719" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.719">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.11.8" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue8.207165" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue8.207165" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue8.207165">Share-based compensation related to stock options</link:label>
    <link:loc xlink:label="loc_CommonStockMember.1087.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockMember.1087.11.6" xlink:to="lab_CommonStockMember.2694.205657" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockMember.2694.205657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockMember.2694.205657">Common Stock [Member]</link:label>
    <link:loc xlink:label="loc_EquityComponentDomain.1873.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityComponentDomain.1873.11.6" xlink:to="lab_EquityComponentDomain.5824.205658" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityComponentDomain.5824.205658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityComponentDomain.5824.205658">Equity Component [Domain]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.8" xlink:to="lab_NetIncomeLoss.138697.205659" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138697.205659" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138697.205659">Net loss for the period</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4652.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4652.11.7" xlink:to="lab_RetainedEarningsMember.138685.205661" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.138685.205661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.138685.205661">Accumulated Deficit [Member]</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4652.11.6" xlink:to="lab_RetainedEarningsMember.16154.205660" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.16154.205660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.16154.205660">Retained Earnings [Member]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.11.6" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.11.6" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.406720" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.406720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.406720">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.11.12" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.11.12" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures12.406722" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures12.406722" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures12.406722">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.11.7" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.11.7" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures7.406723" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures7.406723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures7.406723">Share-based compensation related to restricted stock award, net of forfeitures</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.11.6" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.11.6" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.406721" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.406721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.406721">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.11.12" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.11.12" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares12.406724" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares12.406724" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares12.406724">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.11.7" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.11.7" xlink:to="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares7.406725" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares7.406725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares7.406725">Share-based compensation related to restricted stock award, net of forfeitures (in shares)</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.17056.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.17056.11.10" xlink:to="lab_SharesOutstanding.138690.205663" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138690.205663" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138690.205663">Beginning Balance (in shares)</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.17056.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.17056.11.11" xlink:to="lab_SharesOutstanding.138702.205664" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138702.205664" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138702.205664">Ending Balance (in shares)</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.17056.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.17056.11.6" xlink:to="lab_SharesOutstanding.17653.205662" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.17653.205662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.17653.205662">Shares, Outstanding</link:label>
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementEquityComponentsAxis.5169.11.6" xlink:to="lab_StatementEquityComponentsAxis.17875.205665" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementEquityComponentsAxis.17875.205665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementEquityComponentsAxis.17875.205665">Equity Components [Axis]</link:label>
    <link:loc xlink:label="loc_StatementLineItems.5164.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementLineItems.5164.11.6" xlink:to="lab_StatementLineItems.17869.205666" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementLineItems.17869.205666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementLineItems.17869.205666">Statement [Line Items]</link:label>
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.5166.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.11.6" xlink:to="lab_StatementOfStockholdersEquityAbstract.138674.205667" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfStockholdersEquityAbstract.138674.205667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfStockholdersEquityAbstract.138674.205667">CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</link:label>
    <link:loc xlink:label="loc_StatementTable.5163.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementTable.5163.11.6" xlink:to="lab_StatementTable.17867.205668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementTable.17867.205668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementTable.17867.205668">Statement [Table]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.10" xlink:to="lab_StockholdersEquity.138688.205669" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138688.205669" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138688.205669">Beginning Balance</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.17302.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.17302.11.11" xlink:to="lab_StockholdersEquity.138700.205670" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138700.205670" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138700.205670">Ending Balance</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.138692.205674" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.138692.205674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.138692.205674">Common stock issued for cash (net of issuance costs) (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.17271.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.17977.205673" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.17977.205673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.17977.205673">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.205676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.205676" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106.205676">Exercise of options granted to employees (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.205675" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.205675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984.205675">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.7" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.138694.205680" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.138694.205680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.138694.205680">Common stock issued for cash (net of issuance costs)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.17285.11.6" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.17939.205679" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.17939.205679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.17939.205679">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.11.7" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696.205682" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696.205682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696.205682">Exercise of options granted to employees</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.11.6" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.205681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.205681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935.205681">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.205683" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.205683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735.205683">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.205684" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.205684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770.205684">Common stock issued for cash, issuance costs</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.7131.11.8" xlink:to="lab_CommonStockParOrStatedValuePerShare.138774.205686" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.138774.205686" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.138774.205686">Common Stock, par value</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.7131.11.6" xlink:to="lab_CommonStockParOrStatedValuePerShare.2741.205685" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.2741.205685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.2741.205685">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.7144.11.8" xlink:to="lab_CommonStockSharesAuthorized.138777.205688" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.138777.205688" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.138777.205688">Common Stock, Authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.7144.11.6" xlink:to="lab_CommonStockSharesAuthorized.2742.205687" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.2742.205687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.2742.205687">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7431.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7431.11.52" xlink:to="lab_CostOfRevenue.138492.205626" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.138492.205626" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.138492.205626">COST OF REVENUES</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7431.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7431.11.6" xlink:to="lab_CostOfRevenue.3224.205625" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.3224.205625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.3224.205625">Cost of Revenue</link:label>
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1761.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareAbstract.1761.11.6" xlink:to="lab_EarningsPerShareAbstract.5712" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareAbstract.5712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareAbstract.5712">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.9078.11.6" xlink:to="lab_EarningsPerShareBasicAndDiluted.5415.205627" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.5415.205627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.5415.205627">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.11.6" xlink:to="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.5692" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.5692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.5692">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.11.7" xlink:to="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.370331.488042.237445" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.370331.488042.237445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.370331.488042.237445">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE:</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.6" xlink:href="plx-20140331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.6" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.205632" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.205632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138496.205632">Grants And Reimbursements Received Or Receivable</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.12" xlink:href="plx-20140331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.12" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.205634" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.205634" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138498.205634">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.7" xlink:href="plx-20140331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.11.7" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.205633" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.205633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138500.205633">Less - grants and reimbursements</link:label>
    <link:loc xlink:label="loc_GrossProfit.10776.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10776.11.9" xlink:to="lab_GrossProfit.138487.205636" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.138487.205636" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.138487.205636">GROSS PROFIT</link:label>
    <link:loc xlink:label="loc_GrossProfit.10776.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10776.11.6" xlink:to="lab_GrossProfit.7981.205635" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.7981.205635" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.7981.205635">Gross Profit</link:label>
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementAbstract.2649.11.6" xlink:to="lab_IncomeStatementAbstract.138470.205637" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementAbstract.138470.205637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementAbstract.138470.205637">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.13265.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.13265.11.9" xlink:to="lab_NetIncomeLoss.138521.205638" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138521.205638" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138521.205638">NET LOSS FOR THE PERIOD</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.9078.11.7" xlink:to="lab_Netlosspershareofcommonstock-basicanddiluted.167675.205639" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Netlosspershareofcommonstock-basicanddiluted.167675.205639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Netlosspershareofcommonstock-basicanddiluted.167675.205639">BASIC AND DILUTED</link:label>
    <link:loc xlink:label="loc_NonoperatingIncomeExpense.13395.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NonoperatingIncomeExpense.13395.11.6" xlink:to="lab_NonoperatingIncomeExpense.12540" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NonoperatingIncomeExpense.12540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NonoperatingIncomeExpense.12540">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:label="loc_NonoperatingIncomeExpense.13395.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NonoperatingIncomeExpense.13395.11.9" xlink:to="lab_NonoperatingIncomeExpense.406513" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NonoperatingIncomeExpense.406513" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NonoperatingIncomeExpense.406513">FINANCIAL INCOME (EXPENSES) - NET</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13592.11.6" xlink:to="lab_OperatingIncomeLoss.12364.205640" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.12364.205640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.12364.205640">Operating Income (Loss)</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13592.11.9" xlink:to="lab_OperatingIncomeLoss.138511.205641" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.138511.205641" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.138511.205641">OPERATING LOSS</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.23595.11.6" xlink:href="plx-20140331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.23595.11.6" xlink:to="lab_OtherGainsLosses.138475.205642" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138475.205642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138475.205642">Other Gains Losses</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.23595.11.12" xlink:href="plx-20140331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.23595.11.12" xlink:to="lab_OtherGainsLosses.138482.205644" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138482.205644" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138482.205644">The Company's share in collaboration agreement.</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.23595.11.7" xlink:href="plx-20140331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.23595.11.7" xlink:to="lab_OtherGainsLosses.138484.205643" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138484.205643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138484.205643">COMPANY'S SHARE IN COLLABORATION AGREEMENT</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingExpense.13989.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingExpense.13989.11.6" xlink:to="lab_OtherNonoperatingExpense.13500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingExpense.13500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingExpense.13500">Other Nonoperating Expense</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingExpense.13989.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingExpense.13989.11.52" xlink:to="lab_OtherNonoperatingExpense42.171749.406514" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingExpense42.171749.406514" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingExpense42.171749.406514">FINANCIAL EXPENSES</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingIncome.14001.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingIncome.14001.11.6" xlink:to="lab_OtherNonoperatingIncome.13517" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingIncome.13517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingIncome.13517">Other Nonoperating Income</link:label>
    <link:loc xlink:label="loc_OtherNonoperatingIncome.14001.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherNonoperatingIncome.14001.11.7" xlink:to="lab_OtherNonoperatingIncome.145200.406515" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherNonoperatingIncome.145200.406515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherNonoperatingIncome.145200.406515">FINANCIAL INCOME</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15880.11.6" xlink:to="lab_ResearchAndDevelopmentExpense.15873.205645" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense.15873.205645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense.15873.205645">Research and Development Expense</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15880.11.52" xlink:to="lab_ResearchAndDevelopmentExpense42.140375.205646" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense42.140375.205646" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense42.140375.205646">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.6" xlink:href="plx-20140331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.6" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.205647" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.205647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504.205647">Research Development And Engineering Expense Net</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.12" xlink:href="plx-20140331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.12" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.205649" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.205649" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505.205649">Research and development expenses, net.</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.55" xlink:href="plx-20140331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.11.55" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.205648" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.205648" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370.205648">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:loc xlink:label="loc_Revenues.16160.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.16160.11.7" xlink:to="lab_Revenues.134146.205651" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.134146.205651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.134146.205651">REVENUES</link:label>
    <link:loc xlink:label="loc_Revenues.16160.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.16160.11.6" xlink:to="lab_Revenues.16307.205650" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.16307.205650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.16307.205650">Revenues</link:label>
    <link:loc xlink:label="loc_SellingGeneralAndAdministrativeExpense.16773.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SellingGeneralAndAdministrativeExpense.16773.11.6" xlink:to="lab_SellingGeneralAndAdministrativeExpense.17918" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SellingGeneralAndAdministrativeExpense.17918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SellingGeneralAndAdministrativeExpense.17918">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:label="loc_SellingGeneralAndAdministrativeExpense.16773.11.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SellingGeneralAndAdministrativeExpense.16773.11.52" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense.406505" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense.406505" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_us-gaap_SellingGeneralAndAdministrativeExpense.406505">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.7" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.205653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.205653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681.205653">BASIC AND DILUTED</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.11.6" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.205652" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.205652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243.205652">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1761.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareAbstract.1761.11.7" xlink:to="us-gaap_EarningsPerShareAbstract_lbl.237442" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract_lbl.237442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl.237442">LOSS PER SHARE OF COMMON STOCK:</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5919.11.6" xlink:to="lab_AllocatedShareBasedCompensationExpense.852.205769" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense.852.205769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense.852.205769">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5919.11.7" xlink:to="lab_AllocatedShareBasedCompensationExpense7.138668.205770" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense7.138668.205770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense7.138668.205770">Share-based compensation</link:label>
    <link:loc xlink:label="loc_CostOfSalesMember.1254.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfSalesMember.1254.11.6" xlink:to="lab_CostOfSalesMember.3372" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfSalesMember.3372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfSalesMember.3372">Cost of Sales [Member]</link:label>
    <link:loc xlink:label="loc_CostOfSalesMember.1254.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfSalesMember.1254.11.7" xlink:to="lab_CostOfSalesMember7.155717.275820" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfSalesMember7.155717.275820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostOfSalesMember7.155717.275820">Cost of Revenue [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.205771" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.205771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595.205771">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpenseMember.2476.11.6" xlink:to="lab_GeneralAndAdministrativeExpenseMember.7876.205773" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpenseMember.7876.205773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpenseMember.7876.205773">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementLocationAxis.2652.11.6" xlink:to="lab_IncomeStatementLocationAxis.8839" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementLocationAxis.8839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementLocationAxis.8839">Income Statement Location [Axis]</link:label>
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementLocationDomain.2671.11.6" xlink:to="lab_IncomeStatementLocationDomain.8906" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementLocationDomain.8906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementLocationDomain.8906">Income Statement Location [Domain]</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpenseMember.4573.11.6" xlink:to="lab_ResearchAndDevelopmentExpenseMember.15885.205774" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpenseMember.15885.205774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpenseMember.15885.205774">Research and Development Expense [Member]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.205776" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.205776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738.205776">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:label="loc_AmendmentFlag.144.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmendmentFlag.144.11.6" xlink:to="lab_AmendmentFlag.8.205757" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmendmentFlag.8.205757" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmendmentFlag.8.205757">Amendment Flag</link:label>
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CurrentFiscalYearEndDate.155.11.6" xlink:to="lab_CurrentFiscalYearEndDate.20.205758" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CurrentFiscalYearEndDate.20.205758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CurrentFiscalYearEndDate.20.205758">Current Fiscal Year End Date</link:label>
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.23587.11.6" xlink:href="plx-20140331.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.11.6" xlink:to="lab_DocumentAndEntityInformationAbstract.138116.205759" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentAndEntityInformationAbstract.138116.205759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentAndEntityInformationAbstract.138116.205759">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.206.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalPeriodFocus.206.11.6" xlink:to="lab_DocumentFiscalPeriodFocus.123.205760" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalPeriodFocus.123.205760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalPeriodFocus.123.205760">Document Fiscal Period Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.205.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalYearFocus.205.11.6" xlink:to="lab_DocumentFiscalYearFocus.122.205761" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalYearFocus.122.205761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalYearFocus.122.205761">Document Fiscal Year Focus</link:label>
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentPeriodEndDate.161.11.6" xlink:to="lab_DocumentPeriodEndDate.30.205762" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentPeriodEndDate.30.205762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentPeriodEndDate.30.205762">Document Period End Date</link:label>
    <link:loc xlink:label="loc_DocumentType.210.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentType.210.11.6" xlink:to="lab_DocumentType.32.205763" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentType.32.205763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentType.32.205763">Document Type</link:label>
    <link:loc xlink:label="loc_EntityCentralIndexKey.186.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCentralIndexKey.186.11.6" xlink:to="lab_EntityCentralIndexKey.101.205764" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCentralIndexKey.101.205764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCentralIndexKey.101.205764">Entity Central Index Key</link:label>
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.190.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCommonStockSharesOutstanding.190.11.6" xlink:to="lab_EntityCommonStockSharesOutstanding.105.205765" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCommonStockSharesOutstanding.105.205765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCommonStockSharesOutstanding.105.205765">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_EntityFilerCategory.183.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityFilerCategory.183.11.6" xlink:to="lab_EntityFilerCategory.98.205766" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityFilerCategory.98.205766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityFilerCategory.98.205766">Entity Filer Category</link:label>
    <link:loc xlink:label="loc_EntityRegistrantName.185.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityRegistrantName.185.11.6" xlink:to="lab_EntityRegistrantName.100.205767" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityRegistrantName.100.205767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityRegistrantName.100.205767">Entity Registrant Name</link:label>
    <link:loc xlink:label="loc_TradingSymbol.176.11.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TradingSymbol.176.11.6" xlink:to="lab_TradingSymbol.60.205768" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TradingSymbol.60.205768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TradingSymbol.60.205768">Trading Symbol</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureAbstract.2913.11.6" xlink:to="lab_InventoryDisclosureAbstract.138059.205557" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureAbstract.138059.205557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureAbstract.138059.205557">INVENTORIES [Abstract]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11845.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11845.11.6" xlink:to="lab_InventoryDisclosureTextBlock.9626.205558" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock.9626.205558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock.9626.205558">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11845.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11845.11.7" xlink:to="lab_InventoryDisclosureTextBlock7.138804.205559" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock7.138804.205559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock7.138804.205559">INVENTORIES</link:label>
    <link:loc xlink:label="loc_InventoryWriteDown.11859.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWriteDown.11859.11.8" xlink:to="InventoryWriteDown.1903521.403139" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="InventoryWriteDown.1903521.403139" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="InventoryWriteDown.1903521.403139">Inventory write-down</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11837.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoodsNetOfReserves.11837.11.6" xlink:to="lab_InventoryFinishedGoodsNetOfReserves.10003" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoodsNetOfReserves.10003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoodsNetOfReserves.10003">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11837.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoodsNetOfReserves.11837.11.7" xlink:to="lab_InventoryFinishedGoodsNetOfReserves.134479.182856" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoodsNetOfReserves.134479.182856" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoodsNetOfReserves.134479.182856">Finished goods</link:label>
    <link:loc xlink:label="loc_InventoryNet.11816.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11816.11.9" xlink:to="lab_InventoryNet.138062.205779" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138062.205779" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138062.205779">Total inventory</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11840.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterialsNetOfReserves.11840.11.6" xlink:to="lab_InventoryRawMaterialsNetOfReserves.10009" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterialsNetOfReserves.10009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterialsNetOfReserves.10009">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11840.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterialsNetOfReserves.11840.11.7" xlink:to="lab_InventoryRawMaterialsNetOfReserves7.134480.182859" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterialsNetOfReserves7.134480.182859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterialsNetOfReserves7.134480.182859">Raw materials</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11877.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcessNetOfReserves.11877.11.6" xlink:to="lab_InventoryWorkInProcessNetOfReserves.10065" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcessNetOfReserves.10065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcessNetOfReserves.10065">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11877.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcessNetOfReserves.11877.11.7" xlink:to="lab_InventoryWorkInProcessNetOfReserves.134478.182861" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcessNetOfReserves.134478.182861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcessNetOfReserves.134478.182861">Work in process</link:label>
    <link:loc xlink:label="loc_InventoryWriteDown.11859.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWriteDown.11859.11.6" xlink:to="lab_InventoryWriteDown.10035" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWriteDown.10035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWriteDown.10035">Inventory Write-down</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.11.6" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.205570" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.205570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock.16610.205570">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.11.7" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.205571" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.205571" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817.205571">Inventory</link:label>
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountingPoliciesAbstract.414.11.6" xlink:to="lab_AccountingPoliciesAbstract.137967.205554" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountingPoliciesAbstract.137967.205554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountingPoliciesAbstract.137967.205554">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.7" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.205556" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.205556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803.205556">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.11.6" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.205555" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.205555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457.205555">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.205497" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.205497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005.205497">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.11.7" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.205498" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.205498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029.205498">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.205499" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.205499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010.205499">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.582.11.6" xlink:to="lab_AntidilutiveSecuritiesNameDomain.1007.205500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesNameDomain.1007.205500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesNameDomain.1007.205500">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.11.6" xlink:to="lab_ArrangementsAndNonarrangementTransactionsMember.288" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ArrangementsAndNonarrangementTransactionsMember.288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ArrangementsAndNonarrangementTransactionsMember.288">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.11.6" xlink:href="plx-20140331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.23585.11.6" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138005.205501" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138005.205501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138005.205501">Collaborative Arrangement Profit Share Percentage</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.11.12" xlink:href="plx-20140331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.23585.11.12" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138007.205503" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138007.205503" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138007.205503">Collaborative arrangement profit sharing percentage.</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.11.7" xlink:href="plx-20140331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.23585.11.7" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138010.205502" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138010.205502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138010.205502">Pfizer Agreement, future revenues and expense sharing percentage</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.7131.11.7" xlink:to="lab_CommonStockParOrStatedValuePerShare7.134365.205506" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare7.134365.205506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare7.134365.205506">Common stock, par value per share</link:label>
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.6" xlink:href="plx-20140331.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.6" xlink:to="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.239032" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.239032" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.239032">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.12" xlink:href="plx-20140331.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.12" xlink:to="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits12.239033" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits12.239033" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits12.239033">License And Supply Agreement Potential Future Payment Based On Net Profits</link:label>
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.7" xlink:href="plx-20140331.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.11.7" xlink:to="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits7.239034" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits7.239034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits7.239034">License and supply agreement potential future payment</link:label>
    <link:loc xlink:label="loc_MilestonePayment.23592.11.6" xlink:href="plx-20140331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.23592.11.6" xlink:to="lab_MilestonePayment.138000.205507" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138000.205507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138000.205507">Milestone Payment</link:label>
    <link:loc xlink:label="loc_MilestonePayment.23592.11.12" xlink:href="plx-20140331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.23592.11.12" xlink:to="lab_MilestonePayment.138001.205509" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138001.205509" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138001.205509">Milestone payment.</link:label>
    <link:loc xlink:label="loc_MilestonePayment.23592.11.7" xlink:href="plx-20140331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.23592.11.7" xlink:to="lab_MilestonePayment.138002.205508" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138002.205508" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138002.205508">Milestone payment triggered</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.11.6" xlink:href="plx-20140331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.23594.11.6" xlink:to="lab_NumberOfSubsidiaries.137996.205510" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137996.205510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137996.205510">Number Of Subsidiaries</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.11.12" xlink:href="plx-20140331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.23594.11.12" xlink:to="lab_NumberOfSubsidiaries.137997.205512" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137997.205512" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137997.205512">Number of subsidiaries.</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.11.7" xlink:href="plx-20140331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.23594.11.7" xlink:to="lab_NumberOfSubsidiaries.137998.205511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137998.205511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137998.205511">Number of Subsidiaries</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.11.6" xlink:href="plx-20140331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.23596.11.6" xlink:to="lab_PfizerIncorporationMember.137992.205513" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137992.205513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137992.205513">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.11.12" xlink:href="plx-20140331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.23596.11.12" xlink:to="lab_PfizerIncorporationMember.137993.205515" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137993.205515" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137993.205515">Pfizer Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.11.7" xlink:href="plx-20140331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.23596.11.7" xlink:to="lab_PfizerIncorporationMember.137994.205514" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137994.205514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137994.205514">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14867.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14867.11.7" xlink:to="lab_ProceedsFromCollaborators.137999.205517" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.137999.205517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.137999.205517">Pfizer Agreement, upfront payment received</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14867.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14867.11.6" xlink:to="lab_ProceedsFromCollaborators.14422.205516" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.14422.205516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.14422.205516">Proceeds from Collaborators</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfOtherAssets1.14865.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfOtherAssets1.14865.11.6" xlink:to="lab_ProceedsFromSaleOfOtherAssets1.14898" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfOtherAssets1.14898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfOtherAssets1.14898">Proceeds from Sale of Other Assets</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfOtherAssets1.14865.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfOtherAssets1.14865.11.7" xlink:to="lab_ProceedsFromSaleOfOtherAssets1.406516" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfOtherAssets1.406516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfOtherAssets1.406516">Revenue from sale of products</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.6" xlink:href="plx-20140331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.6" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137989.205518" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137989.205518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137989.205518">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.12" xlink:href="plx-20140331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.12" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137990.205520" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137990.205520" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137990.205520">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.7" xlink:href="plx-20140331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.23598.11.7" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137991.205519" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137991.205519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137991.205519">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.11.6" xlink:href="plx-20140331.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixLtdMember.27186.11.6" xlink:to="lab_ProtalixLtdMember.237459" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixLtdMember.237459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixLtdMember.237459">Protalix Ltd [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.11.12" xlink:href="plx-20140331.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixLtdMember.27186.11.12" xlink:to="lab_ProtalixLtdMember12.237460" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixLtdMember12.237460" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixLtdMember12.237460">Protalix Ltd [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.11.8" xlink:href="plx-20140331.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixLtdMember.27186.11.8" xlink:to="lab_ProtalixLtdMember8.237462" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixLtdMember8.237462" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixLtdMember8.237462">Protalix Ltd. [Member]</link:label>
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.6" xlink:href="plx-20140331.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.6" xlink:to="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.242903" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.242903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.242903">Purchase Amount To Be Satisfied To Receive Entitled Rights</link:label>
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.12" xlink:href="plx-20140331.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.12" xlink:to="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights12.242904" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights12.242904" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights12.242904">The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</link:label>
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.7" xlink:href="plx-20140331.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.11.7" xlink:to="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights7.242905" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights7.242905" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PurchaseAmountToBeSatisfiedToReceiveEntitledRights7.242905">Supply commitment for entitled rights to be received</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.23600.11.6" xlink:href="plx-20140331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.23600.11.6" xlink:to="lab_ScenarioFourMember.501181.205521" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501181.205521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501181.205521">Scenario Four [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.23600.11.12" xlink:href="plx-20140331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.23600.11.12" xlink:to="lab_ScenarioFourMember.501182.205523" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501182.205523" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501182.205523">Scenario Four [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.23600.11.7" xlink:href="plx-20140331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.23600.11.7" xlink:to="lab_ScenarioFourMember.501183.205522" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501183.205522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501183.205522">Upon Near Term Clinical Development Milestones [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.23601.11.6" xlink:href="plx-20140331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.23601.11.6" xlink:to="lab_ScenarioOneMember.137972.205524" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137972.205524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137972.205524">Scenario One [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.23601.11.12" xlink:href="plx-20140331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.23601.11.12" xlink:to="lab_ScenarioOneMember.137973.205526" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137973.205526" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137973.205526">Scenario One [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.23601.11.7" xlink:href="plx-20140331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.23601.11.7" xlink:to="lab_ScenarioOneMember.137974.205525" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137974.205525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137974.205525">Upon each FDA and European Medicine Agency approval [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.11.6" xlink:href="plx-20140331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.23602.11.6" xlink:to="lab_ScenarioThreeMember.501178.205527" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMember.501178.205527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMember.501178.205527">Scenario Three [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.11.12" xlink:href="plx-20140331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.23602.11.12" xlink:to="lab_ScenarioThreeMember.501179.205528" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMember.501179.205528" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMember.501179.205528">Scenario Three [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.11.7" xlink:href="plx-20140331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.23602.11.7" xlink:to="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180.205529" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180.205529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180.205529">Upon FDA Approval [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.11.6" xlink:href="plx-20140331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.23603.11.6" xlink:to="lab_ScenarioTwoMember.137969.205530" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137969.205530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137969.205530">Scenario Two [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.11.12" xlink:href="plx-20140331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.23603.11.12" xlink:to="lab_ScenarioTwoMember.137970.205532" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137970.205532" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137970.205532">Scenario Two [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.11.7" xlink:href="plx-20140331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.23603.11.7" xlink:to="lab_ScenarioTwoMember.137971.205531" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137971.205531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137971.205531">Upon Filing of Pediatric Investigation Plan to EMA [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.11.6" xlink:to="lab_ScenarioUnspecifiedDomain.16504.205533" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioUnspecifiedDomain.16504.205533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioUnspecifiedDomain.16504.205533">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.11.6" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.11.6" xlink:to="lab_SignificantAccountingPoliciesLineItems.137995.205534" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesLineItems.137995.205534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesLineItems.137995.205534">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.11.6" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.11.6" xlink:to="lab_SignificantAccountingPoliciesTable.137976.205535" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137976.205535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137976.205535">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.11.12" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.11.12" xlink:to="lab_SignificantAccountingPoliciesTable.137977.205536" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137977.205536" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137977.205536">Significant Accounting Policies [Table].</link:label>
    <link:loc xlink:label="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.11.6" xlink:to="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.18430" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.18430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.18430">Supply Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:label="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.11.7" xlink:to="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted7.237458" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted7.237458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SignificantSupplyCommitmentRemainingMinimumAmountCommitted7.237458">Total supply commitment</link:label>
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementScenarioAxis.5162.11.6" xlink:to="lab_StatementScenarioAxis.17868.205537" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementScenarioAxis.17868.205537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementScenarioAxis.17868.205537">Scenario [Axis]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.11.6" xlink:href="plx-20140331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.23606.11.6" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168199.205538" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168199.205538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168199.205538">Stock Options And Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.11.12" xlink:href="plx-20140331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.23606.11.12" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168200.205540" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168200.205540" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168200.205540">Stock Options And Restricted Shares [Member].</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.11.7" xlink:href="plx-20140331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.23606.11.7" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168201.205539" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168201.205539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168201.205539">Options and Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.49211.11.6" xlink:href="plx-20140331.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplyCommitmentPerYear.49211.11.6" xlink:to="lab_SupplyCommitmentPerYear.406708" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplyCommitmentPerYear.406708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplyCommitmentPerYear.406708">Supply Commitment Per Year</link:label>
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.49211.11.12" xlink:href="plx-20140331.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplyCommitmentPerYear.49211.11.12" xlink:to="lab_SupplyCommitmentPerYear12.406709" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplyCommitmentPerYear12.406709" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SupplyCommitmentPerYear12.406709">The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</link:label>
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.49211.11.7" xlink:href="plx-20140331.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplyCommitmentPerYear.49211.11.7" xlink:to="lab_SupplyCommitmentPerYear7.406710" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplyCommitmentPerYear7.406710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplyCommitmentPerYear7.406710">Supply agreement maximum consideration payment</link:label>
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TypeOfArrangementAxis.5386.11.6" xlink:to="lab_TypeOfArrangementAxis.19407" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TypeOfArrangementAxis.19407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TypeOfArrangementAxis.19407">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.6" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.205563" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.205563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock.1458.205563">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.11.7" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.205564" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.205564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441.205564">Basis of Presentation</link:label>
    <link:loc xlink:label="loc_DebtPolicyTextBlock.7719.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtPolicyTextBlock.7719.11.6" xlink:to="lab_DebtPolicyTextBlock.3768" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DebtPolicyTextBlock.3768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DebtPolicyTextBlock.3768">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.9080.11.7" xlink:to="lab_EarningsPerSharePolicyTextBlock.138811.205566" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.138811.205566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.138811.205566">Net loss per share</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.9080.11.6" xlink:to="lab_EarningsPerSharePolicyTextBlock.5427.205565" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.5427.205565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.5427.205565">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.23593.11.6" xlink:href="plx-20140331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.23593.11.6" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138808.205567" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138808.205567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138808.205567">Nature Of Operations [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.23593.11.12" xlink:href="plx-20140331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.23593.11.12" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138809.205569" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138809.205569" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138809.205569">The accounting policy related to the nature of operations of the entity.</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.23593.11.7" xlink:href="plx-20140331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.23593.11.7" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138810.205568" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138810.205568" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138810.205568">General</link:label>
    <link:loc xlink:label="loc_DebtPolicyTextBlock.7719.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DebtPolicyTextBlock.7719.11.7" xlink:to="us-gaap_DebtPolicyTextBlock_lbl.267627.275829" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="us-gaap_DebtPolicyTextBlock_lbl.267627.275829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="us-gaap_DebtPolicyTextBlock_lbl.267627.275829">Convertible notes</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.11.6" xlink:to="lab_StockholdersEquityNoteAbstract.138077.205560" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteAbstract.138077.205560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteAbstract.138077.205560">STOCK TRANSACTIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.7" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.138805.205562" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.138805.205562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.138805.205562">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.17310.11.6" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.18039.205561" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.18039.205561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.18039.205561">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfStockLineItems.1018.11.6" xlink:to="lab_ClassOfStockLineItems.2526.205541" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfStockLineItems.2526.205541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfStockLineItems.2526.205541">Class of Stock [Line Items]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.11.6" xlink:href="plx-20140331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.23588.11.6" xlink:to="lab_EmployeeAndNonemployeeMember.138111.205542" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138111.205542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138111.205542">Employee And Nonemployee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.11.12" xlink:href="plx-20140331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.23588.11.12" xlink:to="lab_EmployeeAndNonemployeeMember.138112.205544" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138112.205544" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138112.205544">Employee And Nonemployee [Member].</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.11.7" xlink:href="plx-20140331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.23588.11.7" xlink:to="lab_EmployeeAndNonemployeeMember.138113.205543" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138113.205543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138113.205543">Certain Employees and Non-employees [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.23589.11.6" xlink:href="plx-20140331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.23589.11.6" xlink:to="lab_EmployeeMember.140096.205545" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140096.205545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140096.205545">Employee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.23589.11.12" xlink:href="plx-20140331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.23589.11.12" xlink:to="lab_EmployeeMember.140097.205547" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140097.205547" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140097.205547">Employee [Member].</link:label>
    <link:loc xlink:label="loc_EmployeeMember.23589.11.7" xlink:href="plx-20140331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.23589.11.7" xlink:to="lab_EmployeeMember.140327.205546" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140327.205546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140327.205546">Certain Employee [Member]</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3709.11.6" xlink:to="lab_OptionIndexedToIssuersEquityEquityAxis.12418.205548" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityEquityAxis.12418.205548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityEquityAxis.12418.205548">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.11.6" xlink:to="lab_OptionIndexedToIssuersEquityTypeDomain.12421.205549" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityTypeDomain.12421.205549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityTypeDomain.12421.205549">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.15050.11.7" xlink:to="lab_ProceedsFromStockOptionsExercised.138107.205550" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.138107.205550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.138107.205550">Cash proceeds from exercise of options</link:label>
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4895.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfStockByClassTable.4895.11.6" xlink:to="lab_ScheduleOfStockByClassTable.16952.205551" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfStockByClassTable.16952.205551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfStockByClassTable.16952.205551">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511.205553" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511.205553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511.205553">Common stock issued in connection with exercise of options</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957.205552" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957.205552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957.205552">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresAbstract.2053.11.6" xlink:to="lab_FairValueDisclosuresAbstract.275826" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresAbstract.275826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresAbstract.275826">FAIR VALUE MEASUREMENT [Abstract]</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresTextBlock.9740.11.6" xlink:to="lab_FairValueDisclosuresTextBlock.6756" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresTextBlock.6756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresTextBlock.6756">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_FairValueDisclosuresTextBlock.9740.11.7" xlink:to="lab_FairValueDisclosuresTextBlock7.134437.275827" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_FairValueDisclosuresTextBlock7.134437.275827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_FairValueDisclosuresTextBlock7.134437.275827">FAIR VALUE MEASUREMENT</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>plx-20140331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2014-05-07 @ 12:05 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20140331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20140331.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20140331.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:href="plx-20140331.xsd#plx-ccsocicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" xlink:href="plx-20140331.xsd#plx-ccsocicdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20140331.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20140331.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20140331.xsd#plx-daei" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20140331.xsd#plx-i" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20140331.xsd#plx-isoicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20140331.xsd#plx-it" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20140331.xsd#plx-sap" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20140331.xsd#plx-sapd1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20140331.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20140331.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20140331.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/FairValueMeasurement" xlink:href="plx-20140331.xsd#plx-fvm" xlink:type="simple" />
  <link:presentationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5660.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.12.7" xlink:to="loc_AccountsPayableTradeCurrent.5660.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5690.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.12.7" xlink:to="loc_AccountsPayableOtherCurrent.5690.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.616.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5665.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_AccountsReceivableNetCurrent.5665.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13867.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_OtherReceivablesNetCurrent.13867.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryNet.11816.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.616.12.7" xlink:to="loc_InventoryNet.11816.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.620.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_AssetsCurrentAbstract.616.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.8274.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.15211.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_PropertyPlantAndEquipmentNet.15211.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.620.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Assets.6057.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.9" xlink:to="loc_Assets.6057.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_AssetsCurrent.6084.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.9" xlink:to="loc_AssetsCurrent.6084.12.9" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.422.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7937.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.7" xlink:to="loc_DeferredRevenueCurrent.7937.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredCosts.7792.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.620.12.7" xlink:to="loc_DeferredCosts.7792.12.7" order="3.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.3060.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.12126.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.3060.12.9" xlink:to="loc_LiabilitiesCurrent.12126.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7950.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:to="loc_DeferredRevenueNoncurrent.7950.12.7" order="1.75000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12757.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:to="loc_LongTermDebtNoncurrent.12757.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.14424.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_LiabilitiesCurrentAbstract.3060.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_LiabilitiesNoncurrentAbstract.3062.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.12165.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:to="loc_LiabilitiesNoncurrent.12165.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_Liabilities.12166.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:to="loc_Liabilities.12166.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.7121.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_CommitmentsAndContingencies.7121.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" xlink:to="loc_StockholdersEquity.17302.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.12135.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.9" xlink:to="loc_LiabilitiesAndStockholdersEquity.12135.12.9" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_AssetsAbstract.620.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.5171.12.7" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract.3066.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ConvertibleDebtNoncurrent.7358.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.3062.12.7" xlink:to="loc_ConvertibleDebtNoncurrent.7358.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16900.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_ShareBasedCompensation.16900.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.23586.12.7" xlink:href="plx-20140331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.23586.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.10419.12.52" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.14426.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.14426.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AmortizationOfFinancingCosts.5974.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" xlink:to="loc_AmortizationOfFinancingCosts.5974.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.12.52" xlink:href="plx-20140331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.52" xlink:to="loc_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement.49212.12.52" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.11341.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.11341.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.11237.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.11237.12.52" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.11367.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.52" xlink:to="loc_IncreaseDecreaseInInventories.11367.12.52" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.11306.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.8" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.14347.12.52" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.14301.12.52" order="2.37500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInRestrictedCash.11462.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.52" xlink:to="loc_IncreaseDecreaseInRestrictedCash.11462.12.52" order="1.87500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.20" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.20" xlink:to="loc_NetIncomeLoss.13265.12.20" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3521.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.502.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract.2736.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3520.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3499.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.9113.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6834.12.9" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.10" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.10" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.5168.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.11" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6843.12.11" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.7" xlink:to="loc_SupplementalCashFlowInformationAbstract.5255.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.12.7" xlink:href="plx-20140331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:to="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.23591.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.23584.12.7" xlink:href="plx-20140331.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5255.12.7" xlink:to="loc_CashlessExerciseOfStockOptions.23584.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.13221.12.9" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations.13250.12.9" order="6.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.5168.12.9" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations.13240.12.9" order="8.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1873.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1087.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1873.12.6" xlink:to="loc_CommonStockMember.1087.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityComponentDomain.1873.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.485.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1873.12.7" xlink:to="loc_AdditionalPaidInCapitalMember.485.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4652.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1873.12.7" xlink:to="loc_RetainedEarningsMember.4652.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementTable.5163.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.5169.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.5163.12.6" xlink:to="loc_StatementEquityComponentsAxis.5169.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.5163.12.6" xlink:to="loc_StatementLineItems.5164.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.10" xlink:to="loc_StockholdersEquity.17302.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_SharesOutstanding.17056.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.10" xlink:to="loc_SharesOutstanding.17056.12.10" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.17271.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.17271.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.17285.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.17285.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.17234.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.8" xlink:to="loc_NetIncomeLoss.13265.12.8" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.5164.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.17302.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.11" xlink:to="loc_StockholdersEquity.17302.12.11" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_SharesOutstanding.17056.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.11" xlink:to="loc_SharesOutstanding.17056.12.11" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.5166.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.12.6" xlink:to="loc_StatementTable.5163.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_StatementEquityComponentsAxis.5169.12.6" xlink:to="loc_EquityComponentDomain.1873.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.8" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.5844.12.8" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.12.7" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures.49213.12.7" order="6.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.12.7" xlink:href="plx-20140331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.5164.12.7" xlink:to="loc_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares.49214.12.7" order="7.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY  (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.5166.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5860.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.5166.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.12.8" xlink:to="loc_CommonStockParOrStatedValuePerShare.7131.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.7144.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.5166.12.8" xlink:to="loc_CommonStockSharesAuthorized.7144.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.12.7" xlink:to="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.18039.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1761.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.9078.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EarningsPerShareAbstract.1761.12.7" xlink:to="loc_EarningsPerShareBasicAndDiluted.9078.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.16160.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_Revenues.16160.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherGainsLosses.23595.12.7" xlink:href="plx-20140331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_OtherGainsLosses.23595.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CostOfRevenue.7431.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.52" xlink:to="loc_CostOfRevenue.7431.12.52" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GrossProfit.10776.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_GrossProfit.10776.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15880.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.52" xlink:to="loc_ResearchAndDevelopmentExpense.15880.12.52" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.12.7" xlink:href="plx-20140331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.23590.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.55" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.12.55" xlink:href="plx-20140331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.55" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.23599.12.55" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13592.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_OperatingIncomeLoss.13592.12.9" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.13265.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_NetIncomeLoss.13265.12.9" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_EarningsPerShareAbstract.1761.12.7" order="14.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract.1754.12.7" order="15.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NonoperatingIncomeExpense.13395.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.9" xlink:to="loc_NonoperatingIncomeExpense.13395.12.9" order="10.96875" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_SellingGeneralAndAdministrativeExpense.16773.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.52" xlink:to="loc_SellingGeneralAndAdministrativeExpense.16773.12.52" order="8.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_OtherNonoperatingIncome.14001.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.7" xlink:to="loc_OtherNonoperatingIncome.14001.12.7" order="10.93750" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherNonoperatingExpense.13989.12.52" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.52" xlink:to="loc_OtherNonoperatingExpense.13989.12.52" order="10.87500" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5919.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.7" xlink:to="loc_AllocatedShareBasedCompensationExpense.5919.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2649.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2649.12.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4573.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationDomain.2671.12.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4573.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2476.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationDomain.2671.12.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2476.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationAxis.2652.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationAxis.2652.12.6" xlink:to="loc_IncomeStatementLocationDomain.2671.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementLocationDomain.2671.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CostOfSalesMember.1254.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementLocationDomain.2671.12.7" xlink:to="loc_CostOfSalesMember.1254.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1805.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4815.12.6" xlink:to="loc_IncomeStatementLocationAxis.2652.12.6" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="001 - Document - Document and Entity Information" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:href="plx-20140331.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DocumentType.210.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_DocumentType.210.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AmendmentFlag.144.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_AmendmentFlag.144.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_DocumentPeriodEndDate.161.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.205.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_DocumentFiscalYearFocus.205.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.206.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_DocumentFiscalPeriodFocus.206.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_TradingSymbol.176.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_TradingSymbol.176.12.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityRegistrantName.185.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_EntityRegistrantName.185.12.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCentralIndexKey.186.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_EntityCentralIndexKey.186.12.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_CurrentFiscalYearEndDate.155.12.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityFilerCategory.183.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_EntityFilerCategory.183.12.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.190.12.6" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.23587.12.6" xlink:to="loc_EntityCommonStockSharesOutstanding.190.12.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="102 - Disclosure - INVENTORIES" xlink:role="http://www.protalix.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11845.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_InventoryDisclosureTextBlock.11845.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)" xlink:role="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryNet.11816.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.9" xlink:to="loc_InventoryNet.11816.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryWriteDown.11859.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWriteDown" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.8" xlink:to="loc_InventoryWriteDown.11859.12.8" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11840.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_InventoryRawMaterialsNetOfReserves.11840.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11877.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_InventoryWorkInProcessNetOfReserves.11877.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11837.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_InventoryFinishedGoodsNetOfReserves.11837.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="302 - Disclosure - INVENTORIES (Tables)" xlink:role="http://www.protalix.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2913.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2913.12.7" xlink:to="loc_ScheduleOfInventoryCurrentTableTextBlock.16377.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6322.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.23598.12.7" xlink:href="plx-20140331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.23598.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.23596.12.7" xlink:href="plx-20140331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.7" xlink:to="loc_PfizerIncorporationMember.23596.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.6" xlink:to="loc_SignificantAccountingPoliciesTable.23605.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.23606.12.7" xlink:href="plx-20140331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.582.12.7" xlink:to="loc_StockOptionsAndRestrictedSharesMember.23606.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.582.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.12.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.582.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixLtdMember.27186.12.8" xlink:href="plx-20140331.xsd#plx_ProtalixLtdMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.8" xlink:to="loc_ProtalixLtdMember.27186.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.23603.12.7" xlink:href="plx-20140331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:to="loc_ScenarioTwoMember.23603.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioOneMember.23601.12.7" xlink:href="plx-20140331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:to="loc_ScenarioOneMember.23601.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioThreeMember.23602.12.7" xlink:href="plx-20140331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:to="loc_ScenarioThreeMember.23602.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioFourMember.23600.12.7" xlink:href="plx-20140331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4760.12.7" xlink:to="loc_ScenarioFourMember.23600.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementScenarioAxis.5162.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4760.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementScenarioAxis.5162.12.6" xlink:to="loc_ScenarioUnspecifiedDomain.4760.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.23594.12.7" xlink:href="plx-20140331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_NumberOfSubsidiaries.23594.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14867.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_ProceedsFromCollaborators.14867.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_TypeOfArrangementAxis.5386.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TypeOfArrangementAxis.5386.12.6" xlink:to="loc_ArrangementsAndNonarrangementTransactionsMember.373.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:to="loc_StatementScenarioAxis.5162.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.579.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.23604.12.6" xlink:href="plx-20140331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:to="loc_SignificantAccountingPoliciesLineItems.23604.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePayment.23592.12.7" xlink:href="plx-20140331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_MilestonePayment.23592.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.23585.12.7" xlink:href="plx-20140331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.23585.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.7131.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_CommonStockParOrStatedValuePerShare.7131.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.6016.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.23605.12.6" xlink:to="loc_TypeOfArrangementAxis.5386.12.6" order="3.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_SignificantSupplyCommitmentRemainingMinimumAmountCommitted.17112.12.7" order="4.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.12.7" xlink:href="plx-20140331.xsd#plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits.27333.12.7" order="4.56250" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.12.7" xlink:href="plx-20140331.xsd#plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_PurchaseAmountToBeSatisfiedToReceiveEntitledRights.27799.12.7" order="4.53125" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfOtherAssets1.14865.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherAssets1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_ProceedsFromSaleOfOtherAssets1.14865.12.7" order="4.68750" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SupplyCommitmentPerYear.49211.12.7" xlink:href="plx-20140331.xsd#plx_SupplyCommitmentPerYear" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.23604.12.7" xlink:to="loc_SupplyCommitmentPerYear.49211.12.7" order="4.65625" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.414.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.23593.12.7" xlink:href="plx-20140331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_NatureOfOperationsPolicyTextBlock.23593.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_BasisOfAccountingPolicyPolicyTextBlock.6323.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.9080.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_EarningsPerSharePolicyTextBlock.9080.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DebtPolicyTextBlock.7719.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.414.12.7" xlink:to="loc_DebtPolicyTextBlock.7719.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="104 - Disclosure - STOCK TRANSACTIONS" xlink:role="http://www.protalix.com/role/StockTransactions" xlink:type="extended">
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.17310.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.12.7" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock.17310.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40401 - Disclosure - STOCK TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/StockTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.1018.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.17264.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.15050.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.1018.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.15050.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.1018.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.17260.12.7" order="7.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3709.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3709.12.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.23588.12.7" xlink:href="plx-20140331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.7" xlink:to="loc_EmployeeAndNonemployeeMember.23588.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeMember.23589.12.7" xlink:href="plx-20140331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3712.12.7" xlink:to="loc_EmployeeMember.23589.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4895.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4895.12.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3709.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.1018.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4895.12.6" xlink:to="loc_ClassOfStockLineItems.1018.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.5200.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.5200.12.6" xlink:to="loc_ScheduleOfStockByClassTable.4895.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="103 - Disclosure - FAIR VALUE MEASUREMENT" xlink:role="http://www.protalix.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:label="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_FairValueDisclosuresTextBlock.9740.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_FairValueDisclosuresAbstract.2053.12.7" xlink:to="loc_FairValueDisclosuresTextBlock.9740.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!`=`G4G0$``(\,```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,EUU/PC`4AN]-_`]+;PWK
MBHIH&%SX<:DDX@^HZQEKZ-JF+0C_WJY\Q)`)(9+8FS5;>][WV4EV\FXP6M8B
M68"Q7,D<D31#"<A",2ZG.?J8O'3Z*+&.2D:%DI"C%5@T&EY>#"8K#3;QU=+F
MJ')./V!LBPIJ:E.E0?J=4IF:.G]KIEC38D:G@+M9UL.%D@ZDZ[A&`PT'3U#2
MN7#)\](_7I,8$!8EC^N#C5>.J-:"%]1Y4KR0;,^ELW%(?64X8RNN[97'0+C5
MH=GYW6!3]^9;8SB#9$R->Z6UQ\!+@;^4F7TJ-4L/B[10JK+D!3!5S&O?@=1J
M`Y39"L#5(@UK6E,NM]P'_,-AB\-"S@S2O%\0/I&C&PG'=20<-Y%PW$;"T8N$
MXRX2CGXD'/>1<)`L%I!8)BJ)9:226&8JB66HDEBF*OFOL>I\W`,<KG__7H+,
MD;QAW4J`/?.,6(L><ZZH`?;NC`_&9P?XJ7V(P\?&L5':^@!MX/0N;!-R4]W1
M7@B,X[#+R&U9<^?HP_?IAGMA%YIXSX"U>./P.S'\!@``__\#`%!+`P04``8`
M"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(`````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^U
MC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B
M(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4<IA
M:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[
MRW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*
M<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/5%\```#__P,`4$L#!!0`!@`(````
M(0#NGCLT6@$```X+```:``@!>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@
MH@0!**```0``````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````"\ELUJPS`,
M@.^#O4/P?76<MFD[FO8R!KUNW0.81/FAB1UL[Z=O/]%!UD*G]1!T"<C&TL<G
M!VN]_>K:Z`.<;ZS)A)K$(@*3VZ(Q52;>]L\/2Q'YH$VA6VL@$T?P8KNYOUN_
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MJID;8%84C.)6HP8W\F**W7P#``#__P,`4$L#!!0`!@`(````(0`HPPK#:`(`
M`",&```/````>&PO=V]R:V)O;VLN>&ULE%1=;Z)`%'W?9/\#F?<M'UI;C=I0
MQ.ZD%AM!^TBF,,JDPPR!L;;_?B^XXE23QC[!9;B'<\X]W.'=1\Z-=UI63(H1
MLJ\L9%"1R)2)S0@MH^F?6V14BHB4<"GH"'W2"MV-?_\:[F3Y]BKEFP$`HAJA
M3*EB8)I5DM&<5%>RH`).UK+,B8*RW)A545*25AFE*N>F8UD],R=,H#W"H+P$
M0Z[7+*$3F6QS*M0>I*2<**!?9:RHT'BX9IRN]HH,4A0!R8'W!T<&)Y7R4Z9H
M.D+74,H=_?*@W!;W6\;AM-^Q.L@<MR*?2R.E:[+E*@)Y!W3PR^DZ3J]^L[9B
MQ>BN.C;5I?'QPD0J=_6K8.UG6W6`P*XY>F&IRN#<LJSVV5_*-IDZ/`1X4\-O
M'(3O-%=#-/(.CL0PJ=@7BJG/&(N]^TS""&O7,2BSD5$.&-R4.+5KXCJ*-P\F
M?A#ZDQCNPOD,3]P(BGMWY@:>KZ/<:##.A3!A!&A/.DQ'0VG\OH#,?Q30T6KJ
M:C#=GY%Q-!APO[7F^F<P(*1ET]-@FFA<+@J$M#"ZPS>G;$+\$.`I]MP@BEW/
MFR^#"`</\3.,S,.ZPS;\OJVHVU,8'*S\()HOL!]J7[;[6D__M&?JXD6\<F=+
M/W[RW7"Y@)$&D=9>Y[S]I&V=]H?1W'N,HX4;A*X78<B9WOLEGF?Y_%ZV'@D'
M!GLD<99037@<D5<.2^WHO`/3//:>Y?)[$GJ@'#V8]EDR=1)ADM%TRVDLU_#?
MOL-NTPC9>C*A./EKSQV-)U01QG51MAY+*.J=TF0-%DE">`(;KK[4*Z(9F7G8
M[^-_````__\#`%!+`P04``8`"````"$``S:*?=\"``!;"```&````'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;)16VVZC,!!]7VG_P?)[N>5"$H543:KN5MJ5
M5JN]/#O&@%6,D>TT[=_O&`<:2$N[+P3C,X<S9X9QUM=/HD2/3&DNJP2'7H`1
MJZA,>94G^/>ONZL%1MJ0*B6EK%B"GYG&UYO/G]9'J1YTP9A!P%#I!!?&U"O?
MU[1@@FA/UJR"G4PJ00PL5>[K6C&2-D&B]*,@F/N"\`H[AI7Z"(?,,D[9K:0'
MP2KC2!0KB0']NN"U;MD$_0B=(.KA4%]1*6J@V/.2F^>&%"-!5_=Y)179EY#W
M4S@EM.5N%A?T@E,EM<R,!W2^$WJ9\])?^L"T6:<<,K"V(\6R!-^$J]T"^YMU
MX\\?SH[Z[![I0AZ_*)Y^XQ4#LZ%,M@![*1\L]#ZUCR#8OXB^:PKP0Z&49>10
MFI_R^)7QO#!0[1DD9/-:I<^W3%,P%&B\:&:9J"Q!`%R1X+8SP!#RU/P>>6J*
M!$_FWBP.)B'`T9YI<\<M)4;TH(T4?QTH/%$YDNA$,@'UI_WHHR2^$]3D=TL,
MV:R5/"+H&7BEKHGMP'`%Q&UB3D:7ZEN90HJ6Y,:R-%R0A(;J/&[BR=I_!$?I
M";)U$/@>.DC81^Q:A"T$J.LD0MY#B1.HX.O>MXIL4%]1-.^_;_L*I(_872)F
MLP[2TPC6_;]&&P2=<&9)/.WH&V.W#@(]TKDV0.S&$#V)TTN)TS=;N+71!B48
MKMW[XQ<'G$0'&9,XANA)!))S%\<K;,$#]X85=I!ETY#3:-'W=G>^NXB#;K<G
M:=Z79+^/]YO/!@VDQ1V]<\U!0$)G[+"P8XB>Q/A2XON%M4'O%-9!QB2.(7H2
M[3%X-F7&"VO!`_>&A7405]AH&O6]A8/`$IS*OGQQWDER0]X-0<%4SG:L+#6B
M\F`'>`C-TCUU9\L6SI9F$OO=!LSVFN3L.U$YKS0J60:A@1>#6<J=#FYA9-T,
MH;TT,-6;VP(.<08S,_``G$EIVH4=>]W?@LT_````__\#`%!+`P04``8`"```
M`"$`SLJRM-@"```O"```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R4
M55UOFS`4?9^T_V#YO8!)@"0*J1JJ;I56:9KV\>R`"58!(]MIVG^_:YQ0(%F7
MO(20>^[AW'.<R_+VM2K1"Y.*BSK&Q/$P8G4J,EYO8_SKY\/-#".E:9W14M0L
MQF],X=O5YT_+O9#/JF!,(V"H58P+K9N%ZZJT8!55CFA8#95<R(IJN)5;5S62
MT:QMJDK7][S0K2BOL658R$LX1)[SE-V+=%>Q6EL2R4JJ0;\J>*..;%5Z"5U%
MY?.NN4E%U0#%AI=<O[6D&%7IXG%;"TDW)<S]2J8T/7*W-R?T%4^E4"+7#M"Y
M5NCIS'-W[@+3:IEQF,#8CB3+8WQ'%LD,NZMEZ\]OSO:J]QVI0NR_2)Y]XS4#
MLR$F$\!&B&<#?<S,3]#LGG0_M`%\ERAC.=V5^H?8?V5\6VA(.X"!S%R+[.V>
MJ10,!1K'#PQ3*DH0`)^HXN9D@"'TM;WN>::+&$]")XB\"0$XVC"E'[BAQ"C=
M*2VJ/Q9$#E26Q#^0P/5`0@)GZ@?1[!J6R8$%KD<6W_%G`0G"_VMQ[5RM3?=4
MT]52BCV"HP?*54/-028+8#;^3,#E\_Z`,:;GSC2UK8!6D.G+RO?"I?L"0:0'
MS/H40X:(Y(@P^8&:3A+8=+TDTS22-%9T!C)2=`81=9"!1K"JK_%CNPPXQE.,
M.KM($'2\K:5KBX$SU6&F0T3R$6*@#1YTN38#ALA[SR7A**BUQ<P/04<C7Y-!
M>3+U.]T#53#:Y:H,>*C*]]Z3L(Y93-"J(I'7/;6M)OWJ_!^2PFLD&?!0$@E'
M$:TM)FHE3?W9R,>D7PX"?]))'A@57:/*@,>JQD?+8JRJ,/!'/B;]<C0/WLL#
M5>9]V-L3'Q]X`QZJ\KU9-ZV-SV+LH2+$&^=GRY#BF?^#%69WOEUF#=VR)RJW
MO%:H9#GT>$X$S=)N?'NC1=-NB(W0L*G;KP6\F!EL-,\!<"Z$/MZ8G=2]ZE=_
M`0``__\#`%!+`P04``8`"````"$`O-8\UO$"``#P"```&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6R45EUOFS`4?9^T_X#\7CY#TD0A5:'J-FF3IFD?
MSPX8L`H8V4[3_OM=VPF*24?92X*YQ\?GGFO[LKU[:1OGF7!!69>@P/610[J<
M%;2K$O3KY^/-+7*$Q%V!&]:1!+T2@>YV'S]LCXP_B9H0Z0!#)Q)42]EO/$_D
M-6FQ<%E/.HB4C+=8PI!7GN@YP86>U#9>Z/M+K\6T0X9AP^=PL+*D.7E@^:$E
MG30DG#18@GY1TUZ<V=I\#EV+^=.AO\E9VP/%GC94OFI2Y+3YYDO5,8[W#>3]
M$BQP?N;6@ROZEN:<"59*%^@\(_0ZY[6W]H!IMRTH9*!L=S@I$W0?;+(U\G9;
M[<]O2H[BXMD1-3M^XK3X2CL"9D.95`'VC#TIZ)="O8+)WM7L1UV`[]PI2(D/
MC?S!CI\)K6H)U8XA(977IGA]("('0X'&#6/%E+,&!,"OTU*U,\`0_*+_C[20
M=8*BI1NO_"@`N+,G0CY218F<_"`D:_\84'"B,B3AB20"]:=X.)?$,X)T?@]8
MXMV6LZ,#>P:6%#U6.S#8`/$Y,2-C2/5?F4**BN1>L6@N2$)`=9YWH;_>>L]@
M:7["I`8#!V+`!#8B.R-4)4#>H!$2'VN,H(1OFW^6I";9DN*%O5YZ#0EM1':-
MB.,!8FD$[RXU3FM3X`0M+JP(`W_@U9:F!@.[8[!K)#^;0EC:8*'YVA08MN?%
MNF$P*E1J,&M=Z&@4S$S0$KX<<K-T`6:^+@4>ZQJ5*S48:^EA9>UJ-H6PM"W_
M1YL"OU=/@YG2-H6PM*UL;>K,OG\>U"3;O]OQ"360E2YK'$?+D;V9B;^=@B50
M=;V+2V7Z,"BP+>QZPQF,V7"+:%13$YPA:VW+FN>;FC26-U*0&LS)N&40CHTS
M\2F%IO.8F[DEO"(9:1KAY.R@NDH`)1G>FH:70L/3[<$;`M!P>ER1;YA7M!-.
M0TJ8ZKLK6)>;EF4&DO7Z8MPS":U&/];P94'@(O==`)>,R?-`7<7#M\KN+P``
M`/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M92]T
M:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9EEA3
MHD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+T@8;UM6'
M1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2"L=CS'A,
MVMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VXB+""5Q%4
MQ@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?B8$F39P5
M!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B;6%=
MW_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-K2Q%FO7^
M1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F?7O-P1N0
MQ3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%;P!\
MHYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`;Q)<
MF+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1\<,?
M+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1BR^?
M_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#$%-G!0Z!
M=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X9QTN2@UP
M0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<*QR0F"BD
MY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,KG9LLW<7
M=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX15Q/*O!T
M0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2AAW0
M."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)$E]>
M)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[#Y;H
M'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H8P,U
M9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"G$#?7O,T
MD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-58,ZT
M&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HPF%L3.AL$
M_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%RI(B6@\;
M#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1VVLU
MUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[8>V^
MI+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T74LF
M$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY;6TS
MY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJF)2_(%6*
M8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"5[PP#4$%
M=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)LI20B:B"
MN#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>:W/@
MG^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*6T$K3?O7
M%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_@-J*X/N%
M)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL_CZG
ML?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]</0.?#:8
M,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`"````"$`?;3C
MP-X*``#U7```#0```'AL+W-T>6QE<RYX;6SD7/MOX\81_KU`_@>"UQ8)$%L2
M15F28RDXR69[P-4-<@Y2H"D*BJ)DQGRH)'5G)^C_WIE=/F;UXM*BM`8:(6>1
MXLY\\\WL[)-[\_USX&N?W3CQHG"D=R[;NN:&3C3WPN5(_^G!NACH6I+:X=SV
MH]`=Z2]NHG\__NH/-TGZXKN?'ETWU4!$F(STQS1=7;=:B?/H!G9R&:W<$'Y9
M1'%@IW`9+UO)*G;M>8*%`K]EM-M7K<#V0IU+N`X<&2&!'3^M5Q=.%*SLU)MY
MOI>^,%FZ%CC7'Y9A%-LS'Z`^=TS;R66SBRWQ@>?$41(MTDL0UXH6"\]QMU$.
M6\,62!K?A.O`"M)$<Z)UF(YTH[BE\5\^S$?ZE:YQDZ?1'$#\^3_K*/WNC_S/
MNV_?O6O_^YOO_OFC.__7+U]O__;+-WHK5T-D@@\.R[QL'Q0+/W/)K<R"\<TB
M"HDA!M"$;%T_A=&7T,+?(!C`/'QL?)/\IGVV?;C307A.Y$>QEH*7P3YV)[0#
MES\QM7UO%GOXV,(.//^%WS;P!@N,[+G``S?AS1;7<%X],T23VS1`&()-7;Q#
M;0K`)!MO'K;)_G6'38*N7K6N8_@3=#$K#MO5F*[MN-CB\!A=A:^(GG@Y&^F6
M!3FDTVXCK=1A)U(VG+9!W]F47?7.9EG7ZEK]1BT38G';;ZBP:S5)985"ZWW_
M]FQT-J]LGW59&CY7#<`*URR+'E3=`_6[;^'G''%RY@:M48]!!RY][WO+D#>W
MR7H%/3HG]E8I,K>+WI-:RVP3FAZ6`,H,_>`%;J+=NU^T'Z/`#A$D;5K9TT+/
M0`C_YL5+\M>D8F9>`G9[OE_T*+L]['/!G?$-=&Y3-PXMN-"R[P\O*^AQA=`/
M1\):_+F*IY>Q_=(Q6+]#KD`2^=X<42RGK)^7M;/3JSMK>L?T$F2R*/8(M:QI
M_P1"[R;#:?-(I\-ATT(-"SX-"WW?PT_#0BWX;]H8IUGN,9L"6<C34@_'9>W+
M_G`X''2N!H/!T.QV3).1/,LBV@OG[K.+0[7&:-I&T`,$P^Y@>&4`D+8Y8*K.
MBJ`+`/J]WJ#7&1HF_,^2ZND1-,UI3U?M58)`D5<)`D5>94.#5@.9/ZLI,$NB
MN*X2!(J\2A`H\FJ_X0S<5^Y5@D"15PD"15YE$UH-UE68?51<5PD"15XE"!1Y
MM;'.9Y:!A\J]2A`H\BI!<&ZOYL.J:=ZQWNZ9-=8_SG1A)]YB4REU=+%1(XQ3
M9U$\ATF%?.VC@XL?_-[XQG<7*8Q(8V_YB'_3:`7_SJ(TA465\<W<LY=1:/OP
MM967R/\>*`G+3K#"--+31\]Y`F7"?`+GAJLXE88BZYDXFC#[9KMO]HPK/F!K
M2'7@SKUUL&U=H7MG7`*-R&VUX83#L%"2A4,YL]9"+V3NDRS!7,T\+5D`8B(/
M"<D23=A8SC++VDA*R-E("DC:2$K(V@A59U?ERIF<1VM8\=QTL&4-VFT^E2:K
MY[!``GQ'Q.P&0<IL\UE99`>CE67JV@KY9:MN3`S\L-[Q#DLK2FS;65%@AY45
M)61M%.,F]ZX@O)BZP/2\`\D&W\+CKX,!BGC!',]&$LSR$RXT\*4&Z70GFKNE
M9\.4>GJRI@M:0L?U_4_8-OUC432',,,TOGE>D#5[V$B!B]JX)0"_PC1N]I4W
M??P"(.XK!$OR>PII]FKEO]RO@YD;6VQW!5/![EJ@I[R:L#:[O&9+!('+YLAT
M+N:'.$I=)V6[/]CT]CX\W3UX.ID@&3S'Z#?WZ`>>I/DX1C_,P>ST!_"B5#\$
ME[3^)N,!][ED00TNH$%]"$^3"&"DG2,`)ZA`@/MR,@X@/%4@@!%,C@`"M$0`
M<`Y$Q3'UH$.R&<1`J1+TGTHEY)C<2D'E":W<EWY!_P$K+2']'D4SR;<0Z"7-
M<'$`P%$J]Z5852F&N!UJ6DD!7!R@P()6MYDFK[,OYRLCA"1=P%`R`FG@$"/-
M127)N:"S!'"8D4F#_1`2%)B*5$,`.$H@$$?`5(QZ#(I:8!H-BII@"D%H@\]8
M)V@T""VD(@R`1TFM*/L)':'%.",-!(*J#$FBP5"5(BD&53FR=(6A*D42"*HR
M)/6$JA1),:C*D<05JE(D@0",*,F0U!.J4B3%H"I'EJ[HJDJ1!(*J#$D\T3UQ
MBFS1:5,^B4KG3W'CZ[ZI1W!0/OS?]-7SHG(BM;-OT`2R\N)\],1'CN`+-I8B
M0VE\$\K&[=4X=ZH]1K'W&PPR\8TH!VZXL8YOT*6>0^]\B>W5@_L,0U&^!/.\
MV#"0C2ZS&6)YC.(T:X[UO,C1'Y53VQO<[F6S9`X6'W2MDC:B7)XU27Z.P(*P
MLJE`^"JD=C'(]A)1:3D-&&EUN^/E]2!P6JJN[YO&<,H0:*AR8\Y131,T[\HQ
M4%<A'JDJ(EE;*RL,42Y=7UY?,QK5=D0FPB&?,IX[T)^KI_S`$FA]835:;ES7
M%YL;#5\,P+ECF%<$5*VM%IMXN'&2:=XY#EKCK+VE6#P"2^.\2+J,;\<]:S#5
MR8S_3Y$LZ3&)^O]V@ZEQ9'6"J7'EDA[C+QT=JF,G19:-`IMO-%0UCOFP]K6^
M[VY.=HIC(+&#9['ER7PHN[<#=C@4JKBG_C\%NDJFR,"I!I;=0Z>C^6-;%,7>
M3RT"-^>1WY9[3X"NTKVD;RBX]P18:$4XUI%"/<7U='E/3K)%_5-47*G*L@VW
M?FUYE1''DB[$!)RI],9)KX#[=DD_:=?VV#9_.WK%K/ZJR#RVW88$4$Y=GA)A
MG=9&`%61HE[9>RB&_GLZDDC%0L%\'ELT@642LNE<W')>+*IH>+@*'$G7_I-V
MH;UW,!"*Q((-TFSM^?`6)ZZ6X(*7LT[@!:()OYDM41R2!8M#O&4PL,4@LB`Y
MU)4%$C)9N`A*9,$$85U9H)[+ZH*U1!;LQZ\M"Q:F,UFX1%WB,F$RMRXN*)+)
M$KGO27)O[O(CYC.""TV6P45EE7[$K%[:"`?/U)95^A$7DHDL,+DNKM*/@)#(
M,D%)75FE'\$+5!:$6UU9A1]-D?N>)/=7._THQBJNO,K@HK)*/XJQVI6,52JK
M]*,8JVAR75RE'T$JY1Y^J"NK]*.8)TS)/$%M+/TH<M^3Y'XSHXH1;TA&/)=2
M^@Z^$8YP6"K#$9=2>DV,\JYDE',II;_$^#8EXYM+*3T%\HA%)OP@;U'AHZ[(
MKBG)[L2>YUE7#!A#DA(XO-19^W"H;(1'TK*=!=@[)P;A/C(9@Z:/KO.D3>%%
ML4*06!^P&941=/>\\NW03J/X1</=!(4XT>D]27%_B:*"(U&"`9<R@/X*!_C"
MV<`:\,(9$F,8E^3KB"GJ@DA/1])C.1HHS=&(\8>;0.N@@=)<C)A4L?\D(^9#
MN%H7'A)S*3;=,B(^>N&3.Q<C1V38`)`RDN[==1K;1?R)5<J0).8>7R\L9(@I
M@A^&E[\+F?4_[^%MPIQ$W*]`Z@[VH66`_WV=$AJQ%!$"IUA)"7GP4G@A.J_$
M@@B$)8/C(8(=/H6(C8PB*>-G.PZQM@A5=R-&]UA4[I>"WO_\N7S5E/&>XA'7
M["748CP`1,W=A;WVTX?BQY%>?O\;.VH`@BE[Z@?O<Y0R$2.]_/X1SW"`6@P#
M-$@W'Q,X%P#^:NO8&^F_WTWZP]L[R[@8M">#"[/K]BZ&O<GM1<^<3FYOK6';
M:$__"Y3A>>#7<*#T$>=MLW/!8<=4Q[Q.?#B5.\Z,S<!_*N^-='+!X;/E6X`-
MB[BY$:VD.*]\_#\```#__P,`4$L#!!0`!@`(````(0#%<P_`'QX``+-4```4
M````>&PO<VAA<F5D4W1R:6YG<RYX;6S$G-MN(U=VAN\#Y!TV!`]:#4AJ'=P>
MCV%WP*8H-3,428M4CPTC%T6R1)5=K*+KT&KZ.@\R2"YREX?PO$F>)-]:>]>!
M5:34GG@08.!1D[OV7GL=_G4L?OTO'U>A^>`G:1!'WQR<G9P>&#^:QXL@6GYS
M<#>].O[RP*29%RV\,([\;PXV?GKP+V_^^9^^3M/,\&R4?G/PD&7KKUZ]2N</
M_LI+3^*U'_'-?9RLO(Q_)LM7Z3KQO47ZX/O9*GQU?GKZQ:N5%T0'9A[G4?;-
MP>NS\P.31\'/N=^UGYR??7[PYNLT>/-U]N8RGN<K/\H,9)A>E`79QO0CNS]D
M?_TJ>_/U*UEJEU^8FSC*'E*6+OQ%\]L;+SDQ%V='YOST[//FE^5)G9TGF1\Z
MLS1+O'GV;\TG7S0_*+>:;M9^\\L79Z?'WS8_['#'A=[S*O26S6]?W'MAVMJH
M/&7L)T$LW%F82R_;O^XJ2.=>:+[WO<1<P=>T=0Y\N6A^6![C'G>G[=[@V[/F
MX]/$$X4RD\UJ%H?-;U^,!]\U/W-2OO67@3`<V0^]5>M6+\:WHVEGT/_.O.V/
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M04MSX9A@1VH2?^ZS:!;ZQT94KZ4W(Z'8>&GJMW?I1Q_8/$X"OW7`-,Y0F[E3
M@=V/7]T-+R=HG[GM3<:][M2,KDSO9CP8?=_KF=O^]3N8>S<>R??3_FWOAHLW
M+XQ2CWNWT^]-9WAI>M_>]<>RZL@,>ZVEE[VK'LQ#EN\ZM]>]27,K2_%N2DMV
MK;V-\$IY[,WG20[0M*2PGX_-,R_]>Q\C62`&.)D_Q\8P\&9!&&0[^#T8#:_-
MM'=[8P;]SMO^H#_M]W;H1XS$DBR0*T1QUCYOX$[8F"#"X421/\]P&^8QR![X
M=QAZLQ@[DX]P7?:OYJ5>_/K77__:_+#:&%]D_-4ZC#>^;Y)@^8`6YFLV3/PL
M2'P!]>;#5C0XU:7)_&1EGN"#6[J?4=W1S4U_*EK2TH!N9]P'(@V:TN_V>\/N
M]WL(J78WD9^9^-[,O74@"K_P[X-Y0%30`JD]6#*9`BE*C6B_*'-GV@=L/@U5
M_(]S?YU9)#,++_-^"]#4O?M%\Z:_E=S]WOZV][XWO&O;&X(8=X;?OYB`HYW;
MGN!`=S08=-Z.+`M,Y_JVM]/HNZ.)8L6^G:]O1Y.)`1JN^BT4`&IZG=ON.P6,
M2T@;C!0R3.^[L4!]2RD&`MO'9BF.-56[3_Q@-<N35%4U;3+NV0-V@M.D-QCT
MA]='YKHW1`4&2E[G\J8_[$^FPH_WO;T4.J7!_@?<NTG/57^(L^JSY;X;5BL(
M!$8WO?T[V._-8;'32QBS`VGY2$DQ5Z-;0ZAAT.K^Z+*YKU`K7SGYH_YBF\#]
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M<_9=#J\4:ER9Q>1VQ(WX/7%_+;O_E`T(-[,DF$N8:O?R'KUD<50X$3SCO1]D
M.<N:/.U]]).YA(WX&D>`A22V@K+"G[:>&^*>PA@$$Z^+'AJ<-KE/:_M(<XX]
MO*F'S7M5L<5A<T@(D6J,W8J-?U]F/772#V<M/?Y47CZU+7E,39F>6ME9+`C8
MX@B#6'O!XABF=%VPL,^JB3;S56[5C@B1@"+;R_9;?XVZ@#'BFXRWDJC>:*J1
M/?#!9V>MS.YWL+%/0[7_^T'[@XJZ2A[!V,20Z.0MJ]Y>ULFS!Y(50*^I_\^1
M:EU'9_+.7`U&?]D;G'6K%5>WHYLBG,.O=+JX\-TQ>6&B39HZBQ_S-!,W(%D:
MJ9SD"=@Z&5L<S<ER%3;4N/E4XE!-^G*!?I3,A><@'B68X(,F#2U_IG9HK+MX
M"M(O1<OF@74?4EEZ3(+,-XOXD8/NS7WPD4-WITY7003>!JB_;YU9*M;"8?Y+
M"WR'4MT*-WP]1V.7[!K<DQ410_MI"SBZNB25"VKZQ;%%,K!1C"N0\!,SBVO.
M-N0>UG"`R5SJ8+(]5D6&KL'];]RSLXI)L7XI?>W"GV4F2--<_`Y)E/A9X:%^
MOJ#&)#;;E'[MHC5):A:N#Q>W)A5L294*`B5$G`77("'9SC"5^V&N\!7%T7&1
MHJ^%Z#AJ<;P?59O!\F;50(G1JL8>^9?$B-25K)="5["_=%`^P;+RQ%V)=_TJ
M57+8NH$8V+.FT>)_PY3[P_>]B8:(3YCR.">($\9C$^M$Y$;U540MYJL17?,8
MJ:!8(W<Z5\0'"W\=IT%++=`ME.7OTU,UMR8!+>:(8-),G%N%&\V'FCCG,HBG
M<6Z'VVWN6Q(#\SX$8H@SK-H"R),$]:ZNBOK1=Y1WB`\-25-/2CT:*Y)4",VM
M\TA4+GO=VUYG8O-/$;I4DO2"4DYZWQGLJA04%4!)*/8]8SI3\[9WW1\.);%@
MY>XLZ%.WZD'6WDTF=^/Q0'/ESNWW1,8D7C=:1S#<O*:Z[+%+5F8XFLJRT>"]
MT%J)MP4MD_[UL$]UI",UR&YW=#=4FQA3&Z5BTDH^GUG^1(\`BGKFC/SRF2V:
M(O5:\8Y+1[87)M(K&2=2I`P^FK=!/*7*Z:W]G$0MI2(>48,]E'J7U+_(QS:V
M`A9@>FD^2X-%X$G5\TACZ@/"C+47;0[P:&+MLNKQ@8<WQSA(M+A\9'-DRD,'
MV>*$]8EO9D&\)DY>>7,]'U<IOMB+.`"?1M^!+?!1$KXO:LFA',7"E60&7*-R
M.!(AK&9B-ID\5-Q+("GS@RAU#M]MZ8A_D2ID<:O,2S9"9M</P]Y'RS?X)?\;
M\Q\I(';"8!E)R/7-09H#<^D\"=;9P2O:2K_8C\].Y5]PT.8=*]IA9_))<D6_
MR2Z9!BLN./0?S6V\\B+Y]MY;!?!:-];EK_3([,VO_]VBXQ]SDO3IODK7B.*;
M`V*>E+S:/WA3L$YB&#Z4!J!)-REILCD\*%EU\/($S3$32G*:KM,V._U30^(2
MI*R0IQ=9I[E'3^@7+"B[B\A#[Y&^P;W^#4`B3Q)8:2F4FO3VY#V:A+=L%FSE
M\5XNCHA4X,9?D$E$L+RSE`(EE/=N.@<OC;=>AY0GM*B+BA!V:7RU]?!=Q)5/
M:&CX6E9`V=&7[)&<N&8-JLQ)$7`0E&X9$(2C?$0)>I.#2>W!DX-2NK7>Y`B:
MO8VQ[<=S:VIW)Y,3>G&Q,)#N79(O3;W$@%@.#ZXNW:UP(G!:3'P9YG/L`,_L
MA?>>!HI!]*.M;=N-*RNX#Q+:M3#%/KZ0,_A[D<\SS%73+#_Z9;.B>.VO0Q1%
M*S4B%V\-4^E&O-0#A'\2E1QKR3HC]-%@7D3I+?(P(VNAD"_.7(OKGDB/LT4Y
M0)=EA/NW<J<G"A)>>SD]XX3OJ!6E/K)HWXL'O+H5'T%B!06B>7*Z,`,I)_XL
MX8R%<.7PNGOY$KEX"AB%B`NT@:(\E8@`C;.@L//T1V%.F,85[_#>PH5^FGA^
M&)@;6PK:"!'O?"^DI7`HWQ^4"T;OT$>4I&Y"9XC>;?0V\7ZA_R'*O&^KVI)B
M,^K<E-:D5:M*X_9R6B^=D,1?2K9-9]%X-D64#HM0"9<RS1!$O`B(V$M@?^?U
M8;Y<QJH/B@',T94,7<&L+@C9S/F:$EA*?7/DH<0&Z,30;,_0K+P?^?<.4C<M
MC[=;,V98WY)MDI]\*4#!92$7PY9_33**7/1A2M294>]>F(A&LND->H/O)Z/_
M^??_$#F,[TF@$^<A#^R_Q/')9I41H74-OT2.GE$75!,2T]+PSA%!ZA>B810(
M`2(M>,KA>)8USL!;)KZU,4Z7SV=^]NC[485_XDGU&T>;52KWCT[QN*#SM")2
M*$[B?/FPO<^1XQ`3$?;:PBBKG\ZY1\;JV&YFW8V%5RV18#DVU%!:M9D`UQV)
MZ'/)@2/S&"?AXA'VE,P`29W?UUO6>>OO@K=*BDT>8$EYAA*)4G,^Y1",W_7@
MRGO*(4<&@Y_[.OBAKL7=^3"E:3>C/OVXS4U#VF,EQ:X@0-'>GH,(9=WY6<&A
MW=1#14U%FR0#I]`:%"W/$E4!2A*4G`O4PR'_'H"3U$@BCA8V(GNXB))O::J2
MC6G2`F<WY)"O[Q,)4$@W%=;!@,^^.#TY-<0EH7A]N+3+R_H?_3FQ(PMX0HAO
M<EXEEU)^RE!I%N`.[G$,<J9750@_>UT[:AX"<C*`4KOE<5&.AA[2-,:,"E*W
ME!O>N3LM\D3X"?J=-\\ZKQ_6VF_?30$F7+^%*VB3Z[:8O1-<+(&5-3L0$-1L
MN)U4BL;6*SHV"D<CTGB>N9?H&A%KX:O@!BHG2VJ,4G[7+:4LQ^P@%[%YYO/3
M/^A#7_#_5,0"(BQ7`]($X$AL5)JMZJW=-Z+K<G"#+I"T1EF;BD)5MTS.P0H`
M(-JAVW9M7L%FSF!+F'`H):*UYJN1)\HR%T]66-`.EFV!?"D,-0H.%;X7/D^_
MQ/-+:SX,5LIVZS.*8ID*;D6(-A/62X"$$6$_*UH3TG-(F3VQ]ECL698`!<=M
M)0P%6A+/L3H.%PW<U"QM%)E_S='SLR]U#NVB%O@JF!)"P2]Q:`H\$^<U.&#J
MSQ\B,I#E1D9;HI1*&+%OX4VLEW"X5GY,_*$"O@)$O;_]U]_^,S:C]-$+%['I
M)ODO$EX&,7,?O]AD#XYI3"5*8+?2Z&3T[F@_#K%T5GG7W7`E%N1((ZZP3J6,
MD?]?,['I38N.?TPF]L8"AHVG-(9VT)I58F4VS8H5)J4R0F,V-%*!)Z0O(BD5
M''M1-?4_9KY6>(7MV]A[CYD?R^,Z8Z)Q2N3[Z#7&(:D,K58")]UV!P66V!U?
M4/G%.%+R9724C;`5S)_40U46+<D3&1I=8BE"-:M19$LCJ\L+\K=3/*6`>1./
MMI`-B-*?<$ZU)H&JU)9"+LF$DL@F*G*7B#XDYJJ5"JGADW[G]]3[K+/@+YDR
MHE@!,&O)(R9*=K9KHR#(`?,P>7A,H,8%*#<02Q^9!R9ZS,_,1=D-G)V[.TN(
MY\*ZG8[CA'AT@95NR>ZHO+D$&8*F02;<$QJ*@BN$AJ1%+F_[&#!-*T6;SSZO
M/#=Q%0G'SF.-\Y)RK-,W4ENK2D[I2DU2H)6LEYHNT&-7520BOWJSYO<BD!J+
MGG1"NEOT$\-F-4F4A[+"%@%;>BNEU-!J6Q&G[-)8LIP@+)E>7`']W,/D\R\_
MB<O61!RJE?S$(.:295BC$`5I"0-M2B160A0RB.R<!"A8*Q9<6M45"1+7$Z0R
MZ"ESS=:2;`I83#)OAX"$2G&"F<,V.X,GYVA\4ZG1Q<GK,@)4!R?GB'N3M=80
MB$HJ&VWXL>S--#;.JE!,J]X)V+6TB8WU.-:OX-YLA@53%*G$`"N__V2"I/N,
MMU*-*83J3FK\D"J)EPN2A5<%@#HU%^O:KB<**-E2E<L3N.6.$*KR5S./(0D6
M;=/1$<LEF,>Z;216@-2G4>!`PY+0C`!4ERP>@/(%^P`U!)BOBJ9X6ZIGYTVQ
M"J_K0=,A@",C?8+=W%"D_I0`7LIXA;-31X;F15H4D<##$NDG7'Y5!EK*@6)&
M(+6#/%J!<Z9"_+7%2\+OF?]`(4M(VI6,/(6P3RGIUBD")EM(!FNIG&%9`!\H
M@H1?_Z%`$<>S.3=,#=5%$;)EF;L#JX6WN#D@4T1?WM.II/*7#C*S0A*];I.R
M!6)NQTX9R`%0TEO-A"1QZ;:Z60>8??4"D:>29*&I]>0C?A4F2(-:>&TA:F<"
MT"+*8J@<(*$+N*O)(?]._/B^!0_]*@N46RA=:^$,]30;4<M'I%X6NFKULC+4
ML124T:>M\P@KRU1-5'$FA9.B_,!)-K*4R]WX'X-Y?&2Z#S):(%9_1^4S]S;J
M\(H<=1LZ49%Y7+6G+?Q8]!*."7"YI)RCXIF6TG80IE"P,XDLCD7?RN*;TO8C
M<)]2SQ:NIB?&O6H@'K&VOQOWL*R'#465.R7MQ\\H+^ZYK=4]$^4R8R<J79[5
M$E3MH+)\JRT<+:YID9?ME!$[0%+SS`IB;9I9`,M6)>ZHS`8K>5BI-\3Q!!7+
M,)Y1?9%R@RUTB0YU;4H)AI3E!4J:HF8B\B)K33,&!*2])98G5LG\$GZ+3I1X
M._1G9==;QU!\=&(T5^/$LPO-U4ZWU<6+(BJH<T'!(N6_DCF/!\YM56`W"&E1
MJBIVS?0.PSMVG-%,F<E@$)V9&+-X<4>X4GQQV)G>48T$8=P2BKK%W$_E>.Y2
M(M4]:J<?B]W6*_;-ZKO-@:KWJ#K0-[T3S!0FUZZS(EFADY>NA'G:SU9+MM=V
M17#`3I)GR]*)=^\3UW<LBF$W*^\G&=:/CJTALXFT)%C\P0L8Q\=8652J`79W
MA4\G+J>,(&4-]LEEIG.=S]!_\V#K[I+9$%6`MEC/]`&ZA7RIU3VF9:MAQZ8<
MY4I+-?[L4_>9#R^)Q+3DK%"T99$%HU$?N;XPKT`F;B%L*GM7KOTT=E6Y/9(K
M`2ZE&*?34D[Q:^E/58[4>(T"Z%H&]^%"O\)@U'8''&$R]G46%-P6TZ'<UK%A
M2Z$A)=-RS63T-1_@BT$6Z:N57DEK6%)>7Q2R$\OZ$(BIJ?.WIK4?B6KDJLMH
M$;QM>S"7!.@GD0(H),RM%\L$\[9:'4XF=`0:C9^FXC?)8./2X4A,V2)+S:Y2
M"2?I!O@5!7?KU(Z<<U*(:O"%0G6NK+W/;=N<)+U6AJW@KGY=;E=AF+BI*@03
M7D;R-B:E38(YA0SD(6$@P]0+"5^T(F:]F;!3>"EZ+AWQFN$77-B.HE(Z0NH8
M2P9+MI_8\$#`F@2/&_'F)`&-#,W96IO&6;3+L:4-^H(B.=N2P]T=4;&'@!0&
M)2,79F9!'BIS&M[L(FR3W$-ZMFO`$X/CYM4E*?.3]Y!!AZ'+\6M[2_(O",73
M]`5RXK<:C5H9("O%YE1U=\6D.S@C"J]&(>;L0[T0+#0YWC"TQ92MU.SA?IG>
M!=($T]$\S17EHG98'F8A,(:;TY;7'FGH(<*J%*^03RN<DY9;BP)QTO*%M4?>
MCH(DG,]<JOF59CC+JI3.OJZ%!X9M4C^R%1CXRGM5P($,6M08PSS!>EM=7,R$
MBO-NP!JJ)""TP6HA=9AD<WXOQ4G/H&<-]!$9J6+&>39GU%+UYX%I!I2D&`9M
M<6G6^N2ME,'EV3$L1_75&IH(,.4Z,J:G(S#"XSSRB!XD_D<1L!CQ>_Q%?5>%
M28E81E-T)!0U9U2"G?64NC)7$1K7H7?('B("SDD6UKW)&VEN/%!.7=/GF`?P
MN$A`)/(1U&480Y^5W;=@AEKN=:<SIN(K"JAV&*QJQ`75:]-8I9[,01)CLA5B
M%Z#`B")ZEPM8@&$+X'%*[4&%+)9!59E,T<:4<_54A"?)U"Z.J$>2[>(U?2!4
MB]VITY&D",,P40[T:C/"AWSO%=B%:N*KA"]`"W;Y4B4@V3?,J)1/+DY21QPE
M52$KBN(6B)PIA:I44##(&9FHF>@$^U6R<LR@'3NRX`D!3^^C+0?A8T&4S/\$
MV+T,I!"D.Y86F]1;#A:3.%]N(8S"!80V^]ZAH^C^WZ>8-.WR4+K.W(2(%"U$
MF7\DCE4_8V,?#J_I_#.:[EQ>QXJ>`7[!8N1[)44!7G;_<WDAK4;;*M`E@*'I
MB2MB71"_:NJ"-LG="S@HZ9F(!NC4M^I@KYBN9N&*8604RN*(&J[X.<F([+LQ
MO+7!CP^(+VB=J@U339Q0)1YQ_1ZAH&#`+EV6O51T@N8MF)FW/AERO#;XT"+[
M#DE3H@)-<[W9(@AST<+M]1CW8#R1Z28B4+FCKH%9"V;AM<4L-0M]QG'P$0_^
M(!N1&R9862T?U(9D$Z)(H827",Z]3PY*R>1:[IO/Z!B?GFDQR/8R;:^IOAS*
MP&9Q\TJ,J+"Z0&M=+89<NDMR)X`'-!&3*:#GCT>?__'LZ/4?SY0?],G^1/YU
M]OK"O7TC-E0_V@XNA!M!ASH-Q7M%-A&LWE2RK\DW-Y%5CB\ZVRZ)B$9&6`<,
MU!$Y9[SVD]I;QPQN,PX/JS&%K5&?BVITZKDJ[H5>5NK!S3[MC((RR9::15&R
M*4Q8HJICU1B4M\5EF90=3D>W.R99:U\]-[5Z;HYUYG;?3F[R'>^4,>`FLTE%
M85JO5-C<KW\M3-UB-]$!E5CK8>X9+HT?$6!K0+?<L&DPQ;9R6/.[0QVK6\CK
MW33/%)_<#Q>TANEOO4>\$"&KU`R:^WS6_.`OI!RR'Y$+Y;JT]<"5C'$]<"]M
M`3>?GNIO"!1O"FR:7_\.)7^-J:HR_]G)657FQR+U+9?CXBV7DA`W^2/]:Q%(
M$6.WU.FJT[\U[SN#NYZY8<3\;O=/&.Q>]9R27:!DNY]LLFE:\PXK>F0:I:O+
MMV`EABQOH8"%X$KM"[?8AF<"4!6RVU=]5%UK+Z(PF2F1A-V6P)$I"E%9FVX2
MGU&44"?P6%BC*R74G$C14_&(]>1E%ZWDR'MS$D*7K0(2G.)W"G0XB=72PDD(
M'72-!+D<6\P;V:"?O(DW7`@1P0!R)!L?U^ZHTT$M&0KW:E&F`C8S2H;A&X)M
M45[)MVI<(P=+Q*C%+7,(UZ9JQ>M`K(MI&B;Z6QO*N3RJ?1!$>"A)M^$85W5T
MU3<F_I+*,%T$Q@=B(A%-\E*9%PDD/9!2F"^#V#.VF,F(5@L<!IH6GGUEOLT)
M2:D\B$QX'XO`2`-)?Z'3EYHC%'4;<CZYAVPOT321@R#]'O;9F-:^I83"%%*R
M(Y-P<B>?ED"QG.)K[QC&%DS3O,G1#(H(@UKRL5^??V5&%7/=M4JZ2SUT3([P
MG3];#J`EV[>U$W)D&4FLOW0AO-RXM%%_86$/!1=?D5RTY2EL4YEJ-8Z>>`;S
MX$PD=3V9Q-0])9TLRWDV+'N&4TAW-Z,N]C&J+^^"@=OT(L3Q5_MOUXD88N-5
M`N0A5JSY'@T,QFCDYZ:<*FA?C34J,G&T8.".FP,K<M:JL7*7UJMBRX0!@P](
MG]DAJV1L(8FCI"W2:<BE5")63!XN.2Z=[B!5_R)5`\&+--4,&X*J^[4$)B9=
M?5VZU#(IY0T)IB,L[!4)C76*%%5=#:WXO0_GCPFO@!4M"^3THB3UA&AB#2:R
M1-P*K@IA#SX(.?>21,,OA<H6@?K[!X:??1A.Y&4S?@VDB>GM%<_YB\_Q%^VG
MFOO^_2[5!70>EZ3F)TQ]_?KHXHOS(D;D@ZT8E*``T6[]O(P@`'.4Y7ON];V^
M.#H[/R<3UGZ/6&11KBS>S6Q&Y]:*O"5AQY)P12(0VYW<<;"65XJ3I<;%#;#[
M1G#P^<41OW75%M;3;T29PS%UC_FF%4C5`\K#J=3QVV^[RMN!\OM*K=#GF9>B
MS.&E3`R&Z=Y?G#@S3_WNVQ=/?DLD6?Q`U>F?FAHT+J8/>*=*QJV+0?>4^CJH
M2JYK067?N^_C<KS\$Q8S%WA2S@7NI42G!/>==R?CC?QFF"9#%+J`%4_>P81<
M?0\2Y9%08LP\O]@O;\SL?15?J;F@YR7#MDUJ[#D,]7?6MHRW=YL)A61^&(RZ
M7J95)U!/B%,UDM<2GOJ)CF'9PJR_7M.DQ?&X[*#SHT&-L><B,&L^>=.<.B;>
M"I9+J2HUE[8/N<^E$E6&RQH#N:$R10FY)>DO+P#(.%QSOXF=ZYSK^)>BO.;,
M,`>72N?2_I`4(IK)$7;ZN;G'X*FW"]:$1.P&>#E"W0QX<Q-'2-G)P9';.9/"
M55F-V?/T+2$8H^NVJ5]$NVB$-@";1SG$U-\*J?W*0558:#XP<@`)&XJQ+6!6
MBQ3V!T>BJFR@V7=1/)&ZPB?GS<U3MZ!L,B>?RR7*N5<;4OS2\A3#ZD3>0-)S
MX%3+&B7@;!U7H&(M/VNN:;NZYX_MAM)8@6RMYSQI9_H[>Z5+T8FPPG_(!LY/
M-8GJNA9;K_C5GGV@5)<[L6%1*FDZS">/?,6/CK[Y7P$```#__P,`4$L#!!0`
M!@`(````(0"LYQ?5800``*`/```8````>&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULE)==;ZLX$(;O5]K_@+A/P'R&*,G1@:J[1]HCK5;[<4V(DZ`"CC!MVG^_
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ML^H-^K>D9S[Z;/$C.__6EKL_RH:"VU`G48$M8R]"^F,G?H+)SF3V<U^!/UMK
M1_?Y:]7]Q<Z_T_)P[*#<(60D$EON/IXH+\!1"#/W0A&I8!4`P%^K+L72`$?R
M]_[_N=QUQ[7M1_,P=GT"<FM+>?=<BI"V5;SRCM7_H8C(4!C$DT%\H)?CWE>#
M.`C4Y_>4=_EFU;*S!8L&'LE/N5B"9`F!+XDAQI#J9YE"BB+(=Q&ECP5)<"C/
MVR;T5\X;.%I(28H2V!"#A.B*[*(0A0"Z`1'R-A%]J.!U[R]$8I)!%.C/2Z<2
M3U=D4T48#A*-$:PS&8-/U\>%44Q:V\'(DC`:PO?&IBB!2(-K1A;9+86&",\9
M(]ZV3XAAD8Z>&\8&&DJ2OMI1E!CDV7C8#Z/%,%N#@LS&4&+YW:^MF&3`J?#H
M&TI"A%L8Z-EX-'#=ZVB1CG;;+R$VD)(A+"*A).Z19H$;&QLDPW%$GB6QVAV:
M8?$C5$*L4T4J6:1""5+Y/C&&L_&PER3*2`U*''-&$[E?13')@%,Y(QQ*I&4+
M$IK[4QN/XU#M#0TOT?%N5U*(#2SCL2E*$,MS%ZHE]-29-ASX*BD-BD`+>]RT
M?I:!9RRD5&JD;9$;J:HAH"X(?4]%T!&O'`[WZTJPCX][1Z0*@X65&HGHQT29
M)!$QB!1XQ/T,T3@<;M>68$/7T(SJI5)S<2\8=2Z)AD&D(`@\M=%U]T1G'NV*
M.VA";136:*DI0<VE11`#/=/'B3)=YWKH("#3D\!<3ZG4()=OM.),&R6>VDPZ
ME7$2W'%K>@28=4K%^QDX*MU:Q)-=,!XGKL+6N1XZ!LCT'(C4\I!K'S5X<,YB
M/YB441,$OJ<VAX[VT%E`L)5#.8=7B=CH]JG4@#&#1BTBN?HQS'6)CF><"G<J
M.CT.1D>@=`XUT+[$&Z8[']5,PID"9:V.9IP(XK7C_NL:P<:N.:A6LT1$S75[
M).0MB88)-YH'.DBOUCO(Q$&IP=Z5>-$BBB;[U="01>!Y:J$@(%Z4\")1T_9`
M,UI5W"K8J[@$$:C/\"M>T%*XH/6W&6<8@/O1*3_0GWE[*!MN570/4]UY#-ZU
M>,/"+QT[]2_R6];!S:C_>(2;,(5[ASL'\9ZQ[O)%7!V&N_7F?P```/__`P!0
M2P,$%``&``@````A`"C#ZZ<9!0``$10``!@```!X;"]W;W)K<VAE971S+W-H
M965T,BYX;6R46-MNJS@4?1]I_@'QWH#-+41)C@Y4G3G2'&DTFLLS)4Z"&G`$
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M]SM9Y31QO>UZ$.C?BKUVVG>G._+7W]IJ]T?5,%`;\B0R\,CYDX#^V(E+,-F;
MS'X8,O!GZ^S8OG@^]7_QU]]9=3CVD.X(5B06MMJ]W[.N!$4AS()&(E+)3T``
M_CMU)4H#%"G>AL_7:M<?-VX0+Z+$#PC`G4?6]0^5".DZY7/7\_H_!!$9"H-0
M&00^91!";PX2R"#PJ8+0942B^&LJ'BYK4.F^Z(OMNN6O#I0>$._.A2ADLH+(
M0IX`1/Y<'M!%S/DN)@U3`=U!3E^V-%I[+Y"&4D(RA,`N4A`3D7^"2$:(!_1&
MCB#;[1S%)(MC/(8?EI$A9#FD2JPKURX8!$`8G<!U<01XXX;ZRI?6C1$"]3.*
M$YJ(_!K"H`;WF4]-@"&_VGUI:MXX0T@Z)#5)XM0WQW-]?!D'J5J:00O6-I^6
M`)NT`NNV&4*2@19)`JO:<GV8^BD921NDXEM(";!%2H7%^D$(DJ*Q;TF9Z\,D
MC"X4=W(+*0&V2-%QK4@*(4@JCJBZZS"<Z\-)>HF4Z'Z:*UPO>`&V2`46*80@
MJ>4RBBTE<WT\35)?S3<2F)JTYIF5F&31LW9;AA!973&U),V-X2BY4/($;'.^
M:`/:HF55=28QDE?@:YL-DVD!$J)T-70CELM?S^>`MJC9UBDQ$6[(R7XTA\-+
MM"QC_X(6NK/N7H%5W1E!C%3,#T)B$<]-!`G@;ZQ54S-AP;/W`$'#!G<<+3U0
M=8([4V+`JT:,58CY58A)3QCQ?'IHVX9VEEUE!#&H70C6/NHBBTT?CVBDN)O$
MA!?/)X;.K1,+;>\7CVNP@V52PTC+F&1F`*B?7$KI30V`3#N`5L@RI;K')],6
M(&,@]32(E::F9C<U`3+M`J%E69G$X(UIG"S5%I2:Z8V`QG&J-HI)[:960-#(
MH5)4B:MD2,T0`SE3&+O4KD%,>E9+^,)"IKT@5&4LZ>EN'R<DFBAG`OQ0[7.#
M&KVI'PQHTW0GU28Q<H?Z<60UC-P$D.124JG5#^8UTF&61=%BD$F,D5Q565AZ
M$B-K,TB4P*9^5G>827+:)4*[2U"]2]#0M\9S<SR(+R7XI@Y!L4,83J<"8^U)
M#"I#B$^)M7ER"Q%$2X4PU1-N/=N&*7J[04YYE22G^S\!+TNMK9/+*))^Z--$
MQ3#)"<.>3P[M72<7V3U"O`%#C[A>=U<Q)L&;.@6==@K;-3*)06WN@D!_C)3;
M0N\E=S1.0[5Q3'(W=0LX7+&??R.[6T@,OO61SQZ;3,1GCTUX`H-G"S5K#RQG
MIU/GE/Q9G*Y0>%`<K^+)3T96\`8.)R[6]5R<"(GKWC@`!S+GXL!^%NVA:CKG
MQ/80TE\DD-`6CW3P1\_/PRO_(^_A*&;X>H2C-P;O]OX"P'O.^X\?X@;C8=[V
M?P```/__`P!02P,$%``&``@````A`,]_)="4`P``5PP``!@```!X;"]W;W)K
M<VAE971S+W-H965T,2YX;6R4EUV/JS80AN\K]3\@[@]@DI!-E.1H8;7MD5JI
M:GM.KQUP$FL!4]O9[/[[SF"28)-LV9OP]?+.X[''3%9?WZK2>V52<5&O?1)$
MOL?J7!2\WJ_][W\_?WGP/:5I7=!2U&SMOS/E?]W\_-/J).2+.C"F/7"HU=H_
M:-TLPU#E!U91%8B&U?!D)V1%-5S*?:@:R6C1OE2581Q%25A17OO&82G'>(C=
MCN?L2>3'BM7:F$A64@W\ZL`;=7:K\C%V%94OQ^9++JH&++:\Y/J]-?6]*E]^
MV]="TFT)XWXC4YJ?O=N+@7W%<RF4V.D`[$(#.ASS(ER$X+19%1Q&@&GW)-NM
M_4>RS,C4#S>K-D$_.#NIWKFG#N+TB^3%;[QFD&V8)TVW?[&2Y9H5,'.^AS.R
M%>(%7_T&MR((HEH!!E'_GL,\QA@EO(3IGY]#/K?3]H?T"K:CQU+_*4Z_,KX_
M:(@T@S1@-I;%^Q-3.4P#Q`KB&;KFH@0+^/4JCNL)TDC?#!TO]&'M3Y)@-H\F
M!.3>EBG]S-'2]_*CTJ+ZQXA(9V5,XLX$CJ?.A`0/L]DT>9B/=YET+G#L7$@4
MD&F4_#]):$;5)NR):KI927'R8+D"MVHH+GZR!-_;68%TH/81Q6L?R@D&K&!J
M7C?1*GR%Y.>=(C4*^+THB*W(S@J</V"X@$!JQH.@&$%PNI`L-3?Z<6,GKE'$
M+?64S),KN84!.>ACX&J9P$+]."_XTMJ?]D8]L:.G1@%3?<G+U%9D'RDL0@C3
M)_R8#,4P@E[<F1TW-8H^66(KLJ'BRFZ1@<EX,A3;9',[;FH4?;('6Y$-%7?(
MDL^0H=@F6]AQ4Z-(SFLI=IYGYGF?_`[7_#-<*+:YR'41FS(PDGY@XM;?4'*'
M#;^:HW<&%#ML3@&F1F*Q.562#25WV!:?84.QPW:U-7DS$HO-J9-L*+F:6%5`
M8+L8G[A6[=`Y!9AV&@O/*9;LAN8>'^[`HR>6F/VZOX,0IPS33F/QN25Q0W./
M[U-?`F+V]3Y?[%9%I^GSQ6Y9W-#<X\.=>GS^4&W/;^Q6!C$:B\\MC1N:>WS.
M!V+<)PSZM@'G-8"IDD[3YW0DV/ZAS;S=&A>3)$JF@R^M:=M,%U(QN6<9*TOE
MY>*(;1B!5R]W+WUEU_!='D"'UM`]^YW*/:^55[(=O!H%V$Q)T^.9"RV:ML?9
M"@V]67MZ@`:>0<\0!2#>":'/%]B17/X2;/X#``#__P,`4$L#!!0`!@`(````
M(0!YN,AV/P4``!09```9````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;)R9
M78^J.A2&[T]R_@/A?N1#43#JSD8^DWV2DY/S<<U@53)"#3#C[']_5BDB+0Y+
M]UR(EJ<O[=O5EJY9??O,3\H'*:N,%FO5F.BJ0HJ4[K+BL%;_^3MXL56EJI-B
MEYQH0=;J3U*IWS:__[:ZT/*M.A)2*Z!05&OU6-?GI:95Z9'D236A9U+`G3TM
M\Z2&G^5!J\XE279-I?RDF;H^U_(D*U2NL"P?T:#[?982CZ;O.2EJ+E*24U)#
M^ZMC=JZN:GGZB%R>E&_OYY>4YF>0>,U.6?VS$565/%W&AX*6R>L)^OUIS)+T
MJMW\&,CG65K2BN[K"<AIO*'#/CN:HX'29K7+H`?,=J4D^[7ZW5C&QDS5-JO&
MH'\S<JEZWY7J2"]AF>U^9`4!MV&<V`B\4OK&T'C'BJ"R-J@=-"/P9ZGLR#YY
M/]5_T4M$LL.QAN&VH$>L8\O=3X]4*3@*,A/38DHI/4$#X%/),Q8:X$CRV5PO
MV:X^KM7I?&(M]*D!N/)*JCK(F*2JI.]53?/_.&2T4ES$;$6FT/KVOOFTR*P5
M@>M-Q+0MPYH_T11H=-,?N/YZ?^:M"%Q;$=.>+`S=F2X>-V71BL#U*F(\;0I,
MTZ8[</WU[CBM"%RO+;$G,]-:V`\,LL8#IHD_+ZF3S:JD%P4F-81$=4[8$F$L
M0?D:>#Q,NE#\*A(A!)G(=Z;2:$&053!]/C:&/5MI'Q#R:<NXG`$+;HQ(;*\$
MBV\FZ\D%OEP0R`4A+X#/VU-L2WQ.=(<1B?@.8<\[1@/O.@-AUL@&3F'^WY^Y
M5[]8)=$O2[:+(WV[S*X!C3O;(6%)/?6&B&$O1!E_V!;I00%*A$/"<'3Q.=$=
M1FY+?(=QIIV.X#NL4L_[SBHQWZ\1YO("NRO8R@6>7.!?-?H19G=M;(8FN,<X
M(A/>81Q#9*)[C#0Z\3WF%DR"9[`H/^\9J[16X?,VHQPISES.P*K:,;<6\&!%
M"0\E?)0(4")$B0@EXC%"\!L,Z?L]OB8P&/;MGH>&<UMS&A==SEC-"BO%P?9Z
M[\LQ\%#"1XD`)4*4B%`B'B,$AV%O[SO,MB]\]6659*>E5='E#+3CRXA&"8\3
M3C-:<QW^Q-GMHPH!2H0H$?5;80T:$8\)"%;#&U#?ZO%@9K!LL;1(NIP9LQ@E
M/)3P42)`B1`E(I2(.;'@4U<8!\%EV/#[+C\6T*R2[+:TW;B<&7,;)3R4\#DQ
MFS7=U"?2+A!(MZ7E+43U(Y2(QPC!:7C;?=YI5DET&D[*XK1V.3/F-$IX*.&C
M1(`2(2?:F+2'*U2$2L1CA&"W`2_%S_O=U)(-E]Z2W!8:<QQ'/!SQ<23`D;!%
MN.UP=I,#*,(UXE%$])V=9:03'KY%&OP$U'\;,77IC<-MH5'?N<X(XN$J/HX$
M.!*V"/=]=B?:<8UX%!%]9V>9GN_C^Z7!3SZBW[>3#W_[:R'^0C$=Q,VVO3]J
M-G_.".+C*@&.A#@2X4@\BHAVLV/0XW8S6EY6I,W*-3@$4ZU):/@OTGAL,<!K
M@5&W^4-&D`!7"7$DPI%X%!'=9D>@GMOL-64&?4""G!^<H,?=2[6IRT=)2+.R
MH6E71]LQIH8U,+[/+&8+PUI(>X+7RHSXZN-(@",ACD0XPI++K-?WF\NMY\EC
MGKS+27D@6W(Z54I*WUEBF)T)NU*>M':-)630(-4AE?O&$O)FPW+77$(^9%B^
M-9>0%AF6>^82LB-0KG4/@)ST.3F0/Y+RD!65<B)[:)H^8?G6DF>U^8^:GIOT
MURNM(1O=?#W"?Q\()/WT"<![2NOK#_:`[O\9F_\!``#__P,`4$L#!!0`!@`(
M````(0!SJ)B]-`4``#47```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;)286X^K-A#'WROU.R#>3XB-<U62H]VNMCU2*U55+\\L<1*T@"-@;]^^XS$0
M?"'`RVHS&<_X[QG_['CW_3-+O7=>E(G(]SZ9S7V/Y[$X)OEY[__S]_.WM>^5
M590?HU3D?.]_\=+_?OCYI]V'*%[+"^>5!Q'R<N]?JNJZ#8(ROO`L*F?BRG/X
MYB2*+*K@8W$.RFO!HR,.RM*`SN?+((N2W%<1ML68&.)T2F+^).*WC.>5"E+P
M-*I@_N4EN99-M"P>$RZ+BM>WZ[=89%<(\9*D2?6%07TOB[<_SKDHHI<4='\2
M%L5-;/Q@A<^2N!"E.%4S"!>HB=J:-\$F@$B'W3$!!7+9O8*?]OX#V3ZRE1\<
M=KA`_R;\H^S\[Y47\?%KD1Q_3W(.JPUUDA5X$>)5NOXX2A,,#JS1SUB!/POO
MR$_16UK])3Y^X\GY4D&Y%Z!("ML>OYYX&<.*0I@97<A(L4AA`O#7RQ+9&K`B
MT>?>IY`X.5:7O1\N9XO5/"3@[KWPLGI.9$C?B]_*2F3_*2>"DU*Q<&I/414=
M=H7X\*#>X%U>(]D]9`N!FSFI".TL^R8)LY-!'F24O0^-"OE+6-GW`UF37?`.
MJQ'7/H_*!_[>?%J/`&;33@FFT9V2>WF:S-)99I;+):?RJ`S=--2=)M332.4A
MU/1^.CEH[[.N"+INXZL9*!\H22N4M1Z:4`@S7JATAB)!\#8L"<TU5DXC4H/+
M^-32&5.WBUQ;-CV3T50NIZ22SGJJVK+$+NZVR4J/J^JWF:U@;O=K*`?J.92%
M0O4[:]O3-I+&G0US/Y5TUE/5%EL.K&4W+LIA@UKD*#V!LAA:0G<#$E#<37I?
M#'KKR6H39)/@ZU:'R.W>62<$RVHCR390'AQII%'L,$3U["HRB1_H;62K$6+7
M2.X^4Q2;;V;0HP-+IY@`X]LMA+$`YGK3+7H*-0D5I&7%+5MM<FB2>]DHU#A-
M<J"Q<LID:%KV:)H$!F*3H3$Y-#G8L&2SX=:ST4"<;%CU2)H$!V+3H3$Y)#GX
M0)?K$9IL1!`G(V['F+:193&[_7&_T=%;;XK&9&NB+D8LX4XSM)UPH)'%B8B-
MNTYT$B+0V\C6BPCJ0`39@/O`NMF`P$@F(-B\1]$D0%`;$(W)426YJ0U`4+(:
M425%@R[T)/V!&3H@V.T6HW?>)$!0&Q"-R:')`0BZ)B-.)VHCHC89HGJN#W02
M(M#;:+W>&P1U(&)!1ER(<*"1Q84(UG.-D-?F;H?<;W7TUK,U)KM0H0,1=`/M
M.Y!#T:#;>AC):KV>.T0X"1#H;2CJ!43H`@1=CV@]'&FD4=@P6J_G$A%.8@1Z
M&]EJ;.!O9&VKA@8C!JK3@J%SWV:W,[7^&:6\X&][*>^KUB10A#8H&A,T?9N+
M=":D:S78,:#5YD6H3%`T\](<&G"0E^8QW6Y?)#"2U>T]1WQH@&-`D4*#MK=:
M6IB*F(&&\3\#<*3>?[7)Z/:>,YX9Y+@O"KTQ6Z<#%K>#2;5D[36B)=DD@*"W
MH;4&B-:2G0EI+<D,I@QHM>\:&`#;Q2J@`0TLX)R..%5838O.;Y[:I!=PT7-2
MRA^_XT\5]#:64`'$L<^8`0P4M0C'B++A@<',K;;H.2KA?7&**!L>&`!TLAL\
MU(.C>M7+>''FO_`T+;U8O,G'1`;/<:VU?>A\H'*\:6?;!\"^XXMPL7V`W>?X
MAA'X1AT(;31XM+Q&9_Y'5)R3O/12?H)YS'%U"_7LJ3Y4X@I*X.E25/!<B?]>
MX'F:PS/>7%XO3T)4S0?9E^V#]^%_````__\#`%!+`P04``8`"````"$`4T!,
M"[$&```U'```&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;)Q9VXZC1A!]
MCY1_L'@?0W.QP1K/:HRUR4J)%$6Y/#,8VVB-L8#9V?W[5%%]Q]@X+^-Q<ZI\
M^G1U':"?/WVO3K-O1=.6]7GML+GGS(IS7N_*\V'M_/W7YZ?8F;5==MYEI_I<
MK)T?1>M\>OGYI^>/NOG:'HNBFT&&<[MVCEUW6;ENFQ^+*FOG]:4XPY5]W519
M!U^;@]M>FB+;]4'5R?4];^%667EV*,.JF9*CWN_+O-C6^7M5G#M*TA2GK`/^
M[;&\M");E4])5V7-U_?+4UY7%TCQ5I[*[D>?U)E5^>K+X5PWV=L)YOV=A5DN
M<O=?!NFK,F_JMMYW<TCG$M'AG!,W<2'3R_.NA!F@[+.FV*^=5[;:!I'COCSW
M`OU3%A^M]O^L/=8?OS3E[K?R7(#:L$ZX`F]U_16A7W8X!,'N(/ISOP)_-+-=
ML<_>3]V?]<>O17DX=K#<$<P()[;:_=@6;0Z*0IJYW]/(ZQ,0@+^SJL32`$6R
M[_WG1[GKCFLG6,RCI1<P@,_>BK;[7&)*9Y:_MUU=_4L@AJ1D$I\G@4^>A`4W
M`^!J_ZOP*7YU[L<1BQ;XJS=^*>2!\"E^:3%GH3<2Y])L>_&V69>]/#?UQPPJ
M$N;37C*L;[:"7$(U^F6IXYB,,'5,\HI9^ER@4`MK_^UE&3^[WV"Y<@[9$`1V
MFX0P$Y$*!`J*6;?:@`MT)6=0U^8<0+U<7VE!$8-,BE%H$M@01*?HFXA4("3%
M*UDC&6.0AA762=\FBV`H0$VL92+3]N)L")+T8C_YBR1<F("4`%3JO9Q&1!!$
M2QE@$(4JT(EB1=Q7%X-,PK$GTQ-A@D0]8;:PE157I;)B`(LI"$>XPAZQN8:C
M>UY4`@997*U2W!"$N$:>5<JIN"JYTL"2IN;Y:N:&L(LAV?O"8I!%UI)N0Q`B
M&P:FZJFX*+F*`=355S,SF"Y-IK=K%<$60XO$AB"DS],R"-46Z4LCI>M:J1H!
M8>"K]3%XHG=KS>LV3P1;/.T&0!#.$W>(TH>($D`C:D0L_%C-W"":/$(4P191
M2[`-0:#L9#.UII(*A%QW,7`MQ.#*H)5.5[5'FVP'K8ICJ$(3FZF\*JG*$:S1
M9$12ANXP>?%[M$DSMAKFAF-H^9,@BIB7V`7`,5H%6%%AG,2>ZM6FLN@6&N5I
MK961Q^AF,.BM'&,4A#6]5&*4SI1Y),JDCN9A4;_?:?'FQRYEM97)%CAFA`1M
M.XE1U"GS2)1)'9WD<>KD/X;JRH0X=>%1VIX:J"XPBKH8N1IE4H?YV=3O6P;>
M]=JJVY[!,2/Z<=4I#Q:X;#.QM2&V,A'N5;6VYC30<ZP5F#`-<BIC!=3&XBM`
M&-JR410,;BN8L#LEOQ["_'#,6QAZD$;ZMKGT:*N_J,;%R0J;4W(.;MIX'KV_
MW(PR=48WFDZ9O,O0U^K-&R8,K^_$UM547E7BCN!-FFA%TVF2<>DT$W6#Q94E
MC.C<"V\1+BQ,RH0!*K)F5.3Y?J"B#,K^0Y[8H\UB2-36(,H<8VQ`Z]9-0B1C
M.:)5D`PR"3_DCCX]:>D:#TR<8TAC%H?#NSB.T&K7BO&8=N=GTOU?SNA/<$:.
M&7OLD)>5QL(4L>1''SQ\T$JO8;3R^W[81YF%$0\*`S.OG;%G#YY"%YD"^,*,
M/GWX:#O:KIMV\]%'68QM+^&8D0<0>54I+`P0%?:5J9H5@>:CT;W=?O%EB6UY
M=OOE&&/'V6XM,8HL91Z),BFCLTRG3#ZD[[G8:K`;W_"J./(BRWY3CM#+P8QA
M4:!,TZ3[D,'Y9$,ZW610"%>L2K:GONVE/(W.]U:02?@A>_.']C;L:82AK?/D
M,Q;$UI-6RM/HA(T@%@=1HH),PF@P6D%,W')D2[K2@_M]7YB99@2#6A885<MB
MY&J401UOSVSJ]_M;'V5U"[N_<<S(AJ(JD1A)78Y,H&Y9WS35@Z$%QG9]<\QM
MZI1'JY?;4:;JE@W>;GK!%?NSFQ['\`J_\NJ%`W2^E):'C+]\"=!WM.J^0Q;1
M5FG8[:[/N';$.TT6+[7[,5X9E$:G2R,\"&(2IG:"J:[E@'<(DTO!4[,HPDTP
M&$J'0UMCR"2`7J(IAI6)ST\/OFR'4Y2!E)8O;#@&'YSELYOV)H6+28D`)*:(
M)S28FX:(/)VXT*%!532'(BU.IW:6U^]XFA+"2T\Y2B<]&SCIZ8]%['%_!2_0
MX:>L\=<@A*.A\,H5F(8X-')E$!S:7+)#\7O6',IS.SL5>Z#AS9?`O*%C'_K2
MU9?^??];W<%Q3?_O$8[G"CA9\.8`WM=U)[X`*5<>^+W\!P``__\#`%!+`P04
M``8`"````"$`?6#OM5`"``"D!0``&````'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;)14RX[:,!3=5^H_6-X3)T"@1"&C`4H[4BM551]KXSB)11Q'MGG]?:]C
M8&`H%<TBB>-SC\^YCZ1/>UFC+==&J&:*HR#$B#=,Y:(II_CGCV7O`T;&TB:G
MM6KX%!^XP4_9^W?I3NFUJ3BW"!@:,\65M6U"B&$5E]0$JN4-[!1*2VIAJ4MB
M6LUIW@7)FO3#<$0D%0WV#(E^A$,5A6!\H=A&\L9Z$LUK:D&_J41K3FR2/4(G
MJ5YOVAY3L@6*E:B%/72D&$F6O)2-TG15@^]]-*3LQ-TM;NBE8%H95=@`Z(@7
M>NMY0B8$F+(T%^#`I1UI7DSQ<Y3,AYAD:9>?7X+OS,4[,I7:?=(B_R(:#LF&
M,KD"K)1:.^A+[CY!,+F)7G8%^*91S@NZJ>UWM?O,15E9J'8,AIRO)#\LN&&0
M4*`)^K%C8JH&`7!'4KC.@(30???<B=Q64SP8!?$X'$0`1RMN[%(X2HS8QE@E
M?WM0=*3R)/TCR0#4'_?[CY(0+ZCSMZ"69JE6.P0]`T>:EKH.C!(@=L:&=XV!
M(Q?S[(*Z4$`;*,8VFPQ3LH4$LB-D=@OI7R/FMX@X/D,(R#MK!./_K]$%@1>,
M7C6^TG<V9AX";L^0-R[F_T)<283474K\>U^<TN?`T`$7YTY&9^=>FH=$89?<
MZ&-O<+T_O[]_)0OL/R[+@=_(&E\?._.0L5<5A_ZZQL`8.II[&"_/#YIOQ):6
M_"O5I6@,JGD!M0B#,11%^S'S"ZO:KN%6RL)X=*\5_`TY=&,8`+A0RIX6;I#/
M_]?L#P```/__`P!02P,$%``&``@````A`)ND<":^!0``O!4``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3,N>&ULK)A;CZLV$,??*_4[(-Y/"`1R04F.-N&N
M5JJJT_:9)4Z"-N`(V-NW[QACP)XTW=79EV7S8_RW9SRV!Z^_OQ47[854=4[+
MC6Y.IKI&RHP>\O*TT?_Z$7Q;ZEK=I.4AO="2;/1W4NO?M[_^LGZEU5-])J31
M0*&L-_JY::ZN8=39F11I/:%74L*;(ZV*M(&?U<FHKQ5)#VVCXF)8T^G<*-*\
MU+F"6WU$@QZ/>48\FCT7I&RX2$4N:0/CK\_YM19J1?81N2*MGIZOWS):7$'B
M,;_DS7LKJFM%YL:GDE;IXP7\?C/M-!/:[0\D7^1916MZ;"8@9_"!8I]7QLH`
MI>WZD(,'+.Q:18X;_<%T$]/6C>VZ#=#?.7FM1_]K]9F^AE5^^"TO"40;YHG-
MP".E3\PT/C`$C0W4.FAGX(]*.Y!C^GQI_J2O$<E/YP:FVP&/F&/NX=TC=081
M!9F)Y3"EC%Y@`/!7*W*6&A"1]*U]ON:'YKS1+6MB6\YB:8*]]DCJ)LB9IJYE
MSW5#BW^XE=EI<16K4X%GIV(Z(Y4[+6==2WAV+5>3A3E=S1;0^YUV=M<.GF+<
M$VOIF,Z<#?M.0WC;.@S/KN'\8R.==PT7?<./C1166MLA/+L.P=<[`UQU]O#L
M[)<?&Z`)R</GDF41GZ:[0S1X+K2IY:5-NEU7]%6#]0J375]3MOI-EZF*I.*C
M[M/LO[(,THNI/#"9C0Y^0_[4L#1>MN;26ALOD,Y99[.[82-;[(4%RUTFZZG`
M5T&@@E`%D0IB%20C8$!8^MA`BG]%;)@,BXWP:B?`$"PE5'MA(9IX*O!5$*@@
M5$&D@E@%R0A(@8`L_HI`,)F-#LMX2!+'D5-@QVU,&$EO9,LF^]ZDCPXB/B(!
M(B$B$2(Q(LF82$$"O[XB2$P&%B-TTP?`7,[D$.PZHWM1ZDWZ*"'B(Q(@$B(2
M(1(CDHR)%"78BZ4HW3Z\Q+;"K-M@""=VG-A2>)R%')Y];R2:>8CXB`2(A(A$
MB,2()&,B^0['RB=\9]:R[YR`[\*M/2(>(CXB`2(A(A$B,2+)F$B.PKGY"4>9
MM>PH)]9B<+0CPR;J<6+#D36L$V<I)X+?&XF(!4@H1"3J6XVE5[)TW!L)Z60L
M)(6#%>#XC)VPLJ<YY]G3CH(+<`C=6`LS.$OY"<M$Y"AQ8JV&*'4V;0W*#U!.
M;+,]DJVIJ>RE?O]>>!$@C1"1J&_%#GI05;:GN'\O5).QAA0;*'U^/C9,1(Y-
M1W@9S$J)/2(>)_9X$S7G4WF:_=Y(N!(@$B(2(1(CDG`"!3PH2R%A99@4DQMY
M`96O2(S67/:^0S-I<<Q-V;6]L.+U/:^W6-<;76FH5">^:&AU6;68R\J!,&B_
M9]I$#`4:.HL$DD>I=!8+JZZSF:T8),*`?SR-ZS>3%7;CA?<_@>1U(!R]8JYW
MK0+$0SINYDJZ[X75:-T)-&CY`K&9@_)XH61:(-X/34*!!N%(H,$J%H@+KU!\
MN%O@`THT5N^-X\.+_T]N3*Q64U9?AY0T4O:>O;`:4L(3:-Y/@2_0H@V;;2V5
M-`Z$P3C9^)!F@W(DK`;E6""N[#B6,J^),+B16:P*_/G(,15EY7*D))Q2).]9
M=<B6Z9`7GD"PT0[GX5S)!5]8K=I@SAU+J9P"83"D5RC0T%DDT-W.8F'%.UNL
MU#(M$08W,I/5C_?B^X->(7`WC\SQUMB5H8,W.[B@8:$;%U$8>1CY&`48A1A%
M&,48L8NC85S\..`70?QKO2#5B>S)Y5)K&7UFESS08+ON,;^!VMDN5-ZPS%7N
MN%"5WN!S%XJX&]P$(>@`O_$6+A15F$<+%RHBS+VE"S4&YM'2A2H!<V_EPE&)
M.=RM/5@W^([=N=WBE@M?LUAG-W/A"P[S!]M]X`X;?>S@[NR:GLCO:77*RUJ[
MD".$?=KNCA6_?>,_FBX7'VD#EV9M6I[AEI1`U3&=0(UWI+01/Z!GH[]WW?X+
M``#__P,`4$L#!!0`!@`(````(0`<'$SMG@4``&47```8````>&PO=V]R:W-H
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MM5@7L`,INU.+S=+]SN9IP%UOM>@$^K<0;XWQM]/LJK??ZF+]1W$0H#;425;@
MJ:J>)?3'6OX+%GMGJQ^["OQ9.VNQR5[V[5_5V^^BV.Y:*/<$=B0W-E]_/(@F
M!T4AS9A/9*:\V@,!^.F4A3P:H$CVWOU^*];M;ND&T7@2^P$#N/,DFO:QD"E=
M)W]IVJK\#T%,I<(D7"4)@+V*\WN3>$BHV]]#UF:K15V].7!HX)'-,9-'D,TA
M\6EC2*/?ZJ6=PA9EDN\R2Y<+-M%`>5Y7L^G">P5%<P5)$`(-T4.8C4A/"%D(
M8-=3A'U3B@%4<%C[$R.YR&;$(_MYR0#$1J3GB,FDAU@<0;K/<Y2+EFYH2#*;
M]>D[81.$P!GI50MM1'H-85&$YY@4K\LGP7!(C><RW[>?G"!FUI5[%`>AEJ;C
MGEKQ,."ZWA8OV)S)2Y[`\&)KG<HK%]G2,5_G1^T0`S\O:G<-87&,;([7M9-@
MJATGVB%FTFD7Q439%*-Q%V5!%/>++5*Q34H*=[LOY")*+NCSHW"(07)33AHY
M-:,SHZDL;M+XR%BYS4TNHMS(<4\0@]P8":9F<!1KXA:UV5>HR464&CGO"6*0
MVH26U`Q&.F@Q8S#5/J]:MXIRH[-.@9#<B'1*2J)Z"-GT!KSB=E$9CG5[E.@3
MC2=.@519?4T`)TD?-EI9[]`F^26W8#CI86+ULX+Y^OPHD@BZ-E!4GF&(S5/.
M[4]W",-I;XM)U$H4",?'B,_H8$P)(`XOG4<YP3_/$>>^Q9'I)R@M$:3.8QS2
M3F96/-3CTQ91#G"#X/6Y+%_8:!,ST@J)`JG9&P:$>&K%1PQLKQ^>-C5B&?=-
M9S;@'4QO7FEGFL<H/!LU*HFJ?^#[>E#9%(F!W%!OP#D8=0Z&(/7H:6"<+-7)
M%F`VF5YJXR\9"$,#@+.CVYB:1*)`PSVJ6)Z,1.>Y5&;B)C<T'+`1IJNCRFM:
MQ8A'1..46?'H4F]P8B;7F75H8B),UP:9*9!JV@D9XFD?-E33*:RCQ[]D)=TJ
M2I*P2!3H1)+VKQT.]6J;'W&1&^*A,=@3C[H'/[F'_'8T"L[>^>QX--53W68F
M'<`8>??-%2Y7D?=EII^@RHN@:XVA\@Q#;)YR@!L\;RB(X]Y2D)/2)=STA(`,
M[K2/WG'ZI!$8W.[44*XBI\_X3J,T1!">OG..I^@='+_D'WS`/SCU#P52'<+)
M,4BM,#.<VZXO,8\[-1PP$4X&7,(MCYC&]$4LM0'PQ2_2,]0F.>`BM[];<IS^
M]F'4\U\5&D'H=-,HH/<=J<J"@`GW@TL<B8/<*>2`DW#]!,4104@ACJ,9Z:B4
MFX"0@=3#+S/R+9\VS&T=NU5DZ!C?%Y&C`D%C])9-I$ZO0JQZ!\16K@^=#DT:
M^LR-%0B;A05DJJ=6>&JLMGD1.[FOQG"A20?.E/:RPN`E#'U3E%>B,@-&C2_R
M2`YO._$VL!3U5J1BOV^<O'J1-YD,;A_Z_^(M:P*WK-V5I-<'X)+SF&W%SZS>
M%H?&V8L-+/7',=2SQFM2_-!6Q^XV[JEJX7JS^W,'U]D"+@_],8`W5=6>/LC[
MO_Z"?/4_````__\#`%!+`P04``8`"````"$`:L3%)TX&```8&0``&````'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;*R9;8^;.!#'WY]TWP'QOB$0\H225)OP
MK#OI=.K=O6:)DZ`-(0)VM_WV'6,;;$^:[O;V36E^C/_VC,?VX%U]_EJ>C1=2
M-T5U69OV:&P:Y))7^^)R7)O_?`D_+4RC:;/+/CM7%[(VOY'&_+SY_;?5:U4_
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M>?MO/FERB"C(C)PI5<JK,PP`_C7*@J8&1"3[VCU?BWU[6IN.,W*=Z7QA@[WQ
M2)HV+*BF:>3/35N5_S$KFVLQ%8>KP%.H+$:V.YY1C3OM)KP=/'D[>SZ:V^/E
M9'Z_H<L;PI,WG(R<Q=2>_JQ'D.W\A2=ON'Q;PQEO..\;OG&HL-*Z'N'YOJ$N
M>4-XOF^H-F01FU2:3GR^[L;58EG1)9F?M=EF55>O!JQ<F/;FFM%]P/:HK$@O
M-J=]POTHWR#1J,H#E5F;$`'(I`86R<O&GKHKZP42.^<VVQLVJL5.6-`LIK*^
M#@(=A#J(=!#K(-%!*@$+PM+'!I+](V)#96ALA%=;`89@.5H@A(5HXNL@T$&H
M@T@'L0X2':024`(!J_<C`D%EUB:L:"E)IJKG6V9CPTAZ(RV/=KU)'QU$`D1"
M1")$8D021%*9*$$"OSXB2%0&%B-TTP<`+R5N="]*O4D?)40"1$)$(D1B1!)$
M4IDH48)M68G2[6-,;"O4N@N&<&++B`-+5@K/3$VB76\DFOF(!(B$B$2(Q(@D
MB*0R47R'$^8=OE-KU7=&W$F_D^P0\1$)$`D1B1")$4D0266B.`I'Z#L<I=:J
MHXR`H_(DS[5)[HWZ248D0"1$)$(D1B1!))6)XCNMN^4#]7Z"4VO5=T;D24;$
M1R1`)$0D0B1&)$$DE8GB*%0M[W"46JN.,N)TI7-WVN\X&4Y*GQ$7ZA)IM2_4
M1`AZ(Y$((1**$(G[5K+T4I5.>B,AG<I"2CAH\:3$@U52(UKGMJ<B?]I6X`/L
M6S<28@(5$Z^CJ(H:ITX8JO;EL.PYLMT>^1RY=E=\.6-;.S6#P4#X$F*9"*-X
M:$C+.E">:$$:#(1RJLBH8:+%EKP^?BU,K&2#4U)TN;4Y8M]`M'K<8>1SY,HG
MIST;JQX%@Y60#S&*,(HQ2C!*.8*O.)!7HT,K,#DZ-Y(%OKCZ;*'F6K8P-%&6
MS,Q6'=S1^@H:3MA''BNU;S;4"M-`-'1XFLVUHS<4!MU';9?3D4!#9[%`ZBBU
MSA)AQ3N;N)I!*@S8%[1<NM/ZZ3V!Y%6=G$\,391#:*;E_J[K!P(IK\2^H4B>
M0%C1F8,OH[F6;Z%X/W0?"30(QP(-5HE`3'B)XB,/14TT6J#)B?9KRY"7><.(
MMK`G=9FESJRV&>V$U9`2OD"S?DD'`LV[L+G.0DOC4!C(R<;['Y1C834H)P(Q
MY>G4T>8U%08W,HN6=_\_<JQ(A/D32;*EESIT3:H)IWT?[835D!>^0'!2#Z?D
M3,N%0%@MNV#.IHY63X7"8!A2)-#062S0W<X28<4ZFR^G6F>I,.@Z4S.35I7W
MXONENO[H')6W1E:<*@&6ZU56<=@(^1@%&(4811C%&"48I0I28T&K3#D6/SD.
M6%&J^-S7J7)N:)OV#NXO:>I)1:>/48!1B%&$48Q1@A&]1!T&P<+`+D79?55)
MZB/9D?.Y,?+JF5YX0H/-JL?L-G9KS\5UK/[&]>"K%%:;SJ<>?+'=X#,//G!N
M<.B@JUEUG84'M?(->QN$8(KQ&W_I0>V*>;STH/#$'&H\CY9Q^`W4:%YR\PT4
M//"FVPRU\<*]]8-S0VM+[[-O<<>#^R'<]W;BP9T(Y@^N]P`S!"^LOF>XE[YF
M1_)G5A^+2V.<R0&F<=R5R#6[V68_6K[$'ZL6+J2[U7Z"OT`0*.K&(]@F#U75
MBA^T@_YO&IOO````__\#`%!+`P04``8`"````"$`&">+VIL"``#A!@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6R45=N.FS`0?:_4?[#\OAC(A02%
MK+)=I5VI*U55+\^.,6`%8V0[R>[?=XP3-FFBEGWA,AR?,V<\'A;W+[)&>ZZ-
M4$V&HR#$B#=,Y:(I,_SSQ_INAI&QM,EIK1J>X5=N\/WRXX?%0>FMJ3BW"!@:
MD^'*VC8EQ+"*2VH"U?(&OA1*2VKA59?$M)K3O%LD:Q*'X91(*AKL&5(]A$,5
MA6#\4;&=Y(WU))K7U$+^IA*M.;%)-H1.4KW=M7=,R18H-J(6]K4CQ4BR]*EL
ME*:;&GR_1&/*3MS=RQ6]%$PKHPH;`!WQB5Y[GI,Y`:;E(A?@P)4=:5YD>!6E
M#S-,EHNN/K\$/YBS9V0J=?BL1?Y5-!R*#=OD-F"CU-9!GW(7@L7D:O6ZVX!O
M&N6\H+O:?E>'+UR4E87=GH`AYRO-7Q^Y85!0H`GBB6-BJH8$X(JD<)T!!:$O
MW?T@<EME>!0&213.1PFP;+BQ:^$H,6([8Y7\[4'1D<J3Q$<2N)](IL$D"4<1
M:/Z'A/B$.G^/U-+E0JL#@IX!2=-2UX%1"L2W#8$3AUTY<(:AIR%7`YNP7T9)
MLB![J!P[8AX\!JYOF!Y!0+17!K7AR@[LE%UI72H//G`N$]^6&;U'QH$S/#Y/
M/IGUO%[98Z#BO<%QC[@P"#3##3HP[`&0][37M?6@`=(`&2[MP)UT7]QCY+(.
M\]LNI^^1<N!+*1^)I]WQ.V^/Y)*W.W'1)(#4_MVC;MVEA(^`Q%EI9^%M-VY>
M#SX.#GPI=8R,W]SXD>*/G.2ZY)]X71O$U,Z-BQ@.41_M)]DJ=NO_CH_35=?_
MI/\`$Z:E)7^FNA2-034O@!+F"M1(^QGE7ZQJ(4T8$<K";.D>*_B5<#A'H2MH
MH90]O8`PZ7].RS\```#__P,`4$L#!!0`!@`(````(0"RCZ`$30,``'P+```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;)1676^;,!1]G[3_@'@O8)*0
M)@JITE7=)FW2-.WCV0$3K`)&MM.T_W[WVH0%0EKRDH2;XW-\[K4O=W7W4A;.
M,Y.*BRIVB1>X#JL2D?)J%[N_?SW>W+J.TK1*:2$J%KNO3+EWZX\?5@<AGU3.
MF':`H5*QFVM=+WU?)3DKJ?)$S2KX)Q.RI!H>Y<Y7M60T-8O*P@^#(/)+RBO7
M,BSE&`Z193QA#R+9EZS2ED2R@FK8O\IYK8YL93*&KJ3R:5_?)**L@6++"ZY?
M#:GKE,GRZZX2DFX+\/U"IC0Y<IN',_J2)U(HD6D/Z'R[T7//"W_A`]-ZE7)P
M@&EW),MB=T.6]V3A^NN52=`?S@[JY+>C<G'X+'GZC5<,L@UUP@ILA7A"Z-<4
M0[#8/UO]:"KP0SHIR^B^T#_%X0OCNUQ#N6?@"(TMT]<'IA+(*-!XX0R9$E'`
M!N#3*3D>#<@(?3'?!Y[J/'8G,V].@L5D#BQ;IO0C1TK72?9*B_*O!9&&RI*$
M#0E\'TDB;S8/)@0TWR'Q[8:,OP>JZ7HEQ<&!0P.2JJ9X!,D2B(<-@1/$;A`<
MNW"H8:\*JO"\)M%\Y3]#YI(&<V\Q\/D?TR)\$&V506V\,H)1&5.+6[FW@5.9
M<%AF<HT,@F-W>KKYZ+;EM<H6`QEO#4Y;1,<@T(PWB&"H`9"WM.>YM:`1T@`9
M+XU@(]TFMXET\[`8=AE=(X7@KI2-A)&Y?J?'8][E-3>.S#S8VMMG%-=U)6P$
M)$Y2.P^&W6##'GT=$-R5LI$!-XLN+[J9S[%7O.,&UW4E;*3GA@R[(=#HQMLQ
MZ*Y8$QHP1/">GV1JM".SL*=B>T;/TX7[3*[J&P;=4[.M8\A3KU>@IQGQL$6_
M?>;PVO;*U(1ZGB87ZG15JR!MKV@O;!,:\H1WN5>G:/K^-<*W6]^2#?4L76A^
MY*J^8-"],EWL#&2H-03AF#J=-P=#%KL]4[,+=;JJ/9#S_M"$ANHTT"%&U>F\
M0\`@A*7K68IZENRL8V>!DLD=^\2*0CF)V.,<$\+;O8VV,]8FQ#;=CT^7&SM[
M^>T_,/O4=,>^4[GCE7(*E@%G8"HD[?1D'[2HH>HPO`@-4X_YF<.4R^`-'^`9
MS830QP=0]MNY>?T/``#__P,`4$L#!!0`!@`(````(0";,:#TP0<``%TD```8
M````>&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK%K;;MLX%'Q?8/_!T'LMZV([
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M..6/Q:8JZW+7C%$N5$3=,2_"18A*]W?;`B,@V4=5OEL&#]&M2.=!>'\G!?JW
MR%]JX_^C>E^^_%85VS^*4PZU,4\T`X]E^952/V\)0N/0:?U)SL"?U6B;[[+G
M0_-7^?)[7CSM&TSW%".B@=UN?XB\WD!1E!G'4ZJT*0\@@']'QX*6!A3)OLN_
M+\6VV2^#9#:>SB=)A/318UXWGPHJ&8PVSW53'O]329$NI8K$N@C^ZB+Q9'PS
MG::SFSFJ7&B9Z);XJUM>SD]U/OYZZ+H=A6JX4CV1-=G]756^C+`D,:#ZG-$"
MCVY1K)5-5>B$?$U'"$A%'JC*,L!>@D0U)O_;?13/[\)OF+"-SEEY<GC&NLV@
MV:&RP@!"\.U(0]^?0)JJ$.FVNU4+]*.(+89M1MM$&`!CB'FT&298T_[5V*I(
MC98!9L%0\88S6*F<"/UV22E/67<I'4L38331ETV3-LW`V:<J6#_HI>/D3K].
MND2\2^F(FP@C#I(F\<NZ4K+DU]9=*23&^C(8+RP=NZ2VF3`11F<VA`XE<SH*
MB>-N*:X=1)@(ZWL^I&]*YGUKI-\&:XTL3'&2"1='>).B+HDQI&NLX3&7)XN2
M.4.%Q$FOCH,($V%]8Q1FW]+?HOFXM^-W>QQ5XL04$F.1]JLHL2VC2^I6D8DP
MKA$<PB1[62B9S0EIR)3*A02#.`$R7&.FI%JIO&(.]81(>3=,H1WW2D.67DFW
M9J3GK_NLMJ%@$"=,_FL0?D,QY=:,DX+`J>UM3=Z*B38@P2!.@*S5($"*S9)K
MEA?9I[6^-&0)9MM]G]4.03"(\R5'-?B^(9CV7W,2%<26F`.)R(0X`?)0@P`)
M%D>SJQ13=HS!M@-?T<5+S9VY):?V$NNRVH:B;PB($R;C-0B_H9BR:<9).W=/
M<QTYD&`0)T!6:Q!0BBVN4DR[=D]E%2G(6F,S6[$NJU?,A#AA,F.#\!N**>MF
MBIENKEW!@41D0IP`.:Q!0"HV'6/6!QYL(F75C%OGWN8*L\ZZ:]V0>4C7T%YA
M\2#;E]G<]C5D[DD7$@QB>M$YR-8KBM)K5I@L9;%35P)KA5GGVK5N:"K&($YX
MD.WC7&4[JX:88MKV^[TA6!8G\--L'Q0<<@JR!+-/I[HA$ZQKZ"PQ\F-C1US>
MDM2S=2G2$!/,]'AUO\:RN&!DN08!VI)SW&`/WI)T-VYS4Q!UWI_#4NO`NM8-
MD=59&(,XW4&F'[NFKR&FEVOZ+(L3('>U]+I9T*.+H1X6*Y\V/4Q#EF#]X5U9
M;I_5"_:JY\=DQ@;?-Q:8LF[&R71S3<"!A.P&!P:Y2;E@'L^/)MC3`RT_=BU?
M0Y9<]CF_S^KE>M7RZ5G`^^62V=Q4-62N+Q<2#&)R)1[+CZ^Y1,I"%C>?X:?V
M.5\W-/<C@SC=08:?N(:O(::7:_@LBQ/P&/Z5E\C$=7P-62O,/NCW6=T*8Q`G
M/,CQ$]?Q-<04<QV?97$"Y,J&(Y#C3[$R!N['Q/5[#5EJV8?\/JM7J[M0`.)D
M!_E]XOJ]ALQ'."XD&,0)6'Y_V3\3U]-;R'B.TT)P(>.Z:!WMA3^K/]!RFH-L
M/G%M7D/&KE^[D&`0)^"S^>N.JHGK]!JR5I9]5.VS^I7UJM.G@YQ>9G,WU9"I
MF`L)!C'%4H_37W7RDH4L;EZGMT^JNJ$Q`L$@3G>0TZ>NTVL()Z5V=M8N)!C$
M"5A.?WDGIJZ9MY"Q$UN([<2I=4(5_JS^6,9I#O+WU/5W#1FSLG8AP2!.P./O
MR<TU)]34M7@-\8TXM8]<?58[U8)!G.\@BT]=B]<0$TQE&9!@69R`9?%T0;SN
M42'>H]KW0!JR!+//7'U6+YBJI8:@^*IWK.HMX3&OGO)U?CC4HTWY3.]/,<#[
MNPY6+W=7*;W=E>]"G4B,B'RQX4121.3=F!.9(B+WKQ.9(3*CG>U$YHC(]\MV
M)$$_.*9XVB3H!\<$7P3]X&+MB]P@(K>VT\\"D86O33H!-_GZVFX3HQKN:3S]
MQ*B&6PI/)$$U'.Q]$<P"SM"^"&8!AUM?)$%$WDXYW-!&G6><"-JH<Z$3@=9J
M*3D1:*T\V8E`:]P(>[C%F%/<A7HB$=K@B:DO@C9XINF+0&L\,_1%H#6>V'DB
M,;3&<S-?!%KC`94G$J$-7K'X(FB#=QF^"+3&2P9?!%JK^V1;MPA:XSF[KPVT
MQ@-M-X*/,![\O:"!)W]%2\"'TZ+QX`_I[8-_$])>]S18@:F/Z`KSZYU>S*%W
M"C&#<@+#3B5\W''.GO(O6?54G.K1(=_!O";RF6:E/@]1/YKRC$,-/O$H&WS6
M(?^[QV<\.;X_F-#SJ5U9-NT/*!IV'P;=_P\``/__`P!02P,$%``&``@````A
M`(]))P\R`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````)R104_#(!B&[R;^AX9["UVG
M64C+$C4[N<3$&8TWA&\;L5`":+M_+^VZ.J,GC^1]>7B^CW+9Z3KY!.=58RJ4
M9P0E8$0CE=E5Z&FS2A<H\8$;R>O&0(4.X-&275Z4PE+1.'APC047%/@DDHRG
MPE9H'X*E&'NQ!\U]%ALFAMO&:1[BT>VPY>*=[P#/"+G&&@*7/'#<`U,[$=&(
ME&)"V@]7#P`I,-2@P02/\RS'W]T`3OL_+PS)65.K<+!QIE'WG"W%,9S:G5=3
ML6W;K"T&C>B?XY?U_>,P:JI,ORL!B/7[J;D/Z[C*K0)Y<V#=FZL3[_<E_IV5
M4@QV5#C@`602WZ-'NU/R7-S>;5:(S4@^3\E52A:;&:'S@A:+UQ*?6N-]-@'U
M*/!OX@G`!N^??\Z^````__\#`%!+`P04``8`"````"$`'-#EM3<"``#D!0``
M$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````"<5$UOXC`0O:^T_R'*O00H0JO*I,J&T$8+`1'#'B,W
MF8#58$>V0=!?OQ,B2MA&*RVW^7CS_#QC#WD^[@KK`$IS*49VK].U+1"IS+C8
MC.P5G3S\L"UMF,A8(06,[!-H^]G]_HTLE"Q!&0[:0@JA1_;6F/+)<72ZA1W3
M'4P+S.12[9A!5VT<F><\A;%,]SL0QNEWNT,'C@9$!ME#^4EHUXQ/!W,O:2;3
M2I]>TU.)@EWBE67!4V;PENZ,ITIJF1LK.*90$*>9)*@NAG2ON#FY7>(T71*G
MK``?B=V<%1J(<PV05V!5TQ:,*^V2@WDZ0&JDLC3_P+;U;>N-::CDC.P#4YP)
M@[(J6.V<[:+41KF_I7K76P"CB8.`.G@VF]BFS0=N;WA&H'6+K!AJ)9BXU4BY
M*4#/\P53ID5R;]C4?%91*ZX%7::8X-M(`F&P7TDHZFESV53^>0=_'HV#*`[&
M"5KQ?!J./8K.3V_J17[P/R4QQ<K9/26].X[IWU'S>$?-H+4F#E^B<!+Z7D03
MS_?GJXB&T4NRP/[Y87L+PF@=1'2^#(.XE7+BA<MD[4U703(+O'BUQ%Y&M!4:
MT[G_*Z%++XH]GX8XMW;8/T6V-[VA,J'L#=_B'=3MLVE2Q[B/LGT!B<SQ@1YP
M\;0?\^6BR1@,X\6-JIOO]-<'FG+QKE<EE6-FX+(A;H,DWC(%&?Z=2_X:(*^X
M'%11D?A;)C:073!?$]4^6]=+V^T-.MW'+JZJ1HPXU_7L_@$``/__`P!02P$"
M+0`4``8`"````"$`0'0)U)T!``"/#```$P``````````````````````6T-O
M;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0```$P"```+
M`````````````````-8#``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(````(0#N
MGCLT6@$```X+```:`````````````````/P&``!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+`0(M`!0`!@`(````(0`HPPK#:`(``",&```/````````
M`````````)8)``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"````"$``S:*
M?=\"``!;"```&``````````````````K#```>&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L!`BT`%``&``@````A`,[*LK38`@``+P@``!D`````````````
M````0`\``'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4``8`"```
M`"$`O-8\UO$"``#P"```&0````````````````!/$@``>&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3````
M`````````````'<5``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@`
M```A`'VTX\#>"@``]5P```T`````````````````/!P``'AL+W-T>6QE<RYX
M;6Q02P$"+0`4``8`"````"$`Q7,/P!\>``"S5```%`````````````````!%
M)P``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"+0`4``8`"````"$`K.<7U6$$
M``"@#P``&`````````````````"610``>&PO=V]R:W-H965T<R]S:&5E=#,N
M>&UL4$L!`BT`%``&``@````A`"C#ZZ<9!0``$10``!@`````````````````
M+4H``'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+`0(M`!0`!@`(````(0#/
M?R70E`,``%<,```8`````````````````'Q/``!X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"+0`4``8`"````"$`>;C(=C\%```4&0``&0``````````
M``````!&4P``>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(
M````(0!SJ)B]-`4``#47```9`````````````````+Q8``!X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L!`BT`%``&``@````A`%-`3`NQ!@``-1P``!@`
M````````````````)UX``'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+`0(M
M`!0`!@`(````(0!]8.^U4`(``*0%```8``````````````````YE``!X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"+0`4``8`"````"$`FZ1P)KX%``"\
M%0``&0````````````````"49P``>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+`0(M`!0`!@`(````(0`<'$SMG@4``&47```8`````````````````(EM
M``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`:L3%
M)TX&```8&0``&`````````````````!=<P``>&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L!`BT`%``&``@````A`!@GB]J;`@``X08``!D`````````````
M````X7D``'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"```
M`"$`LH^@!$T#``!\"P``&0````````````````"S?```>&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````(0";,:#TP0<``%TD```8````
M`````````````#>```!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4
M``8`"````"$`CTDG#S(!``!``@``$0`````````````````NB```9&]C4')O
M<',O8V]R92YX;6Q02P$"+0`4``8`"````"$`'-#EM3<"``#D!0``$```````
M``````````"7B@``9&]C4')O<',O87!P+GAM;%!+!08`````&0`9`*$&```$
%C@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <strong>NOTE 2 - INVENTORIES</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"> Inventory at March 31, 2014 and December&nbsp;31, 2013 consisted of the following:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">March 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">December 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2014</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="WIDTH: 76%; TEXT-ALIGN: left">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 9%; TEXT-ALIGN: right">2,076</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 9%; TEXT-ALIGN: right">2,342</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">170</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">92</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,281</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,523</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,527</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,957</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"> During the three months ended March 31, 2014, the Company recorded approximately $1.1 million for write-down of inventory under cost of revenues.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]D8C$S931F95\X9&9A7S0T-#9?.#0P9%\R
M-S0Y9&1F,&$W93$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9&(Q
M,V4T9F5?.&1F85\T-#0V7S@T,&1?,C<T.61D9C!A-V4Q+U=O<FMB;V]K+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M
M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M
M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]35$%414U%/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$
M7T-/3E-/3$E$051%1%]35$%414U%,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY$
M14Y3141?0T].4T],241!5$5$7U-4051%344S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]3
M5$%414U%-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]22453/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1D%)4E]604Q515]-14%3
M55)%345.5#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-43T-+7U1204Y304-424].4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y)3E9%3E1/
M4DE%4U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y324=.249)0T%.5%]!0T-/54Y424Y'7U!/3$E#244R/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y614Y43U))15-?4V-H
M961U;&5?;V9?26YV96YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4U1/0TM?5%)!3E-!0U1)3TY37T1E=&%I;',\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z
M17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R
M:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z
M06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z
M4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\
M+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM
M;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES
M('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!8
M4"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15!#044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C
M=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA>2`P,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$;V-U;65N="!!;F0@16YT
M:71Y($EN9F]R;6%T:6]N(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`M43QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&
M;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!9
M96%R($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B=1,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R861I;F<@4WEM8F]L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG4$Q8/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES
M=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U!2
M3U1!3$E8($))3U1(15)!4$555$E#4RP@24Y#+CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L
M($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S`P
M,#$P,#8R.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG+2TQ,BTS,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&
M:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)T%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA
M<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3,L-C`V+#0V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?9&(Q,V4T9F5?.&1F85\T-#0V7S@T,&1?,C<T.61D9C!A-V4Q
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1B,3-E-&9E7SAD9F%?
M-#0T-E\X-#!D7S(W-#ED9&8P83=E,2]7;W)K<VAE971S+U-H965T,#(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$50-4%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3D1%
M3E-%1"!#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%531"`D*3QB<CY)
M;B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-54E)%3E0@05-31513.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S<L-CDP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X-BPS
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4M(%1R861E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#<S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#DQ/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!A<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C`Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N
M=&]R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4R-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M.34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@X+#4V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/CDW+#DP,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1E5.1%,@24X@4D534$5#5"!/
M1B!%35!,3UE%12!224=(5%,@55!/3B!2151)4D5-14Y4/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#8R,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y04D]015)462!!3D0@
M15%525!-14Y4+"!.150\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S+#`Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$S+#<Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1$5&15)2140@0TA!4D=%4SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#,L-#$V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$S+#,S,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=6%L<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PV,SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#(U-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#4S,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#`W,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5F97)R960@<F5V96YU97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L-C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.2PS-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPW.#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPV.38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^3$].1R!415)-($Q)04))3$E42453.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO=&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RPQ-3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RPP-#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E9F5R<F5D(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,"PV-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,2PW.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!I;B!C;VYN96-T:6]N('=I
M=&@@8V]L;&%B;W)A=&EO;B!O<&5R871I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,W,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EA8FEL:71Y(&9O
M<B!E;7!L;WEE92!R:6=H=',@=7!O;B!R971I<F5M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#0P-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S8X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&]N9R!T
M97)M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,3`L,C$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$S+#4X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S8L.3DT/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30P+#(W.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-34E4
M345.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#05!)5$%,($1%1DE#245.0UD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,S+#4W."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-BPY-#8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@;&EA8FEL:71I97,@;F5T(&]F(&-A<&ET86P@9&5F:6-I96YC>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#,L-#$V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,3,L,S,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15E1
M044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$
M051%1"!35$%414U%3E13($]&($]015)!5$E/3E,@*%531"`D*3QB<CY);B!4
M:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@
M3T8@3U!%4D%424].4R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D5614Y515,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-BPV.38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-38X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU004Y9)U,@
M4TA!4D4@24X@0T],3$%"3U)!5$E/3B!!1U)%14U%3E0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]35"!/1B!2159%3E5%4SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PP-S,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3<Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=2
M3U-3(%!23T9)5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS
M,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#DY-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4D5314%20T@@04Y$($1%5D5,3U!-14Y4($584$5.4T53/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#$U,BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#<U-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M<W,@+2!G<F%N=',@86YD(')E:6UB=7)S96UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR+#`X-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#,Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D5314%20T@@04Y$($1%
M5D5,3U!-14Y4($584$5.4T53+"!.150\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8L,#8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#4L,S(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4T5,3$E.1RP@1T5.15)!3"!!3D0@
M041-24Y)4U12051)5D4@15A014Y315,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,L-S$Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(L,3`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]015)!5$E.1R!,3U-3/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#0V."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#0R.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9)3D%.
M0TE!3"!%6%!%3E-%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M.3$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1DE.04Y#24%,($E.0T]-13PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&24Y!3D-)04P@24Y#3TU%("A%6%!%3E-%
M4RD@+2!.150\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@W-RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.150@3$]34R!&3U(@5$A%(%!%4DE/1#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@W+#,T-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0L,S(Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,3U-3
M(%!%4B!32$%212!/1B!#3TU-3TX@4U1/0TLZ/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0D%324,@04Y$($1)3%54140\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY714E'2%1%1"!!5D5204=%($Y534)%4B!/1B!32$%215,@3T8@
M0T]-34].(%-43T-+(%53140@24X@0T]-4%5424Y'($Q/4U,@4$52(%-(05)%
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)!4TE#($%.1"!$24Q55$5$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY,BPV.#8L-C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3(L,3@T+#(R,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&(Q,V4T9F5?.&1F85\T-#0V7S@T,&1?
M,C<T.61D9C!A-V4Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1B
M,3-E-&9E7SAD9F%?-#0T-E\X-#!D7S(W-#ED9&8P83=E,2]7;W)K<VAE971S
M+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q3D%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!/
M4$52051)3TY3("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/DEN(%1H;W5S
M86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P
M;65N="!%>'!E;G-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A
M<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E
M<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#(X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X-S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=E;F5R86P@86YD($%D;6EN:7-T<F%T:79E($5X<&5N<V4@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M
M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!!;&QO
M8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?9&(Q,V4T9F5?.&1F85\T-#0V7S@T,&1?,C<T
M.61D9C!A-V4Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1B,3-E
M-&9E7SAD9F%?-#0T-E\X-#!D7S(W-#ED9&8P83=E,2]7;W)K<VAE971S+U-H
M965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$4Q5$%'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y4($]&($-(04Y'
M15,@24X@0T%0251!3"!$149)0TE%3D-9("A54T0@)"D\8G(^26X@5&AO=7-A
M;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,SXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CY-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(V+#DT-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#,L,S4W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E
M;&%T960@=&\@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T;R!R97-T<FEC
M=&5D('-T;V-K(&%W87)D+"!N970@;V8@9F]R9F5I='5R97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,#(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@
M=&\@96UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!F
M;W(@=&AE('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-RPS-#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PS,C$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,S,L-3<X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L,C@S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G
M:6YN:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN
M9R!"86QA;F-E("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY,RPU-3$L,#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3,L-#@Y+#@P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T
M960@=&\@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!R
M96QA=&5D('1O(')E<W1R:6-T960@<W1O8VL@87=A<F0L(&YE="!O9B!F;W)F
M96ET=7)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!R96QA=&5D('1O(')E
M<W1R:6-T960@<W1O8VL@87=A<F0L(&YE="!O9B!F;W)F96ET=7)E<R`H:6X@
M<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U
M+#,V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#0R,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&QO<W,@9F]R('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDS+#8P-BPT-C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY,RPU,#(L,C,P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A
M:60M:6X@0V%P:71A;"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E
M9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.#0L,S0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#$T
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T960@=&\@<W1O8VL@
M;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C
M;VUP96YS871I;VX@<F5L871E9"!T;R!R97-T<FEC=&5D('-T;V-K(&%W87)D
M+"!N970@;V8@9F]R9F5I='5R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#(P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!F;W(@=&AE('!E<FEO9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.#4L,#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@Q+#4S.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C=6UU;&%T960@1&5F:6-I="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R,3$L,S@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$X,RPU.34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T
M;R!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T
M960@=&\@<F5S=')I8W1E9"!S=&]C:R!A=V%R9"P@;F5T(&]F(&9O<F9E:71U
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S(&9O<B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@W+#,T-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T
M+#,R,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N9&EN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#(Q."PW,S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@Q.#<L.3$V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0T/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-
M"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\
M=&0@8V]L<W!A;CTS1#,@=F%L:6=N/3-$=&]P/E)E<')E<V5N=',@86X@86UO
M=6YT(&QE<W,@=&AA;B`D,2X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M9&(Q,V4T9F5?.&1F85\T-#0V7S@T,&1?,C<T.61D9C!A-V4Q#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1B,3-E-&9E7SAD9F%?-#0T-E\X-#!D
M7S(W-#ED9&8P83=E,2]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$4V0D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3D1%3E-%1"!#3TY3
M3TQ)1$%4140@4U1!5$5-14Y4($]&($-(04Y'15,@24X@0T%0251!3"!$149)
M0TE%3D-9("`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E0@3T8@0TA!3D=%4R!)
M3B!#05!)5$%,($1%1DE#245.0UD@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@
M<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K+"!!=71H;W)I>F5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%(
M04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$
M051%1"!35$%414U%3E13($]&($-!4T@@1DQ/5U,@*%531"`D*3QB<CY);B!4
M:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@1DQ/
M5U,@1E)/32!/4$52051)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@W+#,T-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#0L,S(Q*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!9&IU<W1M96YT<R!R97%U:7)E9"!T;R!R96-O;F-I;&4@;F5T(&QO
M<W,@=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:&%R92!B87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8W,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,S8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX@86YD('=R:71E(&1O
M=VX@;V8@9FEX960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9I;F%N8VEA;"!E>'!E;G-E<R`H:6YC;VUE*2P@;F5T
M("AM86EN;'D@97AC:&%N9V4@9&EF9F5R96YC97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#<X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E<R!I;B!A8V-R=65D(&QI
M86)I;&ET>2!F;W(@96UP;&]Y964@<FEG:'1S('5P;VX@<F5T:7)E;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!A
M;6]U;G1S(&9U;F1E9"!I;B!R97-P96-T(&]F(&5M<&QO>65E(')I9VAT<R!U
M<&]N(')E=&ER96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5B="!I<W-U86YC92!C;W-T<R!A
M;F0@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&]P97)A
M=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E(&EN(&1E9F5R
M<F5D(')E=F5N=65S("AI;F-L=61I;F<@;F]N+6-U<G)E;G0@<&]R=&EO;BD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L.3`Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-S0P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YC<F5A<V4@:6X@86-C;W5N=',@<F5C96EV86)L92!A;F0@;W1H97(@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W-#0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M96-R96%S92`H:6YC<F5A<V4I(&EN(&EN=F5N=&]R:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0S,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S,T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5C<F5A<V4@:6X@
M86-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5A;',@*&EN8VQU9&EN9R!L;VYG
M('1E<FT@*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#4P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L
M,#`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L,S0P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DL-3@V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#05-(($9,3U=3($923TT@24Y615-424Y'($%#5$E6251)15,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8T,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5S=&UE;G0@:6X@
M<F5S=')I8W1E9"!D97!O<VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G1S(&9U;F1E9"!I;B!R97-P
M96-T(&]F(&5M<&QO>65E(')I9VAT<R!U<&]N(')E=&ER96UE;G0L(&YE=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#<I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A
M<V@@=7-E9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#8X.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]7
M4R!&4D]-($9)3D%.0TE.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET
M:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5&1D5#5"!/1B!%6$-(04Y'12!2051%($-(04Y'15,@3TX@0T%3
M2#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54
M($1%0U)%05-%($E.($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L-S`X*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#$V-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)!3$%.
M0T4@3T8@0T%32"!!3D0@0T%32"!%455)5D%,14Y44R!!5"!"14=)3DY)3D<@
M3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-BPS
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,BPP,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)!3$%.0T4@3T8@0T%32"!!3D0@0T%32"!%455)5D%,14Y4
M4R!!5"!%3D0@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-RPV.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,2PX-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%262!)3D9/
M4DU!5$E/3B!/3B!)3E9%4U1)3D<@04Y$($9)3D%.0TE.1R!!0U1)5DE42453
M($Y/5"!)3E9/3%9)3D<@0T%32"!&3$]74SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T
M>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L
M;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)
M3D<@4$],24-)15,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\(2TM1$]#5%E012!H=&UL
M(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O
M14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT
M<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M
M96YT+2T^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>#L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B`\<W1R;VYG/DY/
M5$4@,2`M(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\+W-T<F]N
M9SX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4
M+4E.1$5.5#H@+3`N-6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;"<^(#QS=')O;F<^)FYB<W`[/"]S=')O;F<^/"]P
M/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!724142#H@
M,3`P)3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE.+51/4#H@,'!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#`N,C5I;B<^/'-T<F]N9SYA+CPO<W1R;VYG/CPO=&0^
M(#QT9#X\<W1R;VYG/D=E;F5R86P\+W-T<F]N9SX\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@5$585"U)
M3D1%3E0Z("TP+C(U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ
M(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@
M9F]N="US=')E=&-H.B!N;W)M86PG/B!0<F]T86QI>"!":6]4:&5R87!E=71I
M8W,L($EN8RX@*&-O;&QE8W1I=F5L>2!W:71H(&ET<R!S=6)S:61I87)I97,L
M('1H92`B0V]M<&%N>2(I+"!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S:61I
M87)Y+"!0<F]T86QI>"!,=&0N+"!A<F4@8FEO<&AA<FUA8V5U=&EC86P@8V]M
M<&%N:65S(&9O8W5S960@;VX@=&AE(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C
M:6%L:7IA=&EO;B!O9B!R96-O;6)I;F%N="!T:&5R87!E=71I8R!P<F]T96EN
M<R!B87-E9"!O;B!T:&4@0V]M<&%N>28C,SD[<R!P<F]P<FEE=&%R>2!0<F]#
M96QL17@\<W5P/B9R96<[/"]S=7`^('!R;W1E:6X@97AP<F5S<VEO;B!S>7-T
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M:&4@(E-U8G-I9&EA<FEE<RXB/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#%I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E
M=&-H.B!N;W)M86PG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XW-6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;"<^($]N($UA>2`Q+"`R,#$R+"!T:&4@52Y3+B!&
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M;W)M(&]F(&=L=6-O8V5R96)R;W-I9&%S92`H1T-$*2!T:&%T('1H92!#;VUP
M86YY(&1E=F5L;W!E9"!U<VEN9R!0<F]#96QL17@N(%1A;&EG;'5C97)A<V4@
M86QF82!W87,@86QS;R!A<'!R;W9E9"!B>2!T:&4@27-R865L:2!-:6YI<W1R
M>2!O9B!(96%L=&@@*'1H92`B27-R865L:2!-3T@B*2!I;B!397!T96UB97(@
M,C`Q,BP@8GD@=&AE($)R87II;&EA;B!-:6YI<W1R>2!O9B!(96%L=&@@*'1H
M92`B0G)A>FEL:6%N($U/2"(I(&EN($UA<F-H(#(P,3,@86YD(&)Y('1H92!A
M<'!L:6-A8FQE(')E9W5L871O<GD@875T:&]R:71I97,@;V8@8V5R=&%I;B!O
M=&AE<B!C;W5N=')I97,N(%1A;&EG;'5C97)A<V4@86QF82!I<R!T:&4@9FER
M<W0@<&QA;G0@8V5L;"UB87-E9"!R96-O;6)I;F%N="!T:&5R87!E=71I8R!P
M<F]T96EN(&%P<')O=F5D(&)Y('1H92!&1$$@;W(@86YY(&]T:&5R(&UA:F]R
M(')E9W5L871O<GD@875T:&]R:71Y+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X(#!P="`U-BXW<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N
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M;&EX($QT9"X@86YD(%!F:7IE<B`H=&AE(")09FEZ97(@06=R965M96YT(BDN
M(%1H92!#;VUP86YY+"!T:')O=6=H(%!R;W1A;&EX($QT9"XL(&UA<FME=',@
M14Q%3%E33R!I;B!)<W)A96PL(&%N9"!I;B!"<F%Z:6P@=6YD97(@=&AE(&)R
M86YD(&YA;64@55!,65-/+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M(#!P="`Q:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86PG/B!0<F]T86QI>"!,=&0N(&=R86YT960@4&9I>F5R
M(&%N(&5X8VQU<VEV92P@=V]R;&1W:61E(&QI8V5N<V4@=&\@9&5V96QO<"!A
M;F0@8V]M;65R8VEA;&EZ92!T86QI9VQU8V5R87-E(&%L9F$@=6YD97(@=&AE
M(%!F:7IE<B!!9W)E96UE;G0L(&)U="!R971A:6YE9"!T:&]S92!R:6=H=',@
M:6X@27-R865L(&%N9"P@<VEN8V4@,C`Q-"P@:6X@0G)A>FEL("AS964@8F5L
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M;'D@=&AE<F5A9G1E<B!A;B!A9&1I=&EO;F%L("0U+C`@;6EL;&EO;B!C;&EN
M:6-A;"!D979E;&]P;65N="UR96QA=&5D(&UI;&5S=&]N92!P87EM96YT+B!4
M:&4@0V]M<&%N>2!R96-E:79E9"!D=7)I;F<@,C`Q,B!A;B!A9&1I=&EO;F%L
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M82!O;B!A(#0P)2!A;F0@-C`E(&)A<VES+"!R97-P96-T:79E;'DL(&5X8V5P
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M:6X@97AP96YS97,@86YD(&-O<W1S(&]F(&=O;V1S('-O;&0N/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B`F;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!F;VYT+7-I>F4M
M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^($]N($IU;F4@
M,3@L(#(P,3,L(%!R;W1A;&EX($QT9"X@96YT97)E9"!I;G1O(&$@4W5P<&QY
M(&%N9"!496-H;F]L;V=Y(%1R86YS9F5R($%G<F5E;65N="`H=&AE(")"<F%Z
M:6P@06=R965M96YT(BD@=VET:"!&=6YD829C8V5D:6P[)F%T:6QD93MO($]S
M=V%L9&\@0W)U>B`H(D9I;V-R=7HB*2P@86X@87)M(&]F('1H92!"<F%Z:6QI
M86X@34](+"!F;W(@=&%L:6=L=6-E<F%S92!A;&9A+B!4:&4@8G)A;F0@;F%M
M92!F;W(@=&%L:6=L=6-E<F%S92!A;&9A(&EN($)R87II;"!I<R!54$Q94T\\
M<W5P/E1-/"]S=7`^+B!4:&4@9FER<W0@=&5R;2!O9B!T:&4@=&5C:&YO;&]G
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M<'5R8VAA<V4@870@;&5A<W0@87!P<F]X:6UA=&5L>2`D-#`@;6EL;&EO;B!W
M;W)T:"!O9B!T86QI9VQU8V5R87-E(&%L9F$@<&5R('EE87(N($%D9&ET:6]N
M86QL>2P@4')O=&%L:7@@3'1D+B!I<R!N;W0@<F5Q=6ER960@=&\@8V]M<&QE
M=&4@=&AE(&9I;F%L('-T86=E(&]F('1H92!T96-H;F]L;V=Y('1R86YS9F5R
M('5N=&EL($9I;V-R=7H@<'5R8VAA<V5S(&%T(&QE87-T(&%P<')O>&EM871E
M;'D@)#(X,"!M:6QL:6]N('=O<G1H(&]F('1A;&EG;'5C97)A<V4@86QF82X@
M5&AE($)R87II;"!A9W)E96UE;G0@8F5C86UE(&5F9F5C=&EV92!D=7)I;F<@
M=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q-"X\+W`^(#QP('-T>6QE/3-$)T9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@1'5R:6YG('1H92!T:')E92!M
M;VYT:',@96YD960@36%R8V@@,S$L(#(P,30L('1H92!#;VUP86YY(')E8V]R
M9&5D(')E=F5N=65S(&]F(&%P<')O>&EM871E;'D@)#,N-2!M:6QL:6]N(&9R
M;VT@=&AE('-A;&4@;V8@<')O9'5C=',@=&\@1FEO8W)U>BX\+W`^(#QP('-T
M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA
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M(&$@;6%X:6UU;2!A;6]U;G0@;V8@87!P<F]X:6UA=&5L>2`D,3(N-2!M:6QL
M:6]N(&9R;VT@:71S(&YE="!P<F]F:71S("AA<R!D969I;F5D(&EN('1H92!L
M:6-E;G-E(&%N9"!S=7!P;'D@86=R965M96YT*2!P97(@>65A<BX@4&9I>F5R
M(&AA<R!A;'-O(&%G<F5E9"!T;R!P97)F;W)M(&-E<G1A:6X@=')A;G-I=&EO
M;F%L('-E<G9I8V5S(&EN($)R87II;"!O;B!0<F]T86QI>"!,=&0N)B,S.3MS
M(&)E:&%L9B!I;B!C;VYN96-T:6]N('=I=&@@=&AE('-U<'!L>2!O9B!T86QI
M9VQU8V5R87-E(&%L9F$@=&\@1FEO8W)U>BX\+W`^(#QP('-T>6QE/3-$)T9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3CH@,'!T(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
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M;G1I;"!T:&4@=&5R;6EN871I;VX@=&AE<F5O9BX\+W`^(#QP('-T>6QE/3-$
M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z
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M96X@9FEL960@:6X@82!N=6UB97(@;V8@8V]U;G1R:65S+CPO<#X@/'`@<W1Y
M;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D
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M('!R;V=R86US+B!/;B!*=6QY(#$S+"`R,#$P+"!T:&4@0V]M<&%N>2!A;FYO
M=6YC960@=&AA="!T:&4@1G)E;F-H(')E9W5L871O<GD@875T:&]R:71Y(&AA
M9"!G<F%N=&5D(&%N($%U=&]R:7-A=&EO;B!496UP;W)A:7)E(&0F(S,Y.U5T
M:6QI<V%T:6]N("A!5%4I+"!O<B!496UP;W)A<GD@075T:&]R:7IA=&EO;B!F
M;W(@57-E+"!F;W(@=&%L:6=L=6-E<F%S92!A;&9A(&9O<B!T:&4@=')E871M
M96YT(&]F($=A=6-H97(@9&ES96%S92X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[
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M:65S+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@
M)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I
M;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86PG/B!);B!A9&1I=&EO;B!T;R!T86QI9VQU8V5R87-E(&%L9F$L('1H92!#
M;VUP86YY(&ES('=O<FMI;F<@;VX@=&AE(&1E=F5L;W!M96YT(&]F(&-E<G1A
M:6X@;W1H97(@<')O9'5C=',@=7-I;F<@4')O0V5L;$5X+CPO<#X@/'`@<W1Y
M;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B!);B!A9&1I=&EO
M;B!T;R!T:&4@87!P<F]V86P@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&9O<B!M
M87)K971I;F<@:6X@=&AE(%5N:71E9"!3=&%T97,L($ES<F%E;"P@0G)A>FEL
M+"!-97AI8V\@86YD(&]T:&5R(&-O=6YT<FEE<RP@<W5C8V5S<V9U;"!C;VUP
M;&5T:6]N(&]F('1H92!#;VUP86YY)B,S.3MS(&1E=F5L;W!M96YT('!R;V=R
M86US(&%N9"!I=',@=')A;G-I=&EO;B!T;R!N;W)M86P@;W!E<F%T:6]N<R!I
M<R!D97!E;F1E;G0@=7!O;B!O8G1A:6YI;F<@=&AE(&9O<F5I9VX@<F5G=6QA
M=&]R>2!A<'!R;W9A;',@<F5Q=6ER960@=&\@<V5L;"!I=',@<')O9'5C=',@
M:6YT97)N871I;VYA;&QY+B!!('-U8G-T86YT:6%L(&%M;W5N="!O9B!T:6UE
M(&UA>2!P87-S(&)E9F]R92!T:&4@0V]M<&%N>2!A8VAI979E<R!A(&QE=F5L
M(&]F(')E=F5N=65S(&%D97%U871E('1O('-U<'!O<G0@:71S(&]P97)A=&EO
M;G,L(&EF(&%T(&%L;"P@86YD('1H92!#;VUP86YY(&5X<&5C=',@=&\@:6YC
M=7(@<W5B<W1A;G1I86P@97AP96YD:71U<F5S(&EN(&-O;FYE8W1I;VX@=VET
M:"!T:&4@<F5G=6QA=&]R>2!A<'!R;W9A;"!P<F]C97-S(&9O<B!E86-H(&]F
M(&ET<R!P<F]D=6-T(&-A;F1I9&%T97,@9'5R:6YG('1H96ER(')E<W!E8W1I
M=F4@9&5V96QO<&UE;G1A;"!P97)I;V1S+CPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`Q:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N
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M961I8W0@=&AE(&]U=&-O;64@;V8@=&AE<V4@86-T:79I=&EE<RX\+W`^(#QP
M('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.1$5.5#H@
M+3`N,C5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86PG/B`\<W1R;VYG/B9N8G-P.SPO<W1R;VYG/CPO<#X@/'1A8FQE
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M/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`P+C(U:6XG/CQS=')O;F<^8BX\+W-T<F]N9SX\+W1D/B`\=&0^/'-T
M<F]N9SY"87-I<R!O9B!0<F5S96YT871I;VX\+W-T<F]N9SX\+W1D/B`\+W1R
M/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P
M=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86PG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@
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M/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0[(&9O;G0M<VEZ
M92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N
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M92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S+"!F:6QE9"!B>2!T:&4@
M0V]M<&%N>2!W:71H('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM
M:7-S:6]N+B!4:&4@8V]M<&%R871I=F4@8F%L86YC92!S:&5E="!A="!$96-E
M;6)E<B`S,2P@,C`Q,R!H87,@8F5E;B!D97)I=F5D(&9R;VT@=&AE(&%U9&ET
M960@9FEN86YC:6%L('-T871E;65N=',@870@=&AA="!D871E+CPO<#X@/'`@
M<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE..B`P<'0@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
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M)U=)1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C(U:6XG/CQS=')O;F<^8RX\+W-T<F]N9SX\+W1D/B`\=&0^/'-T<F]N
M9SY.970@;&]S<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN
M.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;"<^($)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R('-H87)E("@B3%!3(BD@
M87)E(&-O;7!U=&5D(&)Y(&1I=FED:6YG(&YE="!L;W-S(&)Y('1H92!W96EG
M:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF
M(S,Y.W,@0V]M;6]N(%-T;V-K+"!P87(@=F%L=64@)#`N,#`Q('!E<B!S:&%R
M92`H=&AE(")#;VUM;VX@4W1O8VLB*2!O=71S=&%N9&EN9R!F;W(@96%C:"!P
M97)I;V0N/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I
M;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86PG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,"XW-6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;"<^($1I;'5T960@3%!3(&1O97,@;F]T(&EN8VQU9&4@-RPT-S$L
M-3<Q(&%N9"`Q."PY,3,L,34S('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=6YD
M97)L>6EN9R!O=71S=&%N9&EN9R!O<'1I;VYS(&%N9"!R97-T<FEC=&5D('-H
M87)E<R!O9B!#;VUM;VX@4W1O8VL@86YD('-H87)E<R!I<W-U86)L92!U<&]N
M(&-O;G9E<G-I;VX@;V8@=&AE(&-O;G9E<G1I8FQE(&YO=&5S("AI<W-U960@
M:6X@4V5P=&5M8F5R(#(P,3,I(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H(#,Q+"`R,#$S(&%N9"`R,#$T+"!R97-P96-T:79E;'DL(&)E8V%U
M<V4@=&AE(&5F9F5C="!W;W5L9"!B92!A;G1I+61I;'5T:79E+CPO<#X@/"$M
M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&(Q,V4T9F5?.&1F85\T-#0V7S@T
M,&1?,C<T.61D9C!A-V4Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V1B,3-E-&9E7SAD9F%?-#0T-E\X-#!D7S(W-#ED9&8P83=E,2]7;W)K<VAE
M971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY)3E9%3E1/4DE%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DE.5D5.5$]22453(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.
M5D5.5$]22453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M
M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4
M<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ
M+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\
M(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M)SX@/'-T<F]N9SY.3U1%(#(@+2!)3E9%3E1/4DE%4SPO<W1R;VYG/CPO<#X@
M/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[(&9O;G0M
M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@26YV
M96YT;W)Y(&%T($UA<F-H(#,Q+"`R,#$T(&%N9"!$96-E;6)E<B9N8G-P.S,Q
M+"`R,#$S(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO<#X@/'`@<W1Y
M;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B`F;F)S<#L\+W`^(#QT
M86)L92!S='EL93TS1"=724142#H@.3`E.R!"3U)$15(M0T],3$%04T4Z(&-O
M;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM3$5&5#H@,"XU:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G(&YO=W)A
M<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y
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M,B!N;W=R87`],T1N;W=R87`^1&5C96UB97(@,S$L/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!4
M15A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/C(P,30\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@1D].5"U714E'
M2%0Z(&)O;&0[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^,C`Q
M,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9#L@4$%$1$E.
M1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@;F]W<F%P/3-$;F]W<F%P
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^*%4N4RX@9&]L;&%R
M<R!I;B!T:&]U<V%N9',I/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\+W1R/B`\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S='EL93TS1"=72414
M2#H@-S8E.R!415A4+4%,24=..B!L969T)SY287<@;6%T97)I86QS/"]T9#X@
M/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^(#QT9"!S
M='EL93TS1"=724142#H@.24[(%1%6%0M04Q)1TXZ(')I9VAT)SXR+#`W-CPO
M=&0^(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q)1TXZ(&QE9G0G
M/B0\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#DE.R!415A4+4%,24=..B!R
M:6=H="<^,BPS-#(\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E.R!415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@=VAI
M=&4G/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^5V]R:R!I;B!P
M<F]G<F5S<SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXQ-S`\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/CDR/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B!R
M9V(H,C`T+#(U-2PR,#0I)SX@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/D9I;FES:&5D(&=O;V1S/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<^(#0L,C@Q/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`U
M+#4R,SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!4
M15A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@
M=VAI=&4G/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!4
M15A4+4%,24=..B!L969T)SY4;W1A;"!I;G9E;G1O<GD\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX@-BPU,C<\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N
M-7!T.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@
M-RPY-3<\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T
M.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE
M/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT+7-I
M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B!$
M=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-"P@
M=&AE($-O;7!A;GD@<F5C;W)D960@87!P<F]X:6UA=&5L>2`D,2XQ(&UI;&QI
M;VX@9F]R('=R:71E+61O=VX@;V8@:6YV96YT;W)Y('5N9&5R(&-O<W0@;V8@
M<F5V96YU97,N/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D9!25(@5D%,544@345!4U5214U%
M3E0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY&04E2(%9!3%5%($U%05-54D5-14Y4(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9!25(@5D%,
M544@345!4U5214U%3E0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\
M9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE/3-$)T9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T
M(#!P>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86PG/B`\<W1R;VYG/DY/5$4@,R`M($9!25(@5D%,544@345!4U5214U%
M3E0\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,S4N-#5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86PG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@,S4N-#5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86PG/B!4:&4@0V]M<&%N>2!M96%S=7)E<R!F86ER('9A
M;'5E(&%N9"!D:7-C;&]S97,@9F%I<B!V86QU92!M96%S=7)E;65N=',@9F]R
M(&9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S+B!&86ER('9A;'5E
M(&ES(&)A<V5D(&]N('1H92!P<FEC92!T:&%T('=O=6QD(&)E(')E8V5I=F5D
M(&9R;VT@=&AE('-A;&4@;V8@86X@87-S970L(&]R('!A:60@=&\@=')A;G-F
M97(@82!L:6%B:6QI='DL(&EN(&%N(&]R9&5R;'D@=')A;G-A8W1I;VX@8F5T
M=V5E;B!M87)K970@<&%R=&EC:7!A;G1S(&%T('1H92!M96%S=7)E;65N="!D
M871E+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`S-2XT-7!T
M.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`S
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M<F4@9&5S8W)I8F5D(&)E;&]W.CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X(#!P="`S-2XT-7!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`S-2XT-7!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
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M/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`S-2XT-7!T.R!F;VYT+7-I
M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`S-2XT-7!T.R!F
M;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^
M($QE=F5L(#(Z($]B<V5R=F%B;&4@<')I8V5S('1H870@87)E(&)A<V5D(&]N
M(&EN<'5T<R!N;W0@<75O=&5D(&]N(&%C=&EV92!M87)K971S+"!B=70@8V]R
M<F]B;W)A=&5D(&)Y(&UA<FME="!D871A+CPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`S-2XT-7!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE..B`P<'0@,'!X(#!P="`S-2XT-7!T.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^($QE=F5L(#,Z(%5N;V)S
M97)V86)L92!I;G!U=',@87)E('5S960@=VAE;B!L:71T;&4@;W(@;F\@;6%R
M:V5T(&1A=&$@:7,@879A:6QA8FQE+B!4:&4@9F%I<B!V86QU92!H:65R87)C
M:'D@9VEV97,@=&AE(&QO=V5S="!P<FEO<FET>2!T;R!,979E;"`S(&EN<'5T
M<RX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,S4N-#5P=#L@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG
M/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,S4N
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M(&EN(&ET<R!A<W-E<W-M96YT(&]F(&9A:7(@=F%L=64N/"]P/B`\<"!S='EL
M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#,U+C0U<'0[(&9O;G0M<VEZ92UA9&IU
M<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#,U+C0U<'0[(&9O;G0M<VEZ
M92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@5&AE(&9A
M:7(@=F%L=64@;V8@=&AE(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!I;F-L=61E
M9"!I;B!T:&4@=V]R:VEN9R!C87!I=&%L(&]F('1H92!#;VUP86YY(&ES('5S
M=6%L;'D@:61E;G1I8V%L(&]R(&-L;W-E('1O('1H96ER(&-A<G)Y:6YG('9A
M;'5E+CPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&(Q,V4T9F5?
M.&1F85\T-#0V7S@T,&1?,C<T.61D9C!A-V4Q#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V1B,3-E-&9E7SAD9F%?-#0T-E\X-#!D7S(W-#ED9&8P
M83=E,2]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY35$]#2R!44D%.4T%#5$E/3E,\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY35$]#
M2R!44D%.4T%#5$E/3E,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U1/0TL@5%)!3E-!0U1)3TY3/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G
M;65N="TM/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@[(&9O;G0M<VEZ92UA
M9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@/'-T<F]N9SY.
M3U1%(#0@+2!35$]#2R!44D%.4T%#5$E/3E,\+W-T<F]N9SX\+W`^(#QP('-T
M>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[(%1%6%0M24Y$14Y4.B`P
M:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-6EN.R!415A4+4E.1$5.5#H@,&EN.R!F;VYT+7-I>F4M861J=7-T.B!N
M;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^($1U<FEN9R!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!I<W-U
M960@82!T;W1A;"!O9B`U-2PS-C(@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!I
M;B!C;VYN96-T:6]N('=I=&@@=&AE(&5X97)C:7-E(&]F(&$@=&]T86P@;V8@
M-38L,3(R(&]P=&EO;G,@8GD@8V5R=&%I;B!E;7!L;WEE97,@;V8@=&AE($-O
M;7!A;GDN(%1H92!A9V=R96=A=&4@<')O8V5E9',@:6X@8V]N;F5C=&EO;B!W
M:71H('-U8V@@97AE<F-I<V5S('1O=&%L960@87!P<F]X:6UA=&5L>2`D-#,L
M,#`P+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X.R!F;VYT+7-I>F4M
M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^(#QS=')O;F<^
M)FYB<W`[/"]S=')O;F<^/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14M(/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-)1TY)1DE#04Y4($%#
M0T]53E1)3D<@4$],24-)15,@*%!O;&EC>2D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY324=.249)0T%.5"!!0T-/
M54Y424Y'(%!/3$E#2453(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B
M+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P
M.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N
M86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QT
M86)L92!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[(%=)1%1(.B`Q,#`E
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM5$]0.B`P<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9#X\
M<W1R;VYG/D=E;F5R86P\+W-T<F]N9SX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@5$585"U)3D1%3E0Z
M("TP+C(U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86PG/B!0<F]T86QI>"!":6]4:&5R87!E=71I8W,L($EN
M8RX@*&-O;&QE8W1I=F5L>2!W:71H(&ET<R!S=6)S:61I87)I97,L('1H92`B
M0V]M<&%N>2(I+"!A;F0@:71S('=H;VQL>2UO=VYE9"!S=6)S:61I87)Y+"!0
M<F]T86QI>"!,=&0N+"!A<F4@8FEO<&AA<FUA8V5U=&EC86P@8V]M<&%N:65S
M(&9O8W5S960@;VX@=&AE(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA
M=&EO;B!O9B!R96-O;6)I;F%N="!T:&5R87!E=71I8R!P<F]T96EN<R!B87-E
M9"!O;B!T:&4@0V]M<&%N>28C,SD[<R!P<F]P<FEE=&%R>2!0<F]#96QL17@\
M<W5P/B9R96<[/"]S=7`^('!R;W1E:6X@97AP<F5S<VEO;B!S>7-T96T@*")0
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M8G-I9&EA<FEE<RXB/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#%I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86PG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P
M<'0@,"XW-6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;"<^($]N($UA>2`Q+"`R,#$R+"!T:&4@52Y3+B!&;V]D(&%N
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M(&=L=6-O8V5R96)R;W-I9&%S92`H1T-$*2!T:&%T('1H92!#;VUP86YY(&1E
M=F5L;W!E9"!U<VEN9R!0<F]#96QL17@N(%1A;&EG;'5C97)A<V4@86QF82!W
M87,@86QS;R!A<'!R;W9E9"!B>2!T:&4@27-R865L:2!-:6YI<W1R>2!O9B!(
M96%L=&@@*'1H92`B27-R865L:2!-3T@B*2!I;B!397!T96UB97(@,C`Q,BP@
M8GD@=&AE($)R87II;&EA;B!-:6YI<W1R>2!O9B!(96%L=&@@*'1H92`B0G)A
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M871O<GD@875T:&]R:71Y+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X
M(#!P="`U-BXW<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N
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M9"X@86YD(%!F:7IE<B`H=&AE(")09FEZ97(@06=R965M96YT(BDN(%1H92!#
M;VUP86YY+"!T:')O=6=H(%!R;W1A;&EX($QT9"XL(&UA<FME=',@14Q%3%E3
M3R!I;B!)<W)A96PL(&%N9"!I;B!"<F%Z:6P@=6YD97(@=&AE(&)R86YD(&YA
M;64@55!,65-/+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q
M:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86PG/B!0<F]T86QI>"!,=&0N(&=R86YT960@4&9I>F5R(&%N(&5X
M8VQU<VEV92P@=V]R;&1W:61E(&QI8V5N<V4@=&\@9&5V96QO<"!A;F0@8V]M
M;65R8VEA;&EZ92!T86QI9VQU8V5R87-E(&%L9F$@=6YD97(@=&AE(%!F:7IE
M<B!!9W)E96UE;G0L(&)U="!R971A:6YE9"!T:&]S92!R:6=H=',@:6X@27-R
M865L(&%N9"P@<VEN8V4@,C`Q-"P@:6X@0G)A>FEL("AS964@8F5L;W<I+B!4
M:&4@0V]M<&%N>2!H87,@86=R965D('1O(&$@<W!E8VEF:6,@86QL;V-A=&EO
M;B!B971W965N(%!R;W1A;&EX($QT9"X@86YD(%!F:7IE<B!R96=A<F1I;F<@
M=&AE(')E<W!O;G-I8FEL:71I97,@9F]R('1H92!C;VYT:6YU960@9&5V96QO
M<&UE;G0@969F;W)T<R!F;W(@=&%L:6=L=6-E<F%S92!A;&9A+B!4;R!D871E
M+"!T:&4@0V]M<&%N>2!H87,@<F5C96EV960@86X@=7!F<F]N="!P87EM96YT
M(&]F("0V,"XP(&UI;&QI;VX@:6X@8V]N;F5C=&EO;B!W:71H('1H92!E>&5C
M=71I;VX@;V8@=&AE(%!F:7IE<B!!9W)E96UE;G0@86YD('-H;W)T;'D@=&AE
M<F5A9G1E<B!A;B!A9&1I=&EO;F%L("0U+C`@;6EL;&EO;B!C;&EN:6-A;"!D
M979E;&]P;65N="UR96QA=&5D(&UI;&5S=&]N92!P87EM96YT+B!4:&4@0V]M
M<&%N>2!R96-E:79E9"!D=7)I;F<@,C`Q,B!A;B!A9&1I=&EO;F%L("0R-2XP
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M(#0P)2!A;F0@-C`E(&)A<VES+"!R97-P96-T:79E;'DL(&5X8V5P="!W:71H
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M96YS97,@86YD(&-O<W1S(&]F(&=O;V1S('-O;&0N/"]P/B`\<"!S='EL93TS
M1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86PG/B`F;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^($]N($IU;F4@,3@L(#(P
M,3,L(%!R;W1A;&EX($QT9"X@96YT97)E9"!I;G1O(&$@4W5P<&QY(&%N9"!4
M96-H;F]L;V=Y(%1R86YS9F5R($%G<F5E;65N="`H=&AE(")"<F%Z:6P@06=R
M965M96YT(BD@=VET:"!&=6YD829C8V5D:6P[)F%T:6QD93MO($]S=V%L9&\@
M0W)U>B`H(D9I;V-R=7HB*2P@86X@87)M(&]F('1H92!"<F%Z:6QI86X@34](
M+"!F;W(@=&%L:6=L=6-E<F%S92!A;&9A+B!4:&4@8G)A;F0@;F%M92!F;W(@
M=&%L:6=L=6-E<F%S92!A;&9A(&EN($)R87II;"!I<R!54$Q94T\\<W5P/E1-
M/"]S=7`^+B!4:&4@9FER<W0@=&5R;2!O9B!T:&4@=&5C:&YO;&]G>2!T<F%N
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M<V4@870@;&5A<W0@87!P<F]X:6UA=&5L>2`D-#`@;6EL;&EO;B!W;W)T:"!O
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M<G-T('%U87)T97(@;V8@,C`Q-"X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T
M(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L)SX@1'5R:6YG('1H92!T:')E92!M;VYT:',@
M96YD960@36%R8V@@,S$L(#(P,30L('1H92!#;VUP86YY(')E8V]R9&5D(')E
M=F5N=65S(&]F(&%P<')O>&EM871E;'D@)#,N-2!M:6QL:6]N(&9R;VT@=&AE
M('-A;&4@;V8@<')O9'5C=',@=&\@1FEO8W)U>BX\+W`^(#QP('-T>6QE/3-$
M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@5&\@9F%C:6QI=&%T92!T
M:&4@87)R86YG96UE;G0@=VET:"!&:6]C<G5Z+"!09FEZ97(@86UE;F1E9"!I
M=',@97AC;'5S:79E(&QI8V5N<V4@86YD('-U<'!L>2!A9W)E96UE;G0@=VET
M:"!0<F]T86QI>"!,=&0N(%1H92!A;65N9&UE;G0@<')O=FED97,@9F]R('1H
M92!T<F%N<V9E<B!O9B!T:&4@8V]M;65R8VEA;&EZ871I;VX@86YD(&]T:&5R
M(')I9VAT<R!T;R!T86QI9VQU8V5R87-E(&%L9F$@:6X@0G)A>FEL(&)A8VL@
M=&\@4')O=&%L:7@@3'1D+B!!<R!C;VYS:61E<F%T:6]N(&9O<B!T:&4@=')A
M;G-F97(@;V8@=&AE(&-O;6UE<F-I86QI>F%T:6]N(&%N9"!S=7!P;'D@<FEG
M:'1S+"!0<F]T86QI>"!,=&0N(&%G<F5E9"!T;R!P87D@4&9I>F5R(&$@;6%X
M:6UU;2!A;6]U;G0@;V8@87!P<F]X:6UA=&5L>2`D,3(N-2!M:6QL:6]N(&9R
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M87-E(&%L9F$@=&\@1FEO8W)U>BX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T
M(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P
M<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
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M:&4@=&5R;6EN871I;VX@=&AE<F5O9BX\+W`^(#QP('-T>6QE/3-$)T9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[
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M960@:6X@82!N=6UB97(@;V8@8V]U;G1R:65S+CPO<#X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[
M(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS
M1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@
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M86US+B!/;B!*=6QY(#$S+"`R,#$P+"!T:&4@0V]M<&%N>2!A;FYO=6YC960@
M=&AA="!T:&4@1G)E;F-H(')E9W5L871O<GD@875T:&]R:71Y(&AA9"!G<F%N
M=&5D(&%N($%U=&]R:7-A=&EO;B!496UP;W)A:7)E(&0F(S,Y.U5T:6QI<V%T
M:6]N("A!5%4I+"!O<B!496UP;W)A<GD@075T:&]R:7IA=&EO;B!F;W(@57-E
M+"!F;W(@=&%L:6=L=6-E<F%S92!A;&9A(&9O<B!T:&4@=')E871M96YT(&]F
M($=A=6-H97(@9&ES96%S92X\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@,6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;"<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X(#!P="`P+C<U:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
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M<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[(&9O;G0M<VEZ
M92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B!)
M;B!A9&1I=&EO;B!T;R!T86QI9VQU8V5R87-E(&%L9F$L('1H92!#;VUP86YY
M(&ES('=O<FMI;F<@;VX@=&AE(&1E=F5L;W!M96YT(&]F(&-E<G1A:6X@;W1H
M97(@<')O9'5C=',@=7-I;F<@4')O0V5L;$5X+CPO<#X@/'`@<W1Y;&4],T0G
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[
M(&9O;G0M<W1R971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS
M1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@
M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B!);B!A9&1I=&EO;B!T;R!T
M:&4@87!P<F]V86P@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&9O<B!M87)K971I
M;F<@:6X@=&AE(%5N:71E9"!3=&%T97,L($ES<F%E;"P@0G)A>FEL+"!-97AI
M8V\@86YD(&]T:&5R(&-O=6YT<FEE<RP@<W5C8V5S<V9U;"!C;VUP;&5T:6]N
M(&]F('1H92!#;VUP86YY)B,S.3MS(&1E=F5L;W!M96YT('!R;V=R86US(&%N
M9"!I=',@=')A;G-I=&EO;B!T;R!N;W)M86P@;W!E<F%T:6]N<R!I<R!D97!E
M;F1E;G0@=7!O;B!O8G1A:6YI;F<@=&AE(&9O<F5I9VX@<F5G=6QA=&]R>2!A
M<'!R;W9A;',@<F5Q=6ER960@=&\@<V5L;"!I=',@<')O9'5C=',@:6YT97)N
M871I;VYA;&QY+B!!('-U8G-T86YT:6%L(&%M;W5N="!O9B!T:6UE(&UA>2!P
M87-S(&)E9F]R92!T:&4@0V]M<&%N>2!A8VAI979E<R!A(&QE=F5L(&]F(')E
M=F5N=65S(&%D97%U871E('1O('-U<'!O<G0@:71S(&]P97)A=&EO;G,L(&EF
M(&%T(&%L;"P@86YD('1H92!#;VUP86YY(&5X<&5C=',@=&\@:6YC=7(@<W5B
M<W1A;G1I86P@97AP96YD:71U<F5S(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@
M<F5G=6QA=&]R>2!A<'!R;W9A;"!P<F]C97-S(&9O<B!E86-H(&]F(&ET<R!P
M<F]D=6-T(&-A;F1I9&%T97,@9'5R:6YG('1H96ER(')E<W!E8W1I=F4@9&5V
M96QO<&UE;G1A;"!P97)I;V1S+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X(#!P="`Q:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N
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M=&AE(&]U=&-O;64@;V8@=&AE<V4@86-T:79I=&EE<RX\+W`^(#QP('-T>6QE
M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!415A4+4E.1$5.5#H@+3`N,C5I
M;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86PG/B`\<W1R;VYG/B9N8G-P.SPO<W1R;VYG/CPO<#X@/"$M+45N9$9R86=M
M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G
M;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM5$]0.B`P<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T
M;W`G/B`\=&0^/'-T<F]N9SY"87-I<R!O9B!0<F5S96YT871I;VX\+W-T<F]N
M9SX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P
M<'@@,'!T(#4V+C=P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86PG/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)T9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@,"XW-6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
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M;"!Y96%R+CPO<#X@/'`@<W1Y;&4],T0G1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@,'!X(#!P="`U-BXW
M<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86PG/B!4:&5S92!U;F%U9&ET960@8V]N9&5N<V5D(&-O;G-O;&ED
M871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!S:&]U;&0@8F4@<F5A9"!I;B!C
M;VYJ=6YC=&EO;B!W:71H('1H92!A=61I=&5D(&-O;G-O;&ED871E9"!F:6YA
M;F-I86P@<W1A=&5M96YT<R!I;B!T:&4@06YN=6%L(%)E<&]R="!O;B!&;W)M
M(#$P+4L@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S+"!F
M:6QE9"!B>2!T:&4@0V]M<&%N>2!W:71H('1H92!396-U<FET:65S(&%N9"!%
M>&-H86YG92!#;VUM:7-S:6]N+B!4:&4@8V]M<&%R871I=F4@8F%L86YC92!S
M:&5E="!A="!$96-E;6)E<B`S,2P@,C`Q,R!H87,@8F5E;B!D97)I=F5D(&9R
M;VT@=&AE(&%U9&ET960@9FEN86YC:6%L('-T871E;65N=',@870@=&AA="!D
M871E+CPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T
M(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@
M/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM5$]0.B`P<'0[(&9O;G0M<VEZ92UA9&IU
M<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0^/'-T<F]N9SY.970@;&]S<R!P
M97(@<VAA<F4\+W-T<F]N9SX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL
M93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B`F;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!F;VYT+7-I>F4M
M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^($)A<VEC(&%N
M9"!D:6QU=&5D(&QO<W,@<&5R('-H87)E("@B3%!3(BD@87)E(&-O;7!U=&5D
M(&)Y(&1I=FED:6YG(&YE="!L;W-S(&)Y('1H92!W96EG:'1E9"!A=F5R86=E
M(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S,Y.W,@0V]M;6]N
M(%-T;V-K+"!P87(@=F%L=64@)#`N,#`Q('!E<B!S:&%R92`H=&AE(")#;VUM
M;VX@4W1O8VLB*2!O=71S=&%N9&EN9R!F;W(@96%C:"!P97)I;V0N/"]P/B`\
M<"!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86PG/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;"<^($1I
M;'5T960@3%!3(&1O97,@;F]T(&EN8VQU9&4@-RPT-S$L-3<Q(&%N9"`Q."PY
M,3,L,34S('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@=6YD97)L>6EN9R!O=71S
M=&%N9&EN9R!O<'1I;VYS(&%N9"!R97-T<FEC=&5D('-H87)E<R!O9B!#;VUM
M;VX@4W1O8VL@86YD('-H87)E<R!I<W-U86)L92!U<&]N(&-O;G9E<G-I;VX@
M;V8@=&AE(&-O;G9E<G1I8FQE(&YO=&5S("AI<W-U960@:6X@4V5P=&5M8F5R
M(#(P,3,I(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R
M,#$S(&%N9"`R,#$T+"!R97-P96-T:79E;'DL(&)E8V%U<V4@=&AE(&5F9F5C
M="!W;W5L9"!B92!A;G1I+61I;'5T:79E+CPO<#X@/'`@<W1Y;&4],T0G1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M.B`P<'0@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;"<^(#QS=')O;F<^)FYB<W`[/"]S=')O;F<^/"]P/B`\(2TM
M16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DE.5D5.5$]22453("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^24Y614Y43U))15,@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YV96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@
M/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S='EL93TS1"=&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#`N-6EN.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;"<^($EN=F5N=&]R>2!A="!-87)C:"`S,2P@,C`Q
M-"!A;F0@1&5C96UB97(F;F)S<#LS,2P@,C`Q,R!C;VYS:7-T960@;V8@=&AE
M(&9O;&QO=VEN9SH\+W`^(#QP('-T>6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,"XU:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
M;F]R;6%L)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G5TE$5$@Z(#DP
M)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4Q%1E0Z(#`N-6EN
M.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R
M87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M.R!415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO
M=W)A<#Y-87)C:"`S,2P\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%1%6%0M04Q)
M1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D1E8V5M
M8F5R(#,Q+#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!&3TY4+5=%24=(5#H@8F]L9#L@5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS
M<&%N/3-$,CXR,#$T/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B
M;VQD.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[($9/3E0M5T5)1TA4.B!B;VQD.R!415A4+4%,24=..B!C
M96YT97(G(&-O;'-P86X],T0R/C(P,3,\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO
M=&0^(#PO='(^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX@/'1D(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#8@;F]W<F%P
M/3-$;F]W<F%P/BA5+E,N(&1O;&QA<G,@:6X@=&AO=7-A;F1S*3PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R
M87`^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"DG/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#<V)3L@5$585"U!3$E'3CH@;&5F
M="<^4F%W(&UA=&5R:6%L<SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24G
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,24[(%1%6%0M04Q)
M1TXZ(&QE9G0G/B0\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#DE.R!415A4
M+4%,24=..B!R:6=H="<^,BPP-S8\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#$E.R!415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#$E.R!415A4+4%,24=..B!L969T)SXD/"]T9#X@/'1D('-T>6QE/3-$)U=)
M1%1(.B`Y)3L@5$585"U!3$E'3CH@<FEG:'0G/C(L,S0R/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)3L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T
M9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/E=O<FL@:6X@<')O9W)E<W,\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3<P/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXY
M,CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*2<^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SY&:6YI<VAE9"!G;V]D<SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/B`T+#(X,3PO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4%,24=..B!L969T
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX@-2PU,C,\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0M0T],3U(Z('=H:71E)SX@/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^5&]T86P@
M:6YV96YT;W)Y/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!R:6=H="<^(#8L-3(W/"]T9#X@/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^("0\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!R:6=H="<^(#<L.34W/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U!3$E'3CH@;&5F="<^)FYB
M<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE..B`P<'0@
M,'!X(#!P="`P+C5I;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86PG/B`F;F)S<#L\+W`^(#PA+2U%;F1&<F%G;65N="TM
M/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%05)!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY324=.
M249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A$971A:6QS*2`H55-$("0I
M/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#,^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,#D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-#QB<CY0<F]T86QI>"!":6\@5&AE<F%P975T:6-S($EN8V]R<&]R
M871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q-#QB<CY09FEZ97(@26YC;W)P;W)A=&EO;B!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#$X
M+"`R,#$S/&)R/E!R;W1A;&EX($QT9"X@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P.3QB<CY5<&]N($9I
M;&EN9R!O9B!0961I871R:6,@26YV97-T:6=A=&EO;B!0;&%N('1O($5-02!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$R/&)R/E5P;VX@1D1!($%P<')O=F%L(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(%-U8G-I9&EA<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!!9W)E96UE;G0L('5P9G)O;G0@
M<&%Y;65N="!R96-E:79E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N="!T
M<FEG9V5R960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!F:7IE<B!!9W)E96UE;G0L(&9U='5R92!R979E;G5E<R!A
M;F0@97AP96YS92!S:&%R:6YG('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5P<&QY(&-O
M;6UI=&UE;G0@9F]R(&5N=&ET;&5D(')I9VAT<R!T;R!B92!R96-E:79E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQI8V5N<V4@86YD('-U<'!L>2!A9W)E96UE;G0@<&]T96YT:6%L(&9U='5R
M92!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$R+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=7!P;'D@86=R965M96YT(&UA>&EM=6T@8V]N<VED97)A
M=&EO;B!P87EM96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y2979E;G5E(&9R;VT@<V%L92!O9B!P<F]D=6-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#4P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E('!E<B!S:&%R93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M=&EO;G,@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K(&YO="!I;F-L=61E9"!I
M;B!D:6QU=&5D($Q04R!B96-A=7-E('1H92!E9F9E8W0@=V]U;&0@8F4@86YT
M:2UD:6QU=&EV93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L
M.3$S+#$U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<L-#<Q+#4W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?9&(Q,V4T9F5?.&1F85\T-#0V7S@T,&1?,C<T
M.61D9C!A-V4Q#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1B,3-E
M-&9E7SAD9F%?-#0T-E\X-#!D7S(W-#ED9&8P83=E,2]7;W)K<VAE971S+U-H
M965T,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5$2$%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DE.5D5.5$]22453("A38VAE9'5L92!O9B!);G9E;G1O<GD@0V]M<&]N
M96YT<RD@*$1E=&%I;',I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY)3E9%3E1/4DE%4R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%W
M(&UA=&5R:6%L<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M+#`W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,BPS-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=O<FL@:6X@<')O8V5S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9I;FES:&5D(&=O;V1S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(X,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-3(S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@:6YV
M96YT;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4R-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M.34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G9E;G1O<GD@=W)I=&4M9&]W;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3$]!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY35$]#2R!44D%.4T%#5$E/3E,@*$1E=&%I;',I("A54T0@)"D\8G(^26X@
M5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES
M92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P
M<F]C965D<R!F<F]M(&5X97)C:7-E(&]F(&]P=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#97)T86EN
M($5M<&QO>65E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S("AI;B!S
M:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-2PS-C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#87-H('!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(&5X97)C:7-E(&]F(&]P=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V+#$R,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#0N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`X+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,38N:'1M;"(O
M/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7V1B,3-E-&9E7SAD9F%?-#0T
7-E\X-#!D7S(W-#ED9&8P83=E,2TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <strong>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.5in; font-size-adjust: none; font-stretch: normal"> <strong>&nbsp;</strong></p> <table style="MARGIN-BOTTOM: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>a.</strong></td> <td><strong>General</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. ("Pfizer"), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the "Pfizer Agreement"). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Funda&ccedil;&atilde;o Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO<sup>TM</sup>. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil agreement became effective during the first quarter of 2014.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> During the three months ended March 31, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.&#39;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in; font-size-adjust: none; font-stretch: normal"> <strong>&nbsp;</strong></p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>b.</strong></td> <td><strong>Basis of Presentation</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>c.</strong></td> <td><strong>Net loss per share</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Diluted LPS does not include 7,471,571 and 18,913,153 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the three months ended March 31, 2013 and 2014, respectively, because the effect would be anti-dilutive.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001144204-14-028653-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-14-028653-xbrl.zip
M4$L#!!0````(`.Z#J$3%@%9";BX``&CL`0`0`!P`<&QX+3(P,30P,S,Q+GAM
M;%54"0`#H.EK4Z#I:U-U>`L``00E#@``!#D!``#L/6EW&D>VW]\Y[S]4>,D<
M^1Q`+`(D.9X9K,76/%EH))1)/A;=U5!Q;ZFJMD1^_=Q;5;U!@Y"%9$=')[$-
MW;7<?:N%G_]Q%_CD"Q.21^&[6KO9JA$6.I'+P^F[VLUU8WA]='96(U+1T*5^
M%+)WM3"J_>/O__L_/__0:!P)1A5SR61.?N&AHE-&3KD/?279J?UR6GO3:-B6
ML8C<Q(&F44@ZK?9>H]5KM`;DGZ3=.6SUR.4GT_)N(GP"((7R$(;Y_*XV4RH^
MW-V]O;UMXKMF)*:[G5:KNXNO)U2RFFT>^W>EUC"AHCZ_:SI1L(LSMKK==MH8
MA^)K!N<A(NQD@]_-5."7VM]V=>OVP<'!KGZ;-5V"N]04WZ9-79;#H.>7S&E.
MHR^[\`)![C9:[48.="(;4TKCK(M'Y42/;%]4=.$RVNNT!^LP-2ULATU(`FPB
MY&?$XU`Z,Q;0*^81C=>AFL<@'Y('L8^DT\]F@GGO:L"=1LJ$YIUT:V37C`.H
M'@X#%KKP1YWZ=$JX^ZY6>M(<''3ZS5;^7XTX4:C8G;K"H3T1!0TC4FW\7T7V
M6Q<(L=07>O_=H[YD/^\N39U#=)0(@0^Y=*C_&Z/B)'2/0=(U<*M>;AW.1J/=
M@7<&TE6SYD`?1TX29$TNF>"1>PK/I(9ZY=NM@_UO"_'*&5>!C%BM`CA[MW5P
M46NJ`,YF7`;7X%*4B<HW3P&J?5T&N#3K,KAC4,L2E/A@Z\"U6XU_E\'":7)H
M3D+%U?P(G@OJGX4NN_M_-M=@5;[9.GRM5JO=:O4[^Y9XE;,N@1L%011>J\CY
M?#VC@LE1HK0O!!]7A'U-,P1F?S4B5#8BKY&YQ/92<^R0A-RTEGKT&G&9PP,P
M8^]J@-E!M]_J[_5;);S60+2()+AL)HY`=*:1*'*D]'SK_!@Z#H/Q=?R@9RJ"
M7YIZ$=XK-N42N!:J"QJP`L#E%UN'^/)J-!Z>G_U*WI^-QA]/KH:7)S?CLZ/K
M.CF[.&H6P2\#DL,_%A09<#T/)I&O`2\]V3[$Y[\:L$K3&'C`)1\>43GSF90G
M=TPX7+*1IR5F%"L(!XT97M]DVQ#GDGYS?5P4\T87+`P$(B#D]P.^900']R/8
M+2'8S1$</`3!SO[#$8Q\GTXB4"/^A0T%B-R4:9<@(H\KK?K@'1QF@G.-[T-Z
M(`I[S4ZW=[#?['7W^]54*-JP%/$]:%;5+\,_3@0K$J`-)KJY9[%_"(S?@!C]
MKR3&8K_UQ.@_BAC'+!8P'D6!&0:14/Q/\SETAU(R=1;$E`L<R,0&&S=_5IW?
M+^C$YB`^$Q6>S3``T1Y%A0^4A^>1E"/LD81*GB80\+AGX163,7/4R#N!G"V:
M,W;%IS,E;^((7BDN6$:9QPWQO'XBH]7C@/[.Z/=LTM8^V#X!,1:2(*)7C`>3
M1$C]7EXQAX%1<T?"?*(3W]CE![1_5M'JM/9[.7$V!_+9*/%\L<I>M_TX2IR%
MCF!4LK/PG-,)][GB3)Y&`OQ:S(2:7_HP*(QY\D?"XTR/'MSK>4U/-W=7#X;T
MFY#FV01FO]W;!FG..40ZDL'+ZR2._?EP*I@)AR(%?W/JGR8*HJE+.L>G[V$6
M=Q1>,!LNF9C_L8,`\MU>LS-H[Z^+!`OTZY?HUV^T]\T0K<I!UB=!2,:4D(]%
M)*?K)\BXI8K"M*FFT^)#!'H`D6R_U6GVVOW.>KP[);GI(-[=EAFB53G(6GMC
MT+9X+P*6XW%!$=^1-XJQMH#)TF7D<V<^!NC>^Y!":<3N;;7U5/QOOGK[0Z-Q
M/#H:_W9Y0G#)@%S>O#\_.R*UQN[N?[I'N[O'XV/RZ\?QIW/2;K8(Y.RAY`@<
M]7=W3RYJI&)587QEEA_:V-E^;*A"SZ:KW!II-/XV56\1!I=_P8^D\-F"=JVH
M4*>"3I&@IH-NI;0ODFKN,Y"(X=6'LXO&^]%X//IT2%HQ-/K/V?'XXR$!=_#3
M6W(ZNACCYUB1,0^8)!?LEEQ%`0WKYD&=7#/!O;?$#C4>7=IQ/"!P0_(_68.Z
MOR=2'9(0.)P^5X(I9X;/!$@%L(/YOHRIHU>J6N9[3%W7?L_!%RGLOYQ<C<^.
MAN>-X?G9AXM#HJ*XT,Q-20$S1>$4OWU@(8B'CP]W\Z?ZJVE.S&=1^(S$RK[&
MZ=0/I8JF"/RYT_^V>?B6C$]^'3?.+HY/<*0&*%`/GSZ(9@8N&L1OPXF,#2+Q
MMH$%#?]*R"[MDAUYSZ/Q#"@?LT1Q!Z8#?]$D.PXDPA!S0D3AS\DM5S."]EPF
M$\E=3@5'P-2,$<CJ(0<*Y[4W=4)#5[>ZG4'G>2.Z#9F;=YG7\TG/E=N$]H*1
M"8]BR*H#ZNCYJ0^JCP/"!`"]DTBSC(E3N0R`B8P+QJF@88`%&QC19&4D\@BD
M:U$PX2'X-.R4XD5PB9+Q4!)<Q\R&M,!K-OU?]^"MQ'8Q8`?J.4=PCT#03^ZT
MI"::>[JI8%/#4/LP'9VP.\@7):[O$CF7B@5DIY:-4GO3!.(".V-X,6&"=%JM
M@P6B`,Z03KJ`7X30KR(EP<Q`:!1\>BL1<?P,O@8Z@3]W96'<]\U?@-@`'1C5
M$'D*T&F.8I>3!,,`&I)/S.6@WT#VX92%SAP@/_DTK+TA%'P=,$9W`SP=P`\'
M*W6^">%MDXPK2:INHY+@:+X+YC$A`"D5D9*L`0)(22J->%T7.C9K3Z-%[9>F
MW"-@)YV3=AV7_SM&46^:UTUR&D6NUIUCD4S)T`UXJ&OGFKD[M=-CRW`1?4'6
M@/A,_<0!+9*,4-^C*)[`_-^-%-57Z)#'A53Y,"[.9?8DJ#HR%@2&A7]"+`%2
M$/N@^5JEC;:"W('G>*,GTN(-CJ"AF`B(POT/NB5(.W437Y$8`,?<QX@S10'W
MN-8?D)AI&$EN5`/7Y-KD`TT<U"F72XR'05R7\8,.M&@#ZB6#@LJ)`V(G4`3!
M)@+F<+'WSH>CXS<`,55%HJ0V"R!*)"YC9<:@<O9;)(XOHYQVD[D>[DP*RGQ.
M/AE^S1&(CXSZ@/6.5I.LP>@C<)"7K0R*@!WHO:!_0@J`^KYJJ$*3=+!/5#@S
M'*BKA<>.90T#!BQ@$!.?*ES2HHF:14(G&3@TH*<H#&',F8-U#:W**XB/XQKQ
MB3$MT8%&PYCL>RS[$LU`F`D($7+!3![0W^%[!:CSYM,H<*_?'#PXUOK.34LU
MVR8,A3N@XC/#)4;K'L`KX#>(=14`F+NLB4`I"G$]\>3\Y/RWZY'&%^R0"W,#
M^RX]`$G82*1FOF&`46UNEN.`&()KB":UL4&AX&X.%+MS?-#%+V!:3#ZG15KJ
MC([0-*5#*+2H,W7+6+C@I/&-A='HC/V2983HZ@O.$"$743*=+49`AF(R)0/"
M:#39!E.A5=AJXMU<8J<G$MX7YQ3++)QB%8UE;$27E`I&G=Q&PG=O06HR&8$H
MQ9KRI="35?G)G%^+H@&F.%%@A=`JHH^=1=!'Z()NSGZ<I$[`8SA,[^"K%T1A
M1S*0`@#EMBQD9(;>`Z?1014E6#3F'EA(ZD.6;33C7GD&\TB%WG&!P$,P&T.^
MSM.R4>:6,3_G88*>MA"5,P_>*]MJB2@`+5`1;$%)D378PA8OD0])#`E_B,Y]
MGGK['_N0UI.`^S[BL"*297?,2=(TH(KR1M'!XBM?>PB()SQE>(^IK$GAR8^]
MPE2.#UX2DY("E@W!?+V1(DCK(BFH979D.+F)0'JB'UZ<JU.<;&F\59B"9RN8
M/^/W8#1$N\(Z5]AB`VAN[*R-E,OQB]X#8V:VY,2W(=-]=(D/6.U'$EEHJ`*B
MMW&R5@$NO*!DK_63[M2'?\'Y<UG7DICF"'7458AO#%SV33KQ`ERL!-DR%*G(
MEE3/JAH8`I22$D$RQ<W]B#'BR&*CQCK+`Z%Q,,Y(-:F"9"6?2'/[H$53)TEI
M\&2U.@%=!(L4Z#$,6ZE9*3*,"R#FGR#I,=*&]E@X`T.'W)'4M]J;C@FI*EHV
M:;DCE0[7II`@0.O(=U_=RL:YUK\2T-GVOLZVNHL)/;"4"1U^:*-\;0,-(/J8
M.;,P\J/IW)0?O9*Q*@;CQ<#""#TN#5)-%,>!Q-TW=0D0-Q]"J(B,Y"WUW8@<
MB>1/S.MXY,`G4Z,!R0I2$UF*]>NK[78Y[JAN5G!1$!&:V*10.!E_*E9,S)@F
MTM?9G05(Y311*4U@-`G6)"1S1H61UY+&I'+/[A3#!5,-7]G0>J"G#>RN)]-Q
M80@:Q<#)&JL0^Q"XKH+``+L"-#";?!H:\X)`>!YS;`SL10G60^G4:AE',V-A
M1&N5C@*?+8>,;Z58:55&2.1G\`YHP_Y(N+"XE3DWA:1'A":%1EQ"$%/0?UV)
MBV[!K=`P\:BCC!>"3^C+P892TP1TG:7&P$2=,(H]08!!!"@!F`O,\NID!O:-
M_)%0.X`U'!9G-(4VC*XT[4WP0176+L4<PP`TSUQ96QTGD'3JSHKXD+#;BL(=
M#\":PR0_[N6N$P(V4(IJCV+=;YY98CW*B)(5N@P:;;FQ5`741GKJ5CF(O,"'
M+0(8`U%PIB899A+K+U9+<?(P4B4`2G+K<11T+6WKE`F\!2AHBE&*@ER)0V=_
M(R2,BECU+V11S$&#D0O($C-`F@0&83`J!KJO7F<SR(YS.D)J"0E!`$UGDACC
M8NHU75/_VZLO!#!.)%Q=3P&;FI@JS0+3N\U>QG0=1.``&$)@6UO)DP6S]<JU
M#8LG46I_J=5:FF\QM([=4+2>)::!82F:Z@U+%R9:+QD/'>ZGQV_R<#]U)IEU
ML(9C.4S&B4P5S::JZ+_6A0`3ZGS&1F4XAE([*)C<UIP?!H%%U8"P:"#SU!?2
MIXQ\X/Y`KI/`1LH5PM[N+$H[TKH8K^]0=/.>#OMM.K6.`6\*%MV",<L*NSF0
M3.AR<AJ/%]>1(=X17V`&62!HM)"T%S+`"9L!]5=EB^M\\JL./[*,M!@2@.11
MXH$]9A@FX:/>3ZE,6Y%R0``DF>KE;ALH6A9#:Q0W\.!FK2$7@V(1DTI(B)5=
M3"B`4HH&%O,&]/0RH29&Q-C8K/$5/?6JPI")D++RQE+/6U`=($*`0LQ#Z^LK
M4_,EH$PP8D(5$4``HR57Y[^1]RJ0FT%VEF<Z*:'3DI#,O??I\;!>7DH:?<S8
MNY`&Y@6-K+:$!FR"\I'636$FD^+I]2%VQYVH3HYFW#<V\48DTX3.FT7HRG$(
M1U<0F2U!,%.QQ(2"A.[.EF9@JFBB;60%8*MST4+ZERT[:=A^A]A)NMPQ9TZ(
M/>R)$7=A?+,TE/J>?`E<`BF^,$,+#[`U*DG"1*^UX8)7ML3U*K\;05:@?[:>
MJW>&Z#4E94^]&W>VHEZ81PNF7%A9]*QG5;U<3(TR+$CI&BBF?C3!Y"Q;SUFQ
M(I66C4$04`MQJK0**57BZMTS>I^+WBN"P6`B=>D2U"N0A6@K?=0T=2:8&2M,
M$-6WRMI$PQ#DSM$+"K:$>PI4=6:5ZYT@PVZFR:#UPP3><VF$?<R".!(47!IQ
M,YQNP%"G#7:&XYLW=:QBVJ8P]+"D+ZB4-UA.6*&=>=176-)?7)Y_59^-(!L"
M^\8WZ=IY@=L!9/\TY#(@>A-5NBINI,*N^%^FN1Q*W#7U&,B&W?X#5C>@GQG.
MWRAMY8#&7RCW];J_#GFLMH#.G0J\M0"KYJB5,$["<34CF8#U)#,S)=;=().!
M$$8O0P#<"#XN4=W*3`8J!H6I[(I*06Q6684)`Q%C*^UY*G\VE47BI=JP8F=3
MNE%WA4!G[E$R)]&QH+4/A>)<O@JG7=HLDC'D@;Y<])&5"^Q.:B2M0<H"0AAI
MB6AF54$O_X$-HH[>LI4%;'K]`>NX;MK#C";-*<WEK1JOBOA5<=@2'Y?BG]M(
M?$9F5NQO7-HYDU5=%O<1O7+GL5'RBM0853TW(-411;I9(XTL3"!<\-^9%M4A
M#]>*Z"5^FJH5UJJ78XBB-)0"`PR-\V(!(F/P)%&VO]ZL2\18.<(L"Y<-302=
MU5[!.O)I6`H.LIRAF-!*$#(]8R9_N((A3*:&D5"3#'7%7%%]`J)09E'`3;TT
M@U%.:I%+,8LSXX`D[KCS$5FS?=<6):F+&;32=A\K&)`)F!6-#,DZX1Z6K0&*
M>I;)I&/C@H:M4?+0P668`HQZM0-D`2RU7%4UJ:!,MOL5)8,!]`AP@3;$P2L?
M7+W9*:]S<U%8NRYR%0?4=XF\6MA-EUHS&:Y(!!<+#B@%2XS1R1J\,&JIC;`+
MHNZ@8\T59N7F<'-\2L=&^MZE=-\J!#4H&!@(%^1&*A:7M<FFL6`)9KF^E7>-
M.!C)XS(/E1&NNB$2N#/;S!,E"FQ'NL"#E@K%2F_->4HAVMIQB-*)CP5!6SCT
MD6/R0Z-Q$KKEPS*Z2?%X3?K%'%FZ]\A1X0R3SMQ'7G&CN3FV5/'BZ<XW+EY*
M@#<065PJX,C!'Z&;P9/#\MQL*4'0%Q\^Z[',_OX@.SJV",A7P/UL9R;W"D?>
M5L-]:5=,S1'M<?2>78.`28\S=QS9,[CZ7AJ?N5=V5Q]@]O!N>':O?^^QQ^P"
MC,))Q_Y7G'34-S_D^#\<W)Q"5V"7</WQ.'=U>+HTG$(NR-`KGIC-!A?,G'M\
M0/OGE>-6/Q?D!P#Y;)1X-LWH=3O=QU%"7YRB#\2BGX/7VBC#4!`;XVX9?=_.
M\)8*5T*_D7<:"8^E`1I0YA']#=_;K?T!'H`]R#&^D_PPY/Z[FA()^PI!JABR
M3$1[1Z7D53=4=EJM]NZOG\ZO];6.C?P2S-WOAFJ#KZ3:6J%[\53K-_?V>PL8
M/EBVEH=8JY^M_"*$1T#_W9!PL"$)UPK:PTC8;G5:+XJ&((;]7F?+)J]BR)>E
MO(.OI-IZ27SI5'NVD.SE&;IGBN"^*_-F[DA]+/W,*-\DNDLOAOV6>KMM(CY[
ML+<](NK];4=ZZ[B]H!FODS:DJ7[WO+GU7BFU7@&2P<?>+G\X='2%4E[2.:ZS
MZG*$W2=A[FQ?_3Z]`G.%75EU8^;FIF2OUS79X`;`;A6KW@98=<TU[DO--[CN
M=K`=K/#V7[8&J^+[I^;57K][L`ZI(BQ;1>HI6=7K]/8>AU1^01[8PRJLJAH\
MN5X-NKU*M*J`V3)>3\FN3NN@_;5XZ64%O6=A'.5G8RXI=\_"(ZJW3V@/-EEV
M?G\D7'+%KLT.6G-I/\P834,]RB_43\R=CT\]R5^T_O3B>/`7K&:].!Y\@]I8
MN]\I6Y\G1O.%<NX;E.2Z>X-7SFU#Y^ZM,6SI.MY73=N.IMW+K^W4A%[U:UL^
M[:]6:']Q//@+ENTS'IA=X<RMKN+9Q71#R8V:6IGL#;K-#F+PB$!K>8RUQ0;[
MZR$/P^P9J#'8E!KKQ>%AU-";H+Y':O2;G;U!_[&R43'&^A\PZ'R?U!AL2HVU
MLO%`:NP=#!Y/C<*OT8R\4[P6$V_G/M(7.9F?]5S=X)E_(6:A!KD&L"WCN!!+
M/=8CK$%Y.[X@5-SE?H([Q:_Q()'>V'N"MSZXS#T%$%$L$F7Q/:$"-T-+\(M:
M<,QF/4.8;8ST=%)2^<N*[?V#=K?=ZQ8D91M8?/<D?IJ`OY+$@[U!NS=H/RV%
M\7>QK'KJCT]>.&]U]]K]LHG1$V\`UY,N*;6[W<65LI5PE:KUQ2=/3;W]_5Z_
M70%D=4'^?EB?DJ('@X-6%4$K87V/!\%'GEUM`*DU)P"J?J!DLZ:OOU*R^:^4
M?"\_3$)NN:MF[VKX<RE;^942+2IX_.82K"L>XD*2?O/?+'F1%XWC"4W'_!C(
M'$]Z)2%-7'WZ$M3.Q8A8?Y*@I:Z^6<$S\9^Y!4^E9YU+YRL+EW?$@L54V/L[
M'+P3S9Q=U[\DD%D":,9AS!AO3S57]N#M#WBD.EYYT?E.[<-P>%E[8W\L00%U
M@@)P/,1[G[3@-,E0SPP3^?J2<#8G;J3O^8-9T0?CZ<84AT)'?=X1FK'"^;+)
MG."\]O;+,-'77BY31!\WUV?)8A[:$ZC`3#JU]S'BA#2OV9`=O#$K/6(J,$;0
M)QM#?<+J37:=%P"0'X+3(!"/<I%/G&(!>I/X*K][+"60/0N)?$'%@O%R7EEB
MN$TRRBZ,63^.OKL#Z9@"Q8%M/'3U+2Y?V"(PQ>MSS='1PE6;7@(DT==YO?Y,
MP`.T%W+QKU-9.8L2'Z_>QU.0KCV@^WL2+IS0+0Q]SX!62__;WK4V-XHK[;]"
MY>Q6[5;E8L"`G;,S5=Y<YK@V&^=-/+L?IXBM)-1QP`MX)CF__E5+@`%S-Y)A
M1O-ADH`0_;1:4B.IGY[03G&/2#`QKNH:^-?DP<D?45,3BEA*N'>)#8=P^@0T
MBNIQP/<3$&F$(THDS]9_)KT3.]$O0.TGD:->A.>%1GJ2(8TF&)8>S149=;P7
MA'P(9MYYZY9:`G<R0B<>43J%"LC$3$A@\'^@EK3=U@RHK.=197IA\=D2\N=9
MSS8PTT/BP61M6'N9OEFC"H3'UN*`L'^\[^UL?B7)THGT@'VMZ37VNV[GTN3B
M8O;Y=CZ]_23=S;`BIU</Q='`+..:N88U_RBI_L)B`1RBY:,,1<4\YHR'E.BI
MA++-TQ+G6Z0:/+@O(%(-9K-)B%2#(M5@[SNW2#4H4@V*5(,BU:!(-2A2#8I)
M4:0:%*D&1:I!D6I0I!H4J09%JD&1:E"D&A2I!D6J09%JL,^SCD@UV,=6$ZD&
M1:I!D6JPWWU8I!H4J08[99`BU:!(-=AG^Q6I!D6J09%J4*0:%*D&+9%JL,<=
M4:0:[%/KB%2#(M6@2#78KSXL4@W^D*D&?Y3`=J8Q.8]-8G)$8+T(K!>!]2*P
M7O1>$5C?V\#Z`T59YQFK\&9:\&863;P9R.A*CBK#]CPYV'QP5Z;YD-/=P1"<
MQ@49%`B)'>ZR2:5CC^'F[@'B#%TZ/)`R>)Q9XB\9$GE@APT5##[?$!SX@*V*
MKW@^Q(/,=K>-,NKEKZ+`<(3'/I)M"W9V7.DK(4'^:7`Z&,AQH?P@F#DJCB7$
MGUNP:$"$BC[ZZ93+:';\'@WB,C`#W.K8WT->PN,SCH>&?*P9,K$8>70\QG./
MK*FQEHTW"EW;7A$7.=XZSIHN?-&=MC#)6EXE-!"$YFKSO`T9D<DJ&9Y=L8EY
ML84Y>L6WH`AU07^!1Z@WG`BR5+=!JV5'\F@8)3V;EPQL@`.3L!5(`EJ"DQ2A
M?P"K5R<A,62[]#&-F%R2I#(7IO>"'X4?5]A'Q]T,9N:)?V&Z+C37EGR\4DG6
M%(N&H8^39-"5Q&*.F255XTA7QZ/N8<9(RC$K$>9D\?+$9(-4"J]N8%8JM7-H
MV\GBI536<IKHO#7,E.Y_:B]@@1)A_YW\+(">_0!7KNL3K(TJ9I\M*F>M<,LT
M<B(/9+U*SZBDEBASI@<5D.!0.$9@!=E0"^YG#/0%E.`-QOU66,#W!*C5!UA]
MD&\-H&,3]^C.=&<N6=U;DG$A)):.@):4:WOJ_H(][B_$78O;,#9AXL/'S+=<
M-):86QW2>6"F>8;#DUO@T2:QIN^WVJ[9;/-:E)6W@KQM`FNO\1@`B[Y`+M&C
M?^O8BQC7=^Y=U@ZT;LB:G$*4(TIK>%@ZQ[HQ&(Z:X?'\V=,]/;@08(A=X>KJ
M#-,)DQ.BU):;FS,R-M*FE"OV94`<MDTXDKC"/+%!ZFLB\?+:DC)-=3"4ZTH:
M*#R>2R#[%O.O<SV5GR9;C!90,$V-H.I[HT@-C[EWF6<M'^A:MN7OB-(:'I9M
M,Y2-L=X0#P0"_HYL_(M_MS)MFN_BVG'AC^"ZMXNSWE/,QS%=4=+PZTEX,+4P
M'30U8]2F6M+)><CF"/Y"#-?$00DE99@Z$-G?&0KYSAAMM5`B(A/,S)R/(LQ:
M2YBS,MJ4E!'$Z#_<'KG8HQ9[U&*/N@N2B3UJ#GO47<AW4?70></]])(Y/N4T
M$.7-GL+#<_>FCV9V]BX,]2!J/,!WBTU)?NC6$92S3KBM:<GRH"6=7)N62Y;T
M+RUO@2<=B%M*NI:%)81CV:D1Z!8R[JC2B70]F=Y+?TUN/E])?UY-'C[?7_UY
M=3LO'I9:FBA5[72H=?,4]AZBQ>.H7I%)>@$]ET\=*NKOD0Z2O!$4IF>)88+<
M'C(V:89:>'1EF2$/\JETO7W:2B456>.)'='SR-^V9[L#,N`=.C73IN\@A`IK
MTTI20YK16]^/:?":!.QM[BJ@]#,7"5IG&A='^,^MA845$9Z-3F!D=$SZ.[>L
M6)@,<>E,=REA+PX[9I;W0J)88Q;U8N&O`.Q-O5,[P"9!<B+\#QR]1Z!U(OX<
M6-7&CEVP;/REX5'"!B!@H&T6KYC0R%+?[=%US"4-G?6`JMB"J$)@[4#>PK4>
MX8,%6,+/.Z?-#C?T#0E$EL^E_]LXX)R3OHS]Z8U-:T#+7VD(E;]E?@X":D#U
ME&N!..(YW8Y&"]%!!7B@XV,*H<3-LJ%GZRNB_![`P(J\R*!(*&H@<V`\HE_7
M;F[E7)IM^V#0Y%&;1F-[T#GAR_`?:AU.VA(HN?_"<5WGT:'T;H_OX:B,F]\4
MK5.[==1SZ7/&&`E-0\9)PC:#NY`/\ZF+*XCKFR3T">EJ*O4P/&)F=S!5=+!&
MM!M+1,G]*/MTJ/LD&<H&Z*5@<H1[`0L@D!=;_VQ0%*_X9KV2;!LOE"T+^TX9
M5F%#7@9[IV36+!O0@!#:<-S@3CAPV\LHSM.C3`'(!8_J75I`*+XON9;WWY"D
M#H9RSPM#/K?XA)74=*]BW3)8UHH'$0.G>1C>2*-CPSC'D$1G81(ZI70(M`7>
MU(;$,5M`[D!HV2`-`GP$!":`7[P(#D)G-U[#Q:#"K_+4)SXE9*$G`A;O\ZUO
M_\FT[!MLFY]M%Y%T,W0#K<X#?)>"Y&%BV:..H)QUPFTI*+6GW%PEGR"9QQVA
M)2:(8W]S;61532UNQ02I)3&W)E#&8Z.:Q.F3[E,[B('R[LQWF#\F]A)?<3=H
M>;/UW@FX9H_R[9Y#+=ERS63N@,KX14JH@X'&46?W9*V(>BJ%&MH6Y&I"QG!8
M41M;`1ECYV8+0Z5UZ*ES9SFX4Z6X[^[();A3\C$#S:_7*\:P;*2L"7IJXV+`
MM)L[]L5*\';:U#*P,=E:!\IO4\Y0RP:O&CCOHUU\V+_+@9HLQ+59-:,$:U(V
M1G!3C5L0_+9O6[<2"1>V__OVJRVYV5I40.RU=F^O59%.I.GM7U>W\]G]].J!
MRP8KH;OIXBI-8\$BJX>=C62"*9I1/N!RV@*(#A*1U32/+)@'*SL.T'U;]C.C
MO:GVM9\XD1JP$XT'/_];^GUV?WEU?W(QN[F9W#U<G6.PJY6Y]E"#0ZHW5]?S
M\T;"EYU3K7`T]='Q?><UB\&)L'\&I18DG>41?N\WUUQ_.*(_*_,Z@4I._KZ:
M?OK/'-ZX6K974\!2FI(3MP96BPW'N[/>%-GQ040^,/@X^QH[J>,'E%NROCW4
M=#>YO)S>?HI.D\MKOW)U05</'WU<08HS7(%$"/EH?Z_7*O`2&$"Y0>B+1E3&
M$!H;9<,.FR5AT[K*E%ZH83WSM;]\/GTXE98P<[D!@:2S\?"L[OW*$E.=5L`S
M[>3BCT_WL\^WES#;SN[/)??Y\1=E,#Q6-.T8__RU@'[0T'].:F:%GJB1W)O?
M)$@%2#+UY*,-ZI%_KLMA*.>]^*?21\>I1TG>0]I%C@>&WOS5M<3O"&!UJ+``
MO*\-?GNQ?%0V;T5R_.VX9.>8)'1`7H:]555VXW;-UJ]L#%I\UX%`C`LLA+-9
M5!F:,@;0'/.]MFPX8[B4GAUG63!(L9S+,P5+?S#M7?.V,26LO)%<"^L>H]UW
MI3GM6%,*/*@V-,=LV$P+IYQJN>+-(54I'DZ#A8GJB$FE^[4OJ0*[3)O'%<IK
MXH()KV:=L<;5<>,:-:&VV#'ZK#KC>*PQ5QV/@-SO;6VQA6SVZ:3>I_(VI[?C
M2M]</-Z<+)UO)&@R&C*"5'D+Q_/CV:=:.O]5M%&0L^<0SO2?8**_180$"<XM
M1AMII>68$\'@63FUJU0J$U.P+.E`-#R1M@06(OL3J/`%YAQM>*K(%A^_O*:<
M+-5LC'=V*DOEQ-_M?X:?[06VDUN,M>X5_(6>C2E7)(9(6;:>HNZ<BFF(%#Z/
MI_8=3;-7`#6_''/:)"-]3*)4)*98F=*7Y;1J?:@P^5["W)M$%E[F>B:"AF5G
MX@KE2<)(GUA,'4-D2S:HC\?)\RJYYPE+Q&3+-#A0C'%M,2'1`%!=O#@K"+6`
M\'?_/2U[9B'F>A^H0UG/`Y0I$B.43)M-5O&_=E#&R19W+S.?:W4CY93NRK"'
MZ$PG3UT?YUI:F>@I-KW,.\S[BCQ0Y%PKRN/%:P""<5?01O5!./;S'+FO&33&
MV;?ZP77?"!9;!S-%#YPM1A(%=DS@`.(=I+9?HN7O[Y\]M)S:US2HS'Z>1)ES
M*5O_!E^;Q3)H8[3[5<$W(">IH/TD[Z`B>W:&-`<PN)J>OY?.*E;!]_2XFOHJ
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MR\GA+4^HEG#QZT;#-F#1=LU&1>_Q7<@:%8.B(K6"B5]#I5+M5`>U99&`C=;X
M3D7^;?:;+:G<7/FBM(B([?YEZOA)541WYCLA)8-D0+`=CI;>-;8<\GC&"@V!
M6?,9OGP!R?62FJ(>1#?\F%^,]G4S=R:+?S:6BW`5>"SPWR&EE#^QE[#;NGX-
M>T;UXERM1='53)64B\E1&]SL0T\=@FJL#3QG6XZ-"Q!;NG/(B5F+4@CCJW`!
MO:Y7#JD^EI?,R]]3;;E.YC/,<)#J;.W*WTN%L]U@37W`'$[A05UQ9[M&^8/.
MEM7%Y*H/?B-@6_J(S:<7$)-,J+0=-_`1\NZ>CN0*;3\8G\B#""O\17I,^ME*
M6)-P\^1J$1SNIP,55L64/3!F55)JYGLB?3!7:/9$[("FSY1WX.X6X?O=J16@
MW)6M`"H<FIO15%]7;\A=6%Y`3UM:ZI`G1DJ%8X:X9T<[6FUK1=5&XU/5&.RS
MWI]52>&7C+IGRV>[L6'@2%$!]@>F!^-1&EVN-"T#8[I$H1KR3H>M"`Q.YT,(
M'>2NA4P&#BD6]R@*2W`=E4:REOR,*A2M=9S\&,$-;=@<)XU2#"`%(8L\6VGG
MS'(H145!N:E9U5(?-MF"PIB_W,`<'P6#!.M]<UC_2](_5BTLJ"`[$U\LN`L%
M=Z'@+A3<A8*[4'`7"NY"P5THN`L%=R%/P(*[<!\N/L%=*+@+>\;`)[@+!7>A
MX"X4W(6"NY#YZE9#;KZJJ[BIA6*T6EGV\R=D(]=<09:_)60;QA*;D`8\OM=0
MK2C?+=_T'E(U&3FH@%\:4'F@[J^"%]-%OT-:>*"AQ/=IQFH".?,6W\V95#!^
MMD@M(.)W?E[5C6:0O-G&AWU\6$O>HHE?I5O,&9&;5?:EBP(^/?*F.)3!T<>Q
MJ@_TH9Z&$A>H,0JM,HK4)G0#%)HF#\8C!BBP5%51*!$*_%\C%,/1>#08LT"A
MU&B+T*)4I6%;#!1%K6%1V61D_$G63E152R7&+B,<JR4[R^,8)XH^'NK,9"<&
M729[RO[KZ9V=Z$HEM2>,OKKHNI)BZ6K58IC,`UD!B4.65L]@%N"+@<T<D(6!
MG2VQF0$XV](P@QBA2G<HHU-(>7<C;:`QG0<JHDAUB+HHAFD:A9;[1$44J2Y1
M%P5N3(8HE.IMD>@4=5'(FCIFVB^*&2YR.T9-4@M%'AFIO-QM=XV*0-)]HS80
M61VQ[1T5@:2[1TT@\DC5QFP[2.462?:0VD",L;RO!WOK^"@O2W;ETN*<9(N+
MK"VES!Y*)]+#?';QAS2_G]P^3"[FT]DMU\S99.5Z>GMY!74-.IWOI@U1FV?`
ML3QO`_EO))_L*#E/DJ8=J[HBT>4"N("+XNHDTB-A!Q]W+QLMR`K?-\M_(=6A
M(-H#RL?KTH]E19$<&A(B/;Y+"^3Z)JZ$AG\B^H:80*?2'/]A/C^[Z-GT$1P7
M(.$E62_V-AA6^&:/OG4WE\]0/<;C5#HG3Q?Z2LK`<KM&TSV*JD-HQC@])69!
MS>H.PW>6=%VH:*6W_G.\HI@RE[XT'9MF2EOUQ*^CM]Q0K_J/Y=(KMLJGF*TS
M#0\-5756'@S&5669G(VMDC1FJDQ6AHK<4Y4=KF]RL;._S-4&U=99_E,]YSWE
MJ"7V?3&3-W#G<Z6.W`<TJ>)5CU;X5PMC?/NCJRQZU];Y7%-G`C)V0WJAJTRZ
MV+UY?LL6$OHW5#73TG[TM'W3$K?C*3T>F4HUU-(9I8S-D.8:^AO!(4*TG'Q%
M^/L3W6X@;&[V1%ROV"$!_&UD+2#XW%IM_$!-S1YE9TW9!R`4?:3K:NPP2C.Q
M.Z`U-A:6HS5Y-%2403M:>WMT5]8YO)%H('@CN1?=?44FK%E\I'_1(K^=)>^1
MRLZVM676#CTFNVK+<_"GFG&.2S2J>8U+%DH-!9K*_&6-W"\$=NH52PLR:`37
M$H_B-D"$62FZ61<R>>*LJ,;8ZRZ1[;Q:=O$+RYHO_<;=2L.[,=QY^@MZ`%%A
M,R<YJ6ID^^&N1NPJE@)??[*0*WDP(:/$E.VAQ>FS\_7L8OK'T4<\,../$%T9
MR:'(VX?3U7KH.6)WC-U88C'>UBMK8?E_TA#FI?5*J=(^'&W'?-,G/&ETV0_6
MK!P;V"0G;Y87.1>DMDA8^#/T+O0S>O/H8UCC9+D,MBGN3&LYM2_,M>6;*RK"
M;V>9DNTT:!)2>#6AU0#\FLQ1.RJ!?8]+#.WCMB&CNJ-[J8<0'FRVCT!K;U^\
MC#T07HV].KP4V-%^IK7C\0G;BDA58$<`+:],U\93A">,JK)1:89ZJH!E]=RH
M*(-Y9%HWSH(LL.]A4@5T2,*^JMJ7,C1T85\9]E42[R$LK+*%[6X-]-3$Z&?T
MU%ZB-[2<.^2+.]QWI?_7MK;UZNW\*M@G%R95U:1V=P5Z:E'M>UKT)`=9]1'V
M5-6>$H?#N%O2=Z=K]62@)Y:@]!-Y!,<0X6"H8L@C_5131WK?.^_\?8UF3Q/7
M->UG2GO?9/2_<^%,D_5VXR\/V&&#)JMC1$&[,C2B&MMW/36A'V$51ZT_/JG,
MQZ<Z^W;"MKJWBM,WHQ*K./U:Q>F9?8E5G-ZMXO3,PL0G=\<_N7MF3[W^Y.Z>
MKI6$KA7X-%,'\,E-9@=5'RC)?$Y][[P/"V2;6%F-/KG#A^<01W7`+JO4-Z.@
M91F94>VT8,*,P(R^.8<SHK#):AA1V*X',:(^C_L=TG6</T##(L&T.NJA>NG!
M9O_C%DE4>7"G34T54I#T?2S[OI80DX81=YV8&X98`.SF`N#A3$)1M?%([%GM
M[%G]#CXT<LTUVOC6PH/%&W<-J5[Q.W\DVQ#[F3';>++^A]P?TA3$&EGWUL@.
M9PW]=L69:JJ,1T]TFXZZXFKR:Y:Y80A7O/.N.&>3$'-LI^=8SM;0XSF6O::B
M8Y>Z.';9G6.7"1-(G*!D80*%%+D]-8`?P<UB[7^7,,,*R^B>F\75)(2;U7$W
MBZLU]-K-8JNI,C)]T6TZ.L<JC/WO4AIY81E=FV,YFX288SL]QW*VAA[/L:UH
M:F79_SU_<AS?=GQT@_^0WL@E'W_N?SC"Q0C1_5%PU7562<!Q>U+/X/89%(Q4
MF:@^4;6+/&?C`K<BO;HR']'JP]%U4/:+IHZ^K!Y7==X<OH?8/J[0?L8([)//
M#T<?[]$:OQ`ZAV3:DOGJ;&Q?6B'/D_P7?.$G^?2WLX2L"0`K9Y&0?07Q$8X;
MRO;B`IW;OUID-8YKI*UJOV"I0R++=,M,W"1`TUV$4N!?2W0?E#A[,A?^2:P-
MZ!M<Y[5M#(&D3I:U..X2N1^.9%!C0-IYMF/C^#KM#/B7_P=02P,$%`````@`
M[H.H1$)E2'GM"@``DGP``!0`'`!P;'@M,C`Q-#`S,S%?8V%L+GAM;%54"0`#
MH.EK4Z#I:U-U>`L``00E#@``!#D!``#=75]SXC@2?[^J^PX^]F7F`;`Q?Z<F
MM\<0F*4J$ZC`S.[;EK`%J,9(K&22L)]^6\8F3F*#,1;8EX<`0G9W_[K5W9):
MYO.OSRM'>\1<$$9O2D9%+VF86LPF='%3^CXI=R>]X;"D"1=1&SF,XIL29:5?
M__OO?WW^3[G<XQBYV-9F6^T'H2Y:8&U`'+A6:!]*/P:EC^6RWW/-F;VQH"NC
M6DTWZF6]4=9;VO\TH_9);VCC;[N><.W/3_+?#`FL`6]4?%H[SS>EI>NN/U6K
M3T]/%;B5BQSR7+'8JBKOI9NF4?([/\^X8[O[_O)CA?$%]-,;U=V7^ZZ2SJL[
M/YE>7Z/3Z52];_==!8GJ"#<UJG]\NYM82[Q"94(E3!:&JP3Y)+S&.V8AU\,V
M='F8*[.Z%S>VA_Q4#KJ595/9J)5-H_(L[(#%=\)$$RD!RIJVPYDS!S_@N29?
MOS\,XT&6':H]1FU,!;;AC6`.L:7FOR!'2CQ98NP*8,6[[Y+C^4T)U%8.M",9
M_44V6-9LW\W=KL&:!%FM'8"LFBUC$Q?^KS!UQ6C>0V(Y<-A3,@8%L^:791$X
M7"*ZP&)(>VA-X-I;/"<6@8&X3<HRL>S\,#U&''HLL4LLY)P@P?KBIC%:8^Z-
MSZ2VP:[(8AI86>:8WC)K(UGK4KM/7>)NAW3.^,IC,0%3-L(D:Y:&]!$88IS@
M)&I425Y&`GOCX-$\:-SVV&H-<1-T>8M=1)Q$+`JF8$"'^)RBF9,,+#=K+B9D
M00EX"@0F9%EL`S9$%V.P?"N9^@3*W*0/LI1<:\"9;5R4-^\U28P`UK)'S676
MSRE'5"`KJ0L5V9O36RY.T)>;^1`;(,)_(&>#OV$D-MSSX0DXF3^NCG,"3M_:
M.)Z?O8//07_B.G"!KM>TLK:/&_"^-[J_[=]/^K?RW61T-[SM3N'#E^Y=][[7
MUR:_]?O324!5,I]9_K<3`3^[&*ZP=QEG((3#++^7@V;8N2E!PY]=(>#R2E-O
MM"I&O=)\C5@XE9\C,?.2VHTH+Q!:R_S?K&+'%4&+!-<LZX:?'O_B-_LT7K/H
MR.2<\0#F!#SV-ES&8&"U75?,JD\J$<<AT^CR@/DY9ZO#^+KLB&R,VYA[TT+Y
M5]*>,%DLW5U#25MS`L'$W8+UE;2-`/;86K+PDIP@;KVSK-?S$K]'56Q6NQ0"
M(@Y^,QB@3R(5R024@DUB"F_<,5CF3K`!X_*#WR[N&;5\4=NUECHUGLS.)51]
M%D:^.9C%,`<Y[8,D5;[T_]J01^3()*SK]A#G6PBBGI^N--MU4YD))&(A.[7'
M>J=`^R=#4BP'X"=(X@%;&(2#%/<>NP$HC6:SH<YE'Z!\0?TF!<!7:ZT8:AUS
M!G-@=RL=E#?M!--=RRP'A*L8C9IA*-/K(=*7<->)1?<U6B^&1B$*83!*2"4%
M2-]J=6HJH_`+J0M%V&C9BC7H1NX2\Q<_(D*.Q##;376)>CSA"SK2A-(7*R':
M+TEYSL-H&TUE2@R3NJ#:8B4LEGN\(VA&'.(2O!?9J!DU=>IZ3_",B;*?@XS1
M5@Z=*4<V#J4@NO(<+()P%B:82"EO$[$C(!0SO?:%\GSDBU"=BVDV3/C:FHT#
MH5C!/LA9'C#XS\W>4EL=4UV<CZ9Y<7T>%[U803XD/,P7O-7Q)7-``B'G#NY6
M0F&JFP@?(Y\^KD2)TC)U=3.'E,PG-\ZD^@E,]0@"A;53*7+S(LG-E148)W.Q
M@D6/K5;$]:H3Y%HB\W8D,97[D946B*5N-36>\)45FQ"28J5[(3Q"VP'2;B\2
M/D[<%TF2UX3$:'4:ZO+56+(9F^E!M<0D.-$8%,PR&5U,,5_=XIG["H.6P@WD
M:*+7T&@"\8N5"XPQE?7'X#J]Z=28"9=CE^S*)Z!5-N#5VF%;V1#:NQ0QT-7K
M-77[NAES>PT+4@EX;I?:DF,8D9!&I'`Q2.?6E68M?]3<NFB9+'W$W"4S![_Q
MI2VST5:8Q\:0O88K2(1![M3ZN?H6BSOXG+Q8KI6L6&XRA9=O_?OI1!L-M%YW
M\ILVN!O]?G;9W,'3"2>7ST57=8PQJ,4>4HMC)$"WN]=*LVVJ"XVG<)(^J^_/
MY]AR1_/^L^4=07@`,$<TFG:E8QCJZGM.X22+P7V>IH,AGQ:_W$:V2"N16[8@
MRYBS1P+CZ,OV.PS"(1T0BF!B3A==RR6/NT#FS=<WT/9RUJ)BF+6ZNAGB><SE
MQY0R!#EW,2:-=?FR)1%<X4+9><RE=\Q`%TR'K?`=$YZ,"E>*7M'*8D!DKM'0
M&(E!I5@.=;)$'']!7BJS6D-.X]VP8C0[NCI'&4TTU_I.@-/_A:^3Q38B&5(*
MUUK/8R[WD30-R+E=_+LFD&G&=6Z7LF(V.]8<6V0'[XK!G/[OW7MJ>^5SP]4:
M$2YGG94:3.VC-ERC#J>=<-]<N^64\.1V,$7:P(!QX(_NEN:L;>A<Y%=$J$Q`
MOE,8/P[Y&]L50Z\;'66.^116<FTXJ3&-<Q_E?-K.P4T!?P^@_RP3&NPM^*NK
MV#B!DUQ;3EI$?<-I%,/GA)WI:+Z?^N_./S0Z"D]8'J*<:\-("IEO",UB&,+;
M'&U(W]0>5`S#K*M;]CA*/]<V<1IZOF6TBFH9[T\J@G@UA>7&25@HF'T<P=`W
MD79!TH_W\H6>5R-M7^&9LX.T"V85<:CYYM`IK#F\.7DAYVV6Q3?8?E6Y8)BZ
MRF-M:9@JF`&=C'.PC*T7(Q@!AA;&MA@`N%Z5[\AC1_2?,;>(D).XAJYPQ?(H
M?87VDG[W,W0B_03TBK7#`1;O%65,6=?Z:P/SM-CC]R">65<7CY(SHM!6TJ_O
M[VTE'9YQ1I/32!5(*1^A$QH<WI0_`D,IJJ[PB16G<5,(^TF#;-P66TZ-*%A*
M',FU:1E]!QM9_36D#UBL=]4Z7CTNQ@]2#O%]S>"K8"VI4N_4C*B3<)$+^N?1
MRG4VDR&,@1<JBAMZG\B!S"XGEHN]+35(V>I-=:<ECY'/M:,Y";NX':'KV<6Y
MU;!FFFK8T;C_T)T.H4.6U;!Q6_,GE,-^Y>``P$;F!-(*O=52-QT,44I?-.6O
M[H%Y-@V%3\<(R&0Q#@\C'`RJ2,&*-2'P,@T94X0,*B!*S6QTHFK:(N/LVZLO
M!_U!OHM5?"3W1$;S8`F\53=5GB\.D;J<LF(ES%^@*7#U9_3X#A+.5XPW%#Z.
M+H)B1IG10>SWCN&(P,5RS_>,LM<"[7?333/23V=D?7%T+ZG*9,(7R]E[<2LL
MV(M(G;:Z4J4XLIFH\P0;?16^C\&0WU6R(X@D<[K[&7U,#"V6IX+I)(:^RUN(
M\@Y;[W\_94$HQOQ%P_*YA3)7B[+UR!SSA!MG8<VGZ2ZMU`5+?`(Q0;:0I/LQ
MVVBW54[K#M#.0N/G6>Y;2S@.4;'&]5>.=L_\><!D-=MPL5O'V%5D8'L4>H:L
MATZ4(42OT2:_<7ZTG!:-@JW53[`#38NOF((S=.3^N+TBE`A7NL;'E_C>;+74
M'3U.QL3E?7X*<`JF_G?9V0X7$$97N*\70S4W*6H$"+F;>YRW3E[7035:6;LE
MPG*8_'4G^#"\_]&_GXX>AOV)]B'X]3>-S;7]HZBUEQ^`^ZA]\'^=ZN,):^8I
M?U[NY'7S/#\>_####^CI&W(A3B%'/JE=+J8)S!^],J6VPE/\QQG(8G@>T<N[
M9Y\G0Z-8>=9>N-\9_SFD7C6`>"]=2V6)Z%$.KJ'LA'CDSA4GT_9`9@[@\KXR
M9K^73FFU^%$.KJ'MA'CD[LQB;.#UOY#_Y*]30\L_4$L#!!0````(`.Z#J$0%
M>H9:>PT```VD```4`!P`<&QX+3(P,30P,S,Q7V1E9BYX;6Q55`D``Z#I:U.@
MZ6M3=7@+``$$)0X```0Y`0``[5U;D^*Z$7Y/5?Z#PWDYYX&+N<_63DZ\#+.A
M,@/4P&[E/*4\MAB<-1:Q[+GDUZ<E7V#`&/DBH]G*/K",D:6^?%:W6JWVY]]?
M-[;RC%QB8>>ZIC9:-04Y!C8MY^FZ]FU1UQ:CR:2F$$]W3-W&#KJN.;CV^U__
M_*?/?ZG71R[2/60JCV_*=\OQ]">DW%HVW$N47VO?;VN_U>MARZV+3=^`IMA1
MVBVU6V_UZJV!\C=%;7]J]93Y?=`2[OWQB7X\Z@0I0)M#/FWMU^O:VO.VGYK-
MEY>7!G3EZ;;UVC#PIDG[:G4Z:BUL_/KHVJ87MZ=_-K#[!.U:O6;P8]R4CO.N
MYY<.:ZM>75TUV:]Q4V(E-81.U>8_[^\6QAIM]+KE4#$9".XBUB?"+MYA0_>8
M;/=NWZ>JTXS9/=F"_E6/FM7II;K:KG?4QBLQ(Q*/F$D>I`925I1`SBZVT0-:
M*?3_;P^3TT*F#9HC[)C((<B$+P3;EDDU_T6W*<>+-4(>`5)8OVL7K:YKH+9Z
MI!U*Z"_T@F$\QLV\MRV@B5B;K0TB:Y9+V,*#SPUR/#);C72ROK7Q"Q^!!!NK
M:DD$"M>Z\X3(Q!GI6PONO4$KR[#@07SC)=DR3'F(GNLNM%@CSS)T.P,'V\JA
M,=LBESV?O-C`%R0QCUAQZ3*]P89/2=,<<^QXEO<V<5;8W3`2.8@R=6253=+$
M>0:"L&LA'C6*')Y:`M.WT6P577P;X<T6[";H\@9YNF5SD4BP@`=ZC\ZE_FCS
M"<LKFXJ%]>18,%/H`"'#P#Y@R'F:`_(-/O41O71(IY+$KS6@S%0KI8W]SV,C
M@+3RI>9AX\?2U1VB&[Q3*"D?3H=49-"75_HC=JM;[G?=]M$]THGOLCF<@Y+5
M\^8\);IK1,2$7_?IB=T]\,.;IK5IAFV:NGU@*T[XB)%[3/W+'J-L[\[2J7*P
MI^4F[/W-I=.VA@Y=PW]$=;@*MOG(L'$3FM)3Z53'(]1-O-&MO"2?ZJ9\>EGW
M]0W:/"(W+[%)?8B4+%KIONT5%^W[?DY3#`TMQZ+SVAW\&36W/!O:0[=*78E=
M1?@^FDUOQM/%^(9^6\SN)C?:$OY8+.&_^_%TJ<QNE='?M>G7\4*93)61-I\L
MM3OE9GP[&4W&T]$?$4&4;>%+FH!K].HAZ,D,%J81WS8VPE:V_HCLZQI<^-?X
M/SZXF[$_=<.4WU"'@TYCT.@G*H4I9*631Z85G]2?='U+@P:=)K(]$EVA,W*G
MWE+#-?4OX>7D$=_3;],%/G8CM:4R`!UML,,LUCV#;$-M#0>BB#\:C8OP'>(T
M-V)AY>)-%A5X^#R_V#61RR).]%]-V;H6>*;>&^"ZIO@$",1;2L5NI1,^CCEG
MEH!I:,*E*<TTK6#TN6Z9,8A#+KK#GBBEI0Y<N0(YQ1#JLBVG+A^H0^@@<ZR[
M#@U-1M3W>VU16DP>LG+UG>4\5%Q'3L7%UH2M5AL]M=]I],0H[/U0^6?XN)\#
M11'MU2*4@ROA'"2-7`+RSB@C@ARO``1._V>=[LSX`]\+3>`K8Z#;N!*LP7BX
M$G"XIRW19/,_.IQ(.RWV([0=LGD(K\`5_V38&#S6ZYKG^FAW$3L>>*%CF_4$
M?CAZ"I;M)6+R:"E=%(."#%>Y&`2_;XUMT`0)9H.&.NBTA!G=X_$$@C'!VJ;S
M*[>/M%CK+B(SWV,;O>`K`.FM7E^8J@Z'JUA3:=S*[A,!R":$^,B\\5T:"D9`
MG\EBCE/TPGXAP$Y;W!*%BX0+/'I9I!(JN?NAE!S`]AT_`[5B+1_0((6:4^02
MZKGWH?3,8,M^FS'BR/@5'%H+/!?*6D>@\<](CA3:YY-6"(3AAP)"`.R3O(ET
M`[/2(P44..458N%*3BQ,D3=Q#+Q!=YC`7-9I]X59\G=#5:O!DUQ&*S=)_2_-
M_+=//)::L\0GPJ,,AC39SJ3A#^00EAOS@&!-0"P/+9#[;!DH@.P#,O!3(%$V
MD35ZPZZPQUHT\=5"J$)5A*#LRXE)QN278R:)YUH&VY6#"5%[T5T3G"1OMKK%
M[@I9G@]S9:-[U583ML^2LA2*C'.!]5UQ@<1:[TFI]?.1UKZLH>:LV[N"&,F_
MO<L)52[51*@]Q[_('=/4I(\2$3G\61`IB)$+(G*8"9%#T3'-]%R9"DQCL)A@
M]B#!(2O;0`:C?1@S>2R<$`N#BQG+S\T#Z8``?G"G4G4SIE(M:"[5;#Y^T)83
M:*#\^BXY_[?2$JG.'P#(GD:UV=KX#47.;S(*--L.3R[-5J%C_%]D!H[R"!./
M[."E#EL]49N+)=-:8#,K3NPOAZ1@P[([5(6)3@C%9:2P"(9?/+L)UMA/L\4L
M1"&B$C)EF0_",9"93,+XE7Y%C=Z5>B4LFL-%@JQ/;%)`)ZM,Y=Y3#^*;.W\L
M%`_SN-LT!4_0&B)EW/QX/]%IN"1H]P=JQ>R4MC3*HJ8(J;S2J&;)7F2!=)9[
M0:&72X&T6G:J`VE"/(E7&M6LX@O$E3@8$61BBZLUD2%88B-@?JTYY@UZ1C;>
MLM!,8-^B).V>N&,M'..+P^P)M>URUK/(1NY3)%^1`TMW&UC1S`U(BGAT(?^,
MWG/3[@Z$)=IQ47`Q76>5C]S^GL`%IZ@S`Q<+$>3S102)H:@O<B8@6PDLSAC]
M`QG&TV;YP=K23E]09F>KA6ZCZ-R2VNX)2XTX&NUBDV(:WQ?/32X29.^VU):J
MU)4;B]`@F>\B&G.??)U.;B<C;;I4M-%H]FVZG$R_*O/9'3V2O%!^#<LY9(FH
M9RGGD3EZKKDN/=C,8O-@N*8@[-V5_3H4H?(ZXMRXC*3DGYCGH8B_6'BY!HN]
M1;YG&83BV]WB8',B,M:=WM60<[N,O]L2'L:">HN>SGRBD-M-G:_`Q+BG6$CP
M39.U>:H7B93'PZC<3J8&DYEIV3YUDQ?(\($RF-2F^@:%9J4W%';`ZMS8!7;7
M]E)V0;][6]!LGSE64K_%BT:N'LM`9D9]O,M@SL*QW%-(LAC&KX;M@UF]!7%1
M']?W0L<V.I`.;FW@!;\E=Q!DIPR$9;())+O`UA(/I"H52,9'/,\3(P0J\<82
MMT2ES[$3+3U!FS@?]T&K5"`?ZD%+V!?CEZC\J8.1IW_GF9$U'JA#;F_X\&Z)
MO.`TQBX>83@38D7`LX6_.62+#%CC(S,$5G?0;PD[#7=JU"+I9$&7RQ>\Y^IQ
M'\0XO+N4,"6O:'<)5BD\R+V*BDB?.6B/](1MQ%3QQW=?5/R)/,B]6HB1`T+>
M)SYAY9J._]W]EWT"DOGX&'/I+?;=/=H39M%4'>QNOZ@*DKF0O<Q#N#,0,1$=
MQA"VO$L<L;@5.Z$N44P4,L><IR=257((OC3^I5]1IK`L^K16)2@4Q<1E4)BP
MZ.+A7_[EUA):SU9[2YR`YPXL3`1I,''$`M&$'*LS4<$%`1N#Z8CETUX<)L@K
M*OGS:5,$(<@<2@!C4<%HF6"<%%;.*RKI,VY3,RB"!"3J92<DIB6O%<YV5V3K
M\*2M%%UI-[/[<L;JYQ#Z42'4$U+X".5V1<>K!<'ATEL;XD!5B4($SH7E%8).
M$^)=?*Z-"C*A.G3V*?&NA//*O'HO@=S2"C_G%',\"6;B^:<YOYM);)S!/<'H
MG/K4(9JM%OXC@1E"IZ^D8SE8O`0F=5`U`I.JVIWA2^Z(\-S%!D(F"69V&WZA
M27+8)0VU.^P+>T_-R6$E4"B72.2.,M];-B(>=M!<?Z.3%L,C[T[+X<T2J"2-
M'[G+_>X`!/[0WN(10+:R/.8S@>\$#CQ]D39E*ZF&=Z*:,O4L@0YS2R(RVI)N
M;.Z]\&JNNS.7+<N""L615]P8J!UAYU4YQI="^UFD%*E<TE2"@HLD;4/EU^BW
M5&%G0$NA4`+8E"UIR2L-I\0B!44R\D>2Q<4@SDDA]J@E/LFXQ__"WVYM6E%Q
M8['*Q0^(X@3$<0^?&W\3@#3XW6-5RU55W`MS<M,EP6Q0CE#E+NQ\9QGT'+SF
MF`&+VI.+`C\)>_!IZ?:M3\LQAIXP.TL\<Z8H]*-`>H-.AS>IL.A@$F"B3'G%
M]2RE1,;<=XTUD!]`>XF_H`68/4+W_I?X`1F(5E%PV,%;\\%Z6C/>!E<)M<B2
MLY<S=R^!]HO)1.Z$U?TX!#T:/EO-O#5R-4*01U06C!!6<R]];!D4SRT<R=\"
M<V#'P'/]`^DNJ[++G9N<W(<$6N+@+@ZD]7O]=N_#E3?H)I0W6,Y&_U"6#]IT
MH8W"2L%Y*AK0M?)^1D'1*@8C6R=DMF+][G2GMM2AJ'*TB2,62?J+JJJP'K^\
ML?ZCVBA7%535/1JWA&>,3RW'%6[39/#3['.E"$=4.*UDS/[_+5^\6BSU15^R
M^O#[;DLR*[U63]BIMK/#5Z[L3`*1W)5+Q6UBX2\&7'%G&+,3)-G#?E9H%W\#
M12HB`BQ/P#][I>M1QF;TGNC@DT4V.X.6L&H7?"3DMV]I_=,X;G@JH3-0A1UP
MXB.A!&3G5&<$]<RBDOX841:!"#KV(!.^+\#BQ?"=<,(CLZCD/Z"4A25!1KQ$
M[2>R&!4H#0XSH/"O78FT(6]EO[2.!(,S117Q:\TXV93[$/WXF&[>\/Y84H4<
MLR)W5/YL`$9XW>9\0:C"!EP07R4:<-Z:S.<5QV/2$N4CR9F;4S'M\#K]H"](
MABO_`U!+`P04````"`#N@ZA$M=7&P.1&```MPP,`%``<`'!L>"TR,#$T,#,S
M,5]L86(N>&UL550)``.@Z6M3H.EK4W5X"P`!!"4.```$.0$``.U];6_C.+;F
M]P7V/W![/TPWD$I;EFW9C3O:=25.M7%3=M9VU=Q&8S%0;";1'4?*E>1497[]
M\D5OMMY(2J29F@4:U8[-E^=(SSD\)`\/_^U_?7_>@U<8A*[O_?4GX[+W$X#>
MUM^YWN-??_JR_C!=7\WG/X$P<KR=L_<]^->?//^G_V7_]__V;__CPX>K`#H1
MW('[-_#5]2+G$8(;=X_JAN#GG[[>_/3+AP]QR9?`WQVVJ*CO@7[/&'SH#3_T
M+/"_@='_K3<$=Y]I253W'[_A?^Z=$`*$S0M_^WX?['?17W]ZBJ*7WW[]%?]Y
MZ0>/O_9[O>&O],>?DJ*X:EKRV[=OE]],4M:83":_DE_3HJ%;5A`U:OSZ'Y]O
MU]LG^.Q\<#TL^1:B6J'[6TB^O/6W3D0>5ZYZ'I7Y:RI!90G\UX>DV`?\U0>C
M_\$T+K^'NP1B09CR3GY"#PX`^N@"?P]7\`'@_W]9S=/:#TYX3VH>P@^/CO/R
M*R[PZ]ZYA_M?G>]N>`T?G,,>/T?2S%,`'XX?>*$!]!+-7^$^"O$WN+7P`_[J
M0\^(I?B?)>U&;R^(0*'[_+)'C_37EL"W3X[W"&_Q9]1UOU/P%6UW*\!#X#P^
M0R^Z]K<'_']"JT[%J.U!CC#DF4D1XJAEF50R)5+)%!?@U`1,J`0[^!+`+;;#
MU8_^J.H^"$YK8@LTP1;(&!',%6U*P'R-_I&!N]!N9]@]^"CRL.-JIXC+6NL:
MZAT,7'\W\SK&7-ZL'/#KR`EJ3(LX_&+#70NP\2-GWRWT8I-=@U[`CI_V:8.=
M/V7DPW(;DH:G7&BR0]`"CS<JXF1]IF24NT6?XI*XQ1K7DHZ,U%O.M0R_1]#;
MP1WU.-.V_6U<BO3RUY_0%W^?;K?^P8O".^?-N=_#J;=#WP0'9.A<YQY-$2(7
MAE>'($##^O0^C`)G&UT.^OU+P[BT1$=?_,WIX!M_+8+G6/8]]OK]('FL1P]V
M&B1/X"'PG[M[`)&/VG+NA=HRS+$Q&%[V>\.AA7P./]C!`$WP?@(OR.H%;O3V
MUY_07.\0(M'\%^P5.BF-G&#;P(^XQ*];'\V-7J(/^R(+49'29W5"E6ZD8R=U
M5*'3`0S]0T`F>L][A`Y/?Z'WX<OZ)^#NNL)I)TV`%]H&0+-JX.!6G'WXV[_]
MFCT:J1HV^E?7L%$7&F:.!O3%]G\X]<J+QC%@*%.K'+Y,I^YR.A4W`7)M7("X
M%?!GTL[_;:5QR^@)!G&;E\/1I*=J\,IWW*D*U4M4H2M'E8B]&]-W,WQ/:E$G
MQ3E&EQH\-OFM>^JJ&!744K?)S!]5,JT1?<*#=\O;O`B*S785CH)YO@"D:&J-
M6_%X$S@[F+WUD3(3G.^X4Q[72U3!XZ-*Q%A8]/E;[XG*=5*<PP37X+');]U3
M5X4)5DO=)A-\5&G0Z],G/'JWO,V+H-@$5^$H,<&D:$L3O();Z+[B]A8PRKWV
MH70;7-9S-TQFD^F4RJ6UL,$P8X,Q>1=T9A%#J1UF`)1Q.T@+?P`MK',M`Z2:
MYS.QNM)`E]8RD6--'OWX_5(Z+X,J$]T$).-Q5O("H+*B1CH,811>CGI#2QYQ
M21\M*5J!,R4C_=TP3+K@,^[IS;L2N-(I5NS3IM^UHLSDG5!F4D49[+`;](D8
M[X(TQX`Y1MJ*S6`.[AQU;9/=9>`(<RA=IAWU)<YJCKKJ@E*5L(^9E>WM&#VZ
MLS/6?`.@!K8:XU3:=VRDQ%?C2U^:G(F'=*X5YQ8G#PY[O29]=)KOYM8"5S-_
MJ(-@3]?KV68MPK7$;QOUQ@/)=JT;_[\>]3'5TOF5T8^?E>;KX-6HU1BULJYC
MF];*:3]]7Q(=,8DLJW#+CI93Z0K56/-]PCK<"IVT<@2QK[:-=[;%?;;3'?:1
M,5)CXKH<59N$*.5B-D[T)A/Z7#5??FY&K]0"ED(XM80MW;R*-RO1VU-'SPK?
MKRR4S(P57_-]/1;\"CW!>B3VU9?5:K;8`.H8<D;A73GAT]3;X?_-_NO@OCI[
MU%,XC:Z<('ASO<>OSOX`+T?C@2F-KTP0VO%74,J$T&S5R6N)IX=Z[Y@(R:.$
M\"+(;%R:1,UM\0>8U9.I"E(\"^U4H>!ZL%7O&V.ZQ376>Y]%0!K9K@D_I(S_
MY$.NU@5P(I!4!*0FITKXS\]N]$P0($R^%Z&&H+=U87AI&7U#WIA0W7%+^O-(
ME)*^IA*V12,Z&$_T7J?GD$*-K6?&8U\M/W^>;SXC+X=SX8OE=<NQY.<D<-%J
MUU3JCRQJ2B9Z[TTRRR#=0C,"L7,%J7G.%^7EL?<*@\B]W\-K>!\MT`.-UU,L
M<SB6R.**;MMRF%F:C,%55<Q^7W>[6P]=/E]K^[=SOP-<X`)D1;IFJ21GX4PL
M+7$4JJH8P]ZHATR#-1P;FD\.6650Y"2PH3EBL>='O`;V&CY`U"XRYV&$!E)K
M(N^@X5%7[2C:@#JAY7$Q<SS2VV"6P95M)$OZM)/O`/E2W"R6OR4IIE`ZMPHF
M[[B8,3!&XR%52KVG_K6XE9BV.@3V]>QFMEK-KL'5[]/5IQGGM"=I>@5?H7=(
M@^JMB6E)I]YQG]UPL$F.4S*>E"=[CG1K9Z)W]`F;`$KI60LELY$!+28X[%:\
M8*GCKT*B5H[()^7-R9B&5$_T#LEC@:]JQ*[!D+$S+B08V'+257XF,!G*"]NK
M[+93KM9)4T'7O!>.S,&0Q@]-]`Z$89;A'-:U$DW'!K;D9:NPL>JHVV1I\ZL?
MDU'\F/6.%&240+&]K8!18G);3)M<#^X^0@]]B.X0*!H.<>,'^(_X^S`'9-RW
M!C*M,1^<UE1O*WU.!3B;(DY>/(SJ':O36C95UKX52OOFR^)Z#>8+L)JM[V97
M&["\`;//=[?+/V8SL)I_^GVS!E_NEOCWS7PUPSMEJI1-UOCQ/I2M;+SA;&I@
M)CN=>L=MMI1,P?C4`IX=5P=Q.8#K7(#XC,^#'Y`ODE];+`;./30L(FZ^+2".
MO1]+#`3-=]5./QI`)]P_+H:#M.*%`KUW/.I@*QD>:@#8R6_<6\;E[TR*M99-
MM(*1/2HV&0UI+.!$[Q7G:M"R36-ESRF[WLAA?3Z"Y7(37AI]8R2/7[F>VM&K
M'G+"KJ-2O3ASW:BG=WA,-6C9[*KLV<[]T@&UI!PDDTNMPBFRHU)XH6="'Y;>
M&[(UJ#G&1_$39-7]Q^?']AT0;>KMUI&__<>3OT<O(L1AM-$;?I6FO-PY3=UW
M1DE6X4IX6E&U9TQ&]"WHO57!*8E"8\D`)V]!20@A+22+X[(M[%DY7F>+*ZKB
M(.3X7>B];<PKBFJKS0*J:,J!!R/@/X"M\^+BGW9HZKUUH;?M6`&RM-P]-4YL
M+0JY^E`M*ZM:Y([+&I9)WY[>&RB"$IU[*"B'53$D")]/YB:,E*4J396CL,+%
M_L[P^GW\TO3>%Q<52<G*F"`X^W8^_3B_G6_FLS58S,AVR=7T;KZ9WH+KV<W\
M:CY;7/TAK"AI+%3?Z"L9,#J)46(2H(3H:>%>;S*@3UCOC8I&[`HM>RF`O`T7
M#$FJ>YFRW7CI;*QSU?-QB$.#/E&]MZB;P:MVQ\MAG.3BZ6)-Y31S!1I7Y<4<
MR;JGB4>>:L+FO3F:B'_4TWN_@ED&]>:T'$BI6>W",:YZ[;)=8=4TKG-WRY+0
M#.(13>_M778A5+NT]7#2Q#XY9Y8SNT^NKWQL4=^0F`^^M,_.J%LK1@EM\^5[
MR0S!>#=;>97P%=K<*@S'YE8T'J;AW<KV9151M,ZC/8W]IONGQKO9$JS&K]JO
MK422K"W[WB-`IONY$^<VZRT_D,H[-US;M03V5DM52^*\;Q9/+HQWLT78*,99
M[&XYEBK[VX7'6\,"V4[O>;A=Y_J6O0AL7OKT3;R;K<%F.50[P(V([-OEXA/8
MS%:?VWC!R.QOD-4_32#1MR3>+E/>:4LJLPJ2DKBB@M'K#^DCUGSGC@6_=)/,
M`,+&A3X0UX*FT)E]W^X/.YQV+UF'^.Q$AT#$XVAXZ7+L\1G86S3!%16PA8B?
MO.9;:TP"J#&Z+%!2C^(-N!Y`C\"#6_P`P3<W>D)_[U%+?N"0K_P72#_QL9E<
MGIO=$18>WXPWDF>/JSMNQVHN@1)FUU7J#XWXA>B]R\8L@VS[S`J$WCN>NZ`N
M;'-#'<M[EV*:STGD@HFNKX3^HP]?[PTZ=B&4F&IF.#&A12[-N(->B![YU-N1
M-NY\Y'W#R`T@SE:)OL5?P.>7O?^&O\B=J0LKEEL&@[Z\TZ`=HVVG)_(?7:)<
MG?=DCL9T=T'SW%QR!9<]'DE%;\>MD]`_JO_''9`?CKL`^3.M:-#K9-U>FAI(
M&33_-2Q(87CNGHIHND#WVS7/8BI9<B6.@%P9<I,]?+R=-@0A"-S'IR@$AQ=D
M9++N.(U#@*>'T1L&@Y'B8,T7W`PYUCOL&_)N#JCKNJ7:\@F5ZF!M-7-@&/0(
MA.99K'G$4*,=[(#LN]7R;K;:_`&FBVLP^S]?YG<X0\H%#@V606PY3O"9B5UT
M3VNK#28&C13HZQULP2&%=,>1&8J=%+T@/EV4'@0AQ07.\J\C)R)V?OEPXWJ.
MMW6=/1I>7/QJTJV9H6')HS<+@G8T%Y,Q83M3;3S"]NGAY+[>>]XBXLCFOP`F
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M?I&=")+N2-Z&/>H*?XL_DWM9T7O>X;`"/^D).&E7G`%=,E5#SHWQ_U+6I7A?
MO8S.K#Y=W]'\KF7ILLMV(F0+<&1/D,%(N\"K&(!V`G[&W?R"?R9WW"9=@?LW
M\/,7:EA^`6F'(.M1>.HW??:#R/TG"7%*YZ/>([VL9SB1F/NXKN>62L\E4ZJ]
M=;4F`[U]\&;PTO6G"8&=+X'S':5EZ,5C,F\QSXZ2_=#7F&=B\MUCCCV?^!21
M[I<[B\C#3GUD65U_MXZ<(!)S3$7PV<DJ'LG>LOZ=[-Z0#W@+Y^OT%M\'#:8;
M\''V:;Y8S!>?<,F[V6J^O):J-,:_AM(8+92&KC%H?HV5D#R\2C/S=M)5)D7'
MK#(S]'VGRG)'A$7N6@"=$%Y#^G]$)G,@[1PO#Q(9FL,J<[W^5+1"7BSUDC6_
MH*B-6!RK(N)'A%L`M''VL.O9U6HV7<_P!2R56J5`B>3<\:ZW$A5O@N=II=\?
MT/A_S>_]%!=*]O1%&)E-9NHX,(%\R%6^`+0Z2.J#GY,6?N'7HCT,P]EW&&S=
M$"X?R([&DKS,\+)O#L=EBO.R_XZU8=`S8UU`7S2TU9[Y7#CS9*^I:`QPXB/Z
MQ/4^"L<GB`I2,Z.QD](@*0Z6#X!4`'$-.:S-\@UH3ML,*`=OC7A'0>^S07R"
ML/-VYV\/>,F3+/K(X&^&BAKBW0$"_&;!?>#_@YX:<L,([@",VPCQTE,:!1P2
M>OMQ@W+X;;T3>A=V2UD>/TW3H?F5;GR"*-G!Y()DIQ89<3<F*W@,'"^B6Y()
MG;DOS7T)X-8ENIE?G$5^$+D0;O[\XK@!5E]"DK(4P*5D9F^W';%;X<\N,F1N
MA&P0T^!4S>_@$A=*MDLBC,S.UP1'>PFH+KW!$&2UY6L"D]NBLRH4W1G>ET.6
M#RS-;PP3%TJ5FR.,T-X\0>`\/@;PT8D@<G%>H(<&"1RA\NBY_Z2!*!$JDZ3,
MHDNUZ"LG`LZ>D`PY1*2$'Y)+2"($T,41<?2X-9G8NM[IMVC,H4V%M*W[^.0E
M\;P.=)S"K=+BEV"Z#WW4#,X5D_3WY`2/&+SC>JAGZ`2>ZSWB2)OPL">;VZ0M
M7/0;HA,$._\;V36,$22_N@'8Q@O%X!6O%&-L]/L']-#H=YR.G8@RL3AY.AN#
MDMNT^4A)#]QI?@6JN%!*G$)A>,>#(];98Z5Y<+\C8R"206'V\`"WT?)A]AUI
MK/<(5\AB++WRU;++B6&8TD)7>9"TTY]V,B<*Q-4*68T?4KNN]V9B&[&4*%$+
M@/;LYB:Y=?X_KGZ?+C[-P&JZF0'Z>0V6=&-$@0I)V0/17(4*<S.N5H:#0?PB
M]0YA$1=*]MQ,&)E-:^*1)JD+<&6`!J/*[1$^);KQ`^@^>C1#T/9M$SA>Z)"L
M;9^0!XG#)K]X`73VV.N]-'H#8X(9->S+4",>+.W4J*W4B2+QM8-=BS%]MWKO
MR+<1BT&9)E29/#*[$HQN:0'13D^')C.[$/SLDD#A7R[(@8.?GU$;^S?T<ZQT
M.Q<I(NX(AIQ;C&),DS)*Z:Y>A6&*JQG+M'KT#>N]52\NE.QA2AB9'=<$2560
MJPMPY3@`_P)D+?"I48)@B>=O!S3*W1R\'3XEL(+A"QU<X[7Z%<D_\^7%1S\E
MV6<N!Y.^478\IW0YH5U?[32G<SD376K;<&]D:9Y0M",)96M9-S!MHE6X';`D
MJ_:X)4";`G,/Q(WA2(.D.4#;`[A!L!+,S-05/YD6^7\$12QN!K1K&;5***!W
MV$-G,JK:*N@*,-7+G_?DN!E>,HPU\X%JIHMSHE'-S$=+E.=,XUQ=[XJQIW.[
M'U8UB].Y=BT/8Q;HO87=F8R*)GI=X:6:V5(E^33R-+YU[DVW6]+YG?.&TV/@
M_8?M-CB@9Y-E7$34-'ORKDH7`]5.8SM[$(FBBC9H3GIFO`Z@MY9V(Z"2?8%.
MH-I);:R/3EP?O-`&R#*G@YMP]G2I)KX;);N0C7-5IBTAI:S/O$?-+,PS!1L<
MCXUX.4%OQ[8+\63/,#O`:)<<K<":F30$[G*:&;>5SPO>E39FUQ@@LO5->=>[
ML$"0I6FU0C;K5:[ZV!K'>T=ZAXOP"W,^G:E`U*@A63V9RB!G(TXW;2C.U%CJ
M#_K4R:#O3/-+F\4$4C0'$P*7:4C>I0O2"F3L\(6OH"EBNH8/,`C@;@5?H8>/
MMN,LW@KG42?]=ZT@S>)5*T>A+GY3`_JF]`Z+XI;E3'.>>E1'TYM=7!3I`BE[
M-*7Q?.]#&E6,(Q5]K_7<II(YBERI<RD&@Q-U6A<-\7WZTO0.=N*41+W[5`>G
MRG=*ZH"X4EO>SSW4#.)6/&.5>#MD;=]=\[U>K&JNY^N-D76BKT/O:`D.*=1S
MO`I*%;]SY:506]5D0#6W6=S_7,7$$Z7'>32_HII3DK,Y_'6H,N\&.S(9W]WN
M^)[FYKQR7MS(V:>90/N6J7*OI`I'UWK`+F^U2E2V0=Y>;*WTCND1%^I,TP!&
M>/85B2L-3Q):9T<#]]E:*F=R:P$N*7*)M-$=!E^ILHWQ>$A7R36_.UY4)/5>
M%!.N*I<JR]D<UQ9.V%P$MH*H(7>+!E%\Q`(19S"2E^*]J?NNE:11N&K=.*DZ
M&6A^4)U1`O7,+X-11?2L+#GP(XO;JJ80YR$WRT3BM.Y@-$1FB`01O;=-M7I1
MSC:5J(5EXXD&3><?AV8EM-_!%WR9FQCSYUYN=_K&#RKO2L0G]R=EBZ.E89#<
MS7?#]#;2G#*?O2WLPH[B[9WW$:4A+)NJL4`48#9*S+U\W`5`;8"DD?ANSVG^
M;D]EVL,4X/]^U*<8QB_X"BWZ"M_'4"(L&[O^M`O;;POT:(\Z-^<F5YJ_I)?D
MOJ27Y,*T(66:Q)(!Y_TH4N6Z%=\KC`\?:AYKWUHVI:M8HBCM.]3!DT.S4R5*
M<ZPM?,JR@%'9A5#IO38E%T*9@XF\@]/\>-JI5Q?R)^HET)9A6".Z4JGY)=2M
M99/MYK4%:.,KS&IN+,MN>NK@QK(6K).R^?*.M*XPJ(F\>&13!W1+3?-[B=L+
MIV18:PW3)E=TW-PN_[8&-ZOE9W`S7TP75_B>J.G59OYUOIG/UIR[,^R@KGPO
M<KT#^BY>XR;IB\W^H*?!.%<&3I7V,3X8?E4L;[C?M_1V,KL14)^AL`:ER'AX
M`;(&0=;B>=16RC56/X+:%NZZ:MDP64W^48;16@DYQE+Q&["ZP4K4=XO5]R6G
MO@^ITF87>G>BG70GH<)S&_:5CZ,U>*0H(9?\#7I7UY9AC`=T,:"O=S11:]G.
M-$@R`VP:'].&),X765BG<KZHH]:QSA=K7SR>J\1O7N_=N/;"G7.^R`ZS,%^<
M+[[.UAL9\\424%7^U5"'<4Z9XRG^8/A5L6JBHOD=-MT(J,]06(-29#R4.5_D
M9J?*^>*[4EO6^2)KPV2&HO=)D8XD/.=\D1-K-E\\4(TE)TJHPG8\5TSCB,N]
M-GFG9?GQ2%%`+OD;=*ZN+3Q=H>=`3;V#AEO+=J8!DAE@T]B81=;+FRNRL$[E
M7%%'K6.=*]:T9:%Q<SR9T(TM4^^#[1U(=\[9(@?.PG1Q>3=;3:5,%TM05;E7
M6@QUROQ.\0?#KXU5\Q3S7;J=G`+J,QK6H!09$F5.%[G9J7*Z^*[4EG6ZR-HP
MF:#H?0"T(PG/.5WDQ%J<+N:.5HM/%^?D9B"<@AKS:324.3YF?;76FUK8.37(
MES/&([J:;6H?^%D)6\%(4]4W(2#],;[P!DRC*'#O#Q%)>!?YX,X)1,*ARUYF
MO_<^29CA+F?AT+1&QN2R;UJ#@=['9&IQL_.0'&MT7\4G(I4@""'Q711\A+MS
MWG#0?GP&8`OA+KQ!;W6)<S66+.%=&@.S)V_:P(FF'6?;BYZ0FKLETQS&<T.]
M)P3M!)-MGENALY/:Y/S7STD#Y%)TY/Z37*5E>T:*U$O.X?SWH5_%H_O\;WK2
M2Y8_]7;=6TK&H&)='.QOA]*>MKB&A=S2*:9T&W^Z_:\#:J?F=-O`',A+%<D.
MI!M-$Q+X5,=8&C&'V/'`;U?O*$!AF50-7;S`LE$+33#BJFD2@`N:!>""G,<4
M3`,@0B6Y8Y6.RE,]0C6W$J=4'!CTG>H=S]=&+,5CDP#$SD\SWT$O1*\+=4J&
MQCL_C+*1["/TX(,;S>@]U(A,@[Z\E'P<2%JJ3RN14_7A:<4<6=2-'^@=5R`N
ME/3A1Q29'=<D2D(G2<>505P;Q-45Z(^4J`&]]:<0*,#W0B<]DRYD#O0.$&@A
ME9+``'%\^:2P3GRG5I*3YHVL2'1Z.V5^TK:._.T_EN3%AK/O,-BZ(=Q=&L,>
MC;8<2]&FIOY;ZI"`>*GF--=%;VY()[,#O<.]N65AUY)7&-S[PGK"B<M.?L!^
M&7VFO.MN[(R0XWYI0_BBJ]5<=S":4!]YH/GLA%,4Z6X5'Q[[:-$9D!H@K@+2
M.GS$7S\Y`?R(IC2[*_\9CSQDW_S2&$UZ\MA>WFD[BC,+DO"ZJ@)R6V/#HO<.
M(Q-^V0QF`6&30A_N<2F0+]8M4Z6X]>=@:L%9+Z]`8D:-^%[6H=XS6T8)E#CA
M;%@H:0$E[5:<M)$3$?][^8"CF&[V_K<LC'MHC,;R;&Q-SRWYRR532N*Z6B3Z
MF6:P'>H]Q>010[KQ9<=B7RT7U[/%>G8-T*?U\G9^/=V@/]8;]+_/L\5F#98W
M(!=U+GJ:8WUX>=D34,X^`37WT`3UF6A/QI/^4%ZT'".(EFH@*FFJ$:P-&)-!
MCSJ!0[UC[P0EDJXG0K#L]9>[NUNB'-/5'V"^N%FN/D\W\^4"H/]RY_<7UZ79
MW\!BN<'%EK=?\0^9;OVF3+GDN$0Z*E?19V)NH)]L\`SUS@DE*)$:GTH(FSP-
MXU.KZ3.^3/>?!.KR(4U<=>6'47@YG%@#:;I4UW,[!>*3"6L-"Z:_[^_WEWUK
MTM-XOL$MAW0-X45DYPOB)<T=O(^`&X8'5`&BV4@8WP1'OM^Y(;D_G9/SNYU+
M7]&=X^[F7GQ%UF?X?`^#R\%8WOA1VW-+TG,)E0P5];4,TYR@BGUK..[K/37A
MDD/)L,"#R,X*@Q=4^H/K9?>VT1J<WA(3&Z3,/\Y-\<)4H[[6:$R&Y-%0[^!R
M=B%D3RB8D>1)?=<1J?_S0*_`P@%,Y3C(TM7]Z0K7"L<HA6X$US!X=;?P#J(7
MO%O!K?_HD5:^.OL#O!R.!P.)BB$7?5O=4OUL,_V4W+/NMPJI>0#R[8("*>Q<
M+R2J]]C$@,S$7("JG9<+D'8(XAX![1+D^M34,DF)./G_EFE0&NXBN^<Q&BHM
M8Z3WH1MU#T%1@(TR@8[V?O/;:""`>QS#C2U82`(9A.)V$+1GWR.1$,FLHC>6
M=T"GT%T[M69`G^AAL6A_-!E0/U/OH)L&Y++'Y/KN;?IS'$LCYI+C\P+1&U82
MWT,:=>T_.ZYW:8PM4QH/2[MLQT5&*1(^EA=',_GXT>H=^,B`7C8OFR'8M`A(
MRX`_:2G^!'MEN1:DN%'R4T04/)33<N/1Q**/4.\I3RUN17Y`'88T000)+X^>
M('@A8ST?^58P0HR%NYD3>*[W&"8+5:-A7]H*<WF?[=C(*D?"RHKR^!&/253&
M:*3W:C*;`$J6D9F@V-/M]O!\H$[E-7QPMVXD.*`WO&LI(_H9.%L8TZN>\\@8
MTD%II.^N'S-^V>,Z"P@[*0224H),+8]E7,$P"MPM4@3BUDZ_.<$N1-9\^7#C
M!P_0C0Y(CLO!I&^4>:BEETBWZ$A&L*RHA/41M8RM]D967V]%Z$(\Z4%9[3'&
M,;H?"\N;(&LFGMG1A@!V:98/(-?6&?3-Z/_P"F<4\AVT:-;HTQ>N>>QC)P*R
M:]W.1^X.#K@J'DB0JWT9VCA/#XY0">@"X#\A3840O94M^>T.`<Z-E4TER,PB
MR'25+@0ZI-O+,VBF]<,K)N/9$J96+<H#S:,FNY!/R2RG"Z1,R^WE"D?R9F%5
M?CC#X$BJ4IJ6!1]TK8BTN[.I8Z6T'2AETC;F@]X+#-T)J;&K>HRT"X>5[NF?
M3S5E>Z^:Z6:GGBQM/'&@](ZVZU+,=^#5GF+^$515LCNKF:9VZ=K2MF.W2N_8
ME`ZEU-W-/<';L;,+?G8]$)(N?A%0V7!YB,+(\79HBGMI6+TA2;QE2$G$7^BP
M`R5LPG^D5<>%\;9ACZYMOX/)8!UV=@V@"QCKR`FB%GI0@\7^"!]=#V\.H$%H
M3P[^2"&H\<X):C`1U*+I2$:C=^!TU6'G)>C,$\R2VH3$GI%OI7)37NXA)=0L
MG]:?E!T-3?I(W\'J=@UT)5/PZOZI*Q!>@%P)P40M)W%9X?2[&^*L)A/YF5K*
MNF[)3CZI"KE:2JL9UMB*PRXT=XTYQ)!.8'8LA;@_?+<N*L4;&Y#T>.MZ<(X^
MDA<N[VQ7L;^.N%N#OT#8K"QZI*,)?:1ZWSG0B%T9-2L`V&D!\"<N`D@9438N
M'\@,[\G?HS<24JKGLT=)'/E9('3$63XI2W)DU53'\P0KCB72._1?2!YE=.<`
MU9@^BV3/^GVZ^#1;@_D"7$WOYIOI+;B>W<ROYK/%U1_B.7\2N!M\3R#FCKQC
M!<=]=:0*%;@+G*?EL.6A(<@CO8\0U.)6QN&2SO/FFOS,3;A3I4#MF[V^Q.6L
M0H]MJ<<B04;`8FD<63RF#U3O0P3-X%4N:36!*:YI=4A-.0M9*JE97,HJ?:!6
MCRX26IH'H3:"5[>8U03E9#5+@)7S,#S`W36)<*-G8NF2Q`)^(S]AG[IO&?*R
M\C&!Z("\(H(>\9FA`;P03E<:+<W7:X4$4K//)@(M.0Y+M\I<4IL$:9*KTW^.
M-\V.,Y']TF+MEY-0DIQ>_32GQ$MF;&!B44?0TGPG3D0>^5XU/RB;QH#06H!6
MBU.IQ.E7P@N`ZM(2O+$@=8`J+HRP^B-Y^2KY`4G4&]8'P*1#5=?,C(W>B+YK
MW5<1VPIW_E&)!6;953_@,7"\.-XCN0:K33A'"]*I'Z$TTSJ^D:NJL<F8+KU9
MNF\PM93MK",:`\#*JUO`-`CPA71DF>G^[2C16'S!*HV+O$@N*+I(;R@BE]C=
M">02J)"&9!PZ<J(D9J]EPB!%_1K%;-"XT_K8\:<O>OP.%A)XY3GG:%:+3&B*
M)55/5(Y99]03UI&I4']BTJU0ZQTL!7.*<Z;QIPY3[82*5.Q\/D5:K?1K3.73
MJ6H\\A2&57P6Y:GTXT<3ZL>/-0]V:RO;V0<?%I3,,REE.J9\(-)+Q[@&J$KG
MW:1Q9&/-#W^V%.V<`Q<#/I9!C!9I>7TK4R+73)9Y[%;&U\",1_+N>&V#K)T*
M=OM,N!(A5[5J)=30>U6^,QEEJV=70+ERJ>=4^@(D30+2YAF45M+=/.]::4NN
M]A%OE=P(:UDT1F"L]SYTIW(J\5Z[1%R[I')QLI8BG%_\S@F6`8FMHVX`&L[)
MJN>E99B&M(2Z#`#:*9Z0A"59R2LKDW<5+W_IO8<F(`V[KK3*T\N/["BQ^05X
M<0+PBHO+H[_LA/OGIW]=4O[*RGV+7G@Y&NN]E\4MBVP?CQ?0">-1'?2X`:U%
MYUQX!D9WJH2U@.Z<30_1$WI[_T33/LN0>"E-3<>=L;Y9HA*V%RH1XT.#8L9Z
MQ^US2*'>N#<@.J%X5JY[/LNVYNKY7&>]"Y608:%!D6.]3U@QRZ#06M<".:$P
M+=N"R6&T?%C!5^CAV]$&=)P>]N60-]=76[K6P\X8FB^';,$@#M7MZ^Y(U^!F
M8.*$,M&#CWCP%K6JU1CLJ^6:'-E;S;[.%E]FZRY8)\EB2B9=B57,%S/[\7TT
MFF?!JD$MW_)5=6WCG_#N6OPCY[52\=4`B;.;'4VU1O((5]5K.^ZQRY+>+U55
M8V@9>N\>-R"73<?Z[NWTPHET+B1\,OFTIX].Z&ZGWN[:W1^0V;Z<]*RQ,IZ>
M=-XM71LEJV+M:<7AP*![#WV]W4HN.50SN@Y,";\O`*D`'&\'XBJ=\GP9/<'@
MV@VW>S_$>01SMFTH;RHE"$JJ7K`_"49]J6QP.)J\KT&`3[`S:U0].C85NP"D
M%9!K1M9`TT@[*5NE[U(!"QNDH@V:%LDB/!B/>WAN;UJ#@=X3A&X%5;)%VBED
M^V^S^:??<<Z:Z=?9:OII!A9?/G^<K?`L>/W[=#5;DQ0VR\^?EPNPWBRO_AU\
MP>EN<#*;Y>>[+YOYXA.X7:[7X`Y5(C5^X]/B3SBT,$3X5]!]OC^@QT)V?U=P
M"]U7)$Y`/Y&$)GUS."D+32I-8<W1<#OM:R=!HG(\K9!E"QJQ:>H]X+602O9H
M)P[-IE4!J@N.*X.D-E@&(*NO0".8[E_06R6*=RIPOR*:4L;4.RJGA53L.M'N
MQ@1QB(EN8)\O.-:-(-$-<KM74A]@UH!'_Q4&'@&\!ZX71FYTH!&PN*&MOT>H
M_(">,7QQ@LA#XV=R31A$C_Z)E-O!5[CW7\@Q0_@=GTHDIPJWAR!`$T(%6LAR
MM8+>2EAP!3FI,(RSYYAZA[2VD$J)DR>.S[Z%80@^T",;97K(JP9^&-X%_H.+
MI@L]RR(9*B<R9DZYGMKRO@YRQNM<*63"QG0[W=1["ZT&-0<O?61E17E9U;_]
M:46F`:OES7S3`<>D+(_)Y5B)3Y^5LB9C&I-DZCTCKL0LWQ\O[]@F/P#Z"Q^Q
MYM[6?X9IXLMT*MP?#>3E;:_HM!W?F"5)J%=5`2MM'")MZKW9P"B!;%JRP6C,
M!$S6499WL]5T,T<%A!<]%S"BB&Z14B`0_=%0VHA\U%<[_C;!3FA[6FX\[,>&
M0._PP5K<2D;F.@3V8K:AJW0WRQ78_#[#JW7SY;6<C=USK*NKV=@M3([00]^C
MQ_V"''U<SW_8DC`V<N($I[UQM\C_WL6M&"-K%%_G8.J=,Z*-6$JF1RT`VA^G
MZ_D5F"ZNP?7\]@LRTIP&V/=\U*\3(<)0A9O1E0:D<^9$7N:4RGY;&F8.<5+6
M5]?I#P=Z9PUJQ"[;GV@"8.<+`%H"_!R7X<SXP_!RY3@.9^-JT:&HK#/HC8:&
MWJM4S>#5N!9-,.R;^6*ZN)I/;\%\<;7\/$.$_8\[[`ZO?P$?`/(^^'B[/.XM
M]FB&D[XTZUK28SNNLHF0L+2T=-\<T9A1S4UJ,WC9-K41@;TL6%1<B-.<UKY3
M*894+2T+QK.\]'AHT)G%0.]D,@SHE9C/9AQVO#`0QU)PLA('?'QR7"_$+<.0
M[.64^:&ENU&GM5O2JQE+RJW3HF1!A;KI`[V#&IJ@2S=W]?W;-,2.%`"T1%>,
M8HHR4$6I8KQ`Z8,9T_,]`[V#`IJ@J]KY;\!A;YX@R?CK>&]_"6DB;9P.YWB'
MWGD,(%DMY=QSKW[7+!OKJGA76`4J?V:Q\Z'W#*,)NI+5G`80-HXTG"[^^,N:
M!AC2X,/;V^G')5U-!]-/JQE991>@6WYRDTTG)V-Y&T15W7;`5S9ACGA;7F78
MTWS.T0!=R1!<W7\\!!\MY<0ENJ:HG%/-Y^)H\;!S59T!FK)8AC68T$6(=S"Z
M,PG!0-PNCD$S`\HM[21+.BT93&=!EVCP[LD[KUK1:\?TK12EDKQ)#7-HZ+W[
MWH!<N7T]ZK[,O-("'7-3RE;F>;A9[K66UABBMT?U7^]0)48)U/FPC5@*"^5\
M?%W%P<YX:SH+=4X'T>%X+"]Q;VW?[;C+*U;"X,9ZEDGG$'K3F$<,V7:7`XN]
MRH?>YTJ+>;J,))#C[IZ?W$7'M[8B]M,&/3-9]-,[:)E3$D4N,!\J>S5;SZ:K
MJ]]IY,CLZ^QV>8>7'`3=XJ3W7-<(R,Q[=#T(@\PA7\"(K#R5+4>4KH)Q--P-
ML<4D.&4Y2RODH$.\+*2W]]Q"*E46GA]:9O#SQAX?@LS53HP_0/45:`33AH3>
M*E'<QN!^1;&5TCNHL(54JC8_Q"$>.T-EYQ`O@`=Y]T.$^#0<OGN5R$004@D\
M<-/(_('>4>,MI.)VDC;B`0SB,)N]I@O^Z+`X;5YX:8P,B9=>)-VTY7\EV(S;
M21%S8`QHEH&AWJ$U59"5++54=&Z+9>TLOB!)RR=RV%3B4*=%S!X]G3G4>R^O
M`K%\1[BL6SOYFO-Z.[A'7SU^@AX,G#VRCM/=L^NY^(A7Y+YF<<HCRS+EW6G'
M!*(=`X4%36^O8VS`FAAZ#]Y\@LAF,Q<:.RY]`>+RQ&L]KB&VBL=+#SG+>3HJ
M0G&!CP\MV4+HZ;V2+2B1H@4_,73V>G9[.U]\0KHR6\Q6TUOBRDZO/\\7\_4&
M!R!]G0FN`?X-NH]/2)SI*P+R"!>'YWL8+!_($<3E(0HCI)4(Z.EI1&/<,R?2
MW%XQ4.UTJ;,'D:B6:(,C:Q0G'ACJ';?7C8!*W/5.H+8]M=F685+\M?>H:@5_
M3K3!27]`MQ*'>@?[=R*?;.^O"Y!VT@B(6P&T&7Q307P?2ZZISM-G%W+_*TDC
MH.@>@Z,!J@G+W_?W>YJ?55_-X))!^C##@\8^SE9[FMZ6,WOM=$^X`G=)W@BX
MPZ<CD`-)=B`27W(X,>0-(VP8VC%<5,[TQEVV^N,A.6EBC?3>RA*01O8(P`_)
M3JM0\X[S9J#/^5IB:P"<7)%S8[5^.E&\A9JI/KG5>#0B"58M2^^57$&)E$Q#
MQ+#9>=78YLJ+7`VV=O8P_`RQ4T62?4B^'BS773NB,Z`_OB8L7]0T+7W=F#K(
MLBUV1;_I[6#D%_`G_8TS2USU&Y-B;97QK6!#"T61`@^'EF%=]JWAN*^WN6P&
MK\0R-L(XO;!.D)2SYY>]_P;A&@:O[A:6V^'83*-/^/*\K?_HX>L_D4/O^CL,
M([QU/3B/X'.(UR3DI=OJ&&S+^:7L)Y?>^])Q1T-\9)H,I7K',TB56_9`(A.\
MG30.XM8KYPH7(.N"VHJD$T![`:0;\"?N")">..U'PX9-/%3T!S+S1[-`:*?K
M@E*F*:>9JEMC:T1?L=[;'`+2R-8V?DAV\R:[X(AZDIOX-E:_Z7<WO.R/AO+2
MI=5TW([]7!)5Y+H^JC0>:YYKM1F\;$8W(K#CG&EI$9"4`7_B4MVP]MI_=EP/
MO65+WK'PVJZE,+=*J@;NQM7&DY[>1[M8X)^)OWD,=0RFY3@Y7'MX+!X#!D.)
ML7X,`+H)W.>2D.GL8C*G'X['L9^I=_(.?F%D,YX;4>-974$'9+U]@KO#'BX?
MNIF$;,B%1H.Q(6]B+P5RRU!"-4\QC<"5TITQLLQXV5SO(4N%^+(-@`(9[*0/
M/)GO?A6`],AI;:;(8NVPU;K9.X^7QJ!I`R6$V\M'__77'72I?4`?3LT"^NJX
MW99[@K40TYV_HU+TD0_U/M%<!5GZOG9YOW;Z/<`_<.Z.X/L@48MNN'7V?Z!Q
M<8;&4>08XF7OCBA5U47+C1%6X.GV2%6%?H\^2;V/6+#`E[Y-UXS!CLL`6@C@
M4F"&'2U4CH^:U_'Y97*^,D+O8NX]^,$SM>+II5_F<&RQYH-@:;$=*P4Q)QQE
MJFZ88\.@*VI#O==S1,21S6$!3'92)T[P@&N!7#7A"\R2=JFN4*?@!GT7HIZ;
M%NY9K6]E']T0O1GZ*;>+-8R^20.Q]-ZB9A-`%7]K462,C<UP['"2@FTXBLUY
M\IJ[\@\J>NB2G]6PR]F9E3?Z<9"@WINV+/#5,K,40X&7Q#UHP4K*Z]3U&S4M
ME_-R\JC];AA9#_F4C\>E3>IGC?2.(FO$KHJ)50`R&L9VL9V#ND&X+OM&4\($
M7N[A9KNA7"G`4Z:10F:LJGIOA5=!5L6KDWXS.N$?.`/!B#=YA2H'SG[N[>#W
M?X=OE\:X*_>OM/V6$5A,D-,PJO+2/8,^/;VW.YK!RZ9<(P([GH_$10`I`U`A
M(1Z2JT/7^.I0>LPM=\KMTIAT9>&:.^N$H3S"G-"UMBI-=6:-]$Y`P"F)(B(S
MPDE93<H#4N&BY.BE",EOW#T,KM!H_^@'V&XU;4SSL?JH]2YH7`_WF+?'92=T
MB7BD]QY4`W(UO*SJ/N$A^1TD!418MX*/)-3-BQ8.SH4^[FKZ7-9\%[QK`'Q,
MO-/"O=C7UGLCIQ&[&O)5`TCHEY4`N`@?_S:!@TWE^NWYWM_C8]@=$>^HW7:,
MJX>84.VXU"A^2GIOVU1BEDVMJH[M^`=`?^$-5WQ%;B:R@-=NN-W[X2%WOK\_
M,>2%>-5TW#94D4.B+%"QNI)ACGO#"7[:0\VWL3FDD$U6=BCV?/%UMM@L5_/9
M6GC?I:2[#?P>?42__0.]\/%`7LA57=>=,[E.J!HN9]4FH_Z(/GF]K2R[$&=@
M<CD2.RT)LJ+@3UP8D-)2."WER.NY.5TX"5M7C9QJ']-,_D/-]\^YY&!G=HOS
ML3R(\J9:D,M_0Z\#7OO?//RRAR1UQ%@J@],..^)MG0"8K64%)SUSV#<N!SW3
MT/B\#@-R=D:^PN#>%^%D,XJ<G?V&RWS8H4*"=+S!Q]6>X.Z3[^_"!8QP!&D(
M@U><.-D8FV5Q2!WSLQI!1X3E$K%@;^MJ]]#;UI;-G%(H\R(:H63TO@!)84!*
M7^!K9VC<,:TAD?1RW0HM2%_M9-35-@<#"UG]<7\\U'L55D`:M0X',RX[58-'
M7%20]>3^#F-LD)6HB51ZM[Y7I@%T@;#QE3V]$=W!MO1U,II@<U!0_,J7&@`V
MN4D&N$D)0;*MG&^?':0DKK,OFI^!O(LXF@%T1$P>`0MTK:F,AL!W0MY&(92Y
M%$U(\AX%*@O2PETY%`QDD.M/:,#V:F^BLK)%QCE\0RH>Y]X[[0O2J/4FF''9
M6`6>DZ*BRQA^\(^Y=Q?X6Q@6&6$IF#=6(^AJH8-'Q`+IZVKW>IH'VG!(H<S(
M-T+)6WE<&/DP("[>E9UGH81<0Z\%ZZM-?5UM/*49$R.D^<D#`6G4FGIF7':B
M!R^T;'=KUI)MN_PUZQK+G15&;^V]&.I3T.KL\DG/N=7IOPFN3F?Y#]*VXC.X
M)*]`;K]L9$IT-5AAM"-I"V&+*3\:FQ@9)&QFJ'FJ<4&)9)->#-91KHV<DY*<
M*Z?9,H#P/CD_@Z3X*+JJ2\%;86V"[OX:%GV/>OLLPC(I\5Q$T65C"6<JF>W6
M/WB1ZSW>^7MWZ\(PC;T:&/(2\U=WVX[S'.*D.6BJJQBF-1G11SS4^ZP2NQ"R
M#3\S$GL]_[28W\ROIHL-F%Y=+;\L-O/%)W"WO)U?M0GPP_=QA<N'.P06:03-
M[>#MUNZCYSZX6\>+BA`S6S@R^WUI=K\-LG9ZT>TS252G5:LD7LBD;-![>[1+
M,94,(AT";M+2,ZBFE`'IG:MF851K1X'!,#;3>L_INQ-2]JC8&5*;M(2G1_FV
M2#;37&L@:PXD[;4(+YZBEG;X;DOW%:[A]H!(@!J<?=_N#SNXNT%4QJD/#U&<
M6;%P^^`SQG(YZAGR+B3H!&)+WU/.4TK]U$Z:-WKTG.U@HO?Y%`G22O=\.X=L
MYYL$69L@:11@]H%<LR1':=PPSF]"3TU?`-KX.;5>SNV&/YK6%^]&[(94YKC7
MGU!:Z7V81XJ\2IQN&<CM)7D;(8A\\(+Z?W)"B&]?Q&D10IP6`7A^!%POM@:N
M!W;T"FIP>[<&]W#KH'<*HB<(X,,#W$;@FW_8[]`/R&&(W`\)7*5VX>-;>0/D
MFHVA)?%Z8'FXSVI"N!YH1W:EMD^C1U?T!Q.]`Y64/0/-/0]F02K]$9';;\K[
MQ!D.X@M+AF-YT_VFSF4H=(UH]5J9JXB\0SH5[.F]*\DGR'GTHP)-%<DO2/8-
MP6MRID&`@)$;=T(T\5^@5Y-]LT&?0F=+1OKD!ER)-^9P8FFI"BT%3S6#LYW^
M6',_5T0>Z7HB`,K.5R+K4*C:AUP]D*\HJ#Y7_A[]Y=.[`G,=W@7^@QN100P-
M9EN\'/8(28KULB0.I6GAN9INIPMMI<CN>N9I!\\HZ)+"L*?WSGPKN63K1AMP
M]E%ED*L-:'6Z3`.R!I2HA]'_(?0C$Z.%@L3#O]Z'E%O)Q:X@NSBC+9DNJ%"4
M%.2)HN1'D1>J*"&JCW<U7K(FE.B*]4.H2F%YD?]EQ<%Z/;VSD+>22\ER81N$
M]MV#^T\8@.EC`$FE"_!PB'`*H0"^0N\`J2,&XRL-BSK#JS)IWM8[)U@&Y/+0
MW5=G?X#)$L*E99B&M&5^!@!MU4E`PDR'&BN3@V7F*'8(](YV$1%'D<9P`[.O
M<FOE%^#%"<`K+H]5@:@%IR;<NENL47CK_O#RLG]+%?#.C]"_KK._(7IXY[SA
M;\G]@TMO`6.M#B_[EFF6S>Q+QY.VO;73"0FR)AK3OFESTC/U'H$ZDU'VQ*8K
MH';<$+DGBS:5#5`@;0S0UD#<'"#M@:5'SAW&39Y+*9DF1#^*5A:G36W;-OJ4
M"WI/HCJ44M64JCO(/X"2LLS$?A0=+?B:;9NV*!'T/LS0G9!*_-+.X*;*B2=O
M(55.)U7.EU0YX[G>"VV/3P\_NWN(O&$O08/7!B9E^ZRE>G5:NYV>,&!)>%\H
M2M:-X@FQWI&,3=!E^W<-_=OI[XFU[XI03-Z4*D85O9WRYV+0YZ)WX$H3=%5^
M20..'+5B6\6Y5EO].EF<`%74*@S2Y8^E3Q^+WMO23="5#*@-((JT`E'@/C["
M`.[X^+4XX&WLY</Z<!^Z.]<)7!B2]UIV\+648V4MM.,9(Z:$:Z7%\4'+"4TV
M;^@=)\0"7_8`R8#!IF7`\@'D2W7)-J;14C7=BJ-F]<.BFWB&WJMR+/!5C9X,
M6!+>^0]H/I`KU27Q6(92U;PK#*G5SVI,GY7>D2TL\)4,K0Q`<IP3MW5T@W+N
M;?W@A>QQ^EX2,X;><=DQP%+>53;3CGP\Z!(&5M<ACX]Z)X;>2Y_,,L@><EF!
M)!O=1R7!G[0L9PPAPTMG&H//Q\GB:-SP'.DI?D/O0]S,,J@:EUD!U9.3<XQF
M>/TL`_7YR%D8LAL>([TIR-![)9I9!B6#-RN:3JTF3H<)=R$]1)2$+/D!\AH&
MXY&\%&F5_;8D,H<X*9&KZ^#'3F\G-/1>A&:600V1&=&4Q+D=7M#+Q+LA\<I/
M`+?0?>5=^&&@@92C-^=C==&?K:DSZ,<>F-Z1:JPB2/=FV7#82;DD:T.NI#A]
MUPY.%KB,GF`P#4,8A09YZ?(N,:WOO#LB,PE6QN;RBIKG/6`30"63*U&<\!B7
MPXL%I"2@1>706;JC<2XZU[H<)14'O=%[LLTU$BAW-ZJQV"L:.T]9'<:L?@G\
MW6$KP.C(V;O?/[K^!O7DO,!#Y&[#J@G4F'D]C+G=UL05QY\C,6LCV.T;QVZ?
M]G9:4"@%MEL,F9W4!*@JR-?M:@;)S26VA3B-E:%DJ8[O]4QH@$Y?[^U;<:&4
M+>:)(N36"MX%/P%6,:T`:JP597X.U]NAH46&WM%9XD*I\H;$X"D:)VZC7<(;
MRQBS;Q6>5N^&WG5H3EF<*VM:`\UOZ:L&K<I1*?2<$0S]U#V+N)P*^32J=A'2
MPN3<AC48O0\GH`RVZF&^!(-D5HVU(M6XD5-C^EST#M.J0<W.J%<8W/MM1\DB
M@B,^78H2*D[F2;-^;OR/<(V('SZX<+?Q5W1/8^9%;K2'NY7[^$0.!:'!F'DT
MY&Z_)26[D"?EK$!C@_Y$\^0M+:22/B(+0[.3JG&&:;#QP4<(TNKX[[@!D+0`
M:!/J%(9MX']'&E/B.G"WA@=(_`XU#\!H(Y<RYZ,%2!O-H\##WO>#+,&S0U4I
M>G(B@$\YH-^>_0""[2&,_&<T\\,+TR2I,V[T#3RC[T%(NGS#.:#)^\0IH^_C
M(ECIT)];&$0.^CT@&,#!(\50.V@V^4P:W;GA=N_CL[ZYU$N\X<9MF,VTPO&.
M-+6XXL'=F$6IHGD07PNQU*QZB`.TXW/R..^Z&Y&HDP>DDJEFQ>I$]4TL'F6]
MA9Z#WND-$B.=$X]Z/59WKUB_'>69\&271!8*#WN&,:8+1WV](_.;P<MVOAH1
MV$D)@(L(3CCJWBB3?Z228D7_INHAT>":OMZ>?S-X59Y*(Q+I7&,9X%52K>3*
MV_)'1,.^^WJOFS2#5S+8-L*PO[SX.)F,$X`-\CW!%6K?W3I[<`U?X=Y_(8-L
M>LPW;,G#I0=SK]W@'533ZMVPL`[-*0FSLG@KQHK55.\I6R-V50-J%8#,QJ$2
MW5.+:S25SZWJL?3D^<3*J7=862-VU2-I%9!RDG'.I&M>*\\X*I]DE:/HR>.A
M1U3Z>L]E&[$K'4.K4-`A%#K;)W!S/24IHV:'P'^!C@<^PYV[=1'OIH_0V[X!
MY^4E\%_1\-K.V&T0U_*OGCEM5$D#W5"Q'M$I&?.EL3]BT3//?;V/[C"@5S6B
M5D/(S!TI(X-H7..J&J95CZV%)T6C+?MZ![<RH%<]OE9#44`YGD%6#>,J!]I<
MZ;K'-X[C&_6.31(72NG0S`V/CMEXN)YV-")_\W,,84XL7JC>$6-KT!3XFI;%
M;LV(:K6I=Z!3(W9EXW`%@)Q)_.9W3RV^$5@ZMVI&WZ/G8U']TSQ??"-VY2-O
M!9!RD@G.;$M>*]>@*YUDU0/N\>.ANS7F^]CLJL2N=OBL0!&/DNX>WUGC/X`[
M-)MUHL#=@KGW"L/(?:1AYG>H=;SK.OL\;6GKOGCA"]RZ>#,XOA!T8(W*-E^[
M.7):V6TW+&:0YI3,Q2K&:-BC:PV:I_-G%4'5V-R`([6>%R!74O!:S+7[Z*'Z
M6\>+IMLM#FQ`*G/G[]VM"\-;UX/S"#Z'Q)@Q9S1E:[,E4T5QI[QE:X"<7Z&7
M`6F>\EY,(.F<%D%EYVJ!K!I(ZH$_<4U`JG;)]XUSOX>$,\QWOS:W)Y'G57B9
M.$XKDW&3)JDU-5]3YQ;FK-PN0]3,:U)+(J79YE\:<;IDAL;XU&D&7%/SS4AN
M893-X7B1L9*;=YJ7M4J#**_2&,H5Q`X/ZN,S^O?Y\$P#,^GO$=Q=&I9AE&TP
M=>2""P/K3'O:/Y`2I>)N=#S0?=&MM7`*1Q(QA$F`<5;O`J0U05PU.6"35E:O
MB5+R+[UG32PN#@DW:M%#T)KO#W8@GIHEIO9`[0T^Y9E<PY7%_G.J';ZC%E=+
MIOW3[VYX.31&$H>VLBY;Z@J;%*D6E!8WK/&(Q@N8F@=<,,"7/J8T8\C6X?_$
M/_+.._"-R$ORH,.IMUO!$*^P(@4@]RB'N65PY@P<3$VV):(8ZHR9+/6-T=B(
MD]":FAMD$7GD<Y<?E$TJ@;@6N9TTJP=H1=%%?C[.L$VRM:-ZR52;]37TX\L`
M!YI/!$3D43;A%@#'Q7G>B3<?>YCV7+7C?-']9G\+\6ZCYG%0(O*H<;`%D-D)
MTYTNK?N)>W\'@S^@$UP.)GV#_:1/>2,MR<R,+*5O58W>R-+\WL@FZ-)]COK^
MBRLL`)4`N$C'=&-S'\["MQ(7H;R*T:?/37/CV`A>V>#?A*3S)!\OB+Q;9P^]
MG1.`-WR,$J?W\)\QQ[^YT9.$K!Z-]&+R(<Y"_**?4%[#(N]+\QM3&[&K&?\;
M4"0&-[N^_MGY3I:QT4,(7?1T:0R7T!WV&X1R^3#-N$R7H\S29*'=+*J5=MF.
MMHQ2))PM+VY,!CV]5]-J<<MV"^HZM_&/V#SF?B:NZ<+W/N0,)=B@CZ&SI;ZK
MR%K;1R=T0P3C>"?VC?Z[@=^CCZC4/RY'9K\L@K\;`K-A:,=H43D3BC/6-P9#
MN@@ZTCLR440<V0HA@,DF=8BBI+4N:&#`&_@S_C^N"DA=N;HA90M20]THN"QL
M]:U+PQP,!G3*/=([Y%%0(B7NC1BV3%/N4!_)=()/'Z[A?71*"LLRRA*_=D/^
MD@[;,9U)@H36985-:Z3W8D<U:-GFN[)G&__2G56>.0'>(@^16T]6YT[[G/3&
M9=F<NF%D0^?MV,DM6<+4IHJ&.1X;L2G0.VR14Q(E!I</D[V`$=C[84@60D)<
M00Z_I5A<+?A=L,1-%8>#/HT6'>D=:<XEAVQ[S0/&3@J3I6E2O#N#OG"B0X`O
MOGN)5U["4RCXDA[F`^2-S;4CL0C:A,?-=;$MZ<73&[W73KAED<UG7D`VK0"6
M#R"KHI3-3/LQ^M"YN$?#^,AI),U([RT;;EE4[>#P`B,;.DYV3.*%$CJ`>R>B
MN=;Q!HQ'R8_F@WY&_J-='<X]&`XBL>S&Z$/[@K?-]D(,&DNC^7216Q8E'C<O
M*OL3]%#)?7?+&5(FCTJ7,XYH6X/@[_O[_65_9(VPMV<-QQJG7^*40CI5^?#8
M5[[W"H/(O=\C\^M'D/.6&1+6].3OT:L)9_]U0"]E@1J9WH=1X&RCRV&_-"5_
M5W'[=7UW$%C'(==10%UU/60A>O$90LWOJ.,31+8;S87&7F^65_\.-JOI8CV]
MVLR7BS7X,RDK$@M=Z/B:QH>@X2!G_"W3D+?$QXQ#!NW9Q*U7@=(VL(M(TR!H
M?KV>L$QJ8DL$T94HBG3M4#@2Z*`=C`-$:1OCGAG/GS1/DB4HTGD&C49<=K[>
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M413I)#B:GKY&GO%3)ITJQ\CL<9AQ1--`\R#(6N!*Q\%2"(613]!"T3/W<V\'
MO^.;KN=A>$C7C^B_Y$B4:?7DA9BS86C'6%$Y$R(SUC?Z`X-&-PWT#CH0DD?V
M6"P"*LX:`>):.+:&UOM+F"QFBIS)JX."#P;&N=M-2V(24C8,\O2B3DX6O<C5
M1Z^L'Z^+Z!O;("S/.?6B"E2S7EP`<L)5[&J!N\#?0K@+;Q"3\LE>9M]AL'5#
MG`5SV!O*VR%N[+^=6HB(EZ@$0UTTB>W1H7RH=UP$MRQ*/"->5/:5$SZAATMK
M`?R:`8S+TO!+4IWW<I@GN#OL8;Q+\?&-;$C0Y-F#\:3LDH&NKH>I[+CEAB^/
M1-D5,=65C-%D2)<6AWKO>+$+(7T7EQ6)G93,ML#NWP#=%!.[:0"W08:(W?4A
MP&=:(7I-<<(N\N]'!ZG6E?_\`KV0S(XO#:L_DAP%Q(>H@XB'UH_@*/:!M[51
M?QAO(`WU7C;N0#HE8T5[G#9.8X,\J9`HF4N:`FCFC1ZC!TG:#YI3J?V(TH9^
M\B*-WHT&ED<?<;<V&<:.@]Z;XNV%DSZ6M4489T"E30#:!J"-7,1I(>/_?[C'
M+8%\4Q<`GP)&NGCC!P_0Q:<9./7QQG&#K\[^D`NB"M,@7`117C:>NI[;*1B?
M3(DBU=?"L?5ZK^8RX9>M#BP@[)OI?`6^3F^_S,#GV73]937[/%MLA`.ZR_K,
M'?:V!O+&CMJNNR=QC51U+,ZEUK&&[X_$I_#/P>$3##8N`TBA7`1IV"*$E.UU
M2YF"G)W$A5E%;36:<<B,SSOIO5_+)XB2N0(7I`I37:!V_HM;]`E]F7R%_L%^
M"_KF_P%02P,$%`````@`[H.H1-K+I"2S'```4ID!`!0`'`!P;'@M,C`Q-#`S
M,S%?<')E+GAM;%54"0`#H.EK4Z#I:U-U>`L``00E#@``!#D!``#L7=USXS:2
M?[^J^Q]TWI?DP;(HZC.5W)Y&EB>J]4@N2Y/</EW1)"3S0I$*27GL_/7;`#]$
M22`)D`1)<38/$X]&!KI_W0TT&MV-G__^OC-:;\AV=,O\Y49J=VY:R%0M33>W
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M"]F-_0;^VVWPM5O\T:W4O96E]KNC!21>,$.?Y`90;K4\G&W+0,]HT\+___H\
MCP<9?^%N:ID:,AVDP0^.9>@:EOPGQ<`<KUX1<AT@A8S[:J/-+S<@MMM`.IC0
MO^$/5/4E_)K[L0=M<O3=W@#([HHE;.7"GSMDNLYR,U6<UP?#^L9&H&.IFW))
M!`I?%7.+G+DY5?8Z_.X]VNBJ#H;XP4JRKFKU(?I)L>$;K\C55<7@X&!?NFHL
M]\@F]LFJ&U:%)&:!U2H<TWM+/6#2)J8V,UW=_9B;&\O>$1(9B-(4I!=-TMQ\
M`X(L6T<L8A0Y/=X)M(.!EIO@PX^IM=O#O@FRO$>NHAM,)#J6`(..T+E67@PV
ML-RBJ5CI6U.'E4(!%5)5ZP`Z9&Z?0/-5-O$Y2N$JG4@2N]2`,DTJE3;R?Y8]
M`D@K'C774O]8VXKI*"KK$NH4KT[G5'#(RRW<Q!X4W?Y-,0[H"U*<@TW6<`9*
M-F^[=$KV-G)@.++0/L('P2_HK@&_T>ET6[>M<..`GZ?+Q?ULL9K=XY]6R\?Y
M_60-?_DT>9PLIK/6ZM?9;+T*IL74%^8`>CR@=Q?!;VB>RQEP85BJ_RU#>4'&
M+S?PP?_YF@T[W`=>F&!K@4_L`](>=>4%#A0NZ/KT8./M;_+BN#:(NMWK=MM2
MMST\A3?J]V\4YX5XP`?G=JLH>WQ8D.^0X3K!)U@2\FU'\GWIO_D?9Z'GE'<#
MN_V6'0B0AWG090WY@[?[@T&G+"ZC$S-Q$U7(B1UPMK&M77%2=2TND"Q;0S8Y
MQ^+_;EI[6X?]SOT`^[AI'1S@Q=IC<H_^DV*K%[I_>G3ROW&W)^[7K?JJ&V?K
M!GP#3X4V"`C2'CW1QHY'!G/AR(W(-[/HR!*\0/O(_K@T'8E.7'<=B0/)UY%N
MXW3$<6`-/@=K(`W$*0=MQNP+(3ZG@P+@_\W^/.AOBH&]YHD[56S[`[P>LK&V
M!Z.>+(PC)A**47PF:06JS0U-TQ?"9Z0B@`',?('<R$;0%[X2TF:N0"-8@6CJ
M:D=6]R/S3H1[21X-AL+T('[B"K2`$05?">2F*4$89`&^VY(T$KC71:>J0-"Q
MG/JB[35-M!X\1URZ`GW<DZD*%&XL]>$BGJ(#3=W%\56!B;1/R(0?W"=#,3TD
M'BP;_\7_W%E8INJO9J/NL"=,`;C)*5-'<F$5[O[]9BG0DVWMD>U^8`3(300X
MQ7L<]R++8[\K2<*4)6GJ,O6"&8*F;OYTG,8UV2$22&X/.OVA8%H%:N*8OHM%
MN;H>IP0'N3.&6(#A44^P&(L_63!*D\+C]9PD^82:$&F4.P+#[SGO$M+$S<-6
M3`25,QK;8&^5C/V,X`QV"*\=AF-97)2!/F=EBI$.P?6L#MF$/[4<V..&P[&X
M6\>3J4H^8M!Y#%W'AAT?&$Q`R*8NXOKX<DP@7^H.2F2BK&7IPE=)X?UZ3CZ9
M/9;CL3^*EK@U*G'J[$I\MK]$@AG#<5^<"Q8[;=$:S2*FF+V6CD7H:PW[-5=M
MSI79,K=K9._NT8L;X5SJ#OOBG"WZI%7J``,,376XGI")BU'@[$$NMY[`)[&1
MJWNY=/`I_@#M]H;U@3^(A$4=*M9MJ=?KB@L=%TQME3HG$OCKV8DS.Y*`$,E%
M?;4,X-7!X5CW(XJZN+M)5BJ*UBY.EN.]-MH!M`'1A%*A3#;U?QN@#Z'H(U%^
M`V1W^?%AQTOT$<V5N!V*4VJ)BG^"1U/O("*<$WY+T>KZ2?V$=U_6_:;)>FKM
M=KI+"@%Q]J=%BG^0B4M_VD,`0%P>;/S$-7$B&*'Q-6-0?\W@V_<N(6M+0[DC
M+O!S.6%-%"$%"5\!ADU3@#3@\/HHE^(;4*>OWX:1CI*O*J/ZJPK?+A*IV7_0
M30762,6`P[Q.8`\@[$M#<=L)"P6%:$PV5D]3'RC79=_!630?<EF6\:8&,,$7
M>4.VJ[\8Z"Q\.Y3[(X$N6\RT5<84F;`(K>OZ;IE_OKM`[Q$^X*C:'K)5;:_6
M\+\OL\5ZU5H^M*:3U:^MA\?E[[GKMQ/[Y/#7<6O_?W`\IWQM/2,5Q*V3PJ2Y
M"62@1\N!S_$T3[;UIL.8GSZ^`D%STV]R8FXGJJN_>>M(N.@(]&I%$)P]R+-Z
M!6W]I!`1[?8@*Z(U;6DP[HB[`Z5/6DSZ21GJ$)X#TL%KP#8><WL.P\.&3>2P
MLV"]_<O[V=2(2S/?[17=QG)H=V'9I5U$T-I2<(Q[?>J2$;.F.BTBL>]WF[]T
M/U@VTK>F=Y^E?D0:TGQ6=!,3\]6T$6S(?R&M+75ZTE@<,CRTU-YPCQ`%EIL=
MZOI?@HT]XS71%CMG!25-^%?ULW>\*R)R+R_N+IJ#DMKK'E^*1`+,UW,7Q;EK
M1#;.,&Y@;KT\XOY88,EFTLS7IU>L.#8UF!TLW$OLBN$"E(<#/G'.S6?D[)'J
M+C<SDGB$T+.^?76=KWL+_BDPO'9OW)6HG@;5J\TW6>V5ZW+#+!+=^M^G9=U"
M`7KP&AQTC[S_1\#V&]R&2'>'LLA&$ZQT9/=6+^<X2SIN2Y+<$W<?D#I_(5:6
M1Z+'OAL\2#4UP)`!23%'FVJ,X[+7$DB]ZY6^E<7G)0U5V<CE!L./6/W#*,5M
M(Y&VRWBQ&)2J-I36V'74EUB,FGMDCS>:I.IKC$ZG3.>#A:@:[];<F#;UJ(X[
MPU$.%.%9DW*@D'MC$CH;B=`T?GJR[^@PB8J0YCR`LI'<A"41H3-[1[:J.SA,
MV.]XI75">$V=OQ`#*D+"D>9"'(C5?S?W;>8-V2]6`5:#MRLGYA@N][VT(3$[
M/#]!.<Q&^?!#%!/USX-NH]B64VVI)_<$^C7LE(BT)#ZIAZ:4$<7ZGR4S7U;X
MB.`.=I%UAH34*1AC6#J2>.5B)*>^&I8)SW#MEG$E>9/4[-(9?`8H;%V%43#X
MX/;U!@(OJ-/FKY\B\2$6+E"CIFE.#*A)P7<`E9A4MU/BKB\DD^'D%J(MR5VO
MHDX88\?)1!H$G^P"@TC`HO[;L^_S[DD2]QM7;='QC;\@)322`CX0E\.<-',N
MC<ZJ$D*X%&3-'!G^#&*-F$`.\*[&2@HIG."`57!ZP=6<R,O&/5N4L?Y1Z$*#
M@BS>8YDK8][H1JDK(R-XUU.R7EJ<N4R5RAMG+E6E&,%K:G;8;+/QLI3>5?+D
M]#-`NS3I3V*UQY(D[GDP'DHJ5*.L@/D*-&Z:`C&A**1,7LR!AB[))P3BTLX=
MG/9@)(OK4L]#27D&<=$&("M@P?&E4W^+R-P2(!Y&24C(ITR3B'L@40QGY3T>
MR2F^;*](2I$H5_T/\'MBS`",[19M!E)CS4`(9W4S`RFG&4A',ZA_/,4S@YG)
M<=NQ.NSW!H%1,0(8Y^;&LG?*:?./;E_<ZZJ,1%3H5&>`*5";QL6-`I]I;D;2
MZ+SKYYC4AJ[<'],BZM0*'>[ABU&+K'9P'EO,ADH#0N6Q6Y*!G#!U;+F))I21
MXGI:F2!5,9+'JH<6</#[G865*5<77M_&`WSF_R.&2)*[W@62D"-K/N(J/,06
MB&J8Y%S[CDM\QUKVD'P<1'UQC__D(ZY^BI<%U;!\]/M0/$K@/@ZB7NF*QTA<
M_10O"ZIA;\_K4[S\/>;ZG#WF2(NY7R>+S[-5:[YH32=/\_7DL74_>YA/Y[/%
M])\!E[F[SH$ZD!L*9V[ZU^_XN6M5QXU=3J'DZ$+GM9S$7<`L$^:XMW:*;K:E
MT9"<YP="+H9H4^8(XUB[G642O_$+VKT@NRUU1D-AU%],5XC-,XHAVM`[EN<*
M#T<L%Y2)G(JYB2Q6X2::IGOX/2FZ%AJC+XC>2%S@)W'F$O20DIG%!D4#4JRH
MJO",7,`':3/%-F$_=0+&!WUQ;3CI<U8A_73NFWIH#_?D-2G7!Z=,W'9Y.E?V
M92L<YTS*SN1==S`+8_$LT*8NUF>.$<CQ`01&$.J]B89L@`>+YO`CH;TG7H#A
M?-5(C<INA9M+/E$)SAG@DU4,\?'OA8BB7LCK&$Q28'DE)7K17_M=+=L]/^X-
M[2P/KN,JI@;[.C#?Z0\$BOQ\P@HDGLSSU;BO^1([+I$26[A4U`(U=YP#TNX/
M-@C.RU/SY+E`W\@_.2#-KM`76UB($*W5],>>^+!I:D.7&"A(\LH)$@(/[TPT
MU$5)$I!I[IDNP5QB^KH,NT+725Z"ZJ(]K)@U-X<^WJAB49%+UZ1X>NJB2(R(
M7<]C=!G#3)<("NF]5:1G%M,.0%1_M(([([`@G]+X8'1-)1'<S;Z2CE=B<\!%
MAS4$45]Z6.,BE3N-ZVNK7^!+W$XXX8N1>.E1C4N!)_/<[$3]8]9$P@N;??]9
M=+%!\R02BLX8XF'V(KQ^$8:O36B=&0&VRZVP^#<M[:+>UT`GC5%B[N+)(O!R
M_M3?,P+.'=U%*V2_Z2KRW&W<6V5KDE&\NI[^J"?.VQ1-?>F.8)GBN)JL9'[/
MDOHVY;&Y'EGA)M\46W/`\UYN'BQ[@W3W`((DSZ_0\HBH!1(Y)BK_?%P0*->3
M4\QY4LZ.C^<E$928:VMR3W=-"D0!*.R><GUJE#]#>%!TAG"K]<,38?H5N;JJ
M&#^6DC)\,F7F_&$^UU-T(\2<?G9V)^L8OL1_*J:*_/?H1@-Q'<#R4%;!N2.Y
MKU\.9*\F'R-[*QX&>,5&A,785B2/'9:CI4VF\Z+^X`*3C:<]E&1)&'\,!%1@
M*1<G"TZ<KB9?A?MP$`'"<TLF!_<5>,//%P\E@8?5A(EKIB!)N%S-W3U-,?)[
M;C*GY[;"KMOR:?8\6<_A"X6Y9<YR$U<SR%.ZY:?=!RL`>/>Z.C&U>]TXP&SD
M28-[W5$-R\%N?*A$TK`O[JHY(U'9MY#?$7Z'%6D34!EEBQ8'7(,`1H0GCX2^
MS^AH2Z..+*Z19C:BBJGA*$HK@J6E`("O9MGA;;9YAG4$S(&X=,.X6;/;4(K.
MM,>=H;@^]BF3"S&*>$&%-P/LD(3'C^L+AJ0U+K)V*-RTCKV^!SUQ*V?,I-EU
MVW]ZV&E+`TG@63R8IA!U94;^6(E'8;*IQV*RA>%WVAV<<(-(FZ`Q+6^7&KH]
M_^UJ!);(P]4<WPI>4(0]+57LBH+C3\M-\*3YL"<+?&_M9*Y25/7RI:MX?NOO
MU^5X#RT1)2&]9PK7U,\V+"Y/MK71P=/I#(<#8:1'9BI%2R_:W\2Q>CT5+7Q-
ME)X!/Y@%]V:]!\LT+-(D<?:.K_906^J/1@(?5DV<O*)5B@.0^C\GDG79^FPK
M..?)U)Z1OGLYP.Y,PDW/2$7Z&QS^;>\GDN:%/0Z:/TSUFC@&KL:ARLIYF!!1
M6UT0Y&OUKV('"ZPZ8M*X*:RYU4V$<)V(;^`+Y#6(I?)&U6B.D<M9T?IQ*QHW
M[_5_V^9T?5OS;7UA$\^3JHO^N"O,NZ',6(V7D\;Z]134<;>,I)78B.H`6;68
MX]F]GAJ->`D7OO>S1'<#X*[@()#YE<?<P&6X*PIPK;$SG;$OMV5:IZMM>):0
MY;'`Y2=NWHJ6(B88CH6.X\%HV*^S%G"^_80,^&C[&9F`@0&F,=%VNJECU/`[
MT2$6@Z%7,B+FO,U&144'[RP0U;_#<-83.%DS+XVF#:>/CK@KX9A9*[S;2($@
MLF#(PWXM-2#'Y524^>-R.1X)O.6(F[>B18$-AJ,6P*9Q=>M`_GRT7KY\-&%E
M`R?Y:<74"<QV>\/Z0$&!&[T<96(0!86?\'T3*7[["VE>,1S)^GX,"UVD44=<
MJZ:"B<U1>^#-@30Z"8%1]<>2N(P,-AJ*2=,1K21AY0$WKDU-IDA;VH54QA<>
M)EZIKT@[&&BY*4:%O$+XWDCJB^L.((+D4G;[R_X!HM&O=Q7^&5Z//G-^,X'N
MP.NN6(8AG4Z=_]:%>I<:='GO"WPBA($`$:J>)CJFN^9+?.JMOBD'=Y^=;F\H
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M[Q<@G)-QZR"=.$9KL_@GFLY3T)7T'A9C7'E7L`V=C%\'<:4Q7J%;RB&V!]U1
M%>.?2+$?X!/8-5-]1%[!G<U0)]'%,U]AH0RW\#P%##A(BTME$U]DCOH)D`Y`
MA74M#")<VPKN$['ZV+U8!D[-+$AL)^/6051QC%98:L)R]B:</J,M"6Z:[D+!
M*3NCHM9&VO!U$%8*VQ664C#+;`JCV(HQAY/*^S_0!U!?E&E1QZ^/U.(9K_!!
M&):XYL&V3_;BT)7J%V5N<5/407@,[%=8Q\)L=@^Z@>PIT+VU;*Q[:;>A?$9W
M,GH=I);,=)4OW;`OE.=-\DZ>QA@7%0-)GZP^\F2$I,JRHV+BB5*GBX.(83$+
M_&6^^&VV6"^?YS.>SGYS\PUF`>;/6\=P!`N#,3Z.]!PE-J9VL"_JHBYVXNRA
M1,J@:P#C$_S;'VU)&O7$)6HF35W0[1V'I(XQ>D9`KCBI,*\]]CI=+\(?8Y&M
M'X*+E9:U:86(MHXON_S8^N$>N8IN.#R)SQ'S/=[<A,,?1_>'%FKB@IK(B#1Q
M7&L.&BR)ZR03G:HT$[XH>XMEN/Z]0[(5NK&@)*2QLEA]_1UD@^ZM;R868G\L
MGHMPPM)T]Z(7=`KS5]/QA+LY>$/=JF?EVQ<X<=FZ8GAOL^#T4_L-=WL$7T)<
M2\MT`FK@8K&!T]P6K8&I6_8?<_/)ME3D7.(P'(I7DG@*:J`EC/"$]\Y-59,'
MG+L,7N]GR](N<9!+4)-X"FJ@)HSP7$]/P<*/;7)B&*7U`\E>RWH@\W[YWU&5
ML[S"X^G4"YP3F"(!A8$L<'UG):,ZZ\T$U'<<>9$NXRZK^>?%_&$^G2S6K<ET
MNORZ6,\7GUM/RT?\0AU/='2E;TU]HZN*Z4Y4U3J8N/;_R3+PFW/9+?MRJ%`M
M>M1'&PNJ?(Z=-KM9XQ9+SG+S%+4$4TN$[:C!`[G;%<9M'LH*L7X.*0>V7Q2:
MW_%RT.OP+PB9(J^)4LD;;IW8-G[GDC2O``U8@*B.GZSA)P?4"'>S\(MIY*$X
M=X"3ENQKR9./\2?=6K\B6]FC@ZNK#BX1L/>6U[XC*$V4^V/:$R[4S'/V<8NQ
M^YRR"Q:#C'!<L>TG:\=&_PO9<=S3GF.E*T/<,/62/1.S37U8(WWG%%(!)\(_
M2MZ[_?;=`VK*-OVE[M3Q2O)=+KMF\'%:\Y(5H%[#74/U-[1"Z@$H`RYP,J5?
MZ-H?B?-<TR;/H8TX,69)</5ZRX?/I9-DF7")&728UU.F(8O125Z9A)K)S753
M]U`ZA+-WU3B`7_H`4..,@8/K%W1>]-/]H`]`JC7[0W$-E@32G=V86/6Q1$0X
MUXAL%B=&7<(:.G94:[Z%9',%A5SGEWZ$>W2U8%D=^FGL(Q;G_/S7JW3*+Q(1
MDIF[FB86W'D(*Q4!8KKUU73V2`4?#VF^+?:&`I^@C)TVSR6$-^3ZFQ79]6FA
M$[JO<_[KA:@G![S'.X(D/IIZ+`RX7IHHPC6M#5"B],)?KUIZ=#Z:ZGN&.@LB
MBO)-.T<E6]]Q@*HE&,?+U>P%&67X8!WL"-O,SZY=_G[5$HSAY(I3(E("`'ZC
MG8!_SQ>7!N).*M0I\V_A\;(6U-XVCS.2JL!L8CE7WD0,ZGTZ2HP6/H8=M+!-
MTB[$^6.CC_F[ER\.>)U8;E:'%P?.J`K.\2'Q>&8*:2,4HT!9X0S?Q4GCK:EN
M"4FB1)KC13,,^!=\WV+93EOJC0;B$I%BYZV'/K#!TM23!FZOM=Q$X@;>>BRG
M=B+(K@_4*7,$)[/%/,3$*@5$G](,@%&"8=0Q,URUV69S+0EQ-Y''*Y04!^7[
M@*&<@'B]V\7Q;BVY;[7Y/#>Q9L#/>[W[D'W1#>2XEHF>E`]LWL3E8X[(G/]V
M/5R71)Z:&IDY^FBPLD1V,_#C-KI+5A]8A50,_):\&#^B=3&@2IEKZ'JH0'8T
MFAKXB31&>5+LI4TV=.TWQ3B@8'=J#R597$]]!@+JHCM<2%U/`7VIJ2*3'8:^
M/>A(M$RB6F2%>"360^D*1_MJJN*S/P^>RY-+/1^&CD)5'>=9G?#58;\W2.,K
MW<6,/",<"08HOL"?N\/.TPWOWV$A:TM#21*7NYB=L'H88D'`AFY$PRJO'W45
M/Q"%BY((.I.MC3S/RG+A3UTQ'@[NP0Y<;_)<Q-)<(-_S`N2'LLR<;Y%WMGJH
M5*&8'15KT&W2.]-/!UM]!<X]HUI;G]`*).+@JZVU]8Q4A%\G,TF-E_:L;U\)
M+,,Q[9E8>F89]_CU4)Z<N!S519:Z_0:I2^1Z`C\JM=R0%[HGCH-<1R)W%.*Z
M]"5/7A.]80<HU)'!J%%/UY_OW^`LX^Z\[=ZX*[$GC=$'J8>063@\2A?O&%<E
MW;REP)2.C*F%P`3^C\+J@+WA3K'Y/AL%+!3LX\`RM$=>/:./S;%^'8=IF5W#
MU.&*R1SG+^'GX[.I615^(X,S_#[.H1C(77%UZVPT5*4G_`@U-=GB/)AU#L&X
M,Q)79)`R>57:P8%)4V^T[M&+>\[V<"C13GS%J`)EPJK$G\+[%5]2Y>_VU+OP
MZ=;+Z3]:Z^?)8C69KN?+!5>#)WS/$TWPR>RKD9%>+0-$X\S^/(`X%I9[[/?5
M[U+3Y(O*L4Z:.T>R-75<:AOXH2R5S9^H)OF\DCRI,^=&ZXI=P/R]FGJ4(]J%
M.6=KSW1NV'E;,DT-Q0&'C8Q[/)Q+'8G6AZB@.W/:E#FM>>XX!Z3='VR\'Y%G
M][PN"-$F";-W9*NZ0^XTN@-QYTQ^@@JQ;T9)GIAU=M@:<!.;'H*EH]#O],7M
M":GS5Z$K?*!4^!J?X"JS)(NAOB-/3$:P`\%'4?V6FG3@0H5JV+6S9T7D841\
M[T40"GPL[T^2OB$/._\:[<Z@(<X-Y-?.^,P'K5:![O`S-C>DW5Y-XMQ`E9Q!
M;I3"L@KIP35HMBA0(_II4DI2,?JQC_3E%N3D5Z:F0G;8I$)YB(,-+8@^TA.?
M231/GOBB`SZ`1ZQ7AW#WCZBX1O(RT8LU7`=O?&+QSG`=ET<<1`]NECA5@ALS
MD(65)A:6A*[VI<89_1@64V=\AQ2/$5/?8*^O!G=]@[]E2I-X)7\X@R8Q2C`$
M!G!FA>RQ68Q12AJ=Z4'Q>#.5!F&QG(U!5%(8\,Q)^42(,?K(J9NC9Y!"F*-/
MJ*N"KZMC<&B0JZ^K7P@)8Z9NB9E%X(TNOJF)(#,Q]_21,%X*-PSA1L3$EY&!
M*>TF_O'93'[C%9NI2!.RYC2\N0ZOU53);:1%%BRO$1TD0[B1BSN?0F5`1%)B
M<2I0!`!02P,$%`````@`[H.H1-:)-BO*"```'TL``!``'`!P;'@M,C`Q-#`S
M,S$N>'-D550)``.@Z6M3H.EK4W5X"P`!!"4.```$.0$``.U;7W/B.!)_OZK[
M#CJ>,@\$2":[E=0P>PZ!C&L)IC#)W3ZEA"U`M4;R2G(2]M-?2\9@\V\,\52\
MM[PDMM3=ZF[]U-T2\I=?WF8!>B%"4LZ:E<9YO8((\[A/V:19>72KEMNR[0J2
M"C,?!YR19H7QRB]?__F/+_^J5EN"8$5\-)JC)\H4GA#4H0'P2G16>>I4/E6K
M"\I0<#_R@)0S=%%O?*[6KZKUG]&_4>/BIGZ%^@\QY9OT;Z0W)3.,%!83HGIX
M1F2(/1AWJE1X4ZN]OKZ>@S2%`_IV[O%938NK7UXV0/.`S`A3'2YF=V2,HT`U
M*W]$0#BFQ*\@,)7)FS!XRR,K)GX;B8!FR'7+.1<3(*U?UBC3GO%(0L^BV79J
M7XF:FH>D!A1$4&_)P%D.'LZJ:WR:R%=+OK165[6X<TDJ_8S\U\N$LE'[[T/7
M->ZN@/<1,O['C(%'%`#"M"6M84C9F"^:H!&F^?<;_6>$)1F0,7HS+8('9(_#
M='?-PX$7!6:([DI`92%A*LBX68%IJB:S\0P,YV!,0J&=TJQ(.@L#DK1AX6T,
MO;"T<7U]73-4-9CLD`A%B:PEJB_=I!OVLR>D&Y19&U>2:X6XRR=CRFA^;P']
MW]A;`1Z1()^C@/1O[*A0$`G1\H!E"!S_%_[2&@Y!>:0?'@?V[GQ@'-7BS"=,
M$A\>)`^HKW/>+0YTX'>GA"A90=2/?>5Y(WFH?DOM$OU6"_YKO7Z!JLB%63*I
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MHFINLS$7,V/L"D0^)K18"#4`-LG8Z4?,?!0K@E*:G!#R<0CI8"J><!"1!X)E
M),R:7R%C_#(K$A@-DZSNJ/0"K@>#EXYE#]"3U7ULHX>VY3X.3$@Y(>+C$&&S
M%["-"TI2=4NA\:%A#H<R,+![3S#MSL!NGPJ2<LR]_GW%CP+BC)/&>8O/0LYT
M97)'%*9!&A^2%[QG_UR_B-/(#IB@LT1#Q,=HJ2-:*?D)G2WT/-4@Y<#4$(^"
M3%1112+F<F]806?QZ"<L?"`67#IA=`S;`BA)/8]'4`JR21]V/EXFVTA<Z):F
ML1E(7/N^9W?LEM4;(JO5<AY[0[MWC_JPNVF=<E!Y,;*1>``J?J/8O',X7$Z)
MIO3`,?_G&=P4&F.V%"O?!4VLTPDS'XD9Q;W?AP(SB;VUHUI9:''2,,=J67P,
MG=:O:#BP>J[5.IW%E@T)FZE&%;S!^;PE9FQ@XI1;"D7'E]KZK<!%2_;VH+D[
M2&$G*11B6^]R[KI0&5\#[7+/"-O#HM^J"5]5-U4;%]7+QCD,G=S].52-)?`.
M5"/A.TH-(T\2[WS"7VH^H?HVZF6UWJCJ^Z@[]-C*HQ^J*^8#-=BX1IK3!0F#
MMOWJ2.=OO_*:1X$T9R]FU(I<ZTEH_/1N=8Y3Y1UZ9":6PM9?JH/QD&);/!^%
MBC&6(V-8)*L3C,/<>FQEK)%`R:3EW?IH/\N"%#*RCE\WB=>]2.B(.M?"+PZ9
MK@SC\JVZ$G.L0KJ$%_.#X9/F2U[>[QZI0J%%-@Y19<EDGJHK]N.#_'5<KC`R
MT3\6YUO9@1`9KGTK>_$Q@M&D6=%W_@(B9?N-"(]*XHQ-G>2$V6+Y^7MTC`:!
M/GYK5I2(]*59_8'"S2B^C-JL^&1DS@)-:PC!A_M#<TO7C\3BQTH9C:2B*M)O
M]X)'8;,2DU-%9A447^J-6V:<0<DDYC;T:#'[[.-:+ZX'>2&6$/KBD.[N"SZF
MRIUB0?I@$3$?B:3,/8QMN_5I.^,Z0.4T$P*TYM;R<]AX1Z`T\ZCQHS4#E-$_
MXV?F6U(29<]"3$7FA[_G0WC*.K?[?ORV8$`!A7[*XES4Z[;B1<_NF3W*2A!*
MV22'C>U9&/`Y(:!U#SRS>'L@LQ$1*]OV4_UPF^*/A6Y\/L.4'6#4+C-*J_@]
MD'6YE(Y>,Y!W9"=B/O%M-H"@3CSEC!,3!G0R5?(QY-"EZ-K/[L_OE?.=%>D)
MXG_,DKR'2*DDP'!`Z&P4"1E?=!H0CT`@]1T1/VG=4]XXA*FTIML,QH8ME@V;
M8SRB`=6?D72XZ,??E,S[`8Z#SQ\1#;-P.(*UM&[H4D_?>`-MW2@,@[DU$21.
MG5S!7XJ#3J0B2)]XKEMOL=G4]\@BM:9*CO=+*FOB>J!02BF@7ZB^LGFSIZPV
M]+#V?>8&HSGM'I(W=1M`:;@R*@?I]PNHXR*[2H;(8U&DLPX4MB"?^A1G+L@\
M;^\M7.]%"U-D0D0.I1TU)4*G$ZGS25KAS9[2QHS^F/X)UC*/BY#'0ZV7!GM(
M2E<E]!=GS[>4#V$.<$A`OB?WVW<`3VD-[BI_EUVIKO*I'PEO"MDCKL6&_):X
M,)S4'^</^:(*,5N&@/AQ/9:R[PC>H]?A89O(@Y<A%)\$@SEWY(4$/%QNEB:4
M$:+W*^VW4&=D2+$K!QS$5-9DYD*E`1&==W@DUA&\K:]T$$Z4=-C&IFI+5VG5
M'T[%YJYP:V=Y37CE.PU8=95/?7VD94IH?;\2%JP9#!:W$M0S'ZU`$66]8N%+
M6,G.&'8G8T)U79<*AN\24MKJY!U6&=9B')2(^D$5IS3B\WACWR6<+@1]+2-M
M<D[ZLAV\[=5[F#W`R$/[`^SSU<UTKH^)HY'QXK&6I@[RS2',$HT&$QO1+!]Y
M^2*<.42`=3>CRIPB$/$;5"XIPW81E*!>B^\PQ#\%P>O_`%!+`0(>`Q0````(
M`.Z#J$3%@%9";BX``&CL`0`0`!@```````$```"D@0````!P;'@M,C`Q-#`S
M,S$N>&UL550%``.@Z6M3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[H.H
M1$)E2'GM"@``DGP``!0`&````````0```*2!N"X``'!L>"TR,#$T,#,S,5]C
M86PN>&UL550%``.@Z6M3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[H.H
M1`5ZAEI[#0``#:0``!0`&````````0```*2!\SD``'!L>"TR,#$T,#,S,5]D
M968N>&UL550%``.@Z6M3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[H.H
M1+75QL#D1@``+<,#`!0`&````````0```*2!O$<``'!L>"TR,#$T,#,S,5]L
M86(N>&UL550%``.@Z6M3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[H.H
M1-K+I"2S'```4ID!`!0`&````````0```*2![HX``'!L>"TR,#$T,#,S,5]P
M<F4N>&UL550%``.@Z6M3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[H.H
M1-:)-BO*"```'TL``!``&````````0```*2![ZL``'!L>"TR,#$T,#,S,2YX
M<V155`4``Z#I:U-U>`L``00E#@``!#D!``!02P4&``````8`!@`4`@```[4`
#````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EP5AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 77,690<span></span></td>
        <td class="nump">$ 86,398<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable- Trade</a></td>
        <td class="nump">1,735<span></span></td>
        <td class="nump">2,091<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other assets</a></td>
        <td class="nump">2,609<span></span></td>
        <td class="nump">1,457<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">6,527<span></span></td>
        <td class="nump">7,957<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">88,561<span></span></td>
        <td class="nump">97,903<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump">1,622<span></span></td>
        <td class="nump">1,578<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump">13,098<span></span></td>
        <td class="nump">13,711<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">DEFERRED CHARGES</a></td>
        <td class="nump">135<span></span></td>
        <td class="nump">141<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">103,416<span></span></td>
        <td class="nump">113,333<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
        <td class="nump">4,639<span></span></td>
        <td class="nump">5,254<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
        <td class="nump">14,533<span></span></td>
        <td class="nump">12,073<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump">7,609<span></span></td>
        <td class="nump">9,369<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">26,781<span></span></td>
        <td class="nump">26,696<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
        <td class="nump">67,151<span></span></td>
        <td class="nump">67,048<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
        <td class="nump">40,655<span></span></td>
        <td class="nump">41,796<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability in connection with collaboration operation</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,371<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
        <td class="nump">2,407<span></span></td>
        <td class="nump">2,368<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump">110,213<span></span></td>
        <td class="nump">113,583<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">136,994<span></span></td>
        <td class="nump">140,279<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY</a></td>
        <td class="num">(33,578)<span></span></td>
        <td class="num">(26,946)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
        <td class="nump">$ 103,416<span></span></td>
        <td class="nump">$ 113,333<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableTradeCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.10)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28361610&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6BAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY  (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (7,345)<span></span></td>
        <td class="num">$ (4,321)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="nump">670<span></span></td>
        <td class="nump">1,367<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DepreciationAmortizationAndAssetImpairment', window );">Depreciation and write down of fixed assets</a></td>
        <td class="nump">828<span></span></td>
        <td class="nump">926<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
        <td class="nump">14<span></span></td>
        <td class="num">(78)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
        <td class="nump">50<span></span></td>
        <td class="nump">60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
        <td class="num">(1)<span></span></td>
        <td class="num">(19)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discount</a></td>
        <td class="nump">109<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenues (including non-current portion)</a></td>
        <td class="num">(2,901)<span></span></td>
        <td class="num">(2,740)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
        <td class="num">(744)<span></span></td>
        <td class="num">(42)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
        <td class="nump">1,430<span></span></td>
        <td class="num">(1,734)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accruals (including long term )</a></td>
        <td class="num">(450)<span></span></td>
        <td class="num">(3,005)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num">(8,340)<span></span></td>
        <td class="num">(9,586)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(263)<span></span></td>
        <td class="num">(642)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Investment in restricted deposit</a></td>
        <td class="num">(57)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
        <td class="num">(50)<span></span></td>
        <td class="num">(47)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num">(370)<span></span></td>
        <td class="num">(689)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
        <td class="nump">31<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
        <td class="nump">31<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
        <td class="num">(29)<span></span></td>
        <td class="nump">110<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num">(8,708)<span></span></td>
        <td class="num">(10,165)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
        <td class="nump">86,398<span></span></td>
        <td class="nump">52,035<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
        <td class="nump">77,690<span></span></td>
        <td class="nump">41,870<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump">138<span></span></td>
        <td class="nump">815<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CashlessExerciseOfStockOptions', window );">Exercise of options granted to employees</a></td>
        <td class="nump">$ 12<span></span></td>
        <td class="nump">$ 28<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CashlessExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash due from broker assisted exercises of employee stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CashlessExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DepreciationAmortizationAndAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DepreciationAmortizationAndAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in liabilities for property, plant and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3095-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromOtherInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
        <td class="nump">$ 6,696<span></span></td>
        <td class="nump">$ 3,568<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherGainsLosses', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
        <td class="nump">687<span></span></td>
        <td class="nump">400<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
        <td class="num">(4,073)<span></span></td>
        <td class="num">(971)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
        <td class="nump">3,310<span></span></td>
        <td class="nump">2,997<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="num">(8,152)<span></span></td>
        <td class="num">(7,754)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants and reimbursements</a></td>
        <td class="nump">2,085<span></span></td>
        <td class="nump">2,431<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
        <td class="num">(6,067)<span></span></td>
        <td class="num">(5,323)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="num">(3,711)<span></span></td>
        <td class="num">(2,103)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(6,468)<span></span></td>
        <td class="num">(4,429)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
        <td class="num">(915)<span></span></td>
        <td class="num">(14)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
        <td class="nump">38<span></span></td>
        <td class="nump">122<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES) - NET</a></td>
        <td class="num">(877)<span></span></td>
        <td class="nump">108<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
        <td class="num">$ (7,345)<span></span></td>
        <td class="num">$ (4,321)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER SHARE OF COMMON STOCK:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED</a></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="nump">$ 0.05<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">BASIC AND DILUTED</a></td>
        <td class="nump">92,686,638<span></span></td>
        <td class="nump">92,184,220<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_GrantsAndReimbursementsReceivedOrReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's share in collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_OtherGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development expenses, net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ResearchDevelopmentAndEngineeringExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>May 01, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">PLX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PROTALIX BIOTHERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001006281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,606,460<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">$ 428<span></span></td>
        <td class="nump">$ 870<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">$ 242<span></span></td>
        <td class="nump">$ 497<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td><strong>General</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health (the "Brazilian MOH") in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by the FDA or any other major regulatory authority.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. ("Pfizer"), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the "Pfizer Agreement"). The Company, through Protalix Ltd., markets ELELYSO in Israel, and in Brazil under the brand name UPLYSO.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel and, since 2014, in Brazil (see below). The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received during 2012 an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel and Brazil, where the Company retained exclusive marketing rights. In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> On June 18, 2013, Protalix Ltd. entered into a Supply and Technology Transfer Agreement (the "Brazil Agreement") with Funda&ccedil;&atilde;o Oswaldo Cruz ("Fiocruz"), an arm of the Brazilian MOH, for taliglucerase alfa. The brand name for taliglucerase alfa in Brazil is UPLYSO<sup>TM</sup>. The first term of the technology transfer is seven years and the agreement may be extended for an additional five-year term, as needed, to complete the technology transfer. The technology transfer is designed to be effected in four stages and is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high quality, and cost effective supply of taliglucerase alfa. Under the agreement, Fiocruz has committed to purchase at least approximately $40 million worth of taliglucerase alfa during the first two years of the agreement. In subsequent years, Fiocruz is required to purchase at least approximately $40 million worth of taliglucerase alfa per year. Additionally, Protalix Ltd. is not required to complete the final stage of the technology transfer until Fiocruz purchases at least approximately $280 million worth of taliglucerase alfa. The Brazil agreement became effective during the first quarter of 2014.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> During the three months ended March 31, 2014, the Company recorded revenues of approximately $3.5 million from the sale of products to Fiocruz.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> To facilitate the arrangement with Fiocruz, Pfizer amended its exclusive license and supply agreement with Protalix Ltd. The amendment provides for the transfer of the commercialization and other rights to taliglucerase alfa in Brazil back to Protalix Ltd. As consideration for the transfer of the commercialization and supply rights, Protalix Ltd. agreed to pay Pfizer a maximum amount of approximately $12.5 million from its net profits (as defined in the license and supply agreement) per year. Pfizer has also agreed to perform certain transitional services in Brazil on Protalix Ltd.&#39;s behalf in connection with the supply of taliglucerase alfa to Fiocruz.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Protalix Ltd. is required to pay a fee equal to 5% of the net proceeds generated in Brazil to its agent for services provided in assisting Protalix Ltd. complete the Brazil Agreement pursuant to an agency agreement between Protalix Ltd. and the agent. The agency agreement will remain in effect with respect to the Brazil Agreement until the termination thereof.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> In addition to the approvals from the FDA, the Israeli MOH and the Brazilian MOH, marketing approval has been granted to UPLYSO in Mexico, Chile and Uruguay. In addition, the Company is cooperating with Pfizer in its efforts to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, Brazil, Chile and Israel. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs and other programs. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in other countries.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all, and the Company expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Obtaining marketing approval with respect to any product candidate in any country is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 1in; TEXT-INDENT: -0.25in; font-size-adjust: none; font-stretch: normal"> <strong>&nbsp;</strong></p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td><strong>Basis of Presentation</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 56.7pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2013, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2013 has been derived from the audited financial statements at that date.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td><strong>Net loss per share</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Diluted LPS does not include 7,471,571 and 18,913,153 shares of Common Stock underlying outstanding options and restricted shares of Common Stock and shares issuable upon conversion of the convertible notes (issued in September 2013) for the three months ended March 31, 2013 and 2014, respectively, because the effect would be anti-dilutive.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <strong>&nbsp;</strong></p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The accounting policy related to the nature of operations of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NatureOfOperationsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <strong>NOTE 4 - STOCK TRANSACTIONS</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; TEXT-INDENT: 0in; font-size-adjust: none; font-stretch: normal"> During the three months ended March 31, 2014, the Company issued a total of 55,362 shares of Common Stock in connection with the exercise of a total of 56,122 options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $43,000.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <strong>&nbsp;</strong></p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory Components) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
        <td class="nump">$ 2,076<span></span></td>
        <td class="nump">$ 2,342<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
        <td class="nump">170<span></span></td>
        <td class="nump">92<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
        <td class="nump">4,281<span></span></td>
        <td class="nump">5,523<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
        <td class="nump">6,527<span></span></td>
        <td class="nump">7,957<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
        <td class="nump">$ 1,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterialsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWorkInProcessNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4542-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWriteDown</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"> Inventory at March 31, 2014 and December&nbsp;31, 2013 consisted of the following:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.5in; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">March 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2" nowrap="nowrap">December 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2014</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" colspan="2">2013</td> <td style="FONT-WEIGHT: bold; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="WIDTH: 76%; TEXT-ALIGN: left">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 9%; TEXT-ALIGN: right">2,076</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">$</td> <td style="WIDTH: 9%; TEXT-ALIGN: right">2,342</td> <td style="WIDTH: 1%; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">170</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">92</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: rgb(204,255,204)"> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 4,281</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 5,523</td> <td style="PADDING-BOTTOM: 1pt; TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: white"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 6,527</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 7,957</td> <td style="PADDING-BOTTOM: 2.5pt; TEXT-ALIGN: left">&nbsp;</td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.5in; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EARAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">3 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Protalix Bio Therapeutics Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Pfizer Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 18, 2013

</div>
          <div>Protalix Ltd. [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009

</div>
          <div>Upon Filing of Pediatric Investigation Plan to EMA [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Upon FDA Approval [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfSubsidiaries', window );">Number of Subsidiaries</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40.00%<span></span></td>
        <td class="nump">60.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights', window );">Supply commitment for entitled rights to be received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">280,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits', window );">License and supply agreement potential future payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplyCommitmentPerYear', window );">Supply agreement maximum consideration payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssets1', window );">Revenue from sale of products</a></td>
        <td class="nump">$ 3,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</a></td>
        <td class="nump">18,913,153<span></span></td>
        <td class="nump">7,471,571<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeArrangementProfitSharePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License And Supply Agreement Potential Future Payment Based On Net Profits</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MilestonePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NumberOfSubsidiaries</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplyCommitmentPerYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplyCommitmentPerYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssets1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow from the sale of other assets as part of operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfOtherAssets1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 31<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Certain Employee [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees (in shares)</a></td>
        <td class="nump">55,362<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 43<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued in connection with exercise of options</a></td>
        <td class="nump">56,122<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1TAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="num">$ (26,946)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (3,357)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="nump">162<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">347<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="nump">508<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,020<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees</a></td>
        <td class="nump">43<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">28<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="num">(7,345)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(4,321)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="num">(33,578)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(6,283)<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="nump">94<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">93<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares)</a></td>
        <td class="nump">93,551,098<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">93,489,809<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock award, net of forfeitures (in shares)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees (in shares)</a></td>
        <td class="nump">55,362<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">12,421<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="nump">94<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">94<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares)</a></td>
        <td class="nump">93,606,460<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">93,502,230<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Additional paid-in Capital [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="nump">184,345<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">180,145<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="nump">162<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">347<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="nump">508<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,020<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees</a></td>
        <td class="nump">43<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">27<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="nump">185,058<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">181,539<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Accumulated Deficit [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="num">(211,385)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(183,595)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock award, net of forfeitures</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="num">(7,345)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(4,321)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="num">$ (218,730)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (187,916)<span></span></td>
      </tr>
      <tr>
        <td colspan="4"></td>
      </tr>
      <tr>
        <td colspan="4">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Represents an amount less than $1.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <strong>NOTE 3 - FAIR VALUE MEASUREMENT</strong></p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> &nbsp;</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 35.45pt; font-size-adjust: none; font-stretch: normal"> The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>37</ContextCount>
  <ElementCount>100</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY  (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY  (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/FairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>104 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesPolicy</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>302 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory Components) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>40401 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2013'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY  (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>plx-20140331.xml</File>
    <File>plx-20140331.xsd</File>
    <File>plx-20140331_cal.xml</File>
    <File>plx-20140331_def.xml</File>
    <File>plx-20140331_lab.xml</File>
    <File>plx-20140331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
